No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d1e9hA_, 1.0000, 0.00, 1.000, 295, 295, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2, d1h27A1, 0.9954, 0.43, 1.000, 295, 295, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
3, d1h26A1, 0.9947, 0.47, 1.000, 295, 295, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
4, d1pkdA1, 0.9944, 0.48, 1.000, 295, 295, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
5, d2wmbA1, 0.9934, 0.52, 1.000, 295, 295, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
6, d1p5eA1, 0.9930, 0.56, 1.000, 295, 295, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
7, d2cciA2, 0.9927, 0.55, 1.000, 295, 295, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
8, d4cfmA1, 0.9925, 0.58, 1.000, 295, 295, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
9, d4cfvA1, 0.9924, 0.61, 0.993, 297, 295, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
10, d2wmaA1, 0.9917, 0.63, 1.000, 295, 295, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
11, d1e9hC1, 0.9916, 0.59, 1.000, 295, 295, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
12, d1pkdC1, 0.9901, 0.64, 1.000, 295, 295, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
13, d1h1rA1, 0.9900, 0.70, 1.000, 295, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
14, d4cfwC1, 0.9896, 0.67, 1.000, 295, 295, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
15, d1h1qA1, 0.9895, 0.71, 1.000, 295, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
16, d2g9xA2, 0.9894, 0.70, 0.993, 297, 295, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
17, d4eooC1, 0.9890, 0.68, 0.997, 295, 295, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
18, d2uzdC_, 0.9889, 0.68, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
19, d1gy3C_, 0.9885, 0.68, 1.000, 295, 295, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
20, d1h1sA1, 0.9883, 0.74, 1.000, 295, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
21, d1gy3A_, 0.9882, 0.70, 1.000, 295, 295, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
22, d5nevC1, 0.9880, 0.74, 1.000, 295, 295, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
23, d1jstA_, 0.9879, 0.73, 1.000, 297, 295, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
24, d4cfuA1, 0.9878, 0.48, 0.993, 295, 293, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
25, d3bhvA1, 0.9878, 0.48, 0.993, 295, 293, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
26, d3ddpA1, 0.9877, 0.75, 1.000, 296, 295, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
27, d2iw8A1, 0.9877, 0.76, 0.983, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
28, d1h28C1, 0.9876, 0.72, 1.000, 295, 295, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
29, d1h28A1, 0.9876, 0.71, 1.000, 295, 295, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
30, d5cyiA1, 0.9874, 0.85, 1.000, 297, 295, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
31, d5cyiC1, 0.9872, 0.79, 1.000, 295, 295, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
32, d4bcnA1, 0.9872, 0.50, 1.000, 295, 293, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
33, d4eomA1, 0.9871, 0.57, 0.983, 294, 293, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
34, d3dogA1, 0.9871, 0.67, 0.993, 296, 294, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
35, d1oi9A1, 0.9871, 0.68, 1.000, 294, 294, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
36, d2cjmC_, 0.9870, 0.63, 1.000, 294, 294, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
37, d1qmzA1, 0.9870, 0.73, 1.000, 295, 295, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
38, d4cfwA1, 0.9869, 0.89, 1.000, 297, 295, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
39, d1jstC_, 0.9869, 0.76, 1.000, 297, 295, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
40, d4bcpA1, 0.9868, 0.87, 0.993, 297, 295, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
41, d1qmzC1, 0.9867, 0.74, 1.000, 295, 295, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
42, d2uzeA_, 0.9866, 0.79, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
43, d2cciC2, 0.9864, 0.75, 1.000, 295, 295, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
44, d2c6tC_, 0.9863, 0.77, 1.000, 295, 295, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
45, d1h1qC1, 0.9862, 0.81, 1.000, 295, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
46, d4eoqA1, 0.9858, 0.41, 0.993, 293, 292, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
47, d4bcoA1, 0.9858, 0.89, 0.993, 297, 295, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
48, d3bhtA2, 0.9858, 0.58, 0.993, 295, 293, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
49, d2uzbA_, 0.9858, 0.78, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
50, d2uzeC_, 0.9856, 0.82, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
51, d2uzlA_, 0.9855, 0.82, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
52, d3my5A1, 0.9854, 0.43, 0.993, 294, 292, CDK2/CYCLINA IN COMPLEX WITH DRB
53, d1h25A1, 0.9854, 0.43, 1.000, 292, 292, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
54, d2uzlC_, 0.9853, 0.82, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
55, d1h24A1, 0.9853, 0.43, 1.000, 292, 292, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
56, d1oiyC1, 0.9852, 0.84, 1.000, 295, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
57, d1h1rC1, 0.9852, 0.83, 1.000, 295, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
58, d3tnwA1, 0.9849, 0.46, 1.000, 294, 292, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
59, d5nevA1, 0.9847, 0.74, 1.000, 294, 294, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
60, d3bhuA1, 0.9847, 0.62, 0.993, 295, 293, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
61, d1h1sC1, 0.9846, 0.85, 1.000, 295, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
62, d1p5eC1, 0.9845, 0.85, 1.000, 295, 295, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
63, d4bcmA1, 0.9839, 0.50, 1.000, 292, 292, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
64, d4bcmC1, 0.9835, 0.65, 1.000, 293, 293, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
65, d3ddqA1, 0.9835, 0.68, 0.993, 295, 293, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
66, d5lmkA1, 0.9833, 0.69, 0.993, 295, 293, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
67, d4bcnC1, 0.9831, 0.66, 1.000, 293, 293, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
68, d4eooA1, 0.9824, 0.41, 0.997, 292, 291, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
69, d2cchA2, 0.9824, 0.98, 1.000, 295, 295, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
70, d4cfnA1, 0.9821, 0.60, 1.000, 293, 292, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
71, d4eopC1, 0.9813, 0.95, 0.997, 295, 295, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
72, d4cfnC1, 0.9807, 0.77, 1.000, 293, 293, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
73, d2bkzC2, 0.9807, 0.87, 0.983, 297, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
74, d3f5xC_, 0.9806, 0.87, 0.980, 298, 294, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
75, d2wxvC1, 0.9805, 0.87, 0.983, 298, 294, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
76, d4ii5C_, 0.9804, 1.00, 1.000, 295, 295, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
77, d4ii5A_, 0.9804, 1.00, 1.000, 295, 295, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
78, d1oguA1, 0.9804, 0.68, 0.993, 293, 292, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
79, d1oiuA1, 0.9803, 0.69, 0.993, 293, 292, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
80, d4i3zC_, 0.9802, 1.01, 1.000, 295, 295, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
81, d4i3zA_, 0.9802, 1.01, 1.000, 295, 295, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
82, d4eojA1, 0.9798, 0.53, 0.983, 293, 291, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
83, d1oiyA1, 0.9798, 0.69, 1.000, 292, 292, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
84, d2c4gC2, 0.9797, 0.90, 0.983, 298, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
85, d4eoiC1, 0.9796, 0.99, 0.993, 295, 295, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
86, d1vywC1, 0.9796, 0.90, 0.983, 298, 294, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
87, d4eosC1, 0.9791, 0.99, 1.000, 295, 295, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
88, d2wihC1, 0.9791, 0.91, 0.983, 298, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
89, d2iw6C2, 0.9790, 0.90, 0.997, 294, 294, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
90, d4eokC1, 0.9789, 0.99, 0.990, 296, 295, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
91, d5if1C_, 0.9786, 0.93, 0.980, 296, 294, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
92, d2wpaC1, 0.9786, 0.92, 0.983, 298, 294, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
93, d2cchC2, 0.9785, 1.08, 1.000, 295, 295, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
94, d2c6tA_, 0.9785, 1.00, 1.000, 295, 295, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
95, d1ol1A_, 0.9785, 0.93, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
96, d2whaA_, 0.9784, 0.95, 0.983, 296, 294,  
97, d2uueC_, 0.9784, 0.94, 0.983, 296, 294, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
98, d2x1nA_, 0.9783, 0.95, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
99, d1h24C1, 0.9782, 0.70, 1.000, 292, 292, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
100, d2uzdA_, 0.9781, 1.00, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
101, d2uueA_, 0.9781, 0.96, 0.983, 296, 294, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
102, d1okwA_, 0.9781, 0.95, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
103, d1finA_, 0.9781, 0.93, 0.980, 298, 294, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
104, d2whbA_, 0.9780, 0.96, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
105, d2c5tA_, 0.9780, 0.96, 0.983, 296, 294,  
106, d2bpmC2, 0.9780, 0.94, 0.983, 298, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
107, d2v22A_, 0.9779, 0.96, 0.983, 296, 294, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
108, d2i40C_, 0.9779, 0.95, 0.983, 296, 294, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
109, d2c5tC_, 0.9779, 0.95, 0.983, 296, 294,  
110, d2c5oA_, 0.9779, 0.96, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
111, d2x1nC_, 0.9778, 0.96, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
112, d2whaC_, 0.9778, 0.96, 0.983, 296, 294,  
113, d2c5xA_, 0.9777, 0.95, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
114, d2c5oC_, 0.9777, 0.97, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
115, d4eolC1, 0.9776, 1.03, 0.990, 296, 295, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
116, d3ddpC1, 0.9776, 1.05, 0.997, 297, 295, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
117, d3f5xA_, 0.9774, 0.87, 0.980, 297, 293, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
118, d2iw6A1, 0.9774, 0.65, 0.997, 291, 291, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
119, d2c5vA_, 0.9774, 0.98, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
120, d1ol2A_, 0.9774, 0.96, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
121, d4eonC1, 0.9773, 1.04, 0.990, 296, 295, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
122, d2iw9A2, 0.9773, 0.68, 0.990, 292, 291, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
123, d1okuA_, 0.9773, 0.98, 0.983, 296, 294,  
124, d3tnwC_, 0.9771, 0.65, 0.997, 291, 291, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
125, d1fvvC_, 0.9771, 0.97, 0.983, 298, 294, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
126, d2v22C_, 0.9770, 0.98, 0.983, 296, 294, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
127, d1ol1C_, 0.9769, 0.98, 0.980, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
128, d1okwC_, 0.9769, 0.98, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
129, d3qhrC1, 0.9768, 1.11, 1.000, 295, 295, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
130, d2uzbC_, 0.9768, 0.74, 1.000, 292, 292, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
131, d2bkzA2, 0.9768, 1.09, 0.983, 298, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
132, d3qhrA1, 0.9767, 1.11, 1.000, 295, 295, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
133, d2c5vC_, 0.9767, 0.99, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
134, d2bpmA2, 0.9767, 1.06, 0.980, 298, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
135, d1vywA1, 0.9767, 1.07, 0.980, 298, 294, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
136, d1okuC_, 0.9767, 0.99, 0.983, 296, 294,  
137, d2wfyC_, 0.9764, 0.99, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
138, d1oi9C1, 0.9764, 1.04, 1.000, 295, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
139, d2c4gA2, 0.9763, 1.06, 0.980, 297, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
140, d3qhwA1, 0.9761, 1.14, 1.000, 295, 295, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
141, d2whbC_, 0.9761, 1.01, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
142, d2c5pA_, 0.9761, 1.00, 0.983, 296, 294,  
143, d2wevA_, 0.9760, 1.01, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
144, d1urcA_, 0.9760, 1.01, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
145, d2wxvA1, 0.9759, 1.08, 0.980, 298, 294, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
146, d1finC_, 0.9759, 0.99, 0.980, 298, 294, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
147, d2wihA1, 0.9758, 1.10, 0.980, 298, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
148, d2wpaA1, 0.9757, 1.10, 0.980, 298, 294, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
149, d4eorA1, 0.9756, 0.73, 0.993, 292, 291, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
150, d3qhwC1, 0.9755, 1.16, 1.000, 295, 295, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
151, d5if1A_, 0.9754, 1.08, 0.980, 298, 294, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
152, d2c5nA_, 0.9754, 1.03, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
153, d2c5xC_, 0.9753, 1.02, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
154, d4eonA1, 0.9752, 1.19, 0.990, 297, 295, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
155, d4bckA1, 0.9749, 1.07, 1.000, 296, 295, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
156, d4eosA1, 0.9748, 0.86, 1.000, 293, 292, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
157, d2c5nC_, 0.9748, 1.09, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
158, d1urcC_, 0.9748, 1.06, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
159, d2wevC_, 0.9746, 1.07, 0.976, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
160, d2wfyA_, 0.9745, 0.95, 0.983, 295, 293, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
161, d2c5pC_, 0.9743, 1.09, 0.976, 296, 294,  
162, d4eopA1, 0.9740, 0.99, 0.997, 294, 293, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
163, d1ol2C_, 0.9738, 1.06, 0.976, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
164, d1h27C1, 0.9733, 0.64, 1.000, 290, 290, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
165, d1fvvA_, 0.9733, 1.10, 0.983, 298, 294, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
166, d1okvC_, 0.9728, 1.08, 0.976, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
167, d1okvA_, 0.9718, 1.01, 0.983, 295, 293, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
168, d4eoiA1, 0.9710, 0.88, 0.993, 293, 291, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
169, d4fx3C_, 0.9709, 1.18, 0.980, 298, 294, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
170, d4fx3A_, 0.9708, 1.16, 0.980, 298, 294, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
171, d3eidA_, 0.9694, 0.91, 0.979, 292, 291, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
172, d1h1pA1, 0.9691, 1.20, 1.000, 295, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
173, d2wipC1, 0.9658, 0.82, 0.983, 291, 289, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
174, d4eolA1, 0.9655, 1.13, 0.986, 293, 292, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
175, d4eokA1, 0.9653, 1.01, 0.990, 292, 291, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
176, d2i40A_, 0.9646, 0.93, 0.983, 291, 290, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
177, d1h1pC1, 0.9644, 1.30, 1.000, 295, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
178, d4bckC1, 0.9625, 1.01, 1.000, 291, 291, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
179, d5uq2A_, 0.9621, 1.49, 1.000, 296, 295, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
180, d3eidC_, 0.9621, 1.07, 0.976, 290, 290, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
181, d2wipA1, 0.9620, 1.04, 0.979, 293, 289, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
182, d4bcqC1, 0.9608, 1.05, 0.997, 291, 291, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
183, d2cjmA_, 0.9596, 0.54, 1.000, 285, 285, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
184, d1w98A2, 0.9544, 1.21, 1.000, 296, 289, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
185, d5l2wA1, 0.9541, 1.24, 1.000, 296, 289, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
186, d2jgzA_, 0.9529, 1.00, 1.000, 288, 287, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
187, d4bcqA1, 0.9518, 1.15, 0.997, 289, 289, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
188, d4nstC_, 0.9458, 1.69, 0.429, 317, 294, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
189, d1fq1B_, 0.9438, 1.56, 0.976, 295, 292, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
190, d4nstA_, 0.9435, 1.74, 0.425, 322, 294, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
191, d5acbC_, 0.9421, 1.71, 0.432, 324, 294, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
192, d4cxaA_, 0.9404, 1.72, 0.422, 329, 294, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
193, d5efqC_, 0.9396, 1.80, 0.435, 325, 294, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
194, d1f5qA_, 0.9392, 1.75, 0.979, 296, 290, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
195, d4un0C_, 0.9386, 1.72, 0.433, 308, 293, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
196, d5efqA_, 0.9385, 1.86, 0.429, 321, 294, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
197, d4imyE_, 0.9382, 1.82, 0.403, 313, 293, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
198, d5acbD_, 0.9378, 1.64, 0.435, 319, 292, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
199, d4cjyC_, 0.9364, 1.77, 0.427, 303, 293,  
200, d4cxaC_, 0.9321, 1.76, 0.433, 330, 291, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
201, d4imyA_, 0.9303, 2.06, 0.401, 314, 294, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
202, d3miaA_, 0.9290, 2.10, 0.401, 324, 294, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
203, d1h25C1, 0.9287, 0.68, 1.000, 277, 277, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
204, d1unlA_, 0.9277, 1.73, 0.597, 292, 288, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
205, d3mi9A_, 0.9276, 2.12, 0.401, 328, 294, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
206, d1jsuA_, 0.9267, 1.65, 0.950, 285, 282, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
207, d4imyC_, 0.9253, 1.90, 0.400, 310, 290, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
208, d4bchA_, 0.9247, 2.04, 0.403, 308, 293, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
209, d3lq5A_, 0.9247, 1.93, 0.395, 307, 291, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
210, d4or5F_, 0.9243, 2.15, 0.405, 324, 294, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
211, d4bcgA_, 0.9240, 2.08, 0.406, 312, 293, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
212, d3o0gA_, 0.9227, 1.72, 0.601, 289, 286, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
213, d3my1A_, 0.9212, 2.15, 0.401, 314, 294, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
214, d4or5A_, 0.9207, 2.20, 0.401, 319, 294, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
215, d4eojC1, 0.9191, 1.15, 0.968, 278, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
216, d4bcjA_, 0.9185, 2.18, 0.403, 309, 293, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
217, d4bciA_, 0.9184, 2.06, 0.405, 308, 291, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
218, d4krcA_, 0.9182, 1.86, 0.569, 297, 288, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
219, d4ogrA_, 0.9181, 2.17, 0.401, 314, 294, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
220, d4bcfA_, 0.9168, 2.15, 0.404, 307, 292, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
221, d4krdA_, 0.9158, 1.79, 0.573, 294, 286, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
222, d3tn8A_, 0.9155, 2.20, 0.405, 304, 291, CDK9/CYCLIN T IN COMPLEX WITH CAN508
223, d1f5qC_, 0.9155, 1.47, 0.972, 288, 281, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
224, d1ungA_, 0.9151, 1.75, 0.588, 288, 284, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
225, d4ogrI_, 0.9128, 2.26, 0.401, 318, 294, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
226, d1unlB_, 0.9123, 1.97, 0.597, 292, 288, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
227, d3blrA_, 0.9118, 2.01, 0.410, 300, 288, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
228, d4yc3A1, 0.9116, 2.01, 0.656, 294, 285, CDK1/CYCLINB1/CKS2 APO
229, d3blqA_, 0.9109, 1.69, 0.413, 295, 283, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
230, d4ogrE_, 0.9085, 2.22, 0.388, 310, 291, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
231, d4eoqC1, 0.9068, 0.76, 0.996, 271, 271, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
232, d1j1cA_, 0.9054, 2.10, 0.322, 354, 286, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
233, p3zuvC_, 0.9051, 1.87, 0.377, 357, 284, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
234, d4eomC1, 0.9050, 0.81, 0.985, 271, 271, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
235, d1j1bA_, 0.9048, 2.11, 0.322, 354, 286, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
236, d3i4bB_, 0.9043, 2.00, 0.323, 347, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
237, p3zuvA_, 0.9032, 1.91, 0.377, 357, 284, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
238, d4cfuC1, 0.9031, 0.64, 1.000, 269, 269, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
239, d2pk9A_, 0.9030, 1.73, 0.562, 287, 281, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
240, d3i4bA_, 0.9026, 2.03, 0.323, 359, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
241, d1j1cB_, 0.9025, 2.02, 0.323, 364, 285, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
242, d2g9xC2, 0.9015, 0.93, 0.996, 273, 271, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
243, d3bhvC1, 0.9013, 0.71, 1.000, 269, 269, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
244, d2erkA_, 0.9013, 2.05, 0.379, 351, 285, PHOSPHORYLATED MAP KINASE ERK2
245, d1j1bB_, 0.9009, 2.05, 0.323, 364, 285, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
246, d3blhA1, 0.9007, 1.63, 0.414, 291, 280, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
247, d4ic7A_, 0.9006, 1.99, 0.391, 355, 284, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
248, d5v60A_, 0.9003, 2.09, 0.375, 347, 285, PHOSPHO-ERK2 BOUND TO AMP-PCP
249, d4acgB_, 0.9001, 2.08, 0.326, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
250, d5a14A_, 0.9000, 2.00, 0.975, 284, 281, HUMAN CDK2 WITH TYPE II INHIBITOR
251, d1q41B_, 0.9000, 2.07, 0.323, 343, 285, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
252, d3bhtC1, 0.8998, 0.75, 1.000, 269, 269, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
253, d4acgA_, 0.8990, 2.08, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
254, d4achB_, 0.8984, 2.09, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
255, p5v61A_, 0.8983, 1.99, 0.373, 348, 284, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
256, p5v62A_, 0.8980, 1.99, 0.373, 349, 284, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
257, d4nm0A1, 0.8979, 2.09, 0.323, 355, 285, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
258, d4acdA_, 0.8979, 2.12, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
259, d4accA_, 0.8979, 2.12, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
260, d1h8fB_, 0.8978, 2.11, 0.326, 350, 285, GLYCOGEN SYNTHASE KINASE 3 BETA.
261, d4acdB_, 0.8977, 2.10, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
262, d4achA_, 0.8976, 2.13, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
263, d1oguC1, 0.8976, 0.86, 1.000, 269, 269, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
264, d1h8fA_, 0.8975, 2.12, 0.326, 352, 285, GLYCOGEN SYNTHASE KINASE 3 BETA.
265, d4accB_, 0.8971, 2.10, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
266, d5hlnA_, 0.8970, 2.10, 0.323, 346, 285, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
267, d3pupB_, 0.8969, 2.07, 0.324, 347, 284, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
268, d4nm5A1, 0.8968, 2.14, 0.323, 360, 285, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
269, d3pupA_, 0.8968, 2.07, 0.324, 346, 284, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
270, d3bhuC1, 0.8967, 0.88, 1.000, 269, 269, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
271, d1o9uA_, 0.8966, 2.11, 0.323, 349, 285, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
272, d4ic7D_, 0.8965, 2.07, 0.394, 353, 284, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
273, d5hq0A1, 0.8963, 2.12, 0.658, 289, 284, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
274, d4y72A1, 0.8963, 2.12, 0.658, 289, 284, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
275, d5f94A_, 0.8962, 2.11, 0.323, 346, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
276, d4ptcA_, 0.8960, 2.11, 0.323, 342, 285, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
277, d3pxzA1, 0.8960, 2.26, 0.968, 298, 284, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
278, d2jldB_, 0.8960, 2.20, 0.323, 349, 285, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
279, d5f94B_, 0.8959, 2.12, 0.323, 349, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
280, p3zu7A_, 0.8959, 2.13, 0.372, 344, 285, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
281, d1h4lB_, 0.8957, 1.44, 0.596, 278, 275, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
282, d3sayB_, 0.8956, 2.13, 0.323, 347, 285, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
283, d2jldA_, 0.8956, 2.09, 0.324, 349, 284, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
284, d3pxfA1, 0.8954, 2.37, 0.972, 298, 285, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
285, d1r0eB_, 0.8953, 2.12, 0.323, 344, 285, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
286, d4nm7A1, 0.8952, 2.14, 0.323, 354, 285, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
287, d3sayA_, 0.8952, 2.04, 0.325, 347, 283, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
288, d3m1sB_, 0.8951, 2.24, 0.323, 349, 285, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
289, d4bcoC1, 0.8950, 0.84, 1.000, 268, 268, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
290, d5lqfA1, 0.8948, 2.00, 0.667, 284, 282, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
291, d1r0eA_, 0.8945, 2.13, 0.323, 344, 285, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
292, d1h4lA_, 0.8944, 1.46, 0.596, 278, 275, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
293, d4ptcB_, 0.8942, 2.15, 0.323, 347, 285, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
294, d4pteB_, 0.8941, 2.16, 0.323, 347, 285, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
295, d4ez7A1, 0.8941, 2.17, 0.979, 298, 283, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
296, d3zrkB_, 0.8940, 2.25, 0.322, 348, 286, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
297, d4eorC1, 0.8939, 0.96, 0.959, 269, 269, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
298, d2o5kA1, 0.8936, 2.33, 0.321, 350, 287, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
299, d5hlnB_, 0.8934, 2.16, 0.323, 346, 285, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
300, d4pteA_, 0.8933, 2.04, 0.325, 341, 283, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
301, d3sd0B_, 0.8933, 2.18, 0.323, 349, 285, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
302, d3m1sA_, 0.8932, 2.09, 0.325, 348, 283, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
303, d3qyiA_, 0.8931, 2.11, 0.380, 346, 284,  
304, d2gphA_, 0.8929, 2.19, 0.375, 345, 285, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
305, d1q5kA_, 0.8924, 2.05, 0.330, 345, 282, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
306, d3sd0A_, 0.8921, 2.19, 0.323, 350, 285, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
307, d3zrlB_, 0.8917, 2.29, 0.322, 347, 286, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
308, d4bcpC1, 0.8916, 0.69, 1.000, 266, 266, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
309, d1uv5A_, 0.8915, 2.21, 0.326, 348, 285, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
310, d3erkA_, 0.8914, 2.16, 0.372, 350, 285, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
311, d5f95A_, 0.8912, 2.03, 0.330, 345, 282, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
312, d4j71A_, 0.8912, 2.19, 0.323, 347, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
313, d2ojjA_, 0.8912, 2.22, 0.368, 344, 285, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
314, d1pyxA_, 0.8912, 1.98, 0.331, 343, 281, GSK-3 BETA COMPLEXED WITH AMP-PNP
315, d4iz5A_, 0.8910, 2.03, 0.375, 347, 283, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
316, d4iz5D_, 0.8909, 2.03, 0.375, 347, 283, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
317, d4iz5B_, 0.8909, 2.03, 0.375, 347, 283, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
318, d3zrmB_, 0.8909, 2.30, 0.322, 347, 286, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
319, d4iz5C_, 0.8908, 2.03, 0.375, 347, 283, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
320, d5nhlA_, 0.8906, 2.22, 0.375, 345, 285, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
321, d4iz7A_, 0.8906, 2.10, 0.375, 344, 283, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
322, d2ojiA_, 0.8905, 2.21, 0.368, 344, 285, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
323, d4cfmC1, 0.8900, 0.64, 1.000, 265, 265, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
324, d3my5C1, 0.8900, 0.63, 1.000, 265, 265, CDK2/CYCLINA IN COMPLEX WITH DRB
325, d5hd7A_, 0.8899, 2.22, 0.372, 347, 285, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
326, d1unhB_, 0.8898, 1.41, 0.590, 276, 273, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
327, d5nhpA_, 0.8897, 2.24, 0.375, 338, 285, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
328, d3f88A_, 0.8897, 2.12, 0.325, 340, 283, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
329, d5lqfD1, 0.8896, 1.92, 0.664, 282, 280, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
330, d2iw9C2, 0.8896, 0.90, 0.996, 267, 267, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
331, d3f88B_, 0.8894, 2.15, 0.325, 340, 283, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
332, d5byyA_, 0.8892, 1.98, 0.389, 338, 280, ERK5 IN COMPLEX WITH SMALL MOLECULE
333, d5nhvA_, 0.8890, 2.23, 0.375, 345, 285, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
334, d4xrlA_, 0.8890, 2.17, 0.373, 337, 284, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
335, d3q3bB_, 0.8890, 1.96, 0.332, 341, 280, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
336, d3q3bA_, 0.8890, 2.03, 0.331, 344, 281, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
337, d1erkA_, 0.8890, 2.16, 0.377, 357, 284, STRUCTURE OF SIGNAL-REGULATED KINASE
338, d4izaA_, 0.8888, 2.20, 0.377, 346, 284, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
339, d4s34A_, 0.8887, 2.22, 0.372, 343, 285, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
340, p6g93A_, 0.8886, 2.09, 0.371, 343, 283, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
341, d5ke0A_, 0.8886, 2.26, 0.375, 340, 285, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
342, d4erkA_, 0.8886, 2.22, 0.372, 350, 285, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
343, d1h26C1, 0.8886, 0.80, 1.000, 266, 266, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
344, d1unhA_, 0.8884, 1.45, 0.593, 276, 273, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
345, d5byzA_, 0.8882, 2.10, 0.397, 348, 282, ERK5 IN COMPLEX WITH SMALL MOLECULE
346, p6gdqA_, 0.8881, 2.22, 0.373, 339, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
347, d4qteA_, 0.8881, 2.27, 0.372, 348, 285, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
348, d4fv3A_, 0.8881, 2.23, 0.373, 346, 284, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
349, d3zrkA_, 0.8881, 2.18, 0.320, 345, 284, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
350, d4s2zA_, 0.8880, 2.24, 0.372, 346, 285, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
351, d4qyyA_, 0.8880, 2.26, 0.375, 337, 285, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
352, d2ojgA_, 0.8880, 2.26, 0.368, 337, 285, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
353, d5nhfA_, 0.8879, 2.20, 0.373, 339, 284, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
354, d4qtbA_, 0.8879, 2.24, 0.379, 351, 285, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
355, d1golA_, 0.8879, 2.18, 0.373, 357, 284, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
356, d4fv2A_, 0.8878, 2.22, 0.373, 344, 284, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
357, d4s33A_, 0.8874, 2.26, 0.372, 347, 285, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
358, d1pyxB_, 0.8874, 1.97, 0.333, 338, 279, GSK-3 BETA COMPLEXED WITH AMP-PNP
359, d4j71B_, 0.8872, 2.23, 0.323, 347, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
360, p6g9aA_, 0.8870, 2.13, 0.371, 341, 283, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
361, d1q3wB_, 0.8870, 2.00, 0.332, 341, 280, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
362, d4zzmA_, 0.8869, 2.19, 0.373, 344, 284, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
363, d4gt3A_, 0.8869, 2.20, 0.373, 347, 284, ATP-BOUND FORM OF THE ERK2 KINASE
364, d5nhhA_, 0.8868, 2.28, 0.375, 348, 285, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
365, d5hd4A_, 0.8868, 2.27, 0.375, 347, 285, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
366, d5nhoA_, 0.8867, 2.22, 0.380, 343, 284, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
367, d5umoA_, 0.8864, 2.25, 0.372, 347, 285, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
368, d3zrlA_, 0.8862, 2.21, 0.320, 345, 284, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
369, d3gb2A_, 0.8862, 2.10, 0.333, 340, 282, GSK3BETA INHIBITOR COMPLEX
370, d4un0D_, 0.8861, 1.52, 0.442, 276, 274, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
371, d3du8A_, 0.8861, 1.97, 0.333, 336, 279, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
372, p6g9hA_, 0.8860, 2.23, 0.373, 343, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
373, p6g8xA_, 0.8860, 2.22, 0.373, 338, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
374, d4fuxA_, 0.8860, 2.21, 0.373, 342, 284, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
375, d1q3dB_, 0.8860, 2.09, 0.332, 339, 280, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
376, d4g6nA_, 0.8859, 2.22, 0.370, 341, 284, CRYSTAL STRUCTURE OF THE ERK2
377, p6g9mA_, 0.8858, 2.24, 0.373, 341, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
378, d4s31A_, 0.8858, 2.27, 0.372, 347, 285, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
379, d4zzoA_, 0.8856, 2.20, 0.377, 339, 284, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
380, d3zrmA_, 0.8855, 2.22, 0.320, 344, 284, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
381, p6g91A_, 0.8853, 2.23, 0.373, 344, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
382, d4s32A_, 0.8853, 2.28, 0.372, 346, 285, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
383, d3du8B_, 0.8853, 1.99, 0.333, 339, 279, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
384, d2ow3B_, 0.8851, 2.32, 0.323, 351, 285, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
385, d4qtbB_, 0.8850, 2.29, 0.379, 348, 285, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
386, d5nguA_, 0.8849, 2.24, 0.377, 339, 284, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
387, d2wmbC1, 0.8849, 0.80, 1.000, 265, 265, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
388, d2pmiC_, 0.8849, 1.72, 0.564, 285, 275, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
389, d1q3wA_, 0.8848, 2.11, 0.327, 344, 281, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
390, d4s30A_, 0.8847, 2.24, 0.370, 342, 284, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
391, d4j1rC_, 0.8847, 2.32, 0.323, 344, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
392, d3pxqA1, 0.8846, 2.18, 0.996, 294, 280, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
393, d1i09B_, 0.8846, 2.04, 0.332, 341, 280, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
394, d4j1rD_, 0.8845, 2.32, 0.323, 345, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
395, d4mygA_, 0.8844, 2.17, 0.388, 335, 281, MAPK13 ACTIVE FORM
396, d4j1rA_, 0.8844, 2.32, 0.323, 343, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
397, d4fv1A_, 0.8844, 2.27, 0.373, 342, 284, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
398, d3r63A_, 0.8844, 2.28, 0.372, 347, 285, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
399, d2ow3A_, 0.8844, 2.32, 0.326, 346, 285, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
400, d4xj0A_, 0.8843, 2.20, 0.375, 345, 283, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
401, p6g9dA_, 0.8842, 2.25, 0.373, 345, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
402, d4cfvC1, 0.8841, 0.59, 0.996, 263, 263, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
403, p6g9nA_, 0.8840, 2.27, 0.373, 344, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
404, d4nifB_, 0.8840, 2.13, 0.372, 349, 282, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
405, d4gvaA_, 0.8840, 2.21, 0.373, 345, 284, ADP-BOUND FORM OF THE ERK2 KINASE
406, d1ykrA_, 0.8840, 2.47, 0.990, 298, 288, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
407, d4nifE_, 0.8839, 2.13, 0.372, 348, 282, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
408, p6g97A_, 0.8837, 2.18, 0.371, 344, 283, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
409, d4afjB_, 0.8837, 2.20, 0.326, 346, 282, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
410, p4h3qA_, 0.8836, 2.27, 0.377, 352, 284, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
411, d3dogC1, 0.8836, 0.87, 0.996, 266, 265, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
412, d4zznA_, 0.8835, 2.24, 0.373, 338, 284, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
413, p6g92A_, 0.8834, 2.25, 0.370, 343, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
414, d5nhjA_, 0.8834, 2.22, 0.373, 345, 284, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
415, d1tvoA_, 0.8834, 2.30, 0.368, 350, 285, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
416, p4fmqA_, 0.8833, 2.27, 0.378, 350, 283, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
417, d3qyzA_, 0.8833, 2.25, 0.373, 339, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
418, d4xozA_, 0.8832, 2.22, 0.373, 341, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
419, p5o7iA_, 0.8831, 2.05, 0.400, 340, 280, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
420, d3f7zB1, 0.8830, 2.12, 0.324, 338, 281, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
421, d5hlpA_, 0.8828, 2.14, 0.331, 337, 281, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
422, d4qnyB_, 0.8826, 2.32, 0.320, 339, 284, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
423, d5lcjA_, 0.8825, 2.26, 0.373, 345, 284, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
424, d3nizA1, 0.8825, 2.33, 0.605, 284, 281, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
425, d2zoqA_, 0.8825, 2.26, 0.387, 351, 284, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
426, p6ge0A_, 0.8824, 2.24, 0.375, 343, 283, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
427, d4qp1A_, 0.8824, 2.29, 0.373, 342, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
428, d2z7lA_, 0.8822, 2.19, 0.369, 329, 282, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
429, d1q3dA_, 0.8820, 2.06, 0.333, 339, 279, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
430, d3qywA_, 0.8819, 2.26, 0.377, 340, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
431, d4qpaB_, 0.8818, 2.24, 0.378, 345, 283, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
432, d5u6iA_, 0.8817, 2.22, 0.367, 339, 283, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
433, d4xneA_, 0.8817, 2.21, 0.375, 344, 283, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
434, d2b53A_, 0.8816, 2.40, 0.965, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
435, d4xrjA_, 0.8812, 2.21, 0.375, 344, 283, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
436, d2wmaC1, 0.8812, 0.81, 0.992, 264, 264, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
437, d3py3A1, 0.8811, 1.92, 0.381, 352, 278, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
438, d4j1rB_, 0.8810, 2.25, 0.329, 346, 283, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
439, d1xo2B_, 0.8810, 2.06, 0.488, 289, 283, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
440, d4qp1B_, 0.8809, 2.24, 0.371, 343, 283, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
441, d4zsjA_, 0.8808, 2.31, 0.397, 344, 282, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
442, d4g6oA_, 0.8808, 2.19, 0.374, 339, 281, CRYSTAL STRUCTURE OF THE ERK2
443, d4afjA_, 0.8808, 2.15, 0.324, 342, 281, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
444, d3ddqC1, 0.8806, 0.86, 0.992, 265, 264, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
445, d1q4lA_, 0.8806, 1.99, 0.335, 342, 278, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
446, d1oiuC1, 0.8806, 0.87, 1.000, 264, 264, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
447, d4kd1A_, 0.8804, 2.55, 0.990, 298, 288, CDK2 IN COMPLEX WITH DINACICLIB
448, d2zoqB_, 0.8803, 2.27, 0.380, 351, 284, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
449, d1q41A_, 0.8801, 2.00, 0.335, 339, 278, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
450, d4xp3A_, 0.8799, 2.31, 0.373, 339, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
451, d4xp2A_, 0.8797, 2.32, 0.373, 337, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
452, d4iz7C_, 0.8797, 2.17, 0.379, 340, 280, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
453, d4iq6B_, 0.8797, 1.98, 0.336, 332, 277, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
454, d4zsgA_, 0.8796, 2.32, 0.390, 347, 282, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
455, d1pmeA_, 0.8795, 2.18, 0.370, 333, 281, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
456, d2b54A_, 0.8792, 2.76, 0.972, 298, 288, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
457, d4fv0A_, 0.8791, 2.20, 0.372, 341, 282, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
458, d2f49A_, 0.8791, 2.17, 0.389, 335, 280, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
459, d5lmkC1, 0.8790, 0.91, 1.000, 264, 264, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
460, d5lckA_, 0.8789, 2.27, 0.375, 345, 283, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
461, d4ptgA_, 0.8789, 1.98, 0.339, 333, 277, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
462, d1wzyA_, 0.8787, 2.35, 0.372, 350, 285, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
463, p6g9jA_, 0.8784, 2.25, 0.376, 347, 282, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
464, p4h3pA_, 0.8782, 2.29, 0.379, 342, 282, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
465, p6gdmA_, 0.8781, 2.23, 0.372, 341, 282, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
466, d1buhA_, 0.8781, 2.18, 0.964, 287, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
467, d2pmiA_, 0.8780, 1.73, 0.560, 284, 273, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
468, d1q5kB_, 0.8777, 2.11, 0.337, 344, 279, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
469, d4qnyA_, 0.8776, 2.34, 0.322, 333, 283, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
470, d4zslA_, 0.8774, 2.31, 0.399, 341, 281, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
471, d3r83A_, 0.8773, 2.41, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
472, d4mygB_, 0.8770, 2.05, 0.391, 335, 279, MAPK13 ACTIVE FORM
473, d3sa0A_, 0.8768, 2.33, 0.371, 354, 283, COMPLEX OF ERK2 WITH NORATHYRIOL
474, d4fv7A_, 0.8767, 2.23, 0.372, 342, 282, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
475, d2iw8C2, 0.8767, 0.97, 0.989, 264, 264, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
476, d3qqlA_, 0.8765, 2.40, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L3
477, d4cjyD_, 0.8764, 1.45, 0.441, 272, 270,  
478, d5aneA_, 0.8763, 2.41, 0.989, 294, 284, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
479, d2fa2A_, 0.8763, 2.21, 0.389, 333, 280, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
480, d4gcjA1, 0.8762, 2.43, 1.000, 298, 285, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
481, d4zxtA_, 0.8761, 2.34, 0.371, 348, 283, COMPLEX OF ERK2 WITH CATECHOL
482, d3f7zA1, 0.8761, 2.09, 0.324, 338, 278, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
483, d1gngA_, 0.8761, 2.45, 0.323, 348, 285, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
484, d4n0sA_, 0.8757, 2.27, 0.372, 348, 282, COMPLEX OF ERK2 WITH CAFFEIC ACID
485, p5nzzG_, 0.8756, 2.18, 0.372, 342, 277, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
486, d3juhA_, 0.8756, 2.41, 0.306, 334, 284, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
487, d5anjA_, 0.8755, 2.60, 0.986, 291, 286, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
488, d3r8pA_, 0.8755, 2.40, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
489, d2f49B_, 0.8755, 2.22, 0.389, 337, 280, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
490, d5hlpB_, 0.8750, 2.12, 0.331, 335, 278, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
491, p5nzzE_, 0.8749, 2.04, 0.373, 343, 276, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
492, d4qp3A_, 0.8748, 2.16, 0.380, 339, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
493, d5m4cA_, 0.8747, 2.31, 0.301, 329, 282, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
494, d3h30A_, 0.8747, 2.34, 0.300, 333, 283, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
495, d3bw5A_, 0.8747, 2.42, 0.306, 334, 284,  
496, d2jd5B_, 0.8747, 2.18, 0.306, 360, 281, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
497, d1jwhA_, 0.8746, 2.18, 0.299, 336, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
498, d1pw2A_, 0.8745, 2.45, 0.989, 294, 284, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
499, d1ymiA_, 0.8744, 2.43, 0.306, 334, 284,  
500, d3pj8A1, 0.8743, 2.41, 0.993, 287, 283, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
501, d3o71A_, 0.8741, 2.24, 0.374, 340, 281, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
502, d4lynA_, 0.8739, 2.59, 0.996, 287, 285, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
503, d4gsbA_, 0.8739, 2.18, 0.371, 343, 280, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
504, d2b9iA_, 0.8738, 2.21, 0.389, 338, 280, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
505, d1q99B_, 0.8738, 2.20, 0.302, 364, 281, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
506, d3nszA_, 0.8737, 2.17, 0.300, 327, 280, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
507, d2exmA_, 0.8735, 2.69, 0.990, 298, 287, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
508, d4xp0A_, 0.8734, 2.32, 0.379, 336, 282, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
509, d4qp6A_, 0.8734, 2.10, 0.381, 339, 278, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
510, d4b99A_, 0.8734, 2.10, 0.399, 335, 276, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
511, p3teiA_, 0.8732, 2.23, 0.376, 339, 279, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
512, d1q97B_, 0.8732, 2.21, 0.306, 361, 281, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
513, d1q8zB_, 0.8730, 2.20, 0.302, 364, 281, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
514, d4qp2A_, 0.8729, 2.11, 0.381, 336, 278, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
515, d3py1A1, 0.8729, 2.55, 1.000, 298, 285, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
516, d2clxA_, 0.8729, 2.41, 0.989, 293, 283, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
517, d1hckA_, 0.8729, 2.48, 0.989, 294, 284, HUMAN CYCLIN-DEPENDENT KINASE 2
518, d2fa2B_, 0.8728, 2.26, 0.389, 332, 280, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
519, d4n4sA_, 0.8727, 2.18, 0.381, 342, 281, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
520, d3w8lA_, 0.8727, 2.25, 0.302, 326, 281, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
521, d3juhB_, 0.8727, 2.46, 0.306, 334, 284, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
522, d3c9wA2, 0.8727, 2.05, 0.384, 335, 276, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
523, p5nzzF_, 0.8726, 2.02, 0.375, 341, 275, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
524, d2rkpA_, 0.8726, 2.44, 0.299, 334, 284,  
525, d1hclA_, 0.8725, 2.49, 0.989, 294, 284, HUMAN CYCLIN-DEPENDENT KINASE 2
526, d1v0oA_, 0.8724, 1.88, 0.610, 276, 272, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
527, d3r7yA_, 0.8723, 2.48, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
528, d4qtaA_, 0.8721, 2.00, 0.382, 335, 275, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
529, d3c9wB2, 0.8719, 2.06, 0.384, 335, 276, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
530, d3r71A_, 0.8716, 2.49, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
531, d3rm6A_, 0.8715, 2.45, 0.972, 293, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
532, d2fysA_, 0.8714, 2.33, 0.372, 348, 282, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
533, d5nqcA_, 0.8713, 2.39, 0.300, 331, 283, CK2ALPHA IN COMPLEX WITH NMR154
534, d3qx2A_, 0.8713, 2.47, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
535, d5k5nA_, 0.8712, 2.09, 0.332, 331, 277, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
536, d3rpoA_, 0.8712, 2.49, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
537, d1wccA_, 0.8710, 2.32, 0.996, 283, 281, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
538, d1q4lB_, 0.8710, 2.08, 0.326, 337, 276, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
539, p4md9P_, 0.8709, 2.40, 0.298, 328, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
540, d4dglC_, 0.8707, 2.25, 0.292, 334, 281, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
541, d4erwA_, 0.8706, 2.46, 0.986, 292, 282, CDK2 IN COMPLEX WITH STAUROSPORINE
542, d3qxoA_, 0.8706, 2.46, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
543, d2b9hA_, 0.8706, 2.21, 0.387, 337, 279, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
544, p6cpwA_, 0.8704, 2.30, 0.379, 328, 280, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
545, d1pxjA_, 0.8704, 2.51, 0.989, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
546, d4qp8B_, 0.8703, 2.14, 0.383, 337, 277, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
547, d4izaC_, 0.8703, 2.05, 0.380, 335, 276, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
548, d2b9jA_, 0.8703, 2.22, 0.391, 337, 279, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
549, d2a0cX_, 0.8702, 2.47, 0.989, 294, 284, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
550, d3kxhA_, 0.8701, 2.37, 0.301, 326, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
551, d4qp2B_, 0.8700, 2.00, 0.389, 329, 275, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
552, d3lfnA_, 0.8700, 2.25, 1.000, 285, 280, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
553, d2ds1A_, 0.8699, 2.37, 0.932, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
554, d4o6eA_, 0.8697, 2.08, 0.382, 328, 275, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
555, d3qtwA_, 0.8697, 2.45, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
556, d2jd5A_, 0.8697, 2.18, 0.305, 353, 279, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
557, d5xvuA_, 0.8696, 2.20, 0.315, 321, 279, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
558, d2oxyA_, 0.8696, 2.37, 0.306, 327, 281, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
559, d3r1qA_, 0.8695, 2.44, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
560, d1q8zA_, 0.8694, 2.23, 0.300, 354, 280, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
561, p4h3pD_, 0.8693, 2.22, 0.381, 338, 278, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
562, d3qx4A_, 0.8693, 2.46, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
563, d1q99A_, 0.8693, 2.23, 0.300, 354, 280, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
564, d1q97A_, 0.8692, 2.13, 0.306, 351, 278, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
565, d1gngB_, 0.8692, 2.50, 0.323, 355, 285, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
566, d3r6xA_, 0.8689, 2.49, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
567, d1pxoA_, 0.8689, 2.58, 0.989, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
568, d1oirA_, 0.8689, 2.22, 0.968, 286, 278, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
569, d1j91B_, 0.8689, 2.49, 0.300, 327, 283, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
570, d3raiA_, 0.8688, 2.50, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
571, d3r7vA_, 0.8688, 2.48, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
572, d1pxiA_, 0.8688, 2.53, 0.989, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
573, d3pxrA_, 0.8687, 2.49, 0.989, 294, 284, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
574, d3qzhA_, 0.8685, 2.47, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
575, d5xvuB_, 0.8684, 2.22, 0.315, 321, 279, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
576, d4grbA_, 0.8684, 2.26, 0.300, 327, 280, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
577, d5xvuC_, 0.8683, 2.26, 0.307, 321, 280, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
578, p4md9K_, 0.8682, 2.41, 0.298, 328, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
579, d4fuyA_, 0.8682, 2.15, 0.379, 329, 277, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
580, d3qwjA_, 0.8682, 2.47, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
581, d2zjwA_, 0.8682, 2.32, 0.302, 332, 281, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
582, d5n1vA_, 0.8681, 2.45, 0.301, 331, 282, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
583, p4md9E_, 0.8681, 2.42, 0.298, 329, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
584, d2oxyB_, 0.8681, 2.41, 0.298, 327, 282, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
585, d2c5yA_, 0.8681, 2.39, 0.989, 290, 281, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
586, d3r73A_, 0.8680, 2.48, 0.951, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
587, d3qwkA_, 0.8680, 2.48, 0.989, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
588, d4qp4A_, 0.8679, 2.25, 0.381, 337, 278, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
589, d5m4fA_, 0.8678, 2.42, 0.301, 330, 282, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
590, d4qp9A_, 0.8678, 2.09, 0.380, 335, 276, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
591, d4qp7A_, 0.8678, 2.18, 0.379, 337, 277, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
592, d5b0xA_, 0.8677, 2.43, 0.301, 329, 282, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
593, d3r28A_, 0.8676, 2.60, 0.944, 294, 285, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
594, d3qziA_, 0.8676, 2.48, 0.979, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
595, d2xnbA_, 0.8676, 2.74, 0.990, 296, 286, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
596, p4md9G_, 0.8675, 2.33, 0.299, 329, 281, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
597, d1q8yA_, 0.8675, 2.21, 0.305, 351, 279, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
598, d1b38A_, 0.8675, 2.39, 0.971, 290, 280, HUMAN CYCLIN-DEPENDENT KINASE 2
599, d5n1vB_, 0.8674, 2.45, 0.301, 331, 282, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
600, d4xj0B_, 0.8674, 2.20, 0.381, 338, 278, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
601, d3royA_, 0.8674, 2.49, 0.951, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
602, d3r1yA_, 0.8674, 2.54, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
603, d3r1sA_, 0.8674, 2.51, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
604, d5clpB_, 0.8671, 2.32, 0.302, 327, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
605, p4md9L_, 0.8670, 2.47, 0.298, 328, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
606, d3ofmA_, 0.8670, 2.44, 0.306, 325, 281, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
607, p5ooiA_, 0.8669, 2.45, 0.301, 329, 282, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
608, d3r7eA_, 0.8669, 2.53, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
609, d2fysB_, 0.8669, 2.40, 0.381, 338, 281, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
610, d3tiyA_, 0.8668, 2.49, 0.982, 293, 283, CDK2 IN COMPLEX WITH NSC 35676
611, p2no3A_, 0.8668, 2.26, 0.364, 357, 280, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
612, d1h0uA_, 0.8668, 2.42, 0.943, 291, 281,  
613, d5mmrA_, 0.8667, 2.26, 0.300, 326, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
614, d3rniA_, 0.8667, 2.63, 0.982, 294, 285, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
615, d3qzfA_, 0.8667, 2.55, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
616, d3lfqA_, 0.8667, 2.28, 0.968, 289, 279, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
617, d1ds5B_, 0.8667, 2.44, 0.301, 328, 282, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
618, d3ns9A_, 0.8666, 2.32, 0.986, 289, 279, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
619, d2xmyA_, 0.8666, 2.61, 0.982, 295, 285, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
620, d1aq1A_, 0.8666, 1.89, 0.971, 277, 273, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
621, d5cx9A_, 0.8665, 2.36, 0.302, 328, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
622, d3lfsA_, 0.8665, 2.36, 0.964, 290, 280, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
623, d5modA_, 0.8663, 2.28, 0.300, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
624, d5ctpB_, 0.8663, 2.35, 0.302, 327, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
625, d5ct0A_, 0.8663, 2.26, 0.296, 326, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
626, d4au8B_, 0.8663, 2.04, 0.600, 277, 275, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
627, d3wikA_, 0.8663, 2.28, 0.307, 334, 280, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
628, p4looA_, 0.8662, 2.19, 0.383, 349, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
629, d3qrtA_, 0.8662, 2.47, 0.940, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
630, d2eufB_, 0.8662, 1.89, 0.505, 282, 273, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
631, d2b9fA_, 0.8662, 2.40, 0.389, 337, 280, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
632, d5cu2A_, 0.8660, 2.35, 0.302, 328, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
633, d4qp3B_, 0.8660, 2.13, 0.388, 331, 276, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
634, d3rk9A_, 0.8660, 2.55, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
635, d3h30B_, 0.8660, 2.46, 0.300, 333, 283, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
636, d1j91A_, 0.8660, 2.46, 0.306, 327, 281, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
637, d5csvA_, 0.8659, 2.33, 0.304, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
638, p4md8G_, 0.8659, 2.48, 0.298, 332, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
639, d3fwqB_, 0.8659, 2.54, 0.299, 334, 284, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
640, d1howA_, 0.8659, 2.32, 0.307, 346, 280, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
641, d4qp6B_, 0.8657, 2.15, 0.388, 334, 276, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
642, d3rm7A_, 0.8657, 2.57, 0.986, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
643, d1pjkA_, 0.8657, 2.36, 0.299, 331, 281, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
644, d5mp8A_, 0.8656, 2.24, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
645, d5cu0A_, 0.8656, 2.27, 0.300, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
646, d4qpaA_, 0.8656, 2.16, 0.384, 331, 276, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
647, d2vtoA_, 0.8656, 2.25, 0.982, 283, 278, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
648, p4md9F_, 0.8655, 2.36, 0.299, 327, 281, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
649, p4md8E_, 0.8655, 2.48, 0.298, 332, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
650, d3uliA_, 0.8655, 2.39, 0.975, 286, 281, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
651, d5mmfA_, 0.8654, 2.28, 0.300, 326, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
652, d4rj3A_, 0.8654, 2.31, 0.964, 287, 279, CDK2 WITH EGFR INHIBITOR COMPOUND 8
653, d3rkbA_, 0.8654, 2.55, 0.989, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
654, d3qqfA_, 0.8654, 2.58, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L1
655, d3q9wA_, 0.8653, 2.43, 0.306, 328, 281, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
656, d5jq5A_, 0.8652, 2.21, 0.964, 287, 277, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
657, d5cu4A_, 0.8652, 2.35, 0.311, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
658, d3rk7A_, 0.8652, 2.57, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
659, p5oulA_, 0.8651, 2.39, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
660, d5k5nB_, 0.8651, 2.17, 0.331, 334, 275, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
661, d5cspA_, 0.8651, 2.33, 0.304, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
662, d4ez3A_, 0.8651, 2.65, 0.986, 294, 284, CDK2 IN COMPLEX WITH NSC 134199
663, d3rk5A_, 0.8651, 2.58, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
664, d2r3fA_, 0.8650, 2.41, 0.943, 290, 280, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
665, d1h01A_, 0.8650, 2.27, 0.968, 286, 278, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
666, p4md8H_, 0.8649, 2.49, 0.298, 331, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
667, d4fklA_, 0.8649, 2.42, 0.943, 290, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
668, d4ek3A_, 0.8649, 2.38, 0.961, 287, 279, CRYSTAL STRUCTURE OF APO CDK2
669, d3q9yA_, 0.8649, 2.38, 0.302, 327, 281, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
670, d1na7A_, 0.8649, 2.35, 0.299, 326, 281, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
671, d3c13A_, 0.8648, 2.44, 0.306, 328, 281, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
672, d1h07A_, 0.8648, 2.36, 0.975, 285, 279, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
673, d1ds5C_, 0.8648, 2.46, 0.301, 328, 282, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
674, p4md9M_, 0.8647, 2.49, 0.298, 331, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
675, d4ek4A_, 0.8647, 2.37, 0.946, 287, 279, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
676, d3owjA_, 0.8647, 2.50, 0.298, 328, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
677, d2vtmA_, 0.8647, 2.40, 0.975, 290, 280, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
678, d5mo8A_, 0.8646, 2.30, 0.300, 325, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
679, d4rllA_, 0.8646, 2.48, 0.298, 329, 282, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
680, d3owlA_, 0.8646, 2.47, 0.294, 330, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
681, d3bqcA_, 0.8646, 2.45, 0.306, 328, 281, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
682, d2f2cB_, 0.8646, 1.79, 0.494, 280, 271, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
683, d2b52A_, 0.8646, 2.22, 0.986, 283, 278, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
684, d4md7H_, 0.8645, 2.43, 0.306, 330, 281, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
685, p4ib5C_, 0.8645, 2.51, 0.298, 332, 282, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
686, d4anmA1, 0.8645, 2.46, 0.301, 327, 282, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
687, d3wblA_, 0.8645, 2.30, 0.993, 283, 279, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
688, d2c6lA_, 0.8645, 2.50, 0.957, 291, 281, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
689, d1h0vA_, 0.8645, 2.44, 0.961, 288, 281, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
690, p4nh1B_, 0.8644, 2.48, 0.301, 332, 282, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
691, d1zoeA_, 0.8644, 2.47, 0.298, 325, 282, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
692, d1gz8A_, 0.8644, 2.40, 0.989, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
693, p4nh1A_, 0.8643, 2.49, 0.301, 330, 282, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
694, d1pxpA_, 0.8642, 2.59, 0.989, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
695, d1lp4A_, 0.8642, 2.45, 0.301, 327, 282, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
696, d5motA_, 0.8641, 2.35, 0.304, 328, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
697, d5mmrB_, 0.8641, 2.25, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
698, d5cvhA_, 0.8641, 2.35, 0.296, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA
699, d4md7G_, 0.8641, 2.44, 0.306, 332, 281, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
700, d3wowA_, 0.8641, 2.33, 0.299, 334, 281, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
701, d3wilA_, 0.8641, 2.37, 0.302, 331, 281, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
702, d3r9dA_, 0.8641, 2.62, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
703, d1dayA_, 0.8641, 2.43, 0.310, 327, 281, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
704, p5oo0A_, 0.8640, 2.38, 0.982, 288, 280, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
705, d3qxpA_, 0.8640, 2.46, 0.979, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
706, d3qu0A_, 0.8640, 2.57, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
707, d2vtlA_, 0.8640, 2.40, 0.961, 290, 280, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
708, d5moeA_, 0.8639, 2.28, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
709, d3axwA_, 0.8639, 2.50, 0.301, 329, 282, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
710, d5mo7A_, 0.8638, 2.31, 0.300, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
711, d4md7E_, 0.8638, 2.49, 0.301, 332, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
712, p2gmxA_, 0.8638, 2.26, 0.358, 357, 279, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
713, d1ckpA_, 0.8638, 2.22, 0.968, 279, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
714, p5otzA_, 0.8637, 2.40, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
715, d5cu0B_, 0.8637, 2.31, 0.296, 325, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
716, d3kxnA_, 0.8637, 2.45, 0.301, 327, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
717, d1lr4A_, 0.8637, 2.47, 0.301, 327, 282, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
718, d5mpjA_, 0.8636, 2.36, 0.300, 326, 280, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
719, p4md8F_, 0.8636, 2.50, 0.298, 332, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
720, p5os8A_, 0.8635, 2.40, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
721, d1ds5A_, 0.8635, 2.47, 0.301, 328, 282, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
722, d5cquA_, 0.8634, 2.39, 0.299, 328, 281, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
723, d4ek5A_, 0.8634, 2.35, 0.978, 289, 279, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
724, d2a4lA_, 0.8634, 2.27, 0.957, 286, 276, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
725, d5mo5A_, 0.8633, 2.27, 0.301, 326, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
726, d3r8zA_, 0.8633, 2.46, 0.989, 290, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
727, d2r3rA_, 0.8633, 2.41, 0.961, 290, 280, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
728, d1b39A_, 0.8633, 2.45, 0.943, 290, 280, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
729, p5n9kA_, 0.8632, 2.47, 0.306, 329, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
730, d4bxbA_, 0.8632, 2.39, 0.299, 328, 281,  
731, d3qtzA_, 0.8632, 2.57, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
732, p2no3B_, 0.8632, 2.35, 0.361, 357, 280, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
733, d1dawA_, 0.8632, 2.46, 0.301, 327, 282, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
734, p4ux9A_, 0.8631, 2.21, 0.366, 343, 276, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
735, d3qruA_, 0.8631, 2.56, 0.940, 295, 285, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
736, d3mb6A_, 0.8631, 2.50, 0.306, 329, 281, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
737, d2vtsA_, 0.8631, 2.12, 0.989, 282, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
738, d1ds5D_, 0.8631, 2.48, 0.301, 328, 282, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
739, d3qtqA_, 0.8630, 2.61, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
740, d1y8yA_, 0.8630, 2.51, 0.989, 292, 282, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
741, d5t1hA_, 0.8629, 2.51, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2
742, d5mowA1, 0.8629, 2.30, 0.297, 326, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
743, d5mo7B_, 0.8629, 2.28, 0.301, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
744, d3qqkA_, 0.8629, 2.58, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L4
745, d2c69A_, 0.8629, 2.57, 0.943, 292, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
746, d3at2A_, 0.8628, 2.37, 0.299, 334, 281, CRYSTAL STRUCTURE OF CK2ALPHA
747, d2uzoA_, 0.8628, 2.51, 0.975, 290, 282, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
748, d5iexA_, 0.8627, 2.52, 0.989, 285, 282, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
749, p4ux9C_, 0.8627, 2.18, 0.364, 333, 275, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
750, p4jqeA_, 0.8627, 2.53, 0.277, 369, 282, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
751, d3rp0C_, 0.8627, 2.52, 0.298, 329, 282,  
752, d3pe2A_, 0.8627, 2.40, 0.299, 327, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
753, d2r3oA_, 0.8627, 2.36, 0.961, 289, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
754, d2r3hA_, 0.8627, 2.36, 0.964, 289, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
755, d4fkuA_, 0.8626, 2.65, 0.986, 293, 283, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
756, d3pwdA_, 0.8626, 2.49, 0.301, 327, 282, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
757, d3iggA_, 0.8626, 2.47, 0.943, 290, 280, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
758, d2qc6A_, 0.8626, 2.49, 0.301, 326, 282, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
759, d2pvrA_, 0.8626, 2.41, 0.299, 328, 281, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
760, d5modB_, 0.8625, 2.30, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
761, d3owkA_, 0.8625, 2.53, 0.298, 330, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
762, d5ievA_, 0.8624, 2.41, 0.996, 284, 280, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
763, d4fkvA_, 0.8624, 2.22, 1.000, 282, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
764, d2oxxA_, 0.8624, 2.50, 0.301, 325, 282, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
765, p3e3bX_, 0.8623, 2.47, 0.306, 334, 281, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
766, d2c6kA_, 0.8623, 2.54, 0.989, 292, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
767, d5mo6B_, 0.8622, 2.29, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
768, d4dgoA_, 0.8622, 2.49, 0.301, 325, 282, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
769, p3vudA_, 0.8622, 2.41, 0.357, 355, 280, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
770, d5h8bA_, 0.8621, 2.53, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
771, d5cu3A_, 0.8621, 2.30, 0.301, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
772, d4md7F_, 0.8621, 2.51, 0.301, 332, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
773, d3pvgA_, 0.8621, 2.50, 0.301, 326, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
774, d2v0dA_, 0.8621, 2.57, 0.957, 292, 282, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
775, d2c68A_, 0.8621, 2.56, 0.943, 290, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
776, d1y91A_, 0.8621, 2.17, 0.989, 286, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
777, d1q8yB_, 0.8621, 2.25, 0.306, 357, 278, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
778, d5mo5B_, 0.8620, 2.30, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
779, d4ubaB_, 0.8620, 2.41, 0.299, 333, 281, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
780, d3u87A_, 0.8620, 2.53, 0.301, 329, 282, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
781, d3s2pA_, 0.8620, 2.23, 0.968, 279, 277, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
782, d3ql8A_, 0.8620, 2.60, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
783, d2oxdA_, 0.8620, 2.49, 0.301, 325, 282, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
784, d5ctpA_, 0.8619, 2.29, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
785, d4xoyA_, 0.8619, 2.24, 0.385, 326, 275, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
786, d3w55A_, 0.8619, 2.13, 0.373, 335, 276, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
787, d3kxjA_, 0.8619, 2.50, 0.301, 326, 282,  
788, d2e14A_, 0.8619, 2.13, 0.373, 335, 276,  
789, d1v0oB_, 0.8619, 1.92, 0.615, 274, 270, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
790, d1m2rA_, 0.8619, 2.53, 0.301, 327, 282, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
791, p5owlB_, 0.8618, 2.52, 0.301, 332, 282, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
792, d5mo6A_, 0.8618, 2.29, 0.301, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
793, d5mmfB_, 0.8618, 2.30, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
794, d5cshA_, 0.8618, 2.30, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
795, p3vuiA_, 0.8618, 2.33, 0.358, 355, 279, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
796, p3vuhA_, 0.8618, 2.43, 0.357, 355, 280, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
797, d3rpvA_, 0.8618, 2.60, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
798, d2w1hA_, 0.8618, 2.44, 0.957, 283, 280, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
799, p2h96A_, 0.8618, 2.34, 0.362, 358, 279, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
800, d5mohA_, 0.8617, 2.30, 0.301, 326, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
801, p3vugA_, 0.8617, 2.27, 0.363, 356, 278, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
802, d1pxlA_, 0.8617, 2.44, 0.943, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
803, p4md9H_, 0.8616, 2.51, 0.298, 328, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
804, d3rjcA_, 0.8616, 2.63, 0.986, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L4-12
805, d2c6oA_, 0.8616, 2.56, 0.943, 290, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
806, d5h8gA_, 0.8615, 2.20, 0.307, 324, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
807, d3u4uA_, 0.8615, 2.35, 0.300, 327, 280, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
808, d3pe1A_, 0.8615, 2.42, 0.299, 327, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
809, d3kxgA_, 0.8614, 2.51, 0.301, 326, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
810, d1zohA_, 0.8614, 2.50, 0.301, 326, 282, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
811, d1m2pA_, 0.8614, 2.51, 0.301, 325, 282, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
812, d3pzhA_, 0.8613, 2.50, 0.301, 327, 282, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
813, d2vtpA_, 0.8613, 2.28, 0.982, 281, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
814, d5ct0B_, 0.8612, 2.30, 0.297, 326, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
815, d3rp0B_, 0.8612, 2.53, 0.298, 329, 282,  
816, d3q04A_, 0.8612, 2.51, 0.301, 328, 282, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
817, d2vtrA_, 0.8612, 2.46, 0.946, 290, 280, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
818, d5movA_, 0.8611, 2.30, 0.306, 325, 278, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
819, d5k4jA1, 0.8611, 2.21, 1.000, 281, 277, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
820, d5ieyA_, 0.8611, 2.50, 0.993, 286, 281, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
821, d3ti1A_, 0.8611, 2.64, 0.989, 294, 284, CDK2 IN COMPLEX WITH SUNITINIB
822, d1lpuA_, 0.8610, 2.51, 0.298, 327, 282, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
823, d5cx9B_, 0.8609, 2.31, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
824, d4dgnA_, 0.8609, 2.51, 0.301, 325, 282, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
825, d3r8uA_, 0.8609, 2.64, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
826, p2pvnA_, 0.8609, 2.51, 0.298, 327, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
827, d1pf8A_, 0.8609, 2.77, 1.000, 298, 286, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
828, d1om1A_, 0.8609, 2.51, 0.301, 325, 282, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
829, p5n9nA_, 0.8608, 2.52, 0.301, 329, 282, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
830, d5cvfA_, 0.8608, 2.33, 0.301, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
831, d3r0tA_, 0.8608, 2.44, 0.299, 327, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
832, d2r3pA_, 0.8608, 2.41, 0.989, 289, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
833, p3v3vA_, 0.8607, 2.42, 0.366, 351, 279, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
834, d1h0wA_, 0.8606, 2.41, 0.975, 283, 280, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
835, d4fkiA_, 0.8605, 2.23, 0.986, 287, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
836, d2c6mA_, 0.8605, 2.60, 0.957, 290, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
837, d1cm8B_, 0.8605, 2.13, 0.366, 327, 273, PHOSPHORYLATED MAP KINASE P38-GAMMA
838, d1cm8A_, 0.8605, 2.13, 0.366, 327, 273, PHOSPHORYLATED MAP KINASE P38-GAMMA
839, d4dgmA_, 0.8604, 2.52, 0.301, 326, 282, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
840, d5buiA_, 0.8603, 2.24, 0.375, 338, 277, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
841, d4ptgB_, 0.8603, 2.01, 0.335, 332, 272, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
842, d4n4sB_, 0.8603, 2.14, 0.379, 337, 277, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
843, p3vukA_, 0.8603, 2.28, 0.363, 355, 278, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
844, d3kxmA_, 0.8603, 2.52, 0.301, 326, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
845, d2r3gA_, 0.8603, 2.34, 0.953, 287, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
846, p2pvmA_, 0.8603, 2.52, 0.298, 327, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
847, d3qtxA_, 0.8602, 2.76, 0.982, 294, 285, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
848, d5mo8B_, 0.8601, 2.33, 0.301, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
849, d5h8eA_, 0.8601, 2.55, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
850, d3rpsA_, 0.8601, 2.40, 0.304, 334, 280, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
851, d3qa0B_, 0.8601, 2.50, 0.306, 330, 281, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
852, d3i60A_, 0.8601, 2.00, 0.384, 335, 271, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
853, d3fwqA_, 0.8601, 2.70, 0.299, 334, 284, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
854, d1w8cA_, 0.8601, 2.45, 0.975, 290, 280, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
855, d1jamA_, 0.8601, 2.52, 0.301, 327, 282, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
856, p5nzzH_, 0.8600, 1.96, 0.380, 335, 271, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
857, d3q9xB_, 0.8600, 2.49, 0.306, 330, 281, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
858, d3ngaA_, 0.8600, 2.55, 0.298, 331, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
859, d1zogA_, 0.8600, 2.52, 0.301, 325, 282, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
860, d5cu6A_, 0.8599, 2.47, 0.295, 327, 281, CRYSTAL STRUCTURE OF CK2ALPHA
861, d5cu2B_, 0.8599, 2.32, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
862, d4fbxA_, 0.8599, 2.38, 0.304, 333, 280, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
863, d3fz1A_, 0.8599, 2.30, 0.982, 284, 278, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
864, p5otyA_, 0.8597, 2.47, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
865, d5f95B_, 0.8597, 2.08, 0.333, 338, 273, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
866, d5cu3B_, 0.8597, 2.34, 0.301, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
867, p2pvjA_, 0.8597, 2.53, 0.294, 326, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
868, d4bxaA_, 0.8596, 2.57, 0.298, 331, 282,  
869, d2c6iA_, 0.8596, 2.61, 0.986, 292, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
870, d1jsvA_, 0.8596, 2.31, 0.986, 287, 277, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
871, p5n9lA_, 0.8595, 2.54, 0.301, 329, 282, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
872, d5mowB_, 0.8595, 2.34, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
873, d5cqwA_, 0.8595, 2.57, 0.298, 331, 282, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
874, d4au8A1, 0.8595, 1.93, 0.598, 274, 271, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
875, d3u87B_, 0.8595, 2.57, 0.301, 329, 282, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
876, d2w17A_, 0.8594, 2.12, 0.960, 278, 275, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
877, d3r8lA_, 0.8593, 2.64, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L3-4
878, p3be9A_, 0.8593, 2.53, 0.294, 327, 282, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
879, d2r64A_, 0.8593, 2.28, 0.982, 279, 277, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
880, p2pvkA_, 0.8593, 2.53, 0.298, 327, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
881, d1e1vA_, 0.8592, 2.51, 0.943, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
882, d3r9hA_, 0.8591, 2.70, 0.986, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
883, d3mb7A_, 0.8591, 2.58, 0.298, 330, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
884, d1ungB_, 0.8591, 1.50, 0.585, 268, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
885, d5k4iA_, 0.8590, 1.98, 0.382, 336, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
886, d4kwpA_, 0.8590, 2.53, 0.298, 329, 282, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
887, d5mpjB_, 0.8589, 2.36, 0.301, 324, 279, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
888, d5cvhB_, 0.8589, 2.37, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA
889, d3s0oA_, 0.8589, 2.63, 0.936, 293, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
890, d3l1sB_, 0.8589, 2.09, 0.332, 330, 271, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
891, p3u9cA_, 0.8588, 2.53, 0.302, 331, 281, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
892, d3qa0A_, 0.8588, 2.59, 0.301, 330, 282, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
893, d2r3iA_, 0.8588, 2.44, 0.989, 289, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
894, d5kwhA_, 0.8586, 2.59, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2
895, d3s00A_, 0.8586, 2.66, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L4-14
896, d3qtuA_, 0.8586, 2.61, 0.940, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
897, d3ngaB_, 0.8586, 2.58, 0.298, 331, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
898, d2vv9A_, 0.8585, 2.19, 0.989, 279, 276, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
899, d2bhhA_, 0.8585, 1.93, 0.974, 274, 272, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
900, d5m56B_, 0.8584, 2.65, 0.305, 328, 282, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
901, d3ig7A_, 0.8584, 2.23, 0.996, 278, 276, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
902, d5m56A_, 0.8583, 2.57, 0.301, 331, 282, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
903, d5moeB_, 0.8582, 2.31, 0.295, 323, 278, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
904, d3nwwA_, 0.8582, 2.14, 0.383, 339, 274, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
905, p2pvlA_, 0.8582, 2.55, 0.298, 327, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
906, d3qqjA_, 0.8581, 2.68, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L2
907, p2pvhA_, 0.8581, 2.56, 0.294, 327, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
908, d4fkgA_, 0.8580, 2.23, 0.986, 286, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
909, d3tizA_, 0.8580, 2.60, 0.982, 293, 283, CDK2 IN COMPLEX WITH NSC 111848
910, p3o17A_, 0.8579, 2.44, 0.364, 357, 280, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
911, d3l1sA_, 0.8579, 1.97, 0.333, 336, 270, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
912, d3fl5A_, 0.8579, 2.56, 0.301, 324, 282, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
913, d5ku8A_, 0.8578, 2.55, 0.302, 328, 281, CRYSTAL STRUCTURE OF CK2
914, d1fvtA_, 0.8578, 2.34, 0.982, 282, 278, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
915, d1e1xA_, 0.8578, 2.51, 0.989, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
916, p5omyA_, 0.8577, 2.40, 0.304, 332, 280, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
917, d3rp0A_, 0.8577, 2.59, 0.301, 329, 282,  
918, d5larA_, 0.8576, 2.55, 0.379, 350, 282, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
919, d3sqqA_, 0.8576, 2.35, 0.986, 288, 279, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
920, d3warA_, 0.8574, 2.47, 0.299, 334, 281, CRYSTAL STRUCTURE OF HUMAN CK2A
921, p3u9cB_, 0.8574, 2.53, 0.306, 331, 281, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
922, d4fkwA_, 0.8572, 2.28, 1.000, 280, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
923, d5h8bB_, 0.8571, 2.60, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
924, d4qp8A_, 0.8571, 2.38, 0.383, 335, 277, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
925, d4ewqA_, 0.8570, 2.28, 0.372, 346, 274, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
926, d3at3A_, 0.8570, 2.47, 0.302, 332, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
927, d2w06A_, 0.8570, 2.38, 0.982, 282, 278, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
928, d1pxnA_, 0.8570, 2.65, 0.951, 294, 283, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
929, d5cs6A_, 0.8569, 2.54, 0.300, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
930, d5cqwB_, 0.8569, 2.60, 0.301, 331, 282, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
931, d5t1hB_, 0.8568, 2.61, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2
932, d5mhqA1, 0.8568, 2.42, 0.953, 288, 278, CCT068127 IN COMPLEX WITH CDK2
933, d4ubaA_, 0.8568, 2.47, 0.299, 333, 281, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
934, d4bxaB_, 0.8568, 2.58, 0.301, 331, 282,  
935, d2f9gA_, 0.8568, 2.23, 0.393, 332, 275, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
936, p4ux9B_, 0.8567, 2.21, 0.359, 327, 273, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
937, d3le6A_, 0.8567, 2.26, 0.960, 283, 275, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
938, d2uznA_, 0.8566, 2.16, 0.989, 279, 275, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
939, d5mp8B_, 0.8565, 2.28, 0.300, 323, 277, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
940, d5h8eB_, 0.8565, 2.62, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
941, d5m4uA_, 0.8564, 2.56, 0.302, 332, 281, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
942, d5cvgA_, 0.8563, 2.31, 0.310, 326, 277, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
943, p4fi1A_, 0.8563, 2.62, 0.277, 371, 282, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
944, d3r7iA_, 0.8563, 2.45, 0.964, 282, 279, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
945, d3at4A_, 0.8563, 2.49, 0.302, 331, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
946, d4rlkA_, 0.8562, 2.57, 0.301, 327, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
947, d3q9xA_, 0.8562, 2.61, 0.301, 330, 282, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
948, p2g01A_, 0.8562, 2.50, 0.357, 355, 280, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
949, d5ci6B_, 0.8561, 2.20, 0.361, 350, 274, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
950, p4mwhA_, 0.8561, 2.59, 0.277, 371, 282, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
951, p4lfiA_, 0.8561, 2.61, 0.277, 370, 282, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
952, d1pxkA_, 0.8561, 2.57, 0.961, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
953, d3rp0D_, 0.8560, 2.61, 0.301, 329, 282,  
954, d4qp7B_, 0.8558, 2.30, 0.384, 335, 276, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
955, p4gubA_, 0.8558, 2.51, 0.299, 329, 281, CASEIN KINASE II BOUND TO INHIBITOR
956, d2r3mA_, 0.8558, 2.09, 0.971, 278, 274, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
957, p4lfiB_, 0.8557, 2.62, 0.277, 371, 282, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
958, d4aguC_, 0.8556, 2.08, 0.397, 278, 272, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
959, d3w8lB_, 0.8556, 2.51, 0.302, 326, 281, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
960, d4qp4B_, 0.8555, 2.36, 0.383, 335, 277, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
961, d5kwhB_, 0.8554, 2.62, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2
962, d1di8A_, 0.8554, 2.42, 1.000, 283, 278, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
963, d2r3qA_, 0.8553, 2.32, 0.986, 286, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
964, d4fv6A_, 0.8552, 1.88, 0.383, 332, 269, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
965, d3qqgA_, 0.8552, 2.71, 0.986, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L2-5
966, d3r7uA_, 0.8550, 2.47, 0.964, 282, 279, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
967, d1m2qA_, 0.8550, 2.65, 0.301, 327, 282, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
968, d3rpsB_, 0.8549, 2.45, 0.304, 334, 280, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
969, d2w05A_, 0.8549, 2.13, 0.989, 276, 273, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
970, d2vtaA_, 0.8549, 2.30, 0.989, 278, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
971, p2h96B_, 0.8549, 2.54, 0.354, 357, 280, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
972, d1f0qA_, 0.8549, 2.64, 0.298, 329, 282, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
973, d3q9zB_, 0.8548, 2.58, 0.306, 332, 281, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
974, d1w0xC_, 0.8548, 2.45, 0.982, 280, 278, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
975, d4fkjA_, 0.8547, 2.18, 0.989, 278, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
976, d3unkA_, 0.8545, 2.80, 0.986, 295, 285, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
977, d3dt1A2, 0.8545, 2.44, 0.380, 352, 276, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
978, d1ke6A_, 0.8545, 2.33, 0.986, 280, 277, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
979, d3r9oA_, 0.8544, 2.52, 0.989, 282, 279, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
980, d3mvlA_, 0.8544, 2.11, 0.385, 339, 273, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
981, d1ke7A_, 0.8544, 2.45, 0.982, 281, 278, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
982, d4yc6E_, 0.8543, 2.69, 0.653, 285, 277, CDK1/CKS1
983, d4ek6A_, 0.8543, 2.14, 0.993, 278, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
984, d3hl7A_, 0.8543, 2.10, 0.386, 336, 272, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
985, d4yc6G_, 0.8542, 2.57, 0.652, 285, 276, CDK1/CKS1
986, p4ib5A_, 0.8542, 2.57, 0.306, 331, 281, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
987, d4aa4A_, 0.8542, 2.61, 0.385, 347, 278, P38ALPHA MAP KINASE BOUND TO CMPD 22
988, d5ku8B_, 0.8541, 2.64, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2
989, d3r8vA_, 0.8541, 2.79, 0.986, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
990, d2vthA_, 0.8541, 2.31, 0.989, 278, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
991, d1jwhB_, 0.8541, 2.50, 0.299, 335, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
992, d5cshB_, 0.8540, 2.30, 0.301, 323, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
993, d5aniA_, 0.8538, 2.29, 0.964, 280, 276, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
994, d4fkqA_, 0.8538, 2.51, 0.975, 283, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
995, d1dm2A_, 0.8538, 2.03, 0.967, 274, 272, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
996, d3hllA_, 0.8537, 1.99, 0.378, 337, 270, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
997, d3ezvA_, 0.8537, 2.13, 0.978, 277, 274, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
998, d2ozaB_, 0.8537, 2.36, 0.385, 340, 275, STRUCTURE OF P38ALPHA COMPLEX
999, d2j9mA_, 0.8536, 2.06, 0.982, 275, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
1000, d1jowB_, 0.8536, 1.73, 0.493, 277, 268, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1001, d1h08A_, 0.8535, 2.39, 0.996, 283, 277, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1002, p3nieA_, 0.8534, 2.65, 0.396, 369, 280, CRYSTAL STRUCTURE OF PF11_0147
1003, d5clpA_, 0.8533, 2.33, 0.304, 322, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1004, d4fv8A_, 0.8533, 1.91, 0.387, 333, 269, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
1005, p6ehuA_, 0.8532, 2.56, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1006, d1ke8A_, 0.8532, 2.41, 0.982, 282, 278, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
1007, d4yc6A_, 0.8531, 2.58, 0.652, 285, 276, CDK1/CKS1
1008, d3qzgA_, 0.8531, 2.76, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
1009, p5owlA_, 0.8530, 2.70, 0.301, 331, 282, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1010, d2vtiA_, 0.8530, 2.40, 0.982, 280, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1011, d1g5sA_, 0.8530, 2.05, 0.985, 275, 272, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
1012, d4yc6C_, 0.8529, 2.77, 0.655, 285, 278, CDK1/CKS1
1013, d3qqhA_, 0.8528, 2.73, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L2-2
1014, d3amyA_, 0.8528, 2.11, 0.305, 318, 272, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
1015, d4fkrA_, 0.8526, 2.40, 0.986, 282, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1016, d1pxmA_, 0.8526, 2.56, 0.975, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
1017, p4ib5B_, 0.8524, 2.74, 0.298, 329, 282, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1018, d4fa2A_, 0.8524, 2.04, 0.385, 339, 270, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
1019, d4f9wA_, 0.8522, 2.07, 0.384, 336, 271, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1020, d1h00A_, 0.8522, 2.18, 0.978, 278, 274, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1021, d4iq6A_, 0.8519, 2.02, 0.338, 324, 269, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1022, d4f9yA_, 0.8518, 2.12, 0.382, 339, 272, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1023, d3bx5A_, 0.8518, 2.30, 0.387, 338, 274, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
1024, d5jq8A_, 0.8517, 2.12, 0.985, 278, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
1025, d4zthA_, 0.8517, 2.15, 0.384, 339, 271, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
1026, d4ek8A_, 0.8517, 2.26, 0.989, 280, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1027, d3o2mA_, 0.8517, 2.30, 0.366, 358, 276, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1028, d2balA_, 0.8516, 2.18, 0.386, 337, 272, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
1029, d4ub7A_, 0.8515, 2.58, 0.293, 334, 280, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
1030, d4bzdA_, 0.8515, 2.21, 0.923, 277, 274, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
1031, d3py0A_, 0.8515, 2.70, 0.951, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR SU9516
1032, p5lw1H_, 0.8514, 2.41, 0.344, 355, 276, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1033, p2gmxB_, 0.8514, 2.33, 0.361, 357, 277, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
1034, p5lw1B_, 0.8513, 2.42, 0.344, 355, 276, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1035, d3pxyA_, 0.8513, 2.76, 0.951, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR JWS648
1036, d3kf7A_, 0.8513, 2.08, 0.376, 337, 271, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
1037, d1ke5A_, 0.8513, 2.50, 0.996, 281, 278, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
1038, d4fktA_, 0.8512, 2.24, 0.989, 278, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1039, d2btsA_, 0.8512, 2.07, 0.971, 274, 272, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
1040, d2vtqA_, 0.8511, 2.01, 0.989, 274, 271, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1041, d4aacA_, 0.8510, 2.50, 0.389, 350, 275, P38ALPHA MAP KINASE BOUND TO CMPD 29
1042, d1ke9A_, 0.8510, 2.40, 1.000, 281, 277, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
1043, p5xyyA_, 0.8509, 2.52, 0.384, 350, 276, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1044, d2r3kA_, 0.8509, 2.19, 0.985, 277, 274, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1045, d1vyzA_, 0.8509, 2.25, 0.993, 279, 274, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
1046, d3rocA_, 0.8506, 2.12, 0.376, 337, 271, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
1047, d3o2mB_, 0.8506, 2.39, 0.365, 358, 277, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1048, d4fksA_, 0.8505, 2.19, 0.989, 275, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1049, d3rzbA_, 0.8505, 2.53, 0.982, 282, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
1050, p3n9xB_, 0.8504, 2.73, 0.409, 362, 281, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1051, d2vu3A_, 0.8504, 2.11, 0.993, 285, 272, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1052, p3o17B_, 0.8503, 2.39, 0.365, 357, 277, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
1053, d4fkpA_, 0.8501, 2.24, 0.989, 279, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1054, d1ywrA_, 0.8501, 2.22, 0.388, 338, 273, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
1055, d1oukA_, 0.8501, 2.48, 0.385, 348, 275, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
1056, d3q9zA_, 0.8499, 2.70, 0.298, 332, 282, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1057, d5m4iA_, 0.8497, 2.55, 0.294, 331, 279, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1058, d4i5hA_, 0.8497, 2.09, 0.381, 335, 270, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
1059, d2vtnA_, 0.8496, 2.13, 0.985, 274, 272, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1060, d4aguA_, 0.8493, 2.17, 0.399, 277, 271, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1061, d3gfeA_, 0.8493, 2.61, 0.379, 352, 277, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
1062, p5lw1E_, 0.8491, 2.44, 0.344, 355, 276, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1063, d5anoA_, 0.8489, 2.23, 0.978, 277, 274, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1064, d2vtjA_, 0.8489, 2.22, 0.993, 276, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1065, d4dglD_, 0.8488, 2.69, 0.301, 328, 282, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1066, d2r3jA_, 0.8487, 2.23, 0.985, 278, 274, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1067, d3ocgA_, 0.8486, 2.14, 0.376, 336, 271, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
1068, d4ehvA_, 0.8485, 2.25, 0.380, 337, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
1069, d3v6rA_, 0.8485, 2.46, 0.350, 349, 277, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1070, d3mvlB_, 0.8485, 2.22, 0.385, 339, 273, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1071, d3bv2A_, 0.8485, 2.22, 0.380, 337, 271, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
1072, d2gtnA_, 0.8485, 2.12, 0.381, 337, 270, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
1073, d1giiA_, 0.8484, 2.48, 0.971, 279, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1074, p4lopB_, 0.8483, 2.25, 0.363, 350, 273, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1075, d3qtrA_, 0.8483, 2.52, 0.978, 282, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
1076, d3oz6A_, 0.8483, 2.62, 0.372, 343, 277, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1077, d2b55A_, 0.8483, 2.24, 0.996, 276, 273, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
1078, d1ouyA_, 0.8483, 2.50, 0.385, 350, 275, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
1079, d4aa5A_, 0.8482, 2.32, 0.392, 340, 273, P38ALPHA MAP KINASE BOUND TO CMPD 33
1080, d2ghmA_, 0.8482, 2.17, 0.384, 336, 271, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
1081, d4acmA_, 0.8481, 2.25, 0.971, 277, 274, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
1082, p3nieB_, 0.8481, 2.66, 0.398, 367, 279, CRYSTAL STRUCTURE OF PF11_0147
1083, d3i5zA_, 0.8480, 2.02, 0.388, 331, 268, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
1084, d4kinB_, 0.8479, 2.35, 0.383, 341, 274, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1085, d3od6X_, 0.8479, 2.45, 0.357, 344, 277, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
1086, d5bveA_, 0.8477, 1.84, 0.383, 330, 266, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1087, d3o0gB_, 0.8477, 1.42, 0.590, 264, 261, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1088, d1yw2A_, 0.8477, 2.09, 0.381, 341, 270, MUTATED MUS MUSCULUS P38 KINASE (MP38)
1089, d1i09A_, 0.8477, 2.07, 0.342, 338, 269, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1090, p6ehuB_, 0.8476, 2.66, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1091, d4nj3A_, 0.8476, 2.21, 0.993, 277, 273, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
1092, p4loqB_, 0.8476, 2.22, 0.363, 351, 273, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1093, p3lhjA_, 0.8475, 2.49, 0.369, 341, 274, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
1094, d3u8wA_, 0.8474, 2.61, 0.379, 349, 277, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
1095, d3ds6D_, 0.8474, 2.55, 0.384, 349, 276, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1096, d3bv3A_, 0.8473, 2.23, 0.380, 338, 271, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
1097, d1m7qA_, 0.8472, 2.49, 0.385, 348, 275, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1098, d3e7oA_, 0.8471, 2.42, 0.342, 342, 275, CRYSTAL STRUCTURE OF JNK2
1099, d4fv5A_, 0.8470, 2.03, 0.384, 330, 268, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
1100, d3unjA_, 0.8470, 2.78, 0.951, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
1101, p4loqA_, 0.8469, 2.22, 0.363, 352, 273, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1102, p4lopD_, 0.8468, 2.42, 0.375, 351, 275, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1103, p4loqD_, 0.8467, 2.24, 0.363, 351, 273, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1104, d2vttA_, 0.8466, 2.05, 0.989, 272, 270, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1105, d3s3iA_, 0.8464, 2.52, 0.380, 349, 276, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1106, d2duvA_, 0.8464, 2.03, 1.000, 272, 270, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
1107, d1gihA_, 0.8464, 2.31, 0.989, 276, 274, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1108, d4kipA_, 0.8462, 2.28, 0.375, 337, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1109, d4eh2A_, 0.8462, 2.11, 0.372, 337, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
1110, d3sw4A_, 0.8462, 2.41, 0.986, 279, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1111, d3queA_, 0.8462, 2.15, 0.381, 343, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
1112, d3hp2A_, 0.8462, 2.17, 0.381, 341, 270, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
1113, d3ezrA_, 0.8462, 2.07, 0.985, 273, 271, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
1114, d5bvdA_, 0.8461, 1.87, 0.383, 330, 266, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1115, d5andA_, 0.8461, 2.27, 0.963, 273, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1116, d4o2zA1, 0.8461, 2.38, 0.342, 357, 272, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
1117, p3n9xA_, 0.8461, 2.73, 0.411, 374, 280, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1118, d3fklA_, 0.8460, 2.30, 0.386, 344, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
1119, d1h06A_, 0.8459, 2.26, 0.982, 277, 274,  
1120, d4fv9A_, 0.8458, 2.02, 0.384, 331, 268, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
1121, d2r3nA_, 0.8458, 2.17, 0.993, 275, 272, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1122, d2lgcA1, 0.8458, 2.43, 0.385, 353, 273, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
1123, d3v6sA_, 0.8457, 2.56, 0.353, 349, 278, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1124, d3rahA_, 0.8457, 2.61, 0.924, 282, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
1125, p4lopA_, 0.8456, 2.43, 0.375, 351, 275, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1126, d4fv4A_, 0.8456, 2.12, 0.384, 329, 268, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
1127, d3qtsA_, 0.8456, 2.63, 0.978, 282, 279, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
1128, d2zb0A_, 0.8456, 2.57, 0.384, 349, 276, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1129, d2r3lA_, 0.8454, 2.21, 0.985, 275, 273, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1130, d3mptA_, 0.8453, 2.37, 0.377, 347, 273, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
1131, d2btrA_, 0.8452, 2.09, 0.996, 275, 271, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
1132, d3ds6A_, 0.8450, 2.51, 0.362, 343, 276, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1133, d5ankA_, 0.8448, 2.18, 0.974, 273, 271, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1134, d3rprA_, 0.8448, 2.62, 0.924, 282, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
1135, d3rmfA_, 0.8448, 2.34, 0.975, 278, 275, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
1136, d4r3cA_, 0.8446, 2.03, 0.377, 335, 268, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
1137, p4jr7A_, 0.8446, 2.57, 0.274, 367, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1138, d2bheA_, 0.8446, 2.15, 0.967, 274, 272, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
1139, p2g01B_, 0.8445, 2.60, 0.361, 356, 280, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
1140, d1v0pA_, 0.8445, 2.62, 0.625, 277, 275, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1141, d1r78A_, 0.8445, 2.14, 0.989, 273, 271, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
1142, d1r3cA_, 0.8445, 2.57, 0.384, 349, 276, THE STRUCTURE OF P38ALPHA C162S MUTANT
1143, d3rpyA_, 0.8444, 2.32, 0.978, 277, 274, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
1144, d1wbwA_, 0.8443, 2.55, 0.385, 351, 275, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1145, d5m44A_, 0.8442, 2.63, 0.301, 329, 279, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1146, d4aguB_, 0.8442, 2.22, 0.400, 276, 270, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1147, d3zyaA1, 0.8442, 2.31, 0.373, 341, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
1148, d2ghlA_, 0.8440, 2.21, 0.381, 334, 270, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
1149, d1w84A_, 0.8439, 2.57, 0.384, 351, 276, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1150, d3o8pA_, 0.8438, 2.18, 0.370, 336, 270, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1151, d1di9A_, 0.8438, 2.57, 0.384, 348, 276, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
1152, d3uvqA_, 0.8437, 2.06, 0.381, 333, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
1153, d3fmhA_, 0.8437, 2.36, 0.382, 347, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1154, d1urwA_, 0.8437, 2.23, 0.911, 274, 271, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
1155, d4eh6A_, 0.8436, 2.12, 0.369, 335, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
1156, d3r9nA_, 0.8436, 2.67, 0.899, 282, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
1157, d1oitA_, 0.8436, 2.15, 0.974, 273, 270, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1158, d5fp6A_, 0.8435, 2.43, 0.978, 278, 276, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
1159, d3s1hA_, 0.8435, 2.31, 0.974, 277, 274, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
1160, d3e3pB_, 0.8434, 2.53, 0.337, 337, 276, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1161, p6gihA_, 0.8433, 2.56, 0.306, 324, 278, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
1162, d2qkrA1, 0.8433, 2.19, 0.577, 269, 267, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
1163, d4ynoA_, 0.8432, 2.49, 0.391, 342, 274, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
1164, d4kinC_, 0.8431, 2.40, 0.376, 338, 274, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1165, d4eh7A_, 0.8430, 2.19, 0.375, 337, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
1166, d3gc9B_, 0.8430, 2.43, 0.370, 339, 273, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1167, d3gc8B_, 0.8430, 2.42, 0.371, 346, 272, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1168, d4kiqB_, 0.8428, 2.30, 0.375, 338, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1169, d1w82A_, 0.8428, 2.46, 0.381, 351, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1170, d4kiqC_, 0.8427, 2.29, 0.375, 338, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1171, d3flyA_, 0.8427, 2.43, 0.381, 347, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1172, d3flwA_, 0.8427, 2.43, 0.374, 345, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
1173, d3e3pA_, 0.8427, 2.44, 0.342, 337, 275, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1174, d3d7zA_, 0.8427, 2.59, 0.385, 348, 275, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1175, d3rakA_, 0.8426, 2.32, 0.974, 277, 274, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
1176, d3r8mA_, 0.8426, 2.79, 0.968, 286, 281, CDK2 IN COMPLEX WITH INHIBITOR L3-3
1177, d1v0bA_, 0.8426, 2.78, 0.621, 286, 277, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1178, p4lopC_, 0.8425, 2.08, 0.377, 341, 268, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1179, d4eh8A_, 0.8425, 2.13, 0.369, 336, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
1180, d3ralA_, 0.8425, 2.34, 0.934, 277, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
1181, d1bl6A_, 0.8424, 2.52, 0.371, 351, 275, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
1182, d5etcA_, 0.8423, 2.59, 0.384, 355, 276, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
1183, p5ax3A_, 0.8423, 2.18, 0.383, 329, 269, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
1184, p4f9bA_, 0.8423, 2.66, 0.266, 318, 278, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1185, d4ic8B_, 0.8422, 2.59, 0.380, 336, 276, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1186, d5ci6A_, 0.8421, 2.19, 0.357, 335, 269, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1187, d5bujA_, 0.8421, 2.08, 0.381, 331, 268, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
1188, d4eh3A_, 0.8421, 2.21, 0.375, 339, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
1189, d3newA_, 0.8421, 2.19, 0.378, 334, 270, P38-ALPHA COMPLEXED WITH COMPOUND 10
1190, d3itzA1, 0.8421, 2.72, 0.379, 353, 277, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1191, d2r7iB_, 0.8421, 2.60, 0.292, 322, 277, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1192, d1v1kA_, 0.8420, 2.31, 0.982, 277, 274, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1193, d4kipB_, 0.8418, 2.27, 0.387, 338, 271, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1194, d4bghA_, 0.8418, 2.31, 0.989, 275, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
1195, d3sw7A_, 0.8417, 2.35, 0.978, 278, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1196, d5bueA_, 0.8415, 2.08, 0.381, 329, 268, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
1197, d3rinA_, 0.8415, 2.74, 0.379, 349, 277, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1198, d3flzA_, 0.8415, 2.44, 0.381, 347, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1199, d2fvdA_, 0.8415, 2.07, 0.981, 284, 270, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
1200, d2r7iD_, 0.8414, 2.61, 0.292, 322, 277, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1201, d3ds6B_, 0.8412, 2.78, 0.380, 343, 279, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1202, d4kiqD_, 0.8411, 2.32, 0.375, 338, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1203, d3nnwA_, 0.8411, 2.49, 0.381, 349, 273, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
1204, d3qudA_, 0.8410, 2.31, 0.380, 345, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
1205, d1wboA_, 0.8410, 2.62, 0.384, 351, 276, FRAGMENT BASED P38 INHIBITORS
1206, d3fmkA_, 0.8408, 2.33, 0.382, 346, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1207, d3e92A_, 0.8408, 2.58, 0.387, 348, 274, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1208, d1zz2A_, 0.8407, 2.30, 0.386, 337, 272, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
1209, d3nnvA_, 0.8406, 2.53, 0.380, 348, 274, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
1210, d2r7iA_, 0.8406, 2.62, 0.292, 322, 277, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1211, d4y5hA_, 0.8404, 2.46, 0.358, 349, 274, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1212, d4fkoA_, 0.8404, 2.45, 0.975, 291, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1213, d3iphA_, 0.8399, 2.48, 0.382, 345, 272, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
1214, d2rg6A_, 0.8399, 2.24, 0.378, 335, 270, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
1215, d2pk9C_, 0.8399, 1.58, 0.573, 266, 260, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1216, d5cs6B_, 0.8398, 2.26, 0.310, 316, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1217, d3mpaA_, 0.8397, 1.99, 0.368, 331, 266, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1218, d3gc8A_, 0.8397, 2.51, 0.371, 347, 272, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1219, d2zb1A_, 0.8397, 2.49, 0.371, 345, 272, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1220, d1wbvA_, 0.8397, 2.49, 0.381, 351, 273, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1221, d1p2aA_, 0.8397, 2.04, 0.978, 271, 269, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
1222, d3tg1A_, 0.8396, 2.13, 0.375, 334, 269, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
1223, d3oz6B_, 0.8396, 2.79, 0.394, 341, 277, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1224, d4y46A_, 0.8395, 2.46, 0.361, 340, 274, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1225, d3nnuA_, 0.8395, 2.35, 0.384, 348, 271, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
1226, d3gc9A_, 0.8395, 2.41, 0.369, 335, 271, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1227, d3ds6C_, 0.8395, 2.53, 0.382, 349, 275, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1228, d1zzlA_, 0.8395, 2.66, 0.380, 351, 276, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
1229, d1bmkA_, 0.8394, 2.70, 0.383, 351, 277, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
1230, d4qtdA_, 0.8393, 2.50, 0.350, 355, 274, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
1231, d3mh1A_, 0.8393, 2.24, 0.374, 337, 270, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1232, d1oveA_, 0.8393, 2.75, 0.379, 349, 277, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
1233, d5n66A_, 0.8392, 2.12, 0.371, 332, 267, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
1234, d4kinA_, 0.8392, 2.47, 0.385, 338, 273, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1235, d4dljA_, 0.8392, 2.16, 0.377, 336, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
1236, d3mvmB_, 0.8392, 2.15, 0.372, 332, 269, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1237, d4l8mA_, 0.8391, 2.38, 0.381, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
1238, d2pv8A_, 0.8391, 2.25, 0.374, 337, 270,  
1239, d1ob3A_, 0.8391, 2.66, 0.625, 277, 275, STRUCTURE OF P. FALCIPARUM PFPK5
1240, d4awiA_, 0.8390, 2.48, 0.349, 352, 272, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
1241, d5ekoA_, 0.8389, 2.45, 0.381, 341, 273, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1242, d5bvfA_, 0.8386, 1.91, 0.379, 327, 264, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1243, d4kkhA_, 0.8386, 2.67, 0.362, 351, 276, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
1244, d2yixA_, 0.8386, 2.58, 0.382, 351, 275, TRIAZOLOPYRIDINE INHIBITORS OF P38
1245, d3gc7A_, 0.8385, 2.71, 0.379, 349, 277, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1246, d4kiqA_, 0.8384, 2.33, 0.375, 338, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1247, d1ua2C_, 0.8384, 2.17, 0.448, 286, 268, CRYSTAL STRUCTURE OF HUMAN CDK7
1248, d2r7iC_, 0.8383, 2.61, 0.293, 321, 276, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1249, d1wbtA_, 0.8383, 2.52, 0.381, 351, 273, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1250, d1bl7A_, 0.8383, 2.61, 0.370, 351, 276, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
1251, d4kkeA_, 0.8382, 2.58, 0.364, 354, 275, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
1252, d3obgA_, 0.8382, 2.06, 0.382, 332, 267, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1253, d4w4wA_, 0.8381, 2.69, 0.362, 349, 276, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
1254, d3hv4A_, 0.8380, 2.45, 0.382, 339, 272, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1255, d4eyjA_, 0.8379, 2.32, 0.391, 338, 271, MAPK13 COMPLEX WITH INHIBITOR
1256, d4d1xA_, 0.8379, 2.23, 0.933, 274, 270, CDK2 IN COMPLEX WITH LUCIFERIN
1257, d2onlB1, 0.8379, 2.39, 0.386, 339, 272, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1258, d2pkjA_, 0.8377, 2.07, 0.378, 332, 267,  
1259, d1lewA_, 0.8377, 2.37, 0.386, 341, 272, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
1260, d2rg5A_, 0.8376, 2.22, 0.379, 333, 269, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
1261, d1lezA_, 0.8376, 2.42, 0.388, 343, 273, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
1262, d1a9uA_, 0.8376, 2.57, 0.366, 351, 276, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
1263, d2gtmA_, 0.8375, 2.13, 0.386, 341, 267, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
1264, d3gcuA_, 0.8374, 2.47, 0.382, 339, 272, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1265, d1ua2D_, 0.8374, 2.19, 0.448, 286, 268, CRYSTAL STRUCTURE OF HUMAN CDK7
1266, d3mh0A_, 0.8373, 2.08, 0.378, 332, 267, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1267, d1ua2B_, 0.8373, 2.21, 0.451, 286, 268, CRYSTAL STRUCTURE OF HUMAN CDK7
1268, d4eymA_, 0.8371, 2.40, 0.390, 340, 272, MAPK13 COMPLEX WITH INHIBITOR
1269, d4eh4A_, 0.8371, 2.20, 0.378, 337, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
1270, d2zazA_, 0.8370, 2.47, 0.384, 345, 271, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
1271, d4kkgA_, 0.8368, 2.56, 0.361, 353, 274, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
1272, d1wbsA_, 0.8368, 2.55, 0.381, 351, 273, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1273, d2onlA1, 0.8366, 2.31, 0.387, 338, 271, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1274, d4ditA_, 0.8365, 2.11, 0.338, 328, 266, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1275, d1r39A_, 0.8365, 2.52, 0.369, 345, 274, THE STRUCTURE OF P38ALPHA
1276, d1kv1A_, 0.8365, 2.17, 0.386, 331, 267, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
1277, p5o90A_, 0.8363, 2.26, 0.386, 330, 267, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
1278, d4ka3A_, 0.8363, 2.26, 0.374, 340, 270, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
1279, p4h3bC_, 0.8363, 2.46, 0.375, 351, 272, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1280, p4h3bA_, 0.8363, 2.46, 0.375, 351, 272, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1281, d3mh3A_, 0.8363, 2.19, 0.369, 334, 268, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1282, d2ptjA_, 0.8363, 2.19, 0.369, 334, 268,  
1283, d4tyhB_, 0.8362, 2.39, 0.385, 335, 270, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
1284, d3hv5A_, 0.8362, 2.49, 0.382, 339, 272, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1285, d1w83A_, 0.8361, 2.58, 0.381, 351, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1286, d3hv3A_, 0.8359, 2.22, 0.377, 335, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
1287, d2okrA_, 0.8359, 2.41, 0.386, 339, 272, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1288, d5mz3A_, 0.8358, 2.57, 0.381, 350, 273, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
1289, d4h36A_, 0.8358, 2.35, 0.373, 353, 271, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
1290, d2ptoA_, 0.8358, 1.97, 0.370, 330, 265,  
1291, d1zyjA_, 0.8356, 2.06, 0.372, 331, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
1292, d3k3iA_, 0.8355, 2.18, 0.386, 332, 267, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
1293, d3cgfA_, 0.8355, 2.62, 0.363, 346, 273, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1294, d3pzeA_, 0.8353, 2.50, 0.351, 347, 271, JNK1 IN COMPLEX WITH INHIBITOR
1295, d3nnxA_, 0.8352, 2.15, 0.391, 336, 266, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
1296, d3o8uA_, 0.8351, 2.20, 0.371, 332, 267, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1297, d3fknA_, 0.8351, 2.43, 0.376, 346, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
1298, d2p33A_, 0.8351, 2.65, 0.363, 332, 273, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1299, d1w7hA_, 0.8350, 2.69, 0.384, 351, 276, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1300, d3kq7A_, 0.8349, 2.62, 0.380, 348, 274, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
1301, d3gcqA_, 0.8349, 2.24, 0.377, 337, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
1302, d1gijA_, 0.8349, 2.27, 0.930, 273, 270, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1303, d3gc0A_, 0.8348, 2.38, 0.550, 278, 271, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
1304, d3cgoA_, 0.8348, 2.35, 0.367, 332, 270, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1305, d3p7bA_, 0.8346, 2.17, 0.375, 332, 267, P38 INHIBITOR-BOUND
1306, d3npcA_, 0.8346, 2.39, 0.359, 357, 270, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1307, d3flsA_, 0.8346, 2.33, 0.377, 343, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1308, d3p78A_, 0.8345, 2.18, 0.378, 332, 267, P38 INHIBITOR-BOUND
1309, d3fskA_, 0.8345, 2.37, 0.378, 342, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
1310, d3fmmA_, 0.8345, 2.49, 0.382, 346, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
1311, d1pyeA_, 0.8345, 1.85, 0.992, 266, 263, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
1312, d4kinD_, 0.8344, 2.39, 0.380, 339, 271, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1313, d3ptgA_, 0.8344, 2.34, 0.374, 340, 270, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
1314, d3mh2A_, 0.8344, 2.00, 0.366, 330, 265, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1315, d3hp5A_, 0.8344, 1.98, 0.375, 330, 264, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
1316, d1yqjA2, 0.8344, 2.66, 0.367, 351, 275, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
1317, d1wbnA_, 0.8344, 2.58, 0.381, 351, 273, FRAGMENT BASED P38 INHIBITORS
1318, d5awmA_, 0.8343, 2.44, 0.336, 345, 271, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
1319, d3ha8A_, 0.8343, 2.55, 0.371, 342, 272, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
1320, d3e93A_, 0.8343, 2.39, 0.385, 346, 270, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1321, p2xs0A_, 0.8342, 2.29, 0.349, 346, 269, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1322, d3flqA_, 0.8341, 2.51, 0.376, 345, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
1323, d2i0hA_, 0.8341, 2.80, 0.379, 349, 277, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
1324, d1ukiA_, 0.8341, 2.24, 0.364, 328, 269, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1325, d1p38A_, 0.8339, 2.76, 0.383, 351, 277, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
1326, d3o8tA_, 0.8337, 2.20, 0.375, 332, 267, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1327, d1jnkA_, 0.8337, 2.55, 0.360, 346, 272, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
1328, d3p79A_, 0.8334, 2.19, 0.375, 332, 267, P38 INHIBITOR-BOUND
1329, d5eknA_, 0.8333, 2.29, 0.383, 336, 269, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1330, d3p5kA_, 0.8333, 2.19, 0.375, 332, 267, P38 INHIBITOR-BOUND
1331, d2o0uA_, 0.8333, 2.62, 0.363, 331, 273, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
1332, d3npcB_, 0.8331, 2.31, 0.362, 356, 268, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1333, d4x21A_, 0.8328, 2.33, 0.364, 336, 269, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1334, d4w4yA_, 0.8328, 2.63, 0.353, 350, 275, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1335, d2zdtA_, 0.8328, 2.60, 0.360, 342, 272, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1336, d5etiA1, 0.8327, 2.64, 0.382, 352, 275, STRUCTURE OF DEAD KINASE MAPK14
1337, d4eh9A_, 0.8327, 2.25, 0.380, 334, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
1338, d4dliA_, 0.8327, 2.24, 0.378, 334, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
1339, d4yr8A_, 0.8326, 2.22, 0.353, 320, 266, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1340, p4loqC_, 0.8326, 2.07, 0.377, 337, 265, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1341, d1pmnA_, 0.8325, 2.60, 0.364, 344, 272, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
1342, d4w4xA_, 0.8322, 2.74, 0.351, 342, 276, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1343, d4w4vA_, 0.8322, 2.67, 0.356, 342, 275, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1344, d3mvmA_, 0.8322, 2.33, 0.390, 335, 269, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1345, d3v6rB_, 0.8318, 2.47, 0.357, 346, 272, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1346, d2i6lA_, 0.8316, 2.44, 0.335, 292, 269, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1347, d5d1jA_, 0.8315, 1.94, 0.943, 265, 263, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
1348, d3fmjA_, 0.8314, 2.38, 0.368, 344, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
1349, d3fkoA_, 0.8314, 2.43, 0.381, 343, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
1350, d1wfcA_, 0.8314, 2.53, 0.376, 340, 271, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
1351, d1ua2A_, 0.8314, 2.28, 0.448, 286, 268, CRYSTAL STRUCTURE OF HUMAN CDK7
1352, d3hvcA_, 0.8312, 1.94, 0.382, 327, 262, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
1353, d2p5aA_, 0.8312, 1.94, 0.382, 327, 262,  
1354, d2okrD_, 0.8312, 2.34, 0.385, 339, 270, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1355, d3p4kA_, 0.8311, 2.39, 0.384, 338, 271, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
1356, d3flnC_, 0.8311, 2.25, 0.390, 343, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
1357, d3c5uA_, 0.8311, 2.41, 0.373, 338, 271, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
1358, p5etaB_, 0.8310, 2.18, 0.378, 335, 267, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1359, d2qd9A_, 0.8310, 2.06, 0.381, 330, 265, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
1360, d4a9yA_, 0.8309, 2.30, 0.381, 334, 268, P38ALPHA MAP KINASE BOUND TO CMPD 8
1361, d3pg1A_, 0.8309, 2.23, 0.338, 341, 269, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
1362, d2bakA_, 0.8309, 2.30, 0.381, 334, 268, P38ALPHA MAP KINASE BOUND TO MPAQ
1363, d2gfsA_, 0.8308, 2.61, 0.375, 344, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
1364, d3p7cA_, 0.8307, 2.24, 0.371, 332, 267, P38 INHIBITOR-BOUND
1365, d3gp0A1, 0.8306, 2.13, 0.360, 332, 264, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
1366, d5n68A_, 0.8304, 2.06, 0.379, 328, 264, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
1367, d5uojA_, 0.8301, 2.58, 0.374, 343, 273, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
1368, d3oc1A_, 0.8301, 2.20, 0.372, 330, 266, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1369, d4u79A_, 0.8300, 2.31, 0.364, 337, 269, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
1370, d3uvpA_, 0.8300, 2.40, 0.356, 334, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
1371, d3lffA_, 0.8299, 2.40, 0.378, 335, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
1372, d3ttiA_, 0.8297, 2.83, 0.361, 341, 274, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
1373, d3ctqA_, 0.8297, 2.44, 0.381, 336, 270, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
1374, d2wajA_, 0.8296, 2.49, 0.362, 348, 271, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
1375, d3objA_, 0.8295, 2.44, 0.375, 332, 269, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1376, d3gbzA_, 0.8295, 2.37, 0.537, 274, 270, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
1377, d2puuA_, 0.8295, 2.16, 0.370, 330, 265, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
1378, d3hrbA_, 0.8293, 2.67, 0.375, 344, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1379, d1oz1A_, 0.8293, 2.58, 0.391, 344, 271, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
1380, d5mtxA_, 0.8291, 2.25, 0.373, 331, 268, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
1381, p4whzA_, 0.8290, 2.95, 0.360, 342, 275, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
1382, d1ianA_, 0.8290, 2.23, 0.385, 328, 265, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
1383, d5angA_, 0.8289, 2.17, 0.872, 268, 265, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1384, d3d83A_, 0.8286, 2.63, 0.382, 347, 272, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1385, d5o8uA_, 0.8284, 2.15, 0.366, 331, 265, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
1386, d3fmnA_, 0.8284, 2.30, 0.375, 341, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
1387, d3ttjA_, 0.8283, 2.61, 0.360, 333, 272, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
1388, d3hegA_, 0.8281, 2.27, 0.375, 333, 267, P38 IN COMPLEX WITH SORAFENIB
1389, d3hv6A_, 0.8280, 2.19, 0.377, 331, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
1390, d5n65A_, 0.8277, 2.33, 0.372, 333, 269, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
1391, d4x21B_, 0.8276, 2.31, 0.364, 336, 269, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1392, d3g9nA_, 0.8271, 2.70, 0.364, 346, 272, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
1393, d1oiqA_, 0.8269, 1.99, 0.916, 264, 262, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1394, d4yr8E_, 0.8268, 2.29, 0.350, 317, 266, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1395, p6f5eB_, 0.8267, 2.24, 0.362, 346, 265, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1396, p5lenB_, 0.8267, 2.24, 0.362, 346, 265, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
1397, d3hv4B_, 0.8267, 2.45, 0.385, 338, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1398, d3fmlA_, 0.8267, 2.43, 0.366, 342, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
1399, d2ewaA_, 0.8267, 2.12, 0.390, 330, 264, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
1400, p4h39A_, 0.8266, 2.26, 0.367, 340, 267, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
1401, d3g90X_, 0.8266, 2.67, 0.358, 345, 271, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
1402, d3mw1A_, 0.8265, 2.48, 0.372, 342, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1403, d4z9lA_, 0.8262, 2.47, 0.363, 333, 270, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
1404, d3hv5B_, 0.8257, 2.47, 0.385, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1405, d3p7aA_, 0.8254, 2.31, 0.375, 332, 267, P38 INHIBITOR-BOUND
1406, d3iw6A_, 0.8253, 2.50, 0.374, 337, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
1407, d5fp5A_, 0.8252, 2.06, 0.955, 264, 264, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
1408, d3v6sB_, 0.8252, 2.33, 0.362, 340, 268, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1409, d3gcuB_, 0.8251, 2.47, 0.385, 337, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1410, d1pmuA_, 0.8251, 2.59, 0.357, 342, 272, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
1411, d2zduA_, 0.8250, 2.54, 0.363, 330, 270, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1412, d3eljA_, 0.8249, 2.45, 0.357, 347, 269, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
1413, d3da6A_, 0.8247, 2.61, 0.362, 328, 271, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
1414, d3hv7A_, 0.8244, 2.30, 0.385, 330, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
1415, d3zsiA_, 0.8243, 2.18, 0.386, 326, 264, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
1416, d3iw7A_, 0.8242, 2.53, 0.374, 335, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
1417, d4l7fA1, 0.8241, 2.53, 0.353, 343, 269, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
1418, d1pmvA_, 0.8236, 2.77, 0.363, 347, 273, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
1419, d2o2uA_, 0.8230, 2.33, 0.363, 319, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
1420, d3mgyA_, 0.8229, 2.16, 0.371, 329, 264, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1421, d3k3jA_, 0.8229, 2.22, 0.379, 329, 264, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
1422, p3vulA_, 0.8228, 2.26, 0.361, 344, 266, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1423, d5n67A_, 0.8222, 2.15, 0.382, 327, 262, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
1424, d2pv5A_, 0.8221, 2.17, 0.367, 329, 264,  
1425, p4ux9D_, 0.8219, 2.65, 0.349, 344, 272, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1426, d3cg2A_, 0.8218, 2.17, 0.384, 327, 263,  
1427, d3lfbA_, 0.8216, 2.42, 0.362, 333, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
1428, d4eh5A_, 0.8215, 2.15, 0.378, 329, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
1429, d4bgqA_, 0.8215, 2.38, 0.386, 276, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1430, d3oefX_, 0.8214, 2.54, 0.381, 334, 270, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
1431, d3fi4A_, 0.8214, 2.33, 0.392, 339, 265, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
1432, d3gcvA_, 0.8213, 2.26, 0.370, 338, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
1433, d3e7oB_, 0.8211, 2.14, 0.350, 326, 263, CRYSTAL STRUCTURE OF JNK2
1434, d1ukhA_, 0.8211, 2.11, 0.352, 321, 264, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1435, d3uvrA_, 0.8210, 2.51, 0.383, 331, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
1436, d3fsfA_, 0.8210, 2.40, 0.375, 340, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1437, d1kv2A_, 0.8208, 1.98, 0.388, 325, 260, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
1438, d2baqA_, 0.8206, 2.20, 0.397, 329, 262, P38ALPHA BOUND TO RO3201195
1439, d1blxA_, 0.8206, 2.99, 0.453, 305, 274, P19INK4D/CDK6 COMPLEX
1440, d2hy81_, 0.8204, 2.16, 0.298, 293, 262, PAK1 COMPLEX WITH ST2001
1441, d5o8vA_, 0.8203, 2.14, 0.379, 328, 261, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
1442, d3oy1A_, 0.8203, 2.42, 0.365, 329, 266, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
1443, d2ok1A_, 0.8203, 2.53, 0.358, 333, 268, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1444, d3hubA_, 0.8201, 2.55, 0.373, 335, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
1445, d5tbeA_, 0.8199, 2.29, 0.365, 332, 266, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
1446, d3gi3A_, 0.8197, 2.28, 0.371, 330, 264, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
1447, d3pg3A_, 0.8196, 2.60, 0.376, 337, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
1448, d3fc1X_, 0.8196, 2.22, 0.369, 330, 263, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
1449, d4e6cA_, 0.8195, 2.20, 0.377, 330, 265, P38A-PERIFOSINE COMPLEX
1450, d3iw5A_, 0.8195, 2.49, 0.368, 336, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
1451, d3rtpA_, 0.8193, 2.23, 0.364, 331, 264, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
1452, d3hecA_, 0.8193, 2.26, 0.367, 329, 264, P38 IN COMPLEX WITH IMATINIB
1453, d3zduA_, 0.8191, 2.61, 0.349, 297, 272, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
1454, d3coiA1, 0.8189, 2.78, 0.391, 342, 274, CRYSTAL STRUCTURE OF P38DELTA KINASE
1455, d3lfeA_, 0.8187, 2.43, 0.373, 334, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
1456, d3hucA_, 0.8186, 2.58, 0.376, 337, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
1457, d3fl4A_, 0.8186, 2.40, 0.385, 339, 265, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
1458, d3oxiA_, 0.8184, 2.27, 0.370, 322, 265, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
1459, d3l8xA_, 0.8184, 2.20, 0.379, 326, 261, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
1460, d4aa0A_, 0.8182, 2.29, 0.390, 328, 264, P38ALPHA MAP KINASE BOUND TO CMPD 2
1461, p3vumA_, 0.8181, 2.34, 0.361, 347, 266, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
1462, d3fv8A_, 0.8180, 2.44, 0.367, 331, 267, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
1463, d3zshA_, 0.8175, 2.51, 0.372, 331, 269, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
1464, d5n64A_, 0.8174, 2.20, 0.378, 329, 262, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
1465, d1jvpP_, 0.8172, 2.36, 0.970, 268, 265, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
1466, d5n63A_, 0.8171, 2.15, 0.377, 325, 260, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
1467, d5mtyA_, 0.8171, 2.20, 0.369, 328, 263, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
1468, d3q53A_, 0.8170, 2.22, 0.294, 291, 262, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1469, d3lfaA_, 0.8167, 2.41, 0.371, 333, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
1470, d3lfcA_, 0.8165, 2.53, 0.369, 334, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
1471, d2excX_, 0.8165, 2.49, 0.363, 335, 267, INHIBITOR COMPLEX OF JNK3
1472, d3kvxA_, 0.8162, 2.36, 0.370, 327, 265, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
1473, d1g3nE_, 0.8160, 2.71, 0.451, 293, 268, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1474, d4d1zA_, 0.8159, 1.96, 0.888, 258, 258, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
1475, d5tcoA_, 0.8158, 2.24, 0.369, 327, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
1476, d3s4qA_, 0.8156, 2.26, 0.375, 326, 261, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
1477, p5xyxA_, 0.8152, 2.28, 0.378, 337, 262, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1478, d2b1pA_, 0.8145, 2.58, 0.360, 331, 267, INHIBITOR COMPLEX OF JNK3
1479, d5dfpA_, 0.8142, 2.25, 0.298, 292, 262, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
1480, d4ic8A_, 0.8141, 2.43, 0.381, 325, 265, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1481, d2yiwA_, 0.8141, 1.97, 0.385, 325, 257, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
1482, d4eqcA1, 0.8140, 2.28, 0.298, 292, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
1483, d3g9lX_, 0.8138, 2.58, 0.361, 336, 266, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
1484, d4dawA_, 0.8134, 2.30, 0.298, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
1485, d1yhwA_, 0.8132, 2.26, 0.298, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
1486, d1v0pB_, 0.8132, 2.12, 0.597, 258, 258, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1487, d1yhvA_, 0.8130, 2.26, 0.298, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
1488, d3q52A_, 0.8120, 2.29, 0.294, 292, 262, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
1489, d3iw8A_, 0.8120, 2.57, 0.368, 334, 269, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
1490, d1g3nA_, 0.8118, 2.83, 0.485, 293, 270, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1491, d4e5aX_, 0.8116, 2.38, 0.386, 332, 264, THE W197A MUTANT OF P38A MAP KINASE
1492, d2yisA_, 0.8113, 2.09, 0.384, 325, 258, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
1493, d2xrwA1, 0.8109, 2.38, 0.354, 346, 263, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1494, d3ocbA_, 0.8107, 2.33, 0.279, 315, 262, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1495, d3l8sA_, 0.8106, 2.52, 0.367, 334, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
1496, d1v0bB_, 0.8106, 2.30, 0.609, 261, 261, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1497, d5deyA_, 0.8105, 2.30, 0.294, 295, 262, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
1498, d3fxzA_, 0.8104, 2.32, 0.298, 292, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
1499, d2y7jA_, 0.8101, 2.23, 0.282, 284, 259, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1500, d3gcsA_, 0.8100, 2.46, 0.375, 331, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
1501, d3iw4C_, 0.8098, 2.35, 0.270, 332, 263, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1502, d4e5bA_, 0.8097, 2.21, 0.375, 324, 261, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
1503, d5veeA_, 0.8094, 2.40, 0.263, 289, 262, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1504, d4tthB_, 0.8094, 1.68, 0.510, 256, 253, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
1505, d4geoA_, 0.8093, 2.26, 0.372, 326, 261, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
1506, d3gcpA_, 0.8092, 2.71, 0.376, 337, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
1507, d2jedB1, 0.8090, 2.41, 0.285, 315, 263, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1508, d1u5rA_, 0.8090, 2.28, 0.271, 308, 262, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1509, d3fi2A_, 0.8087, 2.37, 0.361, 326, 263, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
1510, d4yr8C_, 0.8086, 2.41, 0.338, 318, 263, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1511, d4p41B_, 0.8086, 1.69, 0.510, 256, 253,  
1512, d3ocbB_, 0.8086, 2.29, 0.284, 319, 261, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1513, d2y7jC_, 0.8084, 2.28, 0.282, 284, 259, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1514, d2r9sB_, 0.8083, 2.45, 0.364, 325, 264, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1515, d3cqwA_, 0.8081, 2.32, 0.284, 318, 261, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1516, d5dewA_, 0.8079, 2.34, 0.294, 295, 262, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
1517, d3zsgA_, 0.8078, 2.74, 0.376, 337, 271, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
1518, d3zs5A1, 0.8075, 2.76, 0.376, 339, 271, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
1519, d1u5qA_, 0.8071, 2.32, 0.271, 308, 262, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1520, d3uibA_, 0.8069, 2.29, 0.341, 309, 258, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
1521, d1ob3B_, 0.8069, 2.08, 0.611, 258, 257, STRUCTURE OF P. FALCIPARUM PFPK5
1522, d2fslX_, 0.8067, 2.41, 0.371, 332, 264, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
1523, d3iw4B_, 0.8066, 2.40, 0.270, 325, 263, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1524, d3ow4A_, 0.8064, 2.30, 0.280, 317, 261, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1525, d4e6aA_, 0.8063, 2.25, 0.372, 324, 261, P38A-PIA23 COMPLEX
1526, d2jdoA_, 0.8063, 2.31, 0.284, 314, 261, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1527, d2gcdA_, 0.8059, 2.34, 0.271, 308, 262, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1528, d2r9sA_, 0.8058, 2.38, 0.366, 325, 262, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1529, d3fy0A_, 0.8057, 2.40, 0.298, 292, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
1530, d2ou7A_, 0.8056, 2.34, 0.252, 292, 262, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1531, d4e8aA_, 0.8053, 2.37, 0.376, 327, 263, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
1532, d2x39A_, 0.8049, 2.33, 0.280, 316, 261, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1533, d3iw4A_, 0.8048, 2.44, 0.270, 330, 263, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1534, d3mvhA_, 0.8046, 2.26, 0.285, 311, 260, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1535, d2owbA_, 0.8043, 2.37, 0.252, 294, 262, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1536, d1u5rB_, 0.8041, 2.39, 0.271, 308, 262, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1537, d2npqA_, 0.8040, 2.35, 0.374, 326, 262, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
1538, d2jedA_, 0.8040, 2.41, 0.286, 324, 262, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1539, d4j53A_, 0.8039, 2.37, 0.252, 293, 262, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1540, d3odzX_, 0.8035, 2.74, 0.355, 335, 265, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
1541, d3a8xA1, 0.8034, 2.29, 0.280, 331, 261, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1542, d3g33C_, 0.8032, 3.06, 0.474, 291, 270, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1543, d4c2vA_, 0.8031, 2.24, 0.302, 270, 258, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
1544, p3lfdA_, 0.8030, 2.61, 0.361, 331, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
1545, d2y7jB_, 0.8030, 2.22, 0.283, 281, 258, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1546, d3mv5A_, 0.8028, 2.46, 0.275, 315, 262, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1547, d2gcdB_, 0.8028, 2.39, 0.271, 308, 262, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1548, d4bbmA1, 0.8026, 3.29, 0.384, 306, 276, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1549, d2yacA_, 0.8026, 2.39, 0.252, 290, 262, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1550, d1u5qB_, 0.8025, 2.39, 0.271, 308, 262, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1551, d2fsmX_, 0.8024, 2.34, 0.372, 326, 261, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
1552, d3ow4B_, 0.8018, 2.31, 0.285, 317, 260, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1553, d3fc2A_, 0.8016, 2.39, 0.252, 293, 262, PLK1 IN COMPLEX WITH BI6727
1554, d3kb7A_, 0.8013, 2.42, 0.252, 289, 262, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1555, d4eklA_, 0.8012, 2.38, 0.280, 329, 261, AKT1 WITH GDC0068
1556, d5ta6A_, 0.8011, 2.40, 0.252, 294, 262, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1557, d2uw9A_, 0.8011, 2.38, 0.280, 316, 261, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1558, d4a4lA_, 0.8010, 2.41, 0.252, 290, 262, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1559, d3rcjA_, 0.8009, 2.39, 0.280, 281, 261, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
1560, d3g33A_, 0.8009, 2.95, 0.474, 291, 268, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1561, d3a8xB1, 0.8009, 2.08, 0.287, 325, 258, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1562, d3thbA_, 0.8008, 2.41, 0.252, 287, 262, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1563, d2rkuA_, 0.8008, 2.41, 0.252, 294, 262, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1564, d5mrdA_, 0.8007, 2.46, 0.282, 283, 262, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
1565, d4q9zA1, 0.8004, 2.45, 0.287, 330, 261, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1566, d4ra5A1, 0.8003, 2.46, 0.287, 331, 261, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1567, d4qmwA_, 0.8003, 2.41, 0.273, 286, 260, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1568, d2xh5A_, 0.8003, 2.39, 0.280, 316, 261, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
1569, d4j52A_, 0.8002, 2.43, 0.252, 293, 262, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1570, d4q9zB_, 0.8001, 2.50, 0.286, 308, 262, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1571, d5lvlA_, 0.8000, 2.45, 0.272, 285, 261, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
1572, d5f9eB_, 0.8000, 2.48, 0.286, 293, 262, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1573, d3pvwA2, 0.8000, 2.53, 0.270, 343, 263, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
1574, d5lvmA_, 0.7999, 2.50, 0.279, 283, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
1575, d3qklA_, 0.7999, 2.42, 0.280, 317, 261, SPIROCHROMANE AKT INHIBITORS
1576, d2welA_, 0.7998, 2.49, 0.299, 304, 261, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
1577, d3a7gB_, 0.7997, 2.33, 0.269, 290, 260, HUMAN MST3 KINASE
1578, d4gv1A1, 0.7996, 2.34, 0.281, 328, 260, PKB ALPHA IN COMPLEX WITH AZD5363
1579, d4ra4A_, 0.7995, 2.46, 0.267, 317, 262, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1580, d5f9eA1, 0.7994, 2.54, 0.286, 331, 262, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1581, d4a4oA_, 0.7994, 2.44, 0.252, 290, 262, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1582, d1zysA_, 0.7994, 2.60, 0.274, 271, 263, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
1583, d5ml5A_, 0.7993, 2.55, 0.383, 326, 264, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
1584, d1stcE_, 0.7992, 2.37, 0.269, 334, 260, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1585, d3hrfA_, 0.7991, 2.49, 0.272, 284, 261, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
1586, d4rqvA_, 0.7990, 2.45, 0.272, 288, 261, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1587, d3a7iA_, 0.7990, 2.47, 0.272, 286, 261, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
1588, d2x8dA_, 0.7990, 2.61, 0.278, 279, 263, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
1589, d4qmzA_, 0.7989, 2.49, 0.272, 286, 261, MST3 IN COMPLEX WITH SUNITINIB
1590, d3iecB_, 0.7989, 2.19, 0.312, 313, 256, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1591, d2bajA2, 0.7989, 2.50, 0.392, 334, 260, P38ALPHA BOUND TO PYRAZOLOUREA
1592, d2biyA_, 0.7988, 2.49, 0.267, 287, 262, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
1593, d5lvoA_, 0.7987, 2.53, 0.279, 285, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
1594, d3o7lD_, 0.7987, 2.35, 0.269, 333, 260, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1595, d1bx6A_, 0.7987, 2.40, 0.269, 337, 260, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1596, d3a8wB1, 0.7986, 2.21, 0.283, 324, 258, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1597, d2fstX_, 0.7986, 2.35, 0.369, 324, 260, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
1598, d4xx9A_, 0.7985, 2.52, 0.279, 288, 262, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
1599, d5vedA_, 0.7983, 2.53, 0.264, 289, 261, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1600, d5lvnA_, 0.7983, 2.53, 0.279, 283, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
1601, d4rqkA_, 0.7983, 2.46, 0.272, 285, 261, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
1602, d4w8eA_, 0.7982, 2.49, 0.272, 290, 261, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1603, d4qmxA_, 0.7982, 2.49, 0.272, 287, 261, MST3 IN COMPLEX WITH SARACATINIB
1604, d4qmlA_, 0.7982, 2.43, 0.273, 280, 260, MST3 IN COMPLEX WITH AMP-PNP
1605, d2y7jD_, 0.7981, 2.44, 0.271, 281, 258, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1606, d4a06A_, 0.7980, 2.40, 0.273, 282, 260, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
1607, d3fi3A_, 0.7980, 2.45, 0.364, 328, 261, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
1608, d3a7hB_, 0.7980, 2.34, 0.273, 290, 260, HUMAN MST3 KINASE IN COMPLEX WITH ATP
1609, d4ct1A_, 0.7979, 2.52, 0.282, 283, 262, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
1610, d4nw6A1, 0.7978, 2.40, 0.298, 296, 262, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1611, d4b8mA_, 0.7978, 2.32, 0.302, 270, 258, AURORA B KINASE IN COMPLEX WITH VX-680
1612, d5ta8A_, 0.7976, 2.50, 0.256, 294, 262, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1613, d5kbqA_, 0.7976, 2.56, 0.276, 289, 261, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
1614, d4ra5B_, 0.7976, 2.37, 0.288, 310, 260, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1615, d4o0rA_, 0.7975, 2.53, 0.276, 293, 261, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1616, d2fsoX_, 0.7975, 2.35, 0.377, 325, 260, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
1617, d3qkkA_, 0.7974, 2.38, 0.281, 326, 260, SPIROCHROMANE AKT INHIBITORS
1618, d3d5uA_, 0.7974, 2.43, 0.267, 288, 262, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
1619, d2vrxA_, 0.7973, 2.33, 0.302, 268, 258, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
1620, d1cmkE_, 0.7973, 2.41, 0.273, 348, 260, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
1621, d4nw5A1, 0.7972, 2.40, 0.298, 296, 262, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1622, d3hrcA_, 0.7972, 2.50, 0.276, 279, 261, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
1623, d3cquA_, 0.7972, 2.46, 0.276, 318, 261, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1624, d3a8wA1, 0.7972, 2.08, 0.284, 323, 257, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1625, d2i0eA_, 0.7972, 2.42, 0.252, 326, 262, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1626, d3pvuA2, 0.7971, 2.58, 0.270, 340, 263, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
1627, d2ydiA_, 0.7970, 2.63, 0.278, 279, 263, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
1628, d2vgoA_, 0.7970, 2.33, 0.302, 268, 258, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
1629, d3ztxA_, 0.7969, 2.35, 0.302, 269, 258, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
1630, d4qmtA_, 0.7967, 2.47, 0.273, 284, 260, MST3 IN COMPLEX WITH HESPERADIN
1631, d4qmnA_, 0.7967, 2.45, 0.273, 283, 260, MST3 IN COMPLEX WITH BOSUTINIB
1632, d4b6lA_, 0.7965, 2.55, 0.270, 281, 263, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1633, d2bfxA_, 0.7964, 2.35, 0.302, 269, 258, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
1634, d4figA_, 0.7963, 2.51, 0.264, 292, 261, CATALYTIC DOMAIN OF HUMAN PAK4
1635, d1h1wA_, 0.7963, 2.45, 0.273, 284, 260, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1636, d5ackA_, 0.7962, 2.59, 0.279, 286, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
1637, d4qmyA_, 0.7962, 2.51, 0.268, 287, 261, MST3 IN COMPLEX WITH STAUROSPORINE
1638, d4figB_, 0.7962, 2.51, 0.264, 292, 261, CATALYTIC DOMAIN OF HUMAN PAK4
1639, d2f57B1, 0.7962, 2.64, 0.279, 293, 262, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1640, d1ctpE_, 0.7962, 2.43, 0.273, 332, 260, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
1641, d2jdrA_, 0.7961, 2.39, 0.281, 316, 260, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1642, d4qnaA_, 0.7959, 2.45, 0.273, 284, 260, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
1643, d3orxC_, 0.7959, 2.45, 0.271, 283, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1644, d4a07A_, 0.7958, 2.44, 0.273, 282, 260, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
1645, d3orxD_, 0.7958, 2.45, 0.271, 282, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1646, d1zrzA_, 0.7957, 2.42, 0.284, 310, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
1647, d3orxA_, 0.7956, 2.45, 0.271, 283, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1648, d4o0tA_, 0.7955, 2.58, 0.294, 292, 262, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1649, d3krwA2, 0.7955, 2.63, 0.266, 349, 263, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
1650, d3kk8A_, 0.7955, 2.71, 0.308, 283, 263, CAMKII SUBSTRATE COMPLEX A
1651, d3iecA_, 0.7955, 2.15, 0.311, 311, 254, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1652, d1uvrA_, 0.7954, 2.41, 0.277, 284, 260, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1653, d4aaaA1, 0.7953, 3.16, 0.377, 290, 273, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
1654, d3d5wA_, 0.7953, 2.29, 0.270, 284, 259, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
1655, d2f57A1, 0.7953, 2.56, 0.264, 290, 261, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1656, d4qmuA_, 0.7951, 2.48, 0.273, 286, 260, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
1657, d3l9mA_, 0.7951, 2.40, 0.274, 338, 259, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1658, d1ql6A_, 0.7951, 2.40, 0.282, 281, 259, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
1659, d4qmsA_, 0.7950, 2.52, 0.268, 283, 261, MST3 IN COMPLEX WITH DASATINIB
1660, d4c2wA_, 0.7949, 2.37, 0.302, 268, 258, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
1661, d4hyiA_, 0.7948, 2.53, 0.276, 269, 261, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
1662, d5l2sA_, 0.7946, 2.38, 0.498, 263, 259, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
1663, d3rwqA_, 0.7945, 2.47, 0.273, 283, 260, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1664, d3qkmA_, 0.7943, 2.51, 0.280, 329, 261, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1665, d3orxB_, 0.7943, 2.49, 0.271, 280, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1666, d1smhA_, 0.7943, 2.40, 0.274, 348, 259, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1667, d5li9A1, 0.7941, 2.38, 0.286, 328, 259, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
1668, d5bmsA1, 0.7940, 2.60, 0.264, 289, 261, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1669, d1ia8A_, 0.7940, 2.63, 0.280, 272, 261, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
1670, d3krxA2, 0.7939, 2.64, 0.266, 349, 263, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
1671, d3iecC_, 0.7939, 2.20, 0.311, 311, 254, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1672, d2x4zA1, 0.7939, 2.57, 0.250, 289, 260, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
1673, d4qmmA_, 0.7938, 2.53, 0.268, 288, 261, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
1674, d3ckxA_, 0.7937, 2.31, 0.267, 276, 258, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
1675, d2bfyA_, 0.7937, 2.43, 0.298, 270, 258, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
1676, d3db6A_, 0.7936, 2.45, 0.264, 287, 261, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
1677, d3nuxA_, 0.7934, 2.35, 0.492, 261, 258, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1678, d5k3yA_, 0.7932, 2.40, 0.302, 267, 258, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
1679, d2bcjA3, 0.7932, 2.69, 0.270, 348, 263, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
1680, d6aywB_, 0.7930, 2.72, 0.294, 293, 262, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1681, d4jdiA_, 0.7930, 2.64, 0.264, 289, 261, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1682, d1xhaA_, 0.7930, 2.41, 0.274, 348, 259, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1683, d1xh8A_, 0.7930, 2.41, 0.270, 337, 259, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1684, d4qmvA_, 0.7929, 2.48, 0.269, 288, 260, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
1685, d4crsA1, 0.7929, 2.40, 0.290, 329, 259, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
1686, d3mfuA_, 0.7929, 2.96, 0.297, 302, 263, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
1687, d1rejA_, 0.7929, 2.43, 0.270, 333, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1688, d4ntsB_, 0.7927, 2.44, 0.269, 341, 260, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1689, d4jdhA_, 0.7927, 2.66, 0.264, 289, 261, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1690, d2uw7A_, 0.7926, 2.46, 0.266, 335, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1691, d2ghgA1, 0.7925, 2.60, 0.276, 269, 261, H-CHK1 COMPLEXED WITH A431994
1692, d2e9oA_, 0.7925, 2.52, 0.277, 269, 260, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
1693, d1xh5A_, 0.7924, 2.38, 0.264, 335, 258, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1694, d1szmA_, 0.7924, 2.42, 0.270, 317, 259, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
1695, d4aw0A_, 0.7923, 2.59, 0.280, 283, 261, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
1696, d2ywpA_, 0.7923, 2.61, 0.276, 269, 261, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
1697, d2fgaA_, 0.7923, 2.61, 0.276, 269, 261,  
1698, d2br1A_, 0.7922, 2.65, 0.280, 272, 261, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1699, d4w8dA_, 0.7921, 2.56, 0.268, 289, 261, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
1700, d4o0vA1, 0.7921, 2.62, 0.264, 289, 261, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1701, d1okyA_, 0.7921, 2.37, 0.275, 281, 258, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1702, d4ks8A_, 0.7920, 2.66, 0.280, 286, 261, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1703, d3l9lA_, 0.7920, 2.45, 0.274, 338, 259, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1704, d1svhA_, 0.7920, 2.39, 0.264, 335, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
1705, d2brbA_, 0.7919, 2.57, 0.281, 272, 260, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1706, d3iecD_, 0.7918, 2.25, 0.311, 311, 254, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1707, d2vgoB_, 0.7917, 2.41, 0.292, 277, 257, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
1708, d3mfsA_, 0.7916, 2.90, 0.298, 303, 262, CASK-4M CAM KINASE DOMAIN AMPPNP
1709, d3l9mB_, 0.7914, 2.39, 0.264, 336, 258, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1710, d2e9nA_, 0.7914, 2.54, 0.277, 269, 260, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
1711, d3otuA_, 0.7912, 2.52, 0.271, 276, 258, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
1712, d1phkA_, 0.7912, 2.48, 0.282, 277, 259, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
1713, d5dh3B_, 0.7911, 2.53, 0.284, 283, 261, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1714, d4zy4A_, 0.7911, 2.31, 0.277, 288, 256, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
1715, d3e87B_, 0.7911, 2.45, 0.281, 321, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1716, d3e87A_, 0.7911, 2.45, 0.281, 321, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1717, d3a7jA_, 0.7911, 2.59, 0.273, 286, 260, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
1718, d2hxqA_, 0.7911, 2.56, 0.281, 272, 260, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
1719, d2hxlA_, 0.7911, 2.57, 0.281, 272, 260, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
1720, d2cgxA_, 0.7910, 2.54, 0.281, 265, 260, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1721, d4i6hA_, 0.7909, 2.56, 0.240, 285, 263, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1722, d2uztA_, 0.7909, 2.48, 0.263, 336, 259, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
1723, d2bujA1, 0.7909, 2.35, 0.241, 283, 257, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
1724, d1bkxA_, 0.7909, 2.37, 0.264, 337, 258, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1725, d4otgA_, 0.7907, 2.50, 0.288, 322, 260, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1726, d3c0hB_, 0.7907, 2.98, 0.289, 300, 263, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
1727, d1zltA_, 0.7907, 2.55, 0.277, 272, 260, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
1728, d5vloB_, 0.7906, 2.74, 0.294, 293, 262, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1729, d4otdA_, 0.7906, 2.57, 0.291, 334, 261, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1730, d4nusA_, 0.7906, 2.73, 0.282, 301, 262, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
1731, d4i6fA_, 0.7906, 2.57, 0.240, 285, 263, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1732, d2jdvA_, 0.7906, 2.50, 0.270, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
1733, d4u8zA_, 0.7905, 2.55, 0.268, 289, 261, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
1734, d1xjdA_, 0.7905, 2.45, 0.287, 280, 258, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
1735, d1j3hA_, 0.7904, 2.43, 0.270, 329, 259, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1736, d2aypA_, 0.7903, 2.50, 0.277, 268, 260, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
1737, d1xh9A_, 0.7903, 2.42, 0.264, 336, 258, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1738, d1o6kA_, 0.7903, 2.44, 0.281, 317, 260, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1739, d5l2tA_, 0.7902, 2.28, 0.488, 261, 256, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
1740, d4qo9B_, 0.7902, 2.59, 0.273, 285, 260, MST3 IN COMPLEX WITH DANUSERTIB
1741, d2vo0A_, 0.7902, 2.45, 0.260, 340, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1742, d2e9uA_, 0.7902, 2.55, 0.277, 269, 260, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
1743, d1o6lA_, 0.7902, 2.56, 0.280, 316, 261, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1744, d4qmoA_, 0.7901, 2.55, 0.268, 288, 261, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
1745, d4i5pA_, 0.7901, 2.58, 0.240, 284, 263, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1746, d2cgvA_, 0.7901, 2.49, 0.282, 264, 259, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1747, d3ag9B_, 0.7900, 2.47, 0.274, 317, 259, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1748, d6babD_, 0.7899, 2.76, 0.294, 291, 262, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1749, d4o0xA1, 0.7899, 2.66, 0.264, 289, 261, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1750, d4i6bA_, 0.7899, 2.60, 0.240, 285, 263, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1751, d3pscA2, 0.7899, 2.52, 0.272, 344, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1752, d3e88B_, 0.7899, 2.46, 0.281, 319, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1753, d3e88A_, 0.7899, 2.46, 0.281, 319, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1754, d2uw0A_, 0.7898, 2.47, 0.271, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
1755, d5h9bA_, 0.7897, 2.57, 0.320, 269, 259, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
1756, d4o0yA1, 0.7897, 2.66, 0.264, 289, 261, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1757, d3c0iA_, 0.7897, 2.99, 0.293, 298, 263, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
1758, d2uw6A_, 0.7897, 2.47, 0.267, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1759, d1q8wA_, 0.7897, 2.50, 0.270, 334, 259, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
1760, d5dh3A_, 0.7896, 2.58, 0.284, 287, 261, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1761, d1rekA_, 0.7896, 2.46, 0.270, 336, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1762, d1j3hB_, 0.7896, 2.44, 0.270, 327, 259, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1763, d5vefA_, 0.7895, 2.71, 0.264, 289, 261, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1764, d4ct2A_, 0.7895, 2.25, 0.281, 277, 256, HUMAN PDK1-PKCZETA KINASE CHIMERA
1765, d2vnwA_, 0.7895, 2.47, 0.267, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
1766, d2jdtA_, 0.7894, 2.44, 0.260, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1767, d5li1A1, 0.7893, 2.50, 0.288, 329, 260, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1768, d5k3yB_, 0.7892, 2.53, 0.295, 277, 258, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
1769, d5he1A2, 0.7892, 2.55, 0.268, 342, 261, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
1770, d3l9lB_, 0.7891, 2.43, 0.264, 337, 258, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1771, d4fijA_, 0.7890, 2.73, 0.264, 291, 261, CATALYTIC DOMAIN OF HUMAN PAK4
1772, d4fihA_, 0.7890, 2.72, 0.264, 291, 261, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
1773, d3e8dB_, 0.7890, 2.49, 0.285, 317, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1774, d3e8dA_, 0.7890, 2.49, 0.281, 315, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1775, d2i0eB_, 0.7890, 2.52, 0.252, 300, 262, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1776, d4ks7A_, 0.7889, 2.65, 0.280, 286, 261, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
1777, d2brnA_, 0.7889, 2.62, 0.277, 268, 260, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1778, d5he0A2, 0.7888, 2.56, 0.268, 346, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
1779, d4jdkA_, 0.7888, 2.66, 0.265, 288, 260, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1780, d5he2A2, 0.7886, 2.55, 0.268, 353, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
1781, d3l9nA_, 0.7886, 2.41, 0.264, 332, 258, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1782, d3ambA_, 0.7886, 2.45, 0.267, 340, 258, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
1783, d2i6lB_, 0.7885, 2.88, 0.331, 269, 260, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1784, d2cguA_, 0.7885, 2.52, 0.282, 263, 259, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1785, d2vo3A_, 0.7884, 2.43, 0.261, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1786, d2vn9B_, 0.7884, 2.61, 0.295, 301, 261, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1787, d1fotA_, 0.7884, 2.46, 0.263, 299, 259, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
1788, d4pnkA2, 0.7883, 2.54, 0.272, 350, 261, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
1789, d3d0eB_, 0.7883, 2.51, 0.281, 322, 260, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1790, d3d0eA_, 0.7883, 2.51, 0.281, 322, 260, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1791, d6aywA_, 0.7882, 2.59, 0.300, 293, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1792, d2bfyB_, 0.7882, 2.43, 0.281, 278, 256, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
1793, d5eykB_, 0.7881, 2.52, 0.280, 275, 257, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
1794, d2uw3A_, 0.7881, 2.49, 0.267, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1795, d2broA_, 0.7881, 2.73, 0.280, 272, 261, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1796, d2vnyA_, 0.7880, 2.43, 0.257, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
1797, d2vn9A_, 0.7880, 2.66, 0.303, 301, 261, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1798, d4jdjA_, 0.7879, 2.67, 0.265, 288, 260, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1799, d3mfrA_, 0.7879, 3.01, 0.297, 302, 263, CASK-4M CAM KINASE DOMAIN NATIVE
1800, d3cikA2, 0.7879, 2.77, 0.270, 347, 263, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1801, d2gnlA_, 0.7879, 2.48, 0.275, 338, 258, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
1802, d1uu7A_, 0.7879, 2.47, 0.271, 280, 258, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1803, d4qmqA_, 0.7878, 2.59, 0.268, 289, 261, MST3 IN COMPLEX WITH CP-673451
1804, d3c0hA_, 0.7878, 2.82, 0.291, 300, 261, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
1805, d2xckA_, 0.7878, 2.39, 0.270, 275, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1806, d2ojfE_, 0.7878, 2.50, 0.263, 336, 259, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1807, d1xh6A_, 0.7877, 2.46, 0.260, 331, 258, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1808, d3amaA_, 0.7876, 2.49, 0.267, 342, 258, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1809, d2uvyA_, 0.7876, 2.45, 0.261, 333, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1810, d5ig1A_, 0.7875, 2.66, 0.277, 300, 260, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1811, d2xikA_, 0.7875, 2.56, 0.278, 288, 259, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
1812, d4qmpA_, 0.7874, 2.62, 0.268, 289, 261, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
1813, d6b16A_, 0.7872, 2.33, 0.298, 285, 255, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
1814, d4ae6A_, 0.7872, 2.51, 0.273, 319, 260, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
1815, d1q61A_, 0.7872, 2.48, 0.264, 335, 258, PKA TRIPLE MUTANT MODEL OF PKB
1816, d3agmA_, 0.7871, 2.51, 0.278, 337, 259, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
1817, d1xh4A_, 0.7871, 2.43, 0.265, 334, 257, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1818, d4ntsA_, 0.7870, 2.51, 0.259, 341, 259, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1819, d2c3kA_, 0.7870, 2.51, 0.275, 262, 258, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
1820, d1xh7A_, 0.7870, 2.43, 0.265, 337, 257, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1821, d4c2vB_, 0.7869, 2.56, 0.288, 280, 257, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
1822, d2vgpA_, 0.7869, 2.23, 0.303, 265, 254, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
1823, d5ho7A_, 0.7868, 2.40, 0.273, 280, 256, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1824, d3dneA_, 0.7868, 2.47, 0.264, 336, 258, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1825, d3nayB_, 0.7867, 2.37, 0.277, 278, 256, PDK1 IN COMPLEX WITH INHIBITOR MP6
1826, d1sveA_, 0.7866, 2.47, 0.260, 341, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
1827, d2xchA_, 0.7865, 2.41, 0.273, 278, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1828, d2q0nA_, 0.7865, 2.66, 0.264, 293, 261, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1829, d2c1bA_, 0.7865, 2.49, 0.260, 335, 258, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1830, d2uw5A_, 0.7864, 2.54, 0.271, 333, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1831, d2f7zE_, 0.7864, 2.53, 0.263, 336, 259, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1832, d3pooA_, 0.7863, 2.40, 0.265, 331, 257, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1833, d2uvxA_, 0.7863, 2.56, 0.266, 335, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1834, d2f7eE_, 0.7863, 2.52, 0.263, 336, 259, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1835, d2e9vA_, 0.7863, 2.59, 0.277, 268, 260, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
1836, d2bfxB_, 0.7863, 2.44, 0.290, 275, 255, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
1837, d1ym7D3, 0.7863, 2.77, 0.270, 340, 263, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1838, d1ym7C3, 0.7863, 2.77, 0.270, 346, 263, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1839, d1q62A_, 0.7863, 2.51, 0.260, 336, 258, PKA DOUBLE MUTANT MODEL OF PKB
1840, d4c2wB_, 0.7862, 2.56, 0.288, 277, 257, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
1841, d4b8mB_, 0.7861, 2.66, 0.291, 279, 258, AURORA B KINASE IN COMPLEX WITH VX-680
1842, d2w99B_, 0.7861, 3.11, 0.463, 291, 268, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1843, d1svgA_, 0.7861, 2.47, 0.264, 338, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1844, d1omwA3, 0.7861, 2.65, 0.271, 344, 262, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
1845, d2c1aA_, 0.7860, 2.48, 0.260, 335, 258, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1846, d5l2iA_, 0.7859, 2.47, 0.490, 260, 257, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
1847, d4yr8F_, 0.7858, 2.33, 0.354, 300, 254, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1848, d3dndA_, 0.7858, 2.48, 0.264, 334, 258, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1849, d4o22A1, 0.7857, 2.40, 0.265, 333, 257, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1850, d3sc1A_, 0.7857, 2.41, 0.273, 278, 256, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
1851, d2vo6A_, 0.7857, 2.43, 0.272, 335, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
1852, d2f7xE_, 0.7857, 2.57, 0.269, 336, 260, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1853, d2e9vB_, 0.7857, 2.60, 0.277, 268, 260, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
1854, d3c0gB_, 0.7856, 2.99, 0.286, 320, 262, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1855, d2oh0E_, 0.7856, 2.57, 0.269, 336, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1856, d2cgwA_, 0.7856, 2.52, 0.279, 262, 258, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1857, d4qyeA_, 0.7855, 2.55, 0.280, 271, 257, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
1858, d2uw4A_, 0.7855, 2.51, 0.267, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1859, d2gdoA_, 0.7855, 2.55, 0.282, 269, 259, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
1860, d1ym7B3, 0.7855, 2.68, 0.271, 347, 262, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1861, d3mftA_, 0.7854, 2.92, 0.298, 302, 262, CASK-4M CAM KINASE DOMAIN MN2+
1862, d1ym7A3, 0.7854, 2.68, 0.271, 347, 262, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1863, d1vebA_, 0.7854, 2.54, 0.274, 338, 259, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
1864, d1re8A_, 0.7853, 2.53, 0.270, 337, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1865, d2uzwE_, 0.7852, 2.53, 0.263, 336, 259, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1866, d4rvkA_, 0.7851, 2.44, 0.281, 264, 256, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
1867, d3oogA_, 0.7851, 2.51, 0.264, 333, 258, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1868, d2vo7A_, 0.7851, 2.51, 0.264, 335, 258, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1869, d2uzuE_, 0.7851, 2.58, 0.273, 336, 260, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1870, d4yxrA_, 0.7850, 2.51, 0.264, 334, 258, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1871, d2vgpB_, 0.7850, 2.58, 0.288, 277, 257, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
1872, d2erzE_, 0.7850, 2.50, 0.260, 334, 258, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1873, d5ukmA2, 0.7848, 2.61, 0.272, 353, 261, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
1874, d2uvzA_, 0.7848, 2.49, 0.257, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
1875, d1ydsE_, 0.7848, 2.50, 0.264, 334, 258, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1876, d5oq5A_, 0.7847, 2.52, 0.279, 265, 258, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
1877, d4zy6A_, 0.7847, 2.32, 0.299, 284, 254, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1878, d5fg8A_, 0.7845, 2.65, 0.320, 269, 259, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1879, d4qyfA_, 0.7845, 2.46, 0.281, 269, 256, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
1880, d2uzvA_, 0.7845, 2.52, 0.270, 336, 259, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1881, d1ydrE_, 0.7844, 2.56, 0.270, 334, 259, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1882, d3c0gA_, 0.7843, 2.96, 0.290, 309, 262, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1883, d2gu8A_, 0.7843, 2.42, 0.265, 335, 257, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
1884, d4qo9A_, 0.7842, 2.59, 0.270, 280, 259, MST3 IN COMPLEX WITH DANUSERTIB
1885, d3eqrB_, 0.7842, 2.43, 0.253, 271, 257, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
1886, d2brmA_, 0.7842, 2.58, 0.283, 263, 258, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1887, d4aw1A_, 0.7841, 2.51, 0.272, 283, 257, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
1888, d3a7gA_, 0.7841, 2.63, 0.269, 289, 260, HUMAN MST3 KINASE
1889, d2gnhA_, 0.7841, 2.50, 0.279, 338, 258, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1890, d4l67A_, 0.7840, 2.76, 0.264, 289, 261, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
1891, d4appA1, 0.7838, 2.79, 0.264, 290, 261, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
1892, d3aglB_, 0.7838, 2.51, 0.267, 335, 258, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1893, d2gnjA_, 0.7838, 2.53, 0.275, 335, 258, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1894, d5he3A2, 0.7837, 2.65, 0.268, 346, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
1895, d3p0mA_, 0.7837, 2.52, 0.264, 335, 258, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1896, d4zy5A_, 0.7835, 2.28, 0.281, 283, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
1897, d4ez5A_, 0.7835, 2.38, 0.482, 258, 255, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1898, d2gnfA_, 0.7835, 2.51, 0.279, 339, 258, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1899, d4ae9A_, 0.7834, 2.51, 0.270, 321, 259, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
1900, d1q8uA_, 0.7834, 2.52, 0.264, 341, 258, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
1901, d1nvsA_, 0.7834, 2.47, 0.281, 264, 256, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
1902, d1nvrA_, 0.7832, 2.47, 0.281, 264, 256, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
1903, d2vrxB_, 0.7831, 2.45, 0.291, 274, 254, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
1904, d5jznB_, 0.7830, 2.19, 0.299, 266, 251, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
1905, d3oxtA_, 0.7830, 2.49, 0.268, 335, 257, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1906, d3f3zA_, 0.7830, 2.69, 0.274, 271, 259, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
1907, d4ftiA_, 0.7829, 2.48, 0.281, 270, 256, CRYSTAL STRUCTURE OF THE CHK1
1908, d1nvqA_, 0.7829, 2.48, 0.281, 264, 256, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
1909, d5hngA_, 0.7827, 2.46, 0.273, 280, 256, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1910, d2hy0A_, 0.7827, 2.49, 0.281, 272, 256, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
1911, d2bdwB_, 0.7827, 2.68, 0.310, 309, 261, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
1912, d4fsnA_, 0.7826, 2.42, 0.278, 270, 255, CRYSTAL STRUCTURE OF THE CHK1
1913, d3tkiA_, 0.7826, 2.59, 0.280, 272, 257, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
1914, d3nayA_, 0.7826, 2.43, 0.277, 278, 256, PDK1 IN COMPLEX WITH INHIBITOR MP6
1915, d3a7hA_, 0.7826, 2.66, 0.273, 289, 260, HUMAN MST3 KINASE IN COMPLEX WITH ATP
1916, d1ydtE_, 0.7826, 2.53, 0.264, 334, 258, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
1917, d1q8tA_, 0.7826, 2.53, 0.264, 338, 258, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
1918, d2uw8A_, 0.7825, 2.51, 0.257, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1919, d2gngA_, 0.7824, 2.57, 0.286, 338, 259, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1920, d5oorA_, 0.7823, 2.42, 0.278, 273, 255, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
1921, d2hogA_, 0.7823, 2.47, 0.285, 272, 256, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
1922, d4rvmA_, 0.7822, 2.48, 0.281, 264, 256, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
1923, d3tnqB_, 0.7822, 2.58, 0.271, 331, 258, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1924, d4wbbB_, 0.7821, 2.57, 0.271, 334, 258, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1925, d4ftuA_, 0.7821, 2.54, 0.285, 270, 256, CRYSTAL STRUCTURE OF THE CHK1
1926, d3ag9A_, 0.7820, 2.49, 0.257, 323, 257, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1927, d3e5aA_, 0.7819, 2.66, 0.300, 264, 257, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
1928, d2qvsE_, 0.7818, 2.63, 0.269, 323, 260, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
1929, d1okzA_, 0.7818, 2.30, 0.280, 276, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
1930, d5eykA_, 0.7817, 2.42, 0.299, 263, 254, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
1931, d3nusA_, 0.7817, 2.35, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
1932, d3iopA_, 0.7817, 2.43, 0.275, 275, 255, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
1933, d2c3lA_, 0.7817, 2.52, 0.281, 265, 256, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
1934, d3h9oA_, 0.7816, 2.44, 0.275, 275, 255, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
1935, d2cdzA_, 0.7816, 2.69, 0.266, 289, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1936, d3rwpA_, 0.7815, 2.46, 0.275, 277, 255, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1937, d3nuuA_, 0.7815, 2.34, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
1938, d3idbA_, 0.7815, 2.55, 0.260, 341, 258, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1939, d3e8eI_, 0.7815, 2.52, 0.264, 345, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1940, d1jluE_, 0.7815, 2.54, 0.260, 337, 258, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1941, d2v7oA1, 0.7814, 2.74, 0.300, 297, 260, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
1942, d4ft7A_, 0.7813, 2.46, 0.282, 270, 255, CRYSTAL STRUCTURE OF THE CHK1
1943, d3w2qA1, 0.7813, 2.73, 0.211, 306, 261, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
1944, d3ow3A_, 0.7813, 2.46, 0.265, 334, 257, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1945, d3mvjE_, 0.7813, 2.58, 0.278, 334, 259, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1946, d3e8cF_, 0.7813, 2.54, 0.267, 341, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1947, d5i0bA_, 0.7812, 2.58, 0.267, 288, 258, STRUCTURE OF PAK4
1948, d3nuyA_, 0.7811, 2.36, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
1949, d4ewhB_, 0.7810, 2.53, 0.252, 273, 258, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
1950, d2r2pA1, 0.7810, 2.42, 0.218, 276, 257, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
1951, d5oopA_, 0.7809, 2.47, 0.281, 261, 256, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
1952, d3e8cD_, 0.7809, 2.60, 0.274, 344, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1953, d5vloA_, 0.7807, 2.58, 0.296, 290, 257, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1954, d5ho8A_, 0.7807, 2.35, 0.276, 278, 254, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1955, d3e8cB_, 0.7807, 2.61, 0.274, 344, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1956, d3e8cA_, 0.7807, 2.61, 0.274, 341, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1957, d3e8cE_, 0.7806, 2.61, 0.274, 336, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1958, d3e8cC_, 0.7806, 2.61, 0.274, 341, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1959, d4ewhA_, 0.7805, 2.55, 0.252, 274, 258, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
1960, d3w2oA1, 0.7804, 2.74, 0.211, 304, 261, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
1961, d3nunA_, 0.7804, 2.38, 0.276, 278, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
1962, d3d5xA_, 0.7804, 2.35, 0.267, 279, 255, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
1963, d4qyhB_, 0.7803, 2.50, 0.281, 264, 256, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
1964, d5uklA2, 0.7802, 2.71, 0.272, 353, 261, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
1965, d4j7bA_, 0.7802, 2.38, 0.272, 284, 254, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1966, d3v5wA2, 0.7802, 2.70, 0.272, 355, 261, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
1967, d2jdsA_, 0.7802, 2.53, 0.265, 334, 257, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
1968, d1jbpE_, 0.7802, 2.55, 0.264, 339, 258, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1969, d4qygB_, 0.7801, 2.50, 0.281, 264, 256, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
1970, d3orzB_, 0.7801, 2.54, 0.273, 278, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1971, d2gniA_, 0.7801, 2.56, 0.279, 338, 258, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1972, d3qcqA_, 0.7800, 2.39, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
1973, d3orzD_, 0.7800, 2.54, 0.273, 278, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1974, d4hyhA_, 0.7799, 2.51, 0.281, 263, 256, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
1975, d3qd3A_, 0.7799, 2.39, 0.276, 278, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
1976, d1uu8A_, 0.7799, 2.43, 0.275, 277, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
1977, d4qygA_, 0.7798, 2.53, 0.281, 264, 256, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
1978, d2gfcA_, 0.7798, 2.59, 0.264, 335, 258, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1979, d4qyhA_, 0.7797, 2.54, 0.281, 264, 256, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
1980, d4j7bD_, 0.7797, 2.36, 0.273, 281, 253, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1981, d4ft0A_, 0.7797, 2.43, 0.283, 266, 254, CRYSTAL STRUCTURE OF THE CHK1
1982, d5jznA_, 0.7796, 2.30, 0.294, 268, 252, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
1983, d5jzjA_, 0.7796, 2.23, 0.300, 271, 250, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
1984, d3ztxB_, 0.7796, 2.47, 0.285, 272, 253, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
1985, d4ft3A_, 0.7794, 2.38, 0.283, 269, 254, CRYSTAL STRUCTURE OF THE CHK1
1986, d3nx8A_, 0.7794, 2.64, 0.274, 333, 259, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
1987, d3e8eP_, 0.7794, 2.58, 0.264, 341, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1988, d4njdA1, 0.7793, 2.81, 0.264, 289, 261, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1989, d3qcsA_, 0.7793, 2.40, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
1990, d3qcxA_, 0.7791, 2.40, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
1991, d2qurA_, 0.7790, 2.56, 0.260, 338, 258, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1992, d1q24A_, 0.7790, 2.61, 0.256, 335, 258, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1993, d1eh4B_, 0.7790, 2.62, 0.176, 293, 261, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
1994, d5xdkA_, 0.7789, 2.70, 0.208, 307, 260, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
1995, d3orxE_, 0.7789, 2.39, 0.278, 274, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1996, d2r7bA_, 0.7789, 2.38, 0.280, 274, 254, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
1997, d3ha6A1, 0.7788, 2.35, 0.300, 262, 253, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
1998, d4ft9A_, 0.7787, 2.45, 0.280, 270, 254, CRYSTAL STRUCTURE OF THE CHK1
1999, d6brcA1, 0.7786, 2.55, 0.290, 263, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2000, d4o21A_, 0.7786, 2.55, 0.268, 333, 257, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
2001, d3ionA_, 0.7786, 2.44, 0.276, 274, 254, PDK1 IN COMPLEX WITH COMPOUND 8H
2002, d4auaA_, 0.7785, 2.20, 0.474, 256, 251, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
2003, d3nlbA_, 0.7784, 2.55, 0.277, 261, 256, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
2004, d2e9pA_, 0.7783, 2.77, 0.278, 269, 259, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
2005, d5op7A_, 0.7782, 2.44, 0.275, 261, 255, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2006, d1uu3A_, 0.7782, 2.43, 0.276, 276, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2007, d3w2pA1, 0.7781, 2.76, 0.211, 307, 261, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
2008, d3orxG_, 0.7781, 2.34, 0.280, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2009, d3ot3A_, 0.7780, 2.49, 0.280, 259, 254, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
2010, d3orxF_, 0.7780, 2.35, 0.280, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2011, d3c4eB_, 0.7780, 2.41, 0.256, 273, 254, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2012, d3e8eA_, 0.7778, 2.61, 0.267, 341, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2013, d5uyjA1, 0.7777, 2.59, 0.289, 279, 256, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2014, d5e8xA_, 0.7777, 2.47, 0.217, 304, 254, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
2015, d3orxH_, 0.7777, 2.35, 0.280, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2016, d3e8eE_, 0.7777, 2.58, 0.267, 341, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2017, d3qcyA_, 0.7776, 2.34, 0.281, 275, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2018, d3orzC_, 0.7776, 2.54, 0.275, 276, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2019, d3c4eA_, 0.7776, 2.41, 0.256, 273, 254, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2020, d3orzA_, 0.7775, 2.55, 0.275, 276, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2021, d3fjqE_, 0.7775, 2.63, 0.264, 334, 258, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
2022, d2pe2A_, 0.7775, 2.46, 0.276, 275, 254, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2023, d1apmE_, 0.7774, 2.60, 0.264, 338, 258, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
2024, d5opvA_, 0.7773, 2.46, 0.276, 261, 254, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2025, d3e8eB_, 0.7773, 2.60, 0.267, 337, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2026, d2pe0A_, 0.7773, 2.46, 0.276, 275, 254, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2027, d1uu9A_, 0.7773, 2.42, 0.276, 276, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2028, d5ootA_, 0.7770, 2.43, 0.276, 260, 254, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2029, d3gu5A1, 0.7770, 2.56, 0.265, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
2030, d3a7fA_, 0.7769, 2.48, 0.275, 283, 255, HUMAN MST3 KINASE
2031, d1z5mA_, 0.7769, 2.47, 0.276, 275, 254, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2032, d1fmoE_, 0.7769, 2.61, 0.264, 336, 258, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
2033, d5hkmA_, 0.7768, 2.37, 0.277, 272, 253, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2034, d5dlsA_, 0.7768, 2.45, 0.281, 257, 253, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
2035, d3tkhA_, 0.7766, 2.54, 0.283, 269, 254, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
2036, d3qamE_, 0.7766, 2.63, 0.260, 348, 258, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2037, d3comA_, 0.7766, 2.44, 0.278, 264, 255, CRYSTAL STRUCTURE OF MST1 KINASE
2038, d5ukkA2, 0.7765, 2.76, 0.264, 348, 261, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
2039, d2brgA_, 0.7765, 2.38, 0.281, 257, 253, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2040, d3e8eL_, 0.7764, 2.60, 0.267, 336, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2041, d3comB_, 0.7764, 2.50, 0.280, 279, 257, CRYSTAL STRUCTURE OF MST1 KINASE
2042, d2zm3B2, 0.7764, 2.62, 0.205, 295, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2043, d2cpkE_, 0.7764, 2.59, 0.265, 333, 257, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
2044, d1xwsA_, 0.7764, 2.30, 0.257, 273, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
2045, d1sykA_, 0.7764, 2.62, 0.256, 348, 258, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
2046, d4fsrA_, 0.7763, 2.49, 0.280, 269, 254, CRYSTAL STRUCTURE OF THE CHK1
2047, d1atpE_, 0.7763, 2.63, 0.264, 334, 258, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
2048, d2wtkC1, 0.7762, 2.44, 0.273, 261, 253, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
2049, d1sykB_, 0.7761, 2.62, 0.256, 323, 258, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
2050, d4j96B_, 0.7760, 2.67, 0.245, 305, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
2051, d1rdqE_, 0.7759, 2.56, 0.261, 340, 257, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2052, d1jkkA_, 0.7759, 2.57, 0.265, 277, 257, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2053, d5w4wB_, 0.7758, 2.68, 0.192, 291, 260, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2054, d5ugbA_, 0.7758, 2.70, 0.205, 307, 259, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
2055, d2c30A_, 0.7758, 2.84, 0.251, 289, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
2056, d3o7lB_, 0.7757, 2.49, 0.251, 326, 255, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2057, d2x7fC_, 0.7757, 2.27, 0.263, 285, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2058, d5ui0B_, 0.7755, 2.67, 0.241, 304, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2059, d4ll5A_, 0.7755, 2.33, 0.257, 268, 253, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2060, d2w9zB_, 0.7755, 3.15, 0.466, 287, 266, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2061, d3dlsA_, 0.7754, 2.68, 0.258, 285, 256, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2062, d3c4eC_, 0.7753, 2.46, 0.256, 272, 254, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2063, d5jzjB_, 0.7752, 2.16, 0.298, 261, 248, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2064, d4fsuA_, 0.7752, 2.54, 0.280, 260, 254, CRYSTAL STRUCTURE OF THE CHK1
2065, d4wnpB_, 0.7751, 2.50, 0.295, 272, 254, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2066, d3gu4A1, 0.7751, 2.58, 0.265, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2067, d5em8A_, 0.7750, 2.78, 0.205, 303, 259, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
2068, d2pe1A_, 0.7750, 2.49, 0.276, 275, 254, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2069, d5w4wA_, 0.7749, 2.69, 0.192, 291, 260, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2070, d4x6rA_, 0.7749, 2.65, 0.275, 347, 258, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2071, d3mvjB_, 0.7749, 2.63, 0.264, 320, 258, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2072, d2x7fB_, 0.7749, 2.44, 0.261, 288, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2073, d4wnpA_, 0.7748, 2.61, 0.294, 273, 255, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2074, d1yxsA_, 0.7748, 2.47, 0.256, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
2075, d1ig1A_, 0.7748, 2.58, 0.265, 280, 257, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2076, d5ig1B_, 0.7747, 2.80, 0.278, 304, 259, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2077, d5telA_, 0.7746, 2.38, 0.257, 273, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2078, d3gu7A1, 0.7746, 2.59, 0.265, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2079, d2yexA_, 0.7746, 2.87, 0.272, 269, 261, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2080, d2j2iB_, 0.7746, 2.33, 0.257, 273, 253, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
2081, d2j0lA_, 0.7746, 2.46, 0.255, 274, 255, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
2082, d2bzhB_, 0.7746, 2.32, 0.253, 275, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2083, d4zy4B_, 0.7745, 2.64, 0.311, 292, 254, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2084, d1jksA_, 0.7745, 2.59, 0.265, 280, 257, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2085, d5c1qB_, 0.7744, 2.33, 0.257, 273, 253, SERINE/THREONINE-PROTEIN KINASE PIM-1
2086, d4k1bA_, 0.7744, 2.34, 0.257, 273, 253, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2087, d3vbyA_, 0.7744, 2.38, 0.257, 267, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2088, d3bhhB1, 0.7742, 2.64, 0.309, 288, 256, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2089, d1jklA_, 0.7742, 2.60, 0.265, 280, 257, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2090, d5uy6A1, 0.7741, 2.59, 0.286, 280, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2091, d5mjbB_, 0.7741, 2.64, 0.229, 278, 258, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2092, d4j99B_, 0.7741, 2.71, 0.241, 291, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2093, d3qalE_, 0.7741, 2.57, 0.261, 339, 257, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2094, d2phkA_, 0.7741, 2.75, 0.282, 277, 259, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2095, d5l8kA_, 0.7740, 2.62, 0.302, 266, 255, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
2096, d3odyX_, 0.7740, 2.88, 0.374, 321, 257, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
2097, d3dfcB1, 0.7740, 2.59, 0.265, 276, 257, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2098, d2oi4X_, 0.7740, 2.33, 0.257, 275, 253, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
2099, d2bzjA_, 0.7740, 2.36, 0.257, 273, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
2100, d1ywvA_, 0.7740, 2.36, 0.257, 274, 253, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
2101, d6babB_, 0.7739, 2.75, 0.301, 285, 256, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2102, d4zy5B_, 0.7739, 2.66, 0.311, 287, 254, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2103, d3vbtA_, 0.7739, 2.39, 0.257, 267, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2104, d2qcsA_, 0.7739, 2.63, 0.265, 335, 257, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
2105, d2bikB_, 0.7739, 2.41, 0.257, 272, 253, HUMAN PIM1 PHOSPHORYLATED ON SER261
2106, d3q4zA1, 0.7738, 2.31, 0.271, 281, 251, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2107, d4mbiA_, 0.7737, 2.50, 0.256, 274, 254, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2108, d4b4lA_, 0.7737, 2.72, 0.263, 299, 259, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2109, d3we8A_, 0.7737, 2.38, 0.257, 273, 253, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
2110, d1rqqB_, 0.7737, 2.93, 0.204, 294, 260, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2111, d3qd4A_, 0.7736, 2.39, 0.274, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2112, d2j0iA_, 0.7736, 2.71, 0.268, 289, 257, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2113, d2c3jA_, 0.7736, 2.48, 0.273, 257, 253, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2114, d4rpvA_, 0.7735, 2.35, 0.257, 273, 253, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
2115, d4j96A_, 0.7735, 2.71, 0.245, 302, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
2116, d4bbmB1, 0.7735, 2.92, 0.402, 288, 259, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
2117, d3dgkA1, 0.7735, 2.61, 0.265, 276, 257, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2118, d5ui0A_, 0.7734, 2.71, 0.241, 301, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2119, d4j95B_, 0.7734, 2.66, 0.242, 282, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2120, d2itwA_, 0.7734, 2.61, 0.214, 300, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
2121, d6bqqA1, 0.7733, 2.44, 0.285, 269, 253, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
2122, d5b2lA_, 0.7733, 2.53, 0.235, 288, 255, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
2123, d4medA_, 0.7733, 2.32, 0.262, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
2124, d4ae6B_, 0.7733, 2.63, 0.258, 321, 256, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2125, d3zh8C_, 0.7733, 2.72, 0.288, 312, 260, A NOVEL SMALL MOLECULE APKC INHIBITOR
2126, d3vbxA_, 0.7733, 2.40, 0.257, 268, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2127, d3eqrA_, 0.7733, 2.60, 0.255, 270, 255, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2128, d2gs2A_, 0.7733, 2.69, 0.205, 305, 258, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
2129, d2brhA_, 0.7733, 2.50, 0.285, 257, 253, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2130, d1yxuB_, 0.7733, 2.50, 0.256, 273, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2131, d3mvjA_, 0.7732, 2.67, 0.264, 334, 258, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2132, d2gs6A2, 0.7732, 2.66, 0.202, 308, 258, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
2133, d1u7eA_, 0.7732, 2.57, 0.265, 338, 257,  
2134, d5w4wC_, 0.7731, 2.70, 0.188, 284, 260, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2135, d5texA_, 0.7731, 2.52, 0.256, 274, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2136, d4fszA_, 0.7731, 2.48, 0.281, 268, 253, CRYSTAL STRUCTURE OF THE CHK1
2137, d4as0A_, 0.7731, 2.35, 0.257, 273, 253, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
2138, d5kgkA_, 0.7730, 2.36, 0.257, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
2139, d3nupA_, 0.7730, 2.23, 0.470, 252, 249, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
2140, d3jxwA_, 0.7730, 2.39, 0.257, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2141, d3gu6A1, 0.7730, 2.62, 0.265, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2142, d3fhiA_, 0.7730, 2.58, 0.265, 336, 257, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
2143, d2xuuA_, 0.7730, 2.79, 0.250, 301, 260, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2144, d1yxuA_, 0.7730, 2.36, 0.253, 273, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2145, d6brcB_, 0.7729, 2.44, 0.294, 260, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2146, d5dgzA_, 0.7729, 2.37, 0.257, 273, 253, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2147, d4wt6A_, 0.7729, 2.48, 0.252, 273, 254, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2148, d3bwjA_, 0.7729, 2.54, 0.262, 338, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2149, d2z8cA1, 0.7729, 2.80, 0.202, 297, 258, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
2150, d1m14A_, 0.7729, 2.63, 0.214, 307, 257, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
2151, d1cdkB_, 0.7729, 2.70, 0.267, 342, 258, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2152, d4j98B_, 0.7728, 2.66, 0.242, 304, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2153, d3zh8A_, 0.7728, 2.73, 0.288, 318, 260, A NOVEL SMALL MOLECULE APKC INHIBITOR
2154, d3bu6A_, 0.7728, 2.79, 0.202, 294, 257, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
2155, d1m17A_, 0.7728, 2.81, 0.212, 312, 259, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
2156, d5op4A_, 0.7727, 2.39, 0.278, 259, 252, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
2157, d5kgeA_, 0.7727, 2.38, 0.257, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
2158, d4yznA_, 0.7727, 2.43, 0.228, 269, 250, HUMANIZED ROCO4 BOUND TO COMPOUND 19
2159, d2x8eA_, 0.7727, 2.59, 0.275, 259, 255, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2160, d1yxvA_, 0.7727, 2.38, 0.253, 274, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
2161, d5kgdA_, 0.7726, 2.37, 0.253, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2162, d5auyA_, 0.7726, 2.56, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2163, d4xh6A_, 0.7726, 2.36, 0.253, 273, 253, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
2164, d4pf4A1, 0.7726, 2.62, 0.265, 277, 257, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2165, d2zm3A2, 0.7726, 2.72, 0.212, 299, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2166, d2yerA_, 0.7726, 2.82, 0.273, 268, 260, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2167, d2v7aB_, 0.7726, 2.60, 0.242, 268, 256, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2168, d5eg3A_, 0.7725, 2.74, 0.236, 301, 258, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
2169, d4wsyA_, 0.7725, 2.37, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
2170, d3ehaA1, 0.7725, 2.63, 0.261, 275, 257, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2171, d1yxuC_, 0.7725, 2.39, 0.257, 272, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2172, d6bkuA1, 0.7724, 2.60, 0.283, 264, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2173, d5op5A_, 0.7724, 2.45, 0.277, 259, 253, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2174, d5kgiA_, 0.7724, 2.37, 0.253, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
2175, d4jq8A_, 0.7724, 2.65, 0.214, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
2176, d2w4jA_, 0.7724, 2.63, 0.265, 276, 257, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2177, d5oq6A_, 0.7723, 2.42, 0.274, 257, 252, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2178, d4wrsA_, 0.7723, 2.38, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2179, d3r01A_, 0.7723, 2.39, 0.253, 274, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2180, d2j5eA_, 0.7723, 2.97, 0.206, 309, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
2181, d4j98A_, 0.7722, 2.78, 0.241, 304, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2182, d3vbvA_, 0.7722, 2.40, 0.253, 268, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2183, d3jyaA_, 0.7722, 2.40, 0.253, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2184, d3gu8A1, 0.7722, 2.61, 0.265, 276, 257, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2185, d2qhmA_, 0.7722, 2.46, 0.274, 268, 252, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
2186, d4fsyA_, 0.7721, 2.45, 0.286, 267, 252, CRYSTAL STRUCTURE OF THE CHK1
2187, d3jpvA_, 0.7721, 2.37, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
2188, d5turA_, 0.7720, 2.50, 0.252, 270, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2189, d4uxlA_, 0.7720, 2.43, 0.237, 288, 253, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
2190, d2v7aA_, 0.7720, 2.65, 0.234, 269, 256, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2191, d4k18A_, 0.7719, 2.37, 0.261, 277, 253, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2192, d3zh8B_, 0.7719, 2.74, 0.288, 317, 260, A NOVEL SMALL MOLECULE APKC INHIBITOR
2193, d3qd0A_, 0.7719, 2.42, 0.274, 274, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2194, d2r0uA_, 0.7719, 2.50, 0.281, 269, 253, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
2195, d2o64A_, 0.7719, 2.51, 0.252, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
2196, d6babA_, 0.7718, 2.96, 0.295, 290, 261, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2197, d4wnpD_, 0.7718, 2.58, 0.295, 272, 254, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2198, d3pa3A_, 0.7718, 2.58, 0.283, 259, 254, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
2199, d2o3pA_, 0.7718, 2.52, 0.256, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
2200, d4jq7A_, 0.7717, 2.67, 0.214, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
2201, d2eb2A_, 0.7717, 2.67, 0.202, 305, 257, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
2202, d2bziB_, 0.7717, 2.35, 0.258, 272, 252, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
2203, d1l3rE_, 0.7717, 2.57, 0.266, 338, 256, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2204, d3r04A_, 0.7716, 2.39, 0.253, 271, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2205, d1eh4A_, 0.7716, 2.70, 0.180, 293, 261, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2206, d5ugxA_, 0.7715, 2.78, 0.237, 297, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
2207, d5kcxA_, 0.7715, 2.52, 0.252, 272, 254, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
2208, d4mblA_, 0.7715, 2.39, 0.253, 274, 253, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2209, d4ftrA_, 0.7715, 2.33, 0.280, 258, 250, CRYSTAL STRUCTURE OF THE CHK1
2210, d4ftjA_, 0.7715, 2.47, 0.286, 266, 252, CRYSTAL STRUCTURE OF THE CHK1
2211, d4a7cA_, 0.7715, 2.43, 0.257, 273, 253, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
2212, d3bwfA_, 0.7715, 2.41, 0.257, 273, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
2213, d3bu3A_, 0.7715, 2.82, 0.202, 294, 257, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
2214, d2qhnA_, 0.7715, 2.47, 0.274, 268, 252, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
2215, d1yxxA_, 0.7715, 2.40, 0.253, 274, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
2216, d5xgnA_, 0.7714, 2.64, 0.214, 302, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2217, d5toeA_, 0.7714, 2.54, 0.256, 272, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2218, d5av3A_, 0.7714, 2.59, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2219, d3uzpA_, 0.7714, 2.72, 0.188, 292, 260, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
2220, d3lvpC_, 0.7714, 2.81, 0.208, 293, 260, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2221, d5flfC_, 0.7713, 2.88, 0.240, 283, 258, DISEASE LINKED MUTATION IN FGFR
2222, d5dhjA_, 0.7713, 2.38, 0.253, 273, 253, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2223, d4trlA_, 0.7713, 2.39, 0.213, 268, 253, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2224, d4gh2A_, 0.7713, 2.28, 0.288, 266, 250, CRYSTAL STRUCTURE OF THE CHK1
2225, d2itqA_, 0.7713, 2.66, 0.210, 300, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
2226, d4u44A_, 0.7712, 2.57, 0.275, 286, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2227, d4ty1A_, 0.7712, 2.48, 0.252, 273, 254, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
2228, d3tnpF_, 0.7712, 2.64, 0.265, 334, 257, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2229, d3tnpC_, 0.7712, 2.64, 0.265, 334, 257, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2230, d3f5gA1, 0.7712, 2.60, 0.266, 275, 256, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2231, d2itpA_, 0.7712, 2.77, 0.209, 305, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
2232, d4x6qC_, 0.7711, 2.65, 0.265, 334, 257, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2233, d4f1oA1, 0.7711, 2.60, 0.229, 274, 253, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
2234, d3r00A_, 0.7711, 2.40, 0.253, 274, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2235, d3b2tA_, 0.7711, 2.75, 0.241, 288, 257, STRUCTURE OF PHOSPHOTRANSFERASE
2236, d2bujB1, 0.7711, 2.53, 0.244, 277, 254, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2237, d4jr3A_, 0.7710, 2.69, 0.214, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
2238, d4aluA_, 0.7710, 2.40, 0.253, 274, 253, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2239, d3kulB_, 0.7710, 2.55, 0.207, 271, 256, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2240, d3f5uA1, 0.7710, 2.59, 0.262, 275, 256, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2241, d2o65A_, 0.7710, 2.53, 0.260, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
2242, d4hnfA_, 0.7709, 2.59, 0.191, 289, 257, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2243, d1k3aA_, 0.7709, 2.85, 0.212, 288, 259, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
2244, d5opuA_, 0.7708, 2.54, 0.280, 261, 254, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2245, d4j99C_, 0.7708, 2.79, 0.241, 291, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2246, d3dlsD_, 0.7708, 2.58, 0.260, 284, 254, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2247, d2qg5B1, 0.7708, 2.62, 0.263, 275, 255, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2248, d4lm5A_, 0.7707, 2.37, 0.258, 264, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
2249, d4hnfB_, 0.7707, 2.70, 0.185, 290, 260, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2250, d3vc4A_, 0.7707, 2.41, 0.253, 274, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2251, d3lcdA_, 0.7707, 2.55, 0.220, 290, 255, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
2252, d3eh9A1, 0.7707, 2.60, 0.266, 274, 256, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2253, d2o63A_, 0.7707, 2.54, 0.256, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
2254, d1ir3A_, 0.7707, 2.91, 0.205, 300, 259, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
2255, d5kggA_, 0.7706, 2.41, 0.253, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
2256, d5cavA_, 0.7706, 2.66, 0.214, 306, 257, EGFR KINASE DOMAIN WITH COMPOUND 41A
2257, d5av2A_, 0.7706, 2.61, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2258, d5av1A_, 0.7706, 2.60, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2259, d4tw9B_, 0.7706, 2.72, 0.188, 289, 260, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2260, d4i41A_, 0.7706, 2.37, 0.262, 272, 252, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
2261, d2yakA_, 0.7705, 2.68, 0.260, 277, 258, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2262, d1ol5A_, 0.7705, 2.42, 0.302, 263, 252, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2263, d4jx7A_, 0.7704, 2.41, 0.253, 274, 253, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
2264, d2zm3D2, 0.7704, 2.69, 0.214, 292, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2265, d5auvA_, 0.7703, 2.61, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2266, d4n6yA_, 0.7703, 2.34, 0.258, 273, 252, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
2267, d4kbkB_, 0.7703, 2.71, 0.188, 289, 260, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2268, d4f0fA1, 0.7703, 2.67, 0.236, 274, 254, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
2269, d3ikaA_, 0.7703, 2.64, 0.215, 310, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2270, d5mjbA_, 0.7702, 2.50, 0.231, 276, 255, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2271, d4yo4A1, 0.7702, 2.66, 0.265, 276, 257, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
2272, d4twcB_, 0.7702, 2.73, 0.188, 292, 260, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2273, d4alvA_, 0.7702, 2.41, 0.253, 274, 253, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2274, d1u59A1, 0.7702, 2.64, 0.227, 276, 256, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2275, d6bqlA1, 0.7701, 2.63, 0.287, 276, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
2276, d5x18A_, 0.7701, 2.74, 0.212, 294, 260, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
2277, d4f1mA1, 0.7701, 2.61, 0.225, 274, 253, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
2278, d3uytB_, 0.7701, 2.66, 0.186, 286, 258, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2279, d5flfB_, 0.7700, 2.91, 0.236, 292, 258, DISEASE LINKED MUTATION IN FGFR
2280, d5av0A_, 0.7700, 2.61, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2281, d4u45A_, 0.7700, 2.59, 0.275, 289, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2282, d4id7A_, 0.7700, 2.41, 0.257, 268, 253, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
2283, d4fttA_, 0.7700, 2.45, 0.279, 266, 251, CRYSTAL STRUCTURE OF THE CHK1
2284, d3r02A_, 0.7700, 2.42, 0.253, 271, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2285, d3idcA_, 0.7700, 2.69, 0.260, 341, 258, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2286, d6b16B_, 0.7699, 2.42, 0.300, 281, 250, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2287, d5ipjA_, 0.7699, 2.42, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
2288, d2j6mA_, 0.7699, 2.68, 0.214, 306, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
2289, d5u6bB1, 0.7698, 2.71, 0.216, 289, 259, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2290, d5ng0B_, 0.7698, 2.76, 0.228, 282, 259, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2291, d4jx3A_, 0.7698, 2.41, 0.261, 274, 253, CRYSTAL STRUCTURE OF PIM1 KINASE
2292, d4rc4A_, 0.7697, 2.37, 0.258, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2293, d4mtaA_, 0.7697, 2.42, 0.253, 273, 253, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2294, d3uytA_, 0.7697, 2.61, 0.191, 287, 257, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2295, d3u9nA_, 0.7697, 2.56, 0.281, 257, 253, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
2296, d3aglA_, 0.7697, 2.69, 0.264, 338, 258, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2297, d5hibA_, 0.7696, 2.89, 0.201, 314, 259, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2298, d4dtkA_, 0.7696, 2.42, 0.253, 273, 253, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
2299, d1zwsB_, 0.7696, 2.69, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2300, d5v82A_, 0.7695, 2.41, 0.257, 273, 253, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
2301, d5hu3A_, 0.7695, 2.72, 0.320, 266, 256, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2302, d4rc2A_, 0.7695, 2.38, 0.258, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2303, d4k0yA_, 0.7695, 2.41, 0.253, 274, 253, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2304, d4i23A_, 0.7695, 2.66, 0.203, 304, 256, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
2305, d3up2A_, 0.7695, 2.50, 0.295, 266, 254, AURORA A IN COMPLEX WITH RPM1686
2306, d2itxA_, 0.7695, 2.78, 0.209, 307, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
2307, d1gagA_, 0.7695, 2.92, 0.205, 300, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
2308, d5u6bD1, 0.7694, 2.71, 0.216, 289, 259, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2309, d5autA_, 0.7694, 2.56, 0.267, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2310, d4iaaA_, 0.7694, 2.37, 0.262, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
2311, d2xiyA_, 0.7694, 2.39, 0.258, 273, 252, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2312, d1xqzA_, 0.7694, 2.43, 0.261, 277, 253, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
2313, d5auxA_, 0.7693, 2.62, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2314, d4ypdA1, 0.7693, 2.68, 0.265, 276, 257, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
2315, d5uhnA_, 0.7692, 2.89, 0.241, 282, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
2316, d4xlvA_, 0.7692, 2.85, 0.209, 307, 258, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
2317, d2zm3C2, 0.7692, 2.86, 0.208, 295, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2318, d5uglA_, 0.7691, 2.88, 0.233, 285, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
2319, d5oprA_, 0.7691, 2.47, 0.278, 258, 252, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
2320, d4rc3A_, 0.7691, 2.34, 0.263, 271, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2321, d4fzaB1, 0.7691, 2.74, 0.261, 280, 257, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
2322, d3dcvA_, 0.7691, 2.50, 0.257, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
2323, d3c4eD_, 0.7691, 2.43, 0.253, 273, 253, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2324, d1zwsG_, 0.7689, 2.68, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2325, d5diaA_, 0.7688, 2.43, 0.253, 273, 253, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2326, d4wnoA_, 0.7688, 2.71, 0.294, 272, 255, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
2327, d3zewA_, 0.7688, 2.32, 0.227, 269, 251, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
2328, d1zwsF_, 0.7688, 2.67, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2329, d1rqqA_, 0.7688, 2.87, 0.209, 294, 258, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2330, d5vc5A_, 0.7687, 2.36, 0.236, 261, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
2331, d3ue4B_, 0.7686, 2.50, 0.229, 268, 253, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2332, d3ue4A_, 0.7686, 2.57, 0.239, 270, 255, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2333, d3pa4A_, 0.7686, 2.59, 0.281, 257, 253, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
2334, d3dlsE_, 0.7686, 2.61, 0.265, 282, 253, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2335, d1szmB_, 0.7686, 2.65, 0.259, 320, 255, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2336, d3qc4A_, 0.7685, 2.70, 0.265, 276, 257, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2337, d3bgpA_, 0.7685, 2.39, 0.258, 272, 252, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
2338, d2ydkA_, 0.7685, 2.61, 0.278, 263, 255, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2339, d2xj0A_, 0.7685, 2.45, 0.253, 274, 253, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2340, d2wmrA_, 0.7685, 2.39, 0.280, 254, 250, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2341, d1cdkA_, 0.7685, 2.65, 0.268, 342, 257, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2342, d5vuaB_, 0.7684, 2.38, 0.254, 270, 252, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2343, d4rblA_, 0.7684, 2.34, 0.263, 271, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2344, d4nfmA_, 0.7684, 2.73, 0.184, 293, 261, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
2345, d3uodA_, 0.7684, 2.39, 0.302, 266, 252, AURORA A IN COMPLEX WITH RPM1693
2346, d3f5pC1, 0.7684, 2.75, 0.212, 300, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2347, d3eqpB_, 0.7684, 2.71, 0.255, 270, 255, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2348, d5opsA_, 0.7683, 2.42, 0.279, 258, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2349, d5iisA_, 0.7683, 2.52, 0.257, 273, 253, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
2350, d5eolA_, 0.7683, 2.44, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
2351, d4riwD_, 0.7683, 2.66, 0.211, 297, 256, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2352, d3dlsF_, 0.7682, 2.63, 0.265, 281, 253, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2353, d1zwsD_, 0.7682, 2.69, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2354, d1yxuD_, 0.7682, 2.43, 0.253, 273, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2355, d1yi4A_, 0.7682, 2.36, 0.259, 267, 251, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
2356, d5es1A_, 0.7681, 2.31, 0.329, 304, 246, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2357, d4riyD_, 0.7681, 2.59, 0.212, 297, 255, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2358, d3f5pD1, 0.7681, 2.76, 0.212, 296, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2359, d2pwlB_, 0.7681, 2.87, 0.245, 286, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
2360, d2objA_, 0.7681, 2.39, 0.258, 272, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
2361, d2f4jA_, 0.7681, 2.93, 0.239, 287, 259, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
2362, d1xr1A_, 0.7681, 2.55, 0.261, 277, 253, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
2363, d4xliA_, 0.7680, 2.40, 0.239, 264, 251, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
2364, d3f5pA1, 0.7680, 2.76, 0.212, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2365, d3dlsC_, 0.7680, 2.56, 0.262, 281, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2366, d3bhhA1, 0.7680, 2.68, 0.310, 287, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2367, d5e8wA1, 0.7679, 2.63, 0.213, 302, 254, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
2368, d3vbqA_, 0.7679, 2.45, 0.253, 271, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2369, d3f5pH1, 0.7679, 2.76, 0.212, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2370, d4jiaA_, 0.7678, 2.94, 0.262, 298, 260, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
2371, d4gmyA_, 0.7678, 2.80, 0.257, 298, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
2372, d3ri1A_, 0.7678, 2.91, 0.244, 285, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
2373, d3gubA1, 0.7678, 2.68, 0.265, 276, 257, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
2374, d2xizA_, 0.7678, 2.41, 0.258, 273, 252, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2375, d1wvxA_, 0.7678, 2.68, 0.261, 275, 257, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2376, d5mjaB_, 0.7677, 2.53, 0.231, 274, 255, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
2377, d3sxsA1, 0.7677, 2.51, 0.213, 261, 253, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
2378, d3jvrA_, 0.7677, 2.37, 0.273, 258, 249, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
2379, d5auuA_, 0.7676, 2.60, 0.267, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2380, d4x2nA1, 0.7676, 2.61, 0.213, 302, 254, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2381, d4tl0A_, 0.7676, 2.90, 0.262, 300, 260, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
2382, d4lmuA_, 0.7676, 2.45, 0.266, 265, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
2383, d3f5pT1, 0.7676, 2.73, 0.213, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2384, d3f5pG1, 0.7676, 2.76, 0.212, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2385, d2pvfA_, 0.7676, 2.84, 0.236, 285, 258, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
2386, d5av4A_, 0.7675, 2.60, 0.267, 274, 255, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2387, d4txcA_, 0.7675, 2.74, 0.260, 276, 258, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2388, d4jrvA_, 0.7675, 2.57, 0.209, 300, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
2389, d4fswA_, 0.7675, 2.56, 0.283, 265, 251, CRYSTAL STRUCTURE OF THE CHK1
2390, d3uysC_, 0.7675, 2.72, 0.185, 286, 259, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2391, d3bgzA_, 0.7675, 2.41, 0.258, 267, 252, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
2392, d2ym6A_, 0.7675, 2.36, 0.281, 253, 249, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2393, d1yhsA_, 0.7675, 2.36, 0.259, 267, 251, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
2394, d4alwA_, 0.7674, 2.48, 0.253, 273, 253, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2395, d5auzA_, 0.7673, 2.60, 0.267, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2396, d4xhkB_, 0.7673, 2.39, 0.258, 269, 252, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
2397, d4deaA_, 0.7673, 2.39, 0.298, 266, 252, AURORA A IN COMPLEX WITH YL1-038-18
2398, d4ae9B_, 0.7673, 2.61, 0.259, 321, 255, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2399, d3uytC_, 0.7673, 2.73, 0.192, 286, 260, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2400, d5auwA_, 0.7672, 2.61, 0.267, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2401, d4ft5A_, 0.7672, 2.56, 0.271, 265, 251, CRYSTAL STRUCTURE OF THE CHK1
2402, d3f5pB1, 0.7672, 2.77, 0.212, 297, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2403, d3f2aA_, 0.7672, 2.40, 0.258, 276, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
2404, d2xynC_, 0.7672, 2.62, 0.240, 262, 254, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2405, d2qg5A1, 0.7672, 2.73, 0.266, 268, 256, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2406, d5ci7A_, 0.7671, 2.71, 0.295, 276, 254, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
2407, d4o0sA_, 0.7671, 2.57, 0.296, 265, 253, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2408, d4gfgA1, 0.7671, 2.66, 0.198, 273, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
2409, d4bznA_, 0.7671, 2.42, 0.254, 272, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
2410, d3jy0A_, 0.7671, 2.43, 0.254, 275, 252, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2411, d1wvwA_, 0.7671, 2.67, 0.265, 275, 257, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2412, d2xj1A_, 0.7670, 2.41, 0.258, 273, 252, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
2413, d5ghvB_, 0.7669, 2.39, 0.202, 265, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2414, d5ghvA_, 0.7669, 2.38, 0.202, 265, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2415, d5e8uA1, 0.7669, 2.57, 0.217, 303, 254, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
2416, d5dwrA_, 0.7669, 2.41, 0.258, 273, 252, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
2417, d4xg5B_, 0.7669, 2.39, 0.202, 265, 252,  
2418, d4xg5A_, 0.7669, 2.38, 0.202, 265, 252,  
2419, d5fqdF_, 0.7668, 2.80, 0.196, 294, 260, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2420, d3uo5A_, 0.7668, 2.53, 0.304, 267, 253, AURORA A IN COMPLEX WITH YL1-038-31
2421, d2yabB_, 0.7668, 2.86, 0.259, 299, 259, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2422, d4rixD_, 0.7667, 2.72, 0.214, 297, 257, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2423, d3f5pF1, 0.7667, 2.77, 0.212, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2424, d1oecA_, 0.7667, 2.75, 0.247, 280, 255, FGFR2 KINASE DOMAIN
2425, d5flfA_, 0.7666, 2.95, 0.240, 296, 258, DISEASE LINKED MUTATION IN FGFR
2426, d4bzoA_, 0.7666, 2.42, 0.258, 272, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
2427, d1zwsH_, 0.7666, 2.72, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2428, d4x2kA1, 0.7665, 2.88, 0.214, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2429, d4x2jA1, 0.7665, 2.88, 0.214, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2430, d4tn6B_, 0.7665, 2.73, 0.189, 285, 259, CK1D IN COMPLEX WITH INHIBITOR
2431, d4rvlA_, 0.7665, 2.44, 0.272, 258, 250, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
2432, d4j99D_, 0.7665, 2.80, 0.243, 281, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2433, d3ppzA_, 0.7665, 2.25, 0.258, 264, 248, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2434, d3f5pE1, 0.7665, 2.78, 0.212, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2435, d1gjoA_, 0.7665, 2.77, 0.243, 280, 255, THE FGFR2 TYROSINE KINASE DOMAIN
2436, d5te0A_, 0.7664, 2.70, 0.245, 316, 253, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2437, d3bgqA_, 0.7664, 2.55, 0.257, 272, 253, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
2438, d2ckeC_, 0.7664, 2.95, 0.254, 300, 260, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2439, d2bdwA_, 0.7664, 2.77, 0.304, 309, 260, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2440, d5d9kB_, 0.7663, 2.53, 0.292, 280, 253, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2441, d3eqpA_, 0.7663, 2.57, 0.257, 268, 253, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2442, d2wotA_, 0.7663, 2.73, 0.213, 303, 254, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
2443, d2wotA1, 0.7663, 2.73, 0.213, 301, 254, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
2444, d2ivsA_, 0.7663, 2.79, 0.246, 284, 256, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
2445, d1yi3A_, 0.7663, 2.36, 0.259, 267, 251, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
2446, d4n70A_, 0.7662, 2.43, 0.258, 274, 252, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2447, d4ftcA_, 0.7662, 2.46, 0.276, 266, 250, CRYSTAL STRUCTURE OF THE CHK1
2448, d3nsvC_, 0.7662, 2.64, 0.240, 262, 254,  
2449, d2psqA_, 0.7662, 2.95, 0.236, 287, 258, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
2450, d2ckeB_, 0.7662, 2.89, 0.255, 300, 259, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2451, d4x2gA1, 0.7661, 2.87, 0.214, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2452, d3a99A_, 0.7661, 2.57, 0.257, 273, 253, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
2453, d5vubB_, 0.7660, 2.37, 0.255, 269, 251, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2454, d4j95C_, 0.7660, 2.68, 0.248, 281, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2455, d5j9yA_, 0.7659, 2.69, 0.211, 300, 256, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
2456, d5cxhA1, 0.7659, 2.71, 0.202, 273, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
2457, d4j99A_, 0.7659, 2.86, 0.246, 280, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2458, d4fsmA_, 0.7659, 2.45, 0.280, 265, 250, CRYSTAL STRUCTURE OF THE CHK1
2459, d3dlsB_, 0.7659, 2.58, 0.267, 280, 251, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2460, d2xj2A_, 0.7659, 2.43, 0.258, 273, 252, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2461, d5e90A1, 0.7658, 2.55, 0.218, 300, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
2462, d5c26A1, 0.7658, 2.71, 0.202, 271, 257, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
2463, d3uixA_, 0.7658, 2.38, 0.255, 266, 251, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2464, d2csnA_, 0.7658, 2.78, 0.185, 293, 260, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
2465, d1yxtA_, 0.7658, 2.63, 0.252, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2466, d4zy6B_, 0.7657, 2.46, 0.305, 280, 249, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2467, d4uv0A_, 0.7657, 2.89, 0.250, 300, 260, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
2468, d2ckeD_, 0.7657, 2.94, 0.254, 300, 260, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2469, d1zwsC_, 0.7657, 2.75, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2470, d3uo4A_, 0.7656, 2.45, 0.292, 266, 253, AURORA A IN COMPLEX WITH RPM1680
2471, d5l3aA_, 0.7655, 2.76, 0.258, 290, 256, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
2472, d3f5pM1, 0.7655, 2.77, 0.212, 294, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2473, d2ckeA_, 0.7655, 2.88, 0.255, 301, 259, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
2474, d5o13A_, 0.7654, 2.42, 0.263, 270, 251, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2475, d5flfD_, 0.7654, 2.81, 0.246, 290, 256, DISEASE LINKED MUTATION IN FGFR
2476, d4x2fA1, 0.7654, 2.89, 0.214, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2477, d3f5pI1, 0.7654, 2.75, 0.213, 293, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2478, d1kobA_, 0.7654, 2.82, 0.248, 352, 258, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2479, d5w4wD_, 0.7653, 2.64, 0.187, 287, 256, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2480, d4x0mA1, 0.7653, 2.87, 0.214, 302, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2481, d4wnpC_, 0.7653, 2.60, 0.300, 271, 253, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2482, d4rixB_, 0.7653, 2.62, 0.217, 293, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2483, d3f5pS1, 0.7653, 2.75, 0.213, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2484, d5fqdC_, 0.7652, 2.83, 0.196, 294, 260, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
2485, d5e8zA1, 0.7652, 2.56, 0.218, 300, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
2486, d4n6zA_, 0.7652, 2.45, 0.258, 272, 252, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2487, d2z2wA_, 0.7652, 2.57, 0.227, 260, 251, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
2488, d2pwlA_, 0.7652, 2.94, 0.241, 284, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
2489, d5ax9C_, 0.7651, 2.46, 0.269, 282, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2490, d2xixA_, 0.7651, 2.41, 0.259, 272, 251, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2491, d2chlA_, 0.7651, 2.77, 0.208, 298, 259, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
2492, d1zwsA_, 0.7651, 2.75, 0.264, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2493, d1tkiB_, 0.7651, 2.92, 0.238, 321, 260, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2494, d1tkiA_, 0.7651, 2.92, 0.238, 321, 260, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2495, d3vjnA_, 0.7650, 2.54, 0.202, 297, 253, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
2496, d3naxA_, 0.7650, 2.75, 0.256, 278, 258, PDK1 IN COMPLEX WITH INHIBITOR MP7
2497, d2gqgB1, 0.7650, 2.84, 0.234, 270, 256, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2498, d1m52B_, 0.7650, 2.68, 0.227, 272, 255, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2499, d1koaA2, 0.7650, 2.86, 0.248, 350, 258, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2500, d5gtzA_, 0.7649, 2.92, 0.205, 317, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
2501, d5e8yA_, 0.7649, 2.76, 0.232, 298, 254, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
2502, d5dt3A_, 0.7649, 2.61, 0.303, 263, 254, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2503, d4zogB_, 0.7649, 2.78, 0.223, 268, 256, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2504, d4w9wA_, 0.7649, 2.75, 0.265, 306, 253, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2505, d4twpB_, 0.7649, 2.68, 0.243, 271, 255, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
2506, d4riwB_, 0.7649, 2.64, 0.213, 293, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2507, d3vjoA_, 0.7649, 2.60, 0.206, 298, 253, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
2508, d5l8lA_, 0.7648, 2.61, 0.299, 263, 254, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
2509, d4xg6A1, 0.7648, 2.64, 0.199, 270, 256, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2510, d4hokI_, 0.7648, 2.70, 0.195, 291, 257, CRYSTAL STRUCTURE OF APO CK1E
2511, d2yaaB_, 0.7648, 2.88, 0.259, 299, 259, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2512, d2jiuA_, 0.7648, 2.87, 0.208, 303, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
2513, d4utdA_, 0.7647, 2.65, 0.307, 266, 254, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2514, d2yabA_, 0.7647, 2.77, 0.260, 299, 258, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
2515, d2hz4A_, 0.7647, 2.51, 0.231, 262, 251, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
2516, d1kobB_, 0.7647, 2.87, 0.255, 352, 259, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2517, d5hg5A_, 0.7646, 3.21, 0.199, 302, 261, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
2518, d4tw9A_, 0.7646, 2.81, 0.188, 290, 260, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2519, d4j97A_, 0.7646, 2.65, 0.241, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2520, d4debA_, 0.7646, 2.44, 0.298, 264, 252, AURORA A IN COMPLEX WITH RK2-17-01
2521, d5x17A_, 0.7645, 2.80, 0.188, 290, 260, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2522, d5lmaA_, 0.7645, 2.68, 0.191, 267, 256, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
2523, d4fl1A_, 0.7645, 2.45, 0.206, 268, 252, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
2524, d5d9kA_, 0.7644, 2.44, 0.299, 280, 251, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2525, d4xliB_, 0.7644, 2.55, 0.234, 264, 252, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
2526, d4j8nC_, 0.7644, 2.64, 0.307, 266, 254, AURORA A KINASE APO
2527, d1zwsE_, 0.7644, 2.74, 0.264, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2528, d4xg3B_, 0.7643, 2.61, 0.200, 267, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2529, d4j8nD_, 0.7643, 2.64, 0.307, 265, 254, AURORA A KINASE APO
2530, d3bhhD1, 0.7643, 2.69, 0.306, 285, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2531, d2a2aC_, 0.7643, 2.97, 0.242, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2532, d5vucB_, 0.7642, 2.40, 0.255, 269, 251, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2533, d4li5A1, 0.7642, 2.84, 0.207, 303, 256, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
2534, d4j97B_, 0.7642, 2.77, 0.240, 283, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2535, d4j8nB_, 0.7642, 2.64, 0.307, 266, 254, AURORA A KINASE APO
2536, d3wf9A_, 0.7642, 2.59, 0.310, 287, 252, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
2537, d3bi6A_, 0.7642, 2.49, 0.228, 258, 250, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
2538, d2gqgA1, 0.7642, 2.88, 0.237, 271, 257, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
2539, d2w4kA_, 0.7641, 2.94, 0.250, 301, 260, X-RAY STRUCTURE OF A DAP-KINASE 2-302
2540, d5kziA_, 0.7640, 2.49, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2541, d5hg8A_, 0.7640, 3.08, 0.205, 300, 259, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
2542, d3lm5A1, 0.7640, 2.53, 0.247, 267, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2543, d5e8sA1, 0.7639, 2.48, 0.219, 299, 251, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
2544, d4jikA_, 0.7639, 2.45, 0.281, 256, 249, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
2545, d4j8nA_, 0.7639, 2.65, 0.307, 266, 254, AURORA A KINASE APO
2546, d2a2aD_, 0.7639, 2.95, 0.242, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2547, d4tn6A_, 0.7638, 2.84, 0.188, 292, 260, CK1D IN COMPLEX WITH INHIBITOR
2548, d4ftaA_, 0.7638, 2.56, 0.280, 264, 250, CRYSTAL STRUCTURE OF THE CHK1
2549, d4btjB_, 0.7638, 2.81, 0.184, 293, 261, TTBK1 IN COMPLEX WITH ATP
2550, d5imeA1, 0.7637, 2.34, 0.281, 279, 249, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2551, d3nsvB_, 0.7637, 2.67, 0.244, 264, 254,  
2552, d2xeyA_, 0.7637, 2.35, 0.274, 252, 248, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2553, d3cqeA_, 0.7636, 2.59, 0.227, 258, 251, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
2554, d2xynB_, 0.7636, 2.68, 0.244, 264, 254, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2555, d2hk5A2, 0.7636, 2.59, 0.250, 268, 252, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
2556, d1csnA_, 0.7636, 2.83, 0.185, 293, 260, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
2557, d5usqA_, 0.7635, 2.49, 0.219, 299, 251, ALK-5 KINASE INHIBITOR COMPLEX
2558, d4nfnA_, 0.7635, 2.79, 0.184, 293, 261, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
2559, d4bbeB_, 0.7635, 2.79, 0.258, 288, 256, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2560, d3gqiA_, 0.7635, 2.84, 0.241, 304, 257, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2561, d3bceC_, 0.7635, 2.76, 0.212, 286, 255, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2562, d5x18B_, 0.7634, 2.94, 0.205, 294, 263, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
2563, d5dnrA_, 0.7634, 2.58, 0.300, 264, 253, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
2564, d4zs0A_, 0.7634, 2.33, 0.301, 257, 249, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
2565, d4enxA_, 0.7634, 2.42, 0.255, 266, 251, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
2566, d4bbeC_, 0.7634, 2.79, 0.254, 288, 256, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2567, d3vbwA_, 0.7634, 2.36, 0.257, 264, 249, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2568, d3umwA_, 0.7634, 2.43, 0.263, 264, 251, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
2569, d1yrpB_, 0.7634, 2.67, 0.254, 275, 256, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2570, d1yrpA_, 0.7634, 2.67, 0.254, 275, 256, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2571, d5op2A_, 0.7633, 2.67, 0.273, 263, 256, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2572, d4btkA_, 0.7633, 2.69, 0.178, 287, 258, TTBK1 IN COMPLEX WITH INHIBITOR
2573, d4bbeD_, 0.7633, 2.91, 0.263, 288, 259, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2574, d4bbeA_, 0.7633, 2.91, 0.263, 288, 259, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2575, d4yjoA_, 0.7632, 2.69, 0.191, 267, 256, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
2576, d4l3lA_, 0.7632, 2.66, 0.308, 291, 253, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
2577, d4deeA_, 0.7632, 2.64, 0.299, 271, 254, AURORA A IN COMPLEX WITH ADP
2578, d3wf8A_, 0.7632, 2.60, 0.310, 287, 252, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
2579, d3t9iA_, 0.7632, 2.41, 0.259, 273, 251, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
2580, d3f9nA_, 0.7632, 2.44, 0.273, 253, 249, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
2581, d3bu5A_, 0.7632, 2.73, 0.202, 291, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
2582, d2yaaA_, 0.7632, 2.89, 0.259, 300, 259, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
2583, d2psqB_, 0.7632, 3.00, 0.240, 286, 258, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
2584, d5vc4A_, 0.7631, 2.55, 0.227, 261, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
2585, d5dn3A_, 0.7631, 2.50, 0.298, 264, 252, AURORA A IN COMPLEX WITH ATP AND AA35.
2586, d3bhyA1, 0.7631, 2.43, 0.264, 267, 250, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2587, d6bleA1, 0.7630, 2.72, 0.283, 263, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
2588, d5deyB_, 0.7630, 2.47, 0.305, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2589, d4lg4F_, 0.7630, 2.20, 0.289, 276, 246, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2590, d4j97C_, 0.7630, 2.67, 0.237, 283, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2591, d4hokM_, 0.7630, 2.90, 0.196, 291, 260, CRYSTAL STRUCTURE OF APO CK1E
2592, d4bbfB_, 0.7630, 2.92, 0.263, 288, 259, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2593, d3ri1B_, 0.7630, 2.97, 0.230, 283, 257, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
2594, d2izuA_, 0.7630, 2.73, 0.210, 297, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2595, d1m52A_, 0.7630, 2.72, 0.235, 271, 255, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2596, d4riyB_, 0.7629, 2.69, 0.213, 293, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2597, d3f5pK1, 0.7629, 2.74, 0.214, 292, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2598, d2xynA_, 0.7629, 2.61, 0.225, 264, 253, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
2599, d4bbfC_, 0.7628, 2.93, 0.255, 288, 259, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2600, d2bvaB_, 0.7628, 2.30, 0.257, 274, 249, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2601, d4gihA1, 0.7627, 2.85, 0.230, 287, 256, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
2602, d3f5pR1, 0.7627, 2.78, 0.213, 293, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2603, d5vc6A_, 0.7626, 2.55, 0.228, 259, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
2604, d5t68B_, 0.7626, 2.43, 0.203, 264, 251, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
2605, d4l46A_, 0.7626, 2.53, 0.311, 317, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
2606, d4gj3A1, 0.7626, 2.85, 0.230, 287, 256, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
2607, d3f5pL1, 0.7626, 2.75, 0.214, 292, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2608, d4hokO_, 0.7625, 2.71, 0.191, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2609, d4f1tA1, 0.7625, 2.61, 0.235, 267, 251, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
2610, d3lm0A1, 0.7625, 2.60, 0.246, 271, 252, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2611, d2xzsA_, 0.7625, 3.00, 0.250, 301, 260, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2612, d2of4A_, 0.7625, 2.63, 0.229, 271, 253, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
2613, d2a2aA_, 0.7625, 2.99, 0.242, 304, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2614, d5walA1, 0.7624, 2.72, 0.231, 285, 255, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
2615, d5t68A1, 0.7624, 2.43, 0.203, 264, 251, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
2616, d4xg4A_, 0.7624, 2.42, 0.203, 264, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2617, d4gvjA1, 0.7624, 2.87, 0.234, 288, 256, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
2618, d3cr0A_, 0.7624, 2.57, 0.228, 257, 250, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
2619, d5v5yA_, 0.7623, 2.60, 0.236, 259, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
2620, d4l45A_, 0.7623, 2.45, 0.313, 317, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
2621, d4dedA_, 0.7623, 2.55, 0.300, 265, 253, AURORA A IN COMPLEX WITH YL1-038-21
2622, d3kmmA_, 0.7623, 2.63, 0.225, 270, 253, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
2623, d2x8iA_, 0.7623, 2.49, 0.278, 261, 252, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2624, d2qg5D1, 0.7623, 2.72, 0.267, 267, 255, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2625, d2of2A_, 0.7623, 2.63, 0.229, 271, 253, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
2626, d2clqA_, 0.7623, 2.58, 0.284, 263, 250, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2627, d1x8bA_, 0.7623, 2.46, 0.229, 259, 249, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
2628, d5ax9A_, 0.7622, 2.41, 0.267, 282, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2629, d4twcA_, 0.7622, 2.84, 0.192, 293, 260, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2630, d4k33A_, 0.7622, 2.79, 0.238, 293, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
2631, d4gj2A1, 0.7622, 2.86, 0.230, 287, 256, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
2632, d4btmB_, 0.7622, 2.82, 0.184, 293, 261, TTBK1 IN COMPLEX WITH INHIBITOR
2633, d4btjA_, 0.7622, 2.88, 0.192, 292, 261, TTBK1 IN COMPLEX WITH ATP
2634, d2y0aA_, 0.7622, 2.95, 0.250, 300, 260, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
2635, d5d7aC_, 0.7621, 2.59, 0.257, 286, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2636, d3nsvA_, 0.7620, 2.63, 0.225, 264, 253,  
2637, d2iztA_, 0.7620, 2.73, 0.206, 296, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2638, d5d7aB_, 0.7619, 2.66, 0.256, 286, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2639, d4enyA_, 0.7619, 2.38, 0.256, 261, 250, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
2640, d1xbcA1, 0.7619, 2.44, 0.203, 267, 251, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
2641, d4hokW_, 0.7618, 2.75, 0.191, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
2642, d3up7A_, 0.7618, 2.48, 0.298, 264, 252, AURORA A IN COMPLEX WITH YL1-038-09
2643, d4giiA1, 0.7617, 2.86, 0.230, 287, 256, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
2644, d2wmvA_, 0.7617, 2.35, 0.271, 251, 247, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2645, d5usyB_, 0.7616, 2.82, 0.254, 287, 256, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
2646, d5d7aA_, 0.7616, 2.65, 0.260, 289, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2647, d2dq7X_, 0.7616, 2.49, 0.240, 262, 250, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
2648, d4rx7A1, 0.7615, 2.60, 0.205, 270, 254, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
2649, d1iasB_, 0.7615, 2.76, 0.213, 324, 254, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2650, d5wevA_, 0.7614, 2.78, 0.256, 293, 254, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
2651, d5i3oB_, 0.7614, 2.75, 0.260, 302, 254, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2652, d4ftmA_, 0.7614, 2.44, 0.274, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
2653, d3bceA_, 0.7614, 2.76, 0.220, 285, 255, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2654, d2a2aB_, 0.7614, 3.02, 0.242, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
2655, d6bqpA1, 0.7613, 2.72, 0.287, 262, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2656, d4obpA_, 0.7613, 2.81, 0.275, 285, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2657, d3kulA_, 0.7613, 2.66, 0.205, 267, 254, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2658, d2x7fA_, 0.7613, 2.38, 0.266, 276, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2659, d2g2hB_, 0.7613, 2.88, 0.219, 272, 256, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2660, d5oryA_, 0.7612, 2.73, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2661, d3f5pJ1, 0.7612, 2.77, 0.214, 292, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2662, d3dqwB_, 0.7612, 2.70, 0.244, 278, 254, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2663, d3b2tB_, 0.7612, 2.86, 0.232, 287, 254, STRUCTURE OF PHOSPHOTRANSFERASE
2664, d2wouA_, 0.7612, 2.45, 0.220, 299, 250, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
2665, d2wouA1, 0.7612, 2.45, 0.220, 297, 250, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
2666, d5mjaA_, 0.7611, 2.46, 0.239, 271, 251, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
2667, d5ih6A_, 0.7611, 2.83, 0.188, 286, 260, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
2668, d5ih5A_, 0.7611, 2.82, 0.192, 286, 260, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
2669, d4btmA_, 0.7611, 2.87, 0.188, 292, 261, TTBK1 IN COMPLEX WITH INHIBITOR
2670, d5gmpA_, 0.7610, 2.69, 0.217, 305, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
2671, d5e8tA1, 0.7610, 2.61, 0.218, 300, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
2672, d4xeyA_, 0.7610, 2.53, 0.223, 269, 251, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
2673, d4hokU_, 0.7610, 2.73, 0.195, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
2674, d1jktA_, 0.7610, 2.87, 0.260, 276, 258, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2675, d5oq7B_, 0.7609, 2.46, 0.275, 256, 251, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2676, d3ppzB_, 0.7609, 2.41, 0.242, 264, 248, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2677, d5uoxA_, 0.7608, 2.64, 0.288, 263, 250, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2678, d4j95A_, 0.7608, 2.66, 0.246, 279, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2679, d4ftkA_, 0.7608, 2.45, 0.274, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
2680, d1bi8C_, 0.7608, 2.40, 0.463, 264, 246, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
2681, d1bi8A_, 0.7608, 2.40, 0.463, 264, 246, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
2682, d5v24B_, 0.7607, 2.66, 0.284, 263, 250, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2683, d4py1A_, 0.7607, 2.83, 0.238, 289, 256, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
2684, d4kb8B_, 0.7607, 2.64, 0.189, 285, 254, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2685, d4hokA_, 0.7607, 2.72, 0.191, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2686, d3nrmA_, 0.7607, 2.52, 0.294, 263, 252, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2687, d2a27D_, 0.7607, 2.98, 0.254, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2688, d6babC_, 0.7606, 2.81, 0.295, 284, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2689, d5usyA_, 0.7606, 2.87, 0.254, 287, 256, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
2690, d5nkeA_, 0.7606, 2.81, 0.211, 292, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
2691, d5i3rB_, 0.7606, 2.83, 0.260, 302, 254, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2692, d5cxzA1, 0.7606, 2.49, 0.202, 267, 252, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
2693, d5c27A1, 0.7606, 2.73, 0.203, 271, 256, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
2694, d3tzmA_, 0.7606, 2.49, 0.216, 295, 250, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
2695, d3jvsA_, 0.7606, 2.39, 0.275, 256, 247, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
2696, d3eyhA_, 0.7606, 2.78, 0.252, 285, 254, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2697, d5o11A_, 0.7605, 2.35, 0.257, 268, 249, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2698, d1vjyA_, 0.7605, 2.67, 0.217, 299, 253, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
2699, d3bymA_, 0.7604, 2.66, 0.225, 271, 253, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
2700, d5objA_, 0.7603, 2.54, 0.307, 260, 251, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
2701, d4r5sA_, 0.7603, 2.86, 0.211, 299, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
2702, d4lg4A_, 0.7603, 2.67, 0.277, 289, 253, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2703, d4iwdA1, 0.7602, 2.98, 0.221, 295, 258, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
2704, d4dhfB_, 0.7602, 2.66, 0.298, 258, 252, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2705, d4d0xA_, 0.7602, 2.83, 0.253, 291, 257, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2706, d4dhfA_, 0.7601, 2.44, 0.304, 258, 250, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2707, d2ya9A_, 0.7601, 2.86, 0.264, 299, 258, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2708, d5dr2A1, 0.7600, 2.69, 0.299, 263, 254, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2709, d4rssA_, 0.7600, 2.68, 0.200, 269, 255, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
2710, d3dqwA_, 0.7600, 2.72, 0.244, 278, 254, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2711, d3bhhC1, 0.7600, 2.72, 0.295, 284, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2712, d5opbA_, 0.7599, 2.72, 0.273, 262, 256, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
2713, d5friA1, 0.7599, 2.53, 0.219, 299, 251, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
2714, d4kbaB_, 0.7599, 2.66, 0.180, 285, 255, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
2715, d2ydjA_, 0.7599, 2.31, 0.283, 252, 247, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2716, d2a27B_, 0.7599, 2.91, 0.263, 303, 259, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2717, d1ol7A_, 0.7599, 2.55, 0.290, 261, 252, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2718, d5oq8A_, 0.7598, 2.71, 0.275, 261, 255, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2719, d4bn1A_, 0.7598, 2.77, 0.295, 261, 254, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2720, d3kckA_, 0.7598, 2.70, 0.256, 285, 254, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
2721, d1u4dB_, 0.7598, 2.30, 0.263, 262, 247, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
2722, d2vz6A1, 0.7597, 2.99, 0.301, 285, 256, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
2723, d1qpdA_, 0.7597, 2.69, 0.225, 270, 253, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2724, d1pkgA_, 0.7597, 2.85, 0.224, 290, 255, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
2725, d5orwA_, 0.7596, 2.76, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2726, d5orpA_, 0.7596, 2.76, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2727, d4ythA_, 0.7596, 2.78, 0.258, 287, 256, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2728, d4lg4C_, 0.7596, 2.73, 0.285, 288, 253, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2729, d4jajA_, 0.7596, 2.59, 0.290, 265, 252, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
2730, d4ckiA1, 0.7596, 2.91, 0.246, 288, 256, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
2731, d3ug2A_, 0.7596, 2.61, 0.210, 299, 252, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
2732, d3r7oA1, 0.7596, 3.02, 0.221, 295, 258, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
2733, d2a27H_, 0.7596, 2.98, 0.258, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2734, d1ckiA_, 0.7596, 2.83, 0.185, 292, 260, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
2735, d5eakA_, 0.7595, 2.54, 0.321, 305, 246, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2736, d4kbkC_, 0.7595, 2.69, 0.184, 280, 256, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2737, d3we4A_, 0.7595, 2.67, 0.306, 286, 252, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
2738, d2ivtA1, 0.7595, 2.92, 0.246, 283, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
2739, d2a27F_, 0.7595, 2.99, 0.258, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2740, d4wnmA1, 0.7594, 2.56, 0.206, 269, 253, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
2741, d4hgsA1, 0.7594, 2.87, 0.212, 301, 259, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
2742, d4d1sA_, 0.7594, 2.66, 0.262, 280, 252, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2743, d4ckjA1, 0.7594, 2.93, 0.246, 287, 256, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
2744, d3lxpA_, 0.7594, 3.08, 0.230, 285, 257, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2745, d3bceB_, 0.7594, 2.71, 0.217, 286, 253, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2746, d2zybA_, 0.7594, 2.74, 0.228, 270, 254, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2747, d5ax9B_, 0.7593, 2.32, 0.262, 274, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2748, d4ftlA_, 0.7593, 2.48, 0.270, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
2749, d2a27G_, 0.7593, 2.99, 0.258, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2750, d2a27C_, 0.7593, 2.94, 0.247, 303, 259, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2751, d5oseA_, 0.7592, 2.77, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2752, d5orzA_, 0.7592, 2.76, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2753, d5nkhA_, 0.7592, 2.90, 0.211, 295, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
2754, d5i9vA_, 0.7592, 2.44, 0.217, 279, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
2755, d4g16A1, 0.7592, 2.88, 0.208, 301, 259, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
2756, d3umxA_, 0.7592, 2.42, 0.269, 261, 249, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
2757, d3sxrA1, 0.7592, 2.49, 0.208, 257, 250, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
2758, d3byoA_, 0.7592, 2.66, 0.225, 270, 253, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
2759, d2zm1A_, 0.7592, 2.74, 0.228, 270, 254, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2760, d5osfA_, 0.7591, 2.77, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2761, d5osdA_, 0.7591, 2.56, 0.294, 266, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2762, d5os5A_, 0.7591, 2.66, 0.304, 267, 253, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2763, d4fsqA_, 0.7591, 2.47, 0.278, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
2764, d3fqsA1, 0.7591, 2.48, 0.203, 264, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
2765, d3ac5A_, 0.7591, 2.68, 0.225, 270, 253, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2766, d2x2kA1, 0.7591, 2.94, 0.246, 284, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2767, d2izsA_, 0.7591, 2.80, 0.186, 298, 258, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2768, d2auhA1, 0.7591, 2.99, 0.209, 294, 258, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
2769, d2a27A_, 0.7591, 2.87, 0.252, 304, 258, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2770, d1qpcA_, 0.7591, 2.68, 0.225, 270, 253, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2771, d5os3A_, 0.7590, 2.77, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2772, d4bicB_, 0.7590, 2.42, 0.289, 259, 246, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2773, d3kf4B_, 0.7590, 2.70, 0.230, 270, 252, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2774, d3ac1A_, 0.7590, 2.68, 0.225, 270, 253, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2775, d2g2hA_, 0.7590, 2.87, 0.224, 272, 255, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2776, d5orrA_, 0.7589, 2.76, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2777, d4l42A_, 0.7589, 2.63, 0.310, 299, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
2778, d3q6wA1, 0.7589, 3.00, 0.221, 293, 258, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
2779, d3lckA_, 0.7589, 2.76, 0.228, 270, 254, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
2780, d3ac2A_, 0.7589, 2.64, 0.230, 270, 252, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2781, d2ya9B_, 0.7589, 2.86, 0.260, 299, 258, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2782, d2a27E_, 0.7589, 2.95, 0.247, 303, 259, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2783, d5oroA_, 0.7588, 2.77, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2784, d5ornA_, 0.7588, 2.56, 0.294, 264, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2785, d4wsqA_, 0.7588, 2.79, 0.245, 317, 253, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2786, d3lxnA_, 0.7588, 2.98, 0.233, 287, 257, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2787, d3acjA_, 0.7588, 2.70, 0.233, 270, 253, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2788, d1qpjA_, 0.7588, 2.66, 0.230, 265, 252, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
2789, d4zogA_, 0.7587, 2.82, 0.228, 269, 254, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
2790, d3ma3A_, 0.7587, 2.36, 0.254, 266, 248, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
2791, d5os1A_, 0.7586, 2.78, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2792, d5e91A_, 0.7586, 2.85, 0.233, 297, 253, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
2793, d4z16B_, 0.7586, 2.72, 0.257, 276, 253, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
2794, d1y57A3, 0.7586, 2.63, 0.238, 285, 252, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
2795, d5orxA_, 0.7585, 2.77, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2796, d5orvA_, 0.7585, 2.78, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2797, d5os0A_, 0.7584, 2.78, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2798, d5oq7A_, 0.7584, 2.64, 0.280, 259, 254, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2799, d4zk5A_, 0.7584, 2.84, 0.271, 286, 255, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
2800, d4zimB1, 0.7584, 2.91, 0.253, 292, 257, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
2801, d4gfmA_, 0.7584, 2.82, 0.258, 289, 256, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
2802, d3ug1A_, 0.7584, 2.47, 0.205, 296, 249, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
2803, d3ad5A_, 0.7584, 2.69, 0.225, 270, 253, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2804, d2x2mA1, 0.7584, 2.80, 0.241, 281, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2805, d2vz6B1, 0.7584, 2.98, 0.296, 288, 257, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
2806, d2qocA_, 0.7584, 2.43, 0.216, 283, 250, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
2807, d1qpeA_, 0.7584, 2.75, 0.228, 270, 254, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
2808, d1ckjA_, 0.7584, 2.84, 0.185, 296, 260, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2809, d5ukfA_, 0.7583, 3.05, 0.152, 322, 263, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
2810, d5dosA_, 0.7583, 2.51, 0.304, 259, 250, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2811, d4j97D_, 0.7583, 2.66, 0.235, 285, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2812, d4hokE_, 0.7583, 2.80, 0.195, 291, 257, CRYSTAL STRUCTURE OF APO CK1E
2813, d3sv0A_, 0.7583, 2.92, 0.200, 294, 260, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
2814, d3pa5A_, 0.7583, 2.53, 0.282, 255, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
2815, d3ad6A_, 0.7583, 2.68, 0.225, 272, 253, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2816, d1rw8A_, 0.7583, 2.89, 0.213, 301, 254, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
2817, d5o12A_, 0.7582, 2.33, 0.255, 264, 247, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2818, d4kbcA_, 0.7582, 2.75, 0.184, 288, 256, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
2819, d3e62A_, 0.7582, 2.87, 0.253, 291, 257, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2820, d2py3B_, 0.7582, 2.78, 0.234, 284, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2821, d2j4zB_, 0.7582, 2.58, 0.315, 269, 248, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
2822, d4hokG_, 0.7581, 2.75, 0.191, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2823, d4hokC_, 0.7581, 2.73, 0.191, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
2824, d4dfnA1, 0.7581, 2.53, 0.206, 268, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
2825, d3nz0A1, 0.7581, 2.81, 0.228, 283, 254, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
2826, d3lvpB_, 0.7581, 2.99, 0.213, 295, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2827, d3e64A_, 0.7581, 2.87, 0.261, 291, 257, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2828, d2x2lA1, 0.7581, 2.97, 0.246, 282, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2829, d2py3A_, 0.7581, 2.85, 0.225, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2830, d2ofuA_, 0.7581, 2.68, 0.225, 272, 253, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
2831, d5orsA_, 0.7580, 2.78, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2832, d4hglA1, 0.7580, 2.82, 0.190, 301, 258, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
2833, d3e63A_, 0.7580, 2.88, 0.261, 290, 257, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2834, d2x0gA_, 0.7580, 2.97, 0.251, 318, 259, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2835, d5amnA1, 0.7579, 2.93, 0.246, 282, 256, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
2836, d4g17A1, 0.7579, 2.90, 0.208, 301, 259, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
2837, d3ad4A_, 0.7579, 2.69, 0.225, 270, 253, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2838, d3ackA_, 0.7579, 2.76, 0.228, 270, 254, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2839, d2xzsB_, 0.7579, 2.94, 0.252, 293, 258, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2840, d2ituA_, 0.7579, 2.78, 0.213, 304, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
2841, d2in6A_, 0.7579, 2.44, 0.231, 256, 247, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
2842, d5ih4A_, 0.7578, 2.87, 0.188, 286, 260, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
2843, d3ac4A_, 0.7578, 2.75, 0.228, 270, 254, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2844, d3ac3A_, 0.7578, 2.76, 0.228, 270, 254, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2845, d5ortA_, 0.7577, 2.57, 0.294, 264, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2846, d5tr6A1, 0.7576, 2.49, 0.207, 268, 251, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
2847, d4ftqA_, 0.7576, 2.36, 0.285, 254, 246, CRYSTAL STRUCTURE OF THE CHK1
2848, d3ac8A_, 0.7576, 2.77, 0.228, 270, 254, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
2849, d2zm4A_, 0.7576, 2.76, 0.228, 270, 254, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
2850, d2qnjA1, 0.7576, 2.52, 0.319, 317, 248, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
2851, d1mq4A_, 0.7576, 2.61, 0.286, 261, 252, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
2852, d4rx8A1, 0.7575, 2.55, 0.202, 266, 252, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
2853, d4w9xA_, 0.7574, 2.68, 0.267, 300, 251, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2854, d4e4mD_, 0.7574, 2.88, 0.262, 296, 256, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2855, d2x6dA_, 0.7574, 2.46, 0.293, 255, 249, AURORA-A BOUND TO AN INHIBITOR
2856, d4l43A_, 0.7573, 2.55, 0.313, 316, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
2857, d3kf4A_, 0.7573, 2.76, 0.234, 281, 252, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
2858, d5dt4A_, 0.7572, 2.52, 0.308, 259, 250, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2859, d4e4mB_, 0.7572, 2.89, 0.262, 296, 256, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2860, d4d0wA_, 0.7572, 2.79, 0.255, 289, 255, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2861, d4asxA1, 0.7572, 2.77, 0.234, 295, 252, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
2862, d5os4A_, 0.7571, 2.80, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2863, d4l44A_, 0.7571, 2.63, 0.311, 321, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
2864, d4e20A_, 0.7571, 2.87, 0.228, 282, 254, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
2865, d2itnA_, 0.7571, 2.91, 0.212, 304, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
2866, d6bu6A_, 0.7570, 3.08, 0.152, 322, 263, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
2867, d5e92A_, 0.7570, 2.94, 0.232, 298, 254, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
2868, d2izrA_, 0.7570, 2.79, 0.183, 298, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
2869, d1oplB2, 0.7570, 2.82, 0.228, 267, 254, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2870, d5vdkA_, 0.7569, 2.67, 0.264, 260, 250, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
2871, d5uorB_, 0.7569, 2.66, 0.285, 262, 249, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2872, d5os6A_, 0.7569, 2.80, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2873, d5aepA_, 0.7569, 2.77, 0.263, 287, 255, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
2874, d4ytiA_, 0.7569, 2.77, 0.259, 284, 255, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2875, d4e4mE_, 0.7569, 2.97, 0.261, 296, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2876, d4e4mA_, 0.7569, 2.97, 0.261, 296, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
2877, d5j79A_, 0.7568, 2.68, 0.225, 283, 253, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2878, d5dewB_, 0.7568, 2.56, 0.301, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2879, d4xg9B_, 0.7568, 2.54, 0.202, 265, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2880, d3vf9A_, 0.7568, 2.51, 0.207, 265, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
2881, d3uysD_, 0.7568, 2.61, 0.182, 284, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
2882, d3iokA_, 0.7568, 2.75, 0.256, 285, 254, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2883, d2ittA_, 0.7568, 2.81, 0.213, 302, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
2884, d4cegA_, 0.7567, 2.59, 0.298, 264, 252, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2885, d4bbfD_, 0.7567, 2.87, 0.258, 288, 256, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2886, d3vf8A_, 0.7567, 2.51, 0.207, 265, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
2887, d2c47D1, 0.7567, 2.67, 0.209, 289, 254, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2888, d1xbbA1, 0.7567, 2.52, 0.203, 266, 251, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
2889, d5i9uA_, 0.7566, 2.49, 0.217, 281, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
2890, d4ytfA_, 0.7566, 2.76, 0.256, 283, 254, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2891, d4nt4A1, 0.7566, 2.80, 0.213, 299, 258, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
2892, d3kcfB_, 0.7566, 2.86, 0.213, 324, 254, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
2893, d2clqB_, 0.7566, 2.43, 0.289, 259, 246, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2894, d4jboA_, 0.7565, 2.71, 0.296, 266, 253, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2895, d2ivuA1, 0.7564, 2.92, 0.247, 283, 255, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
2896, d1xbaA1, 0.7564, 2.51, 0.207, 265, 251, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
2897, d5cf5B1, 0.7563, 2.93, 0.257, 292, 257, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2898, d4bbfA_, 0.7563, 2.89, 0.254, 288, 256, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2899, d3op5A_, 0.7563, 3.03, 0.153, 320, 262, HUMAN VACCINIA-RELATED KINASE 1
2900, d2qohA2, 0.7563, 2.70, 0.226, 270, 252, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
2901, d2b4sB_, 0.7562, 2.98, 0.207, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
2902, d4l3jA_, 0.7561, 2.69, 0.306, 291, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
2903, d5mqvC_, 0.7560, 2.89, 0.193, 288, 259, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
2904, d5imeB_, 0.7560, 2.41, 0.302, 280, 245, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2905, d4bibB_, 0.7560, 2.43, 0.290, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2906, d3kxzA_, 0.7560, 2.81, 0.228, 263, 254, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
2907, d5cy3A1, 0.7559, 2.79, 0.200, 274, 255, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
2908, d5cf4B_, 0.7559, 2.94, 0.257, 291, 257, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2909, d4yjpA_, 0.7559, 2.66, 0.194, 263, 253, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
2910, d4p2wB_, 0.7559, 2.26, 0.207, 253, 246,  
2911, d3pp0B_, 0.7559, 2.76, 0.199, 296, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
2912, d1oplA3, 0.7559, 2.89, 0.232, 291, 254, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2913, d5x17B_, 0.7558, 2.92, 0.185, 289, 260, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
2914, d5u94A_, 0.7558, 2.56, 0.264, 263, 250, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2915, d3krrA1, 0.7557, 2.91, 0.253, 290, 257, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
2916, d5lmbB_, 0.7556, 2.60, 0.194, 261, 252, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
2917, d4kbkA_, 0.7556, 2.62, 0.190, 283, 252, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2918, d4fstA_, 0.7556, 2.35, 0.278, 253, 245, CRYSTAL STRUCTURE OF THE CHK1
2919, d2w1iA_, 0.7556, 2.97, 0.254, 284, 256, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2920, d1py5A_, 0.7556, 3.03, 0.224, 301, 255, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
2921, d1iasE_, 0.7556, 2.88, 0.213, 330, 254, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2922, d4px6A1, 0.7555, 2.54, 0.203, 261, 251, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
2923, d4fynA1, 0.7555, 2.48, 0.200, 263, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
2924, d4bicA_, 0.7555, 2.56, 0.291, 260, 247, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2925, d2w1iB_, 0.7555, 2.97, 0.258, 284, 256, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2926, d2q0bB_, 0.7555, 2.83, 0.234, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2927, d2ivvA1, 0.7555, 2.84, 0.249, 277, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
2928, d2pvyD_, 0.7554, 2.77, 0.231, 283, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2929, d5eakB_, 0.7553, 2.34, 0.325, 300, 243, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
2930, d4yjtA_, 0.7553, 2.80, 0.196, 268, 255, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
2931, d4rioA_, 0.7553, 2.80, 0.251, 285, 255, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
2932, d4puzA_, 0.7553, 2.66, 0.194, 263, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
2933, d2q0bA_, 0.7553, 2.83, 0.230, 280, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2934, d2b4sD_, 0.7553, 2.99, 0.207, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
2935, d1opkA3, 0.7553, 2.90, 0.228, 291, 254, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2936, d5lmbA_, 0.7552, 2.53, 0.207, 264, 251, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
2937, d5e8vA_, 0.7552, 2.82, 0.234, 296, 252, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
2938, d4yc8B_, 0.7552, 2.53, 0.225, 264, 249, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
2939, d5tozA_, 0.7551, 2.76, 0.252, 278, 254, JAK3 WITH COVALENT INHIBITOR PF-06651600
2940, d4hokQ_, 0.7551, 2.80, 0.195, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2941, d2z60A1, 0.7551, 2.75, 0.229, 280, 253, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
2942, d5hznC_, 0.7550, 2.94, 0.217, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2943, d4hokK_, 0.7550, 2.81, 0.191, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
2944, d3srvB_, 0.7550, 2.57, 0.195, 263, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
2945, d3q4tB1, 0.7550, 2.53, 0.233, 293, 249, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
2946, d2j5fA_, 0.7550, 3.00, 0.207, 308, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
2947, d5orlA_, 0.7549, 2.61, 0.294, 264, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2948, d5hznG_, 0.7549, 2.94, 0.213, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2949, d4kb8C_, 0.7549, 2.80, 0.195, 277, 256, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
2950, d4hzrA_, 0.7549, 2.34, 0.256, 261, 246, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
2951, d3socB1, 0.7549, 2.81, 0.234, 294, 252, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
2952, d2xezA_, 0.7549, 2.37, 0.269, 249, 245, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2953, d5dpvA_, 0.7548, 2.44, 0.306, 257, 248, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
2954, d4wkqA1, 0.7548, 2.53, 0.209, 294, 249, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
2955, d4kbaC_, 0.7548, 2.80, 0.195, 277, 256, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
2956, d3qc4B1, 0.7548, 2.56, 0.284, 268, 250, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2957, d3dqwD_, 0.7548, 2.77, 0.241, 276, 253, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2958, d2itvA_, 0.7548, 2.85, 0.209, 303, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
2959, d1u54B_, 0.7548, 2.34, 0.260, 261, 246, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
2960, d1u4dA_, 0.7548, 2.40, 0.259, 258, 247, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
2961, d5nk5A_, 0.7547, 2.78, 0.209, 287, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
2962, d5dt0A_, 0.7547, 2.59, 0.300, 259, 250, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
2963, d5ng2B_, 0.7546, 2.88, 0.224, 278, 255, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
2964, d3kcfE_, 0.7546, 2.90, 0.213, 330, 254, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
2965, d2ydjB_, 0.7546, 2.34, 0.285, 251, 246, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2966, d2wmxA_, 0.7546, 2.30, 0.270, 248, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2967, d4bidB_, 0.7545, 2.44, 0.290, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2968, d3dqwC_, 0.7545, 2.77, 0.241, 275, 253, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2969, d1iasD_, 0.7545, 3.10, 0.214, 330, 257, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2970, d5lwmA_, 0.7544, 2.90, 0.253, 290, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
2971, d5hznD_, 0.7544, 2.92, 0.213, 304, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2972, d5d9lA_, 0.7544, 2.53, 0.309, 299, 249, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
2973, d3kcfC_, 0.7544, 2.91, 0.213, 330, 254, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
2974, d1u54A_, 0.7544, 2.38, 0.259, 262, 247, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
2975, d1ckiB_, 0.7544, 2.92, 0.188, 286, 260, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
2976, d5lwnA_, 0.7543, 2.90, 0.253, 290, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
2977, d5hznH_, 0.7543, 2.92, 0.213, 303, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2978, d5dr9A_, 0.7543, 2.48, 0.310, 257, 248, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
2979, d4pv0A1, 0.7543, 2.49, 0.204, 266, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
2980, d4gk4A_, 0.7543, 2.42, 0.218, 275, 248, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
2981, d3q32A_, 0.7543, 2.92, 0.265, 291, 257, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
2982, d2pvyA_, 0.7543, 2.67, 0.232, 288, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
2983, d2c47B_, 0.7543, 2.68, 0.202, 289, 253, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
2984, d6bruA_, 0.7542, 3.13, 0.152, 322, 263, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
2985, d5tt7A1, 0.7542, 2.49, 0.200, 270, 250, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
2986, d4e6qA_, 0.7542, 2.93, 0.261, 296, 257, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
2987, d1iasC_, 0.7542, 3.11, 0.214, 330, 257, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2988, d3sxrB1, 0.7541, 2.47, 0.206, 255, 248, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
2989, d2ityA1, 0.7541, 2.80, 0.217, 299, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
2990, d2hziA_, 0.7541, 2.92, 0.228, 268, 254, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
2991, d2hz4C_, 0.7541, 2.53, 0.230, 259, 248, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
2992, d4jjrA_, 0.7540, 2.77, 0.187, 284, 256, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
2993, d1ckjB_, 0.7540, 2.90, 0.185, 293, 260, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
2994, d3eygA_, 0.7539, 2.69, 0.255, 280, 251, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2995, d2pz5B_, 0.7539, 2.82, 0.231, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2996, d5cwzB_, 0.7538, 2.66, 0.254, 284, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2997, d4i0sA1, 0.7538, 2.54, 0.204, 263, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
2998, d4hokS_, 0.7538, 2.78, 0.192, 286, 255, CRYSTAL STRUCTURE OF APO CK1E
2999, d3lxlA_, 0.7538, 2.81, 0.252, 281, 254, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3000, d3lvpA_, 0.7538, 2.97, 0.212, 289, 255, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3001, d3fqeA1, 0.7538, 2.64, 0.202, 265, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
3002, d2ym5A_, 0.7537, 2.33, 0.266, 248, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3003, d2w1gA1, 0.7537, 2.42, 0.309, 254, 246, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3004, d2qnjB1, 0.7537, 2.56, 0.320, 321, 247, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3005, d5vt1A1, 0.7536, 2.73, 0.292, 264, 253, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
3006, p5oatF_, 0.7536, 3.01, 0.262, 359, 256, PINK1 STRUCTURE
3007, d5hznE_, 0.7536, 2.96, 0.217, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3008, d4z16A_, 0.7536, 2.66, 0.260, 271, 250, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3009, d2bvaA_, 0.7536, 2.18, 0.254, 272, 244, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
3010, d4z16C_, 0.7535, 2.67, 0.260, 271, 250, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3011, d4puzB_, 0.7535, 2.64, 0.202, 265, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
3012, d4lqmA_, 0.7535, 2.94, 0.196, 305, 255, EGFR L858R IN COMPLEX WITH PD168393
3013, d2qo9A_, 0.7535, 2.42, 0.218, 277, 248, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
3014, d2fo0A3, 0.7535, 2.94, 0.231, 291, 255, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
3015, d5hznA_, 0.7534, 2.99, 0.216, 296, 255, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3016, d5ar2B_, 0.7534, 2.93, 0.223, 285, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3017, d2j4zA_, 0.7534, 2.53, 0.308, 263, 247, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3018, d1mqbB_, 0.7534, 2.46, 0.218, 265, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3019, d5drdA_, 0.7533, 2.61, 0.300, 259, 250, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3020, d4f09A_, 0.7533, 2.95, 0.257, 288, 257, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3021, d4aqcB_, 0.7533, 2.99, 0.257, 295, 257, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3022, d2itzA_, 0.7533, 2.96, 0.204, 302, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
3023, d5os2A_, 0.7532, 2.77, 0.298, 261, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3024, d5cf6A_, 0.7532, 2.85, 0.267, 285, 255, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3025, d4u42A_, 0.7532, 2.69, 0.259, 282, 251, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
3026, d3ot8A_, 0.7532, 2.41, 0.282, 251, 245, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
3027, d3op5B_, 0.7532, 3.03, 0.149, 319, 261, HUMAN VACCINIA-RELATED KINASE 1
3028, d1k2pA_, 0.7532, 2.63, 0.199, 258, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3029, d4gk3A_, 0.7531, 2.40, 0.219, 275, 247, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
3030, d3q32B1, 0.7531, 3.00, 0.253, 293, 257, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3031, d4hvgA_, 0.7530, 2.77, 0.252, 281, 254, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
3032, d3io7A_, 0.7530, 2.75, 0.261, 282, 253, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3033, d1yvjA_, 0.7530, 2.83, 0.254, 288, 256, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
3034, d5mqvF_, 0.7529, 2.88, 0.194, 286, 258, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3035, d4ftnA_, 0.7529, 2.42, 0.278, 253, 245, CRYSTAL STRUCTURE OF THE CHK1
3036, d4d55A_, 0.7529, 2.36, 0.264, 260, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3037, d2pzpB_, 0.7529, 2.83, 0.235, 282, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
3038, d2dwbA_, 0.7529, 2.50, 0.309, 259, 249, AURORA-A KINASE COMPLEXED WITH AMPPNP
3039, d3jy9A_, 0.7528, 2.75, 0.257, 282, 253, JANUS KINASE 2 INHIBITORS
3040, d5tq3B_, 0.7527, 2.93, 0.262, 285, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3041, d5cf5A1, 0.7527, 2.87, 0.263, 286, 255, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3042, d4o0rB_, 0.7527, 2.41, 0.311, 282, 244, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3043, d5ikwA_, 0.7526, 2.79, 0.266, 297, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3044, d5hznB_, 0.7526, 3.02, 0.216, 296, 255, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3045, d5dr6A_, 0.7526, 2.52, 0.310, 257, 248, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3046, d5ar5A_, 0.7526, 2.94, 0.230, 284, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
3047, d4rx9A1, 0.7526, 2.53, 0.200, 264, 250, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
3048, d4jjrB_, 0.7526, 2.79, 0.152, 283, 256, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3049, d2pzpA_, 0.7526, 2.84, 0.231, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
3050, d2pz5A_, 0.7526, 2.84, 0.231, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3051, d5v19B_, 0.7525, 2.58, 0.296, 260, 247, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3052, d5hznF_, 0.7525, 3.02, 0.216, 296, 255, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3053, d4yjuA_, 0.7525, 2.80, 0.193, 262, 254, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
3054, d4bieB_, 0.7525, 2.38, 0.299, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3055, d4z16D_, 0.7524, 2.70, 0.260, 271, 250, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3056, d4ytcA_, 0.7524, 2.86, 0.251, 284, 255, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3057, d2xf0A_, 0.7524, 2.40, 0.269, 251, 245, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3058, d5up3A_, 0.7523, 2.51, 0.290, 258, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3059, d4twpA_, 0.7523, 2.64, 0.240, 266, 250, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3060, d4g5pA_, 0.7523, 2.73, 0.212, 299, 255, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
3061, d3fe3B_, 0.7523, 2.61, 0.315, 317, 248, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3062, d2ym4A_, 0.7523, 2.45, 0.286, 251, 245, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3063, d4fyoA1, 0.7522, 2.55, 0.204, 263, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
3064, d3zosA_, 0.7522, 2.95, 0.224, 301, 254, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3065, d3zbfA_, 0.7521, 2.46, 0.240, 281, 246, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
3066, d5j95A_, 0.7520, 2.89, 0.265, 284, 253, MAP4K4 IN COMPLEX WITH INHIBITOR
3067, d4kb8D_, 0.7520, 2.60, 0.188, 278, 250, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3068, d3ohtB_, 0.7519, 3.06, 0.324, 331, 259, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
3069, d3ohtA_, 0.7519, 3.07, 0.324, 331, 259, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
3070, d2hziB_, 0.7519, 2.77, 0.227, 264, 251, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3071, d2cmwA_, 0.7519, 2.89, 0.207, 294, 256, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
3072, d4e6qB_, 0.7518, 2.96, 0.261, 296, 257, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3073, d4dflA1, 0.7518, 2.43, 0.206, 262, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
3074, d3uysA_, 0.7518, 2.57, 0.184, 281, 250, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3075, d3clyA_, 0.7518, 3.18, 0.244, 289, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
3076, d2pzrA_, 0.7518, 2.82, 0.231, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3077, d2jitA_, 0.7517, 2.83, 0.180, 299, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3078, d4p90A_, 0.7516, 2.18, 0.306, 272, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3079, d2c47A_, 0.7516, 2.66, 0.198, 288, 252, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3080, d5ng0A_, 0.7515, 2.73, 0.226, 274, 252, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3081, d4p2wA_, 0.7514, 2.23, 0.217, 250, 244,  
3082, d2wtvB_, 0.7514, 2.62, 0.308, 261, 247, AURORA-A INHIBITOR STRUCTURE
3083, d2qohB2, 0.7514, 2.81, 0.229, 280, 253, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3084, d2np8A_, 0.7514, 2.48, 0.294, 256, 248, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
3085, d5tq8A_, 0.7513, 3.00, 0.253, 291, 257, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3086, d3zepD_, 0.7513, 2.84, 0.262, 272, 252, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3087, d2zvaA1, 0.7513, 2.82, 0.243, 260, 251, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
3088, d1p4fA_, 0.7513, 2.65, 0.267, 269, 251, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3089, d1iasA_, 0.7513, 3.14, 0.214, 330, 257, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3090, d5k00A_, 0.7512, 2.44, 0.328, 311, 244, MELK IN COMPLEX WITH NVS-MELK5
3091, d4kbcB_, 0.7512, 2.88, 0.187, 277, 256, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3092, d2wtvC_, 0.7512, 2.63, 0.308, 261, 247, AURORA-A INHIBITOR STRUCTURE
3093, d5ek7B_, 0.7511, 2.51, 0.222, 286, 248, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
3094, d4wsqB_, 0.7511, 2.80, 0.250, 310, 252, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3095, d3emgA_, 0.7511, 2.46, 0.202, 255, 248, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
3096, d2wmwA_, 0.7511, 2.30, 0.272, 247, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3097, d5vd2A_, 0.7510, 2.70, 0.228, 258, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
3098, d5tq3A_, 0.7510, 2.97, 0.258, 282, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3099, d5fedA_, 0.7510, 2.50, 0.206, 288, 247, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3100, d5ei6A1, 0.7510, 2.25, 0.305, 261, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3101, d4xg2A1, 0.7510, 2.40, 0.198, 258, 247, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
3102, d2pzrB_, 0.7510, 2.85, 0.227, 282, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3103, d5i3oA_, 0.7509, 2.82, 0.262, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3104, d4ivaA_, 0.7509, 3.01, 0.257, 290, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
3105, d2ym3A_, 0.7509, 2.34, 0.267, 247, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3106, d5tq5A_, 0.7508, 3.01, 0.253, 291, 257, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3107, d3kcfD_, 0.7508, 2.94, 0.213, 330, 254, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3108, d5ugxB_, 0.7507, 2.77, 0.244, 282, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
3109, d4aqcA_, 0.7507, 3.00, 0.257, 289, 257, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3110, d3lvpD_, 0.7507, 2.58, 0.217, 282, 249, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3111, d2x2mB1, 0.7507, 2.73, 0.245, 274, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3112, d4f08B_, 0.7506, 3.01, 0.257, 288, 257, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3113, d3rvgA_, 0.7506, 2.91, 0.256, 285, 254, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
3114, d4kbkD_, 0.7505, 2.60, 0.188, 281, 250, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3115, d3pjcA_, 0.7505, 2.86, 0.256, 286, 254, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
3116, d2wmtA_, 0.7505, 2.39, 0.266, 248, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3117, d4zauA_, 0.7504, 2.44, 0.211, 283, 246, AZD9291 COMPLEX WITH WILD TYPE EGFR
3118, d4xg7A1, 0.7504, 2.63, 0.199, 265, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3119, d2r0iA_, 0.7504, 2.48, 0.321, 300, 243, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3120, d4f08A_, 0.7503, 3.01, 0.257, 288, 257, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3121, d3kcfA_, 0.7503, 3.12, 0.215, 328, 256, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3122, d5cf6B1, 0.7502, 2.94, 0.255, 288, 255, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3123, d4ji9B_, 0.7502, 2.95, 0.259, 288, 255, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3124, d5cwzA_, 0.7501, 2.62, 0.259, 284, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3125, d4ixpA_, 0.7501, 2.94, 0.303, 334, 254, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
3126, d5ttvA_, 0.7500, 2.82, 0.253, 280, 253, JAK3 WITH COVALENT INHIBITOR 6
3127, d5mqvA_, 0.7500, 2.88, 0.195, 286, 257, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3128, d4fz6A1, 0.7500, 2.52, 0.201, 262, 249, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
3129, d3lctA_, 0.7500, 2.90, 0.201, 308, 254, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3130, d4j8mA_, 0.7498, 2.55, 0.314, 265, 245, AURORA A IN COMPLEX WITH CD532
3131, d5vc3A_, 0.7497, 2.78, 0.223, 260, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3132, d4zimA_, 0.7497, 2.92, 0.263, 285, 255, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3133, d4g2fA_, 0.7497, 2.40, 0.220, 275, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
3134, d3cekA1, 0.7497, 2.57, 0.301, 252, 246, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
3135, d4o0tB_, 0.7496, 2.59, 0.304, 280, 247, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3136, d2c6eA_, 0.7495, 2.42, 0.314, 251, 245, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3137, d3lcsA_, 0.7494, 2.93, 0.201, 304, 254, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3138, d3dk3B_, 0.7494, 2.98, 0.213, 269, 253, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3139, d5nkgA_, 0.7493, 2.62, 0.217, 292, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
3140, d5nkfA_, 0.7493, 2.63, 0.217, 291, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
3141, d5fm3A_, 0.7493, 3.04, 0.242, 276, 252, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
3142, d5ek7A_, 0.7493, 2.53, 0.222, 286, 248, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
3143, d2r0iB_, 0.7493, 2.39, 0.322, 300, 242, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3144, d5i3rA_, 0.7492, 2.84, 0.262, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3145, d5ehlA1, 0.7492, 2.43, 0.291, 254, 244, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3146, d4bhnB_, 0.7492, 2.46, 0.295, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3147, d3dk7B_, 0.7492, 3.08, 0.220, 268, 254, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3148, d5mqvB_, 0.7491, 2.91, 0.195, 287, 257, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3149, d1b6cF_, 0.7491, 3.13, 0.220, 326, 255, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3150, d5ia2A_, 0.7490, 2.63, 0.217, 287, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
3151, d4jbqA_, 0.7490, 2.48, 0.297, 257, 246, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3152, d1u46A_, 0.7490, 2.36, 0.258, 255, 244, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
3153, d5ukfC_, 0.7489, 3.01, 0.151, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3154, d4i0tA1, 0.7489, 2.57, 0.205, 262, 249, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
3155, d2ym7A_, 0.7489, 2.45, 0.275, 248, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3156, d5ng2A_, 0.7488, 2.73, 0.219, 274, 251, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3157, d5ar5B_, 0.7488, 2.71, 0.231, 279, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
3158, d4xg9A_, 0.7488, 2.59, 0.197, 259, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3159, d4mkcA_, 0.7488, 2.89, 0.202, 303, 253, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
3160, d3hmmA_, 0.7488, 2.70, 0.213, 293, 249, STRUCTURE OF ALK5 + GW855857
3161, d3srvA_, 0.7487, 2.62, 0.200, 262, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3162, d1k2pB_, 0.7487, 2.68, 0.199, 258, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3163, d5nk6A_, 0.7486, 2.59, 0.214, 284, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
3164, d4byiA_, 0.7485, 2.64, 0.306, 254, 248, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3165, d2zv2A_, 0.7485, 2.42, 0.283, 256, 247, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
3166, d6eimB_, 0.7484, 2.69, 0.319, 295, 248, HUMAN STK10 BOUND TO GW683134A
3167, d5caqA_, 0.7484, 2.74, 0.201, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
3168, d4v0gA_, 0.7484, 2.78, 0.264, 267, 250, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3169, d3zhpD_, 0.7484, 2.59, 0.264, 264, 250, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3170, d2io6A_, 0.7484, 2.29, 0.227, 252, 242, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
3171, d5ei2A_, 0.7483, 2.24, 0.306, 256, 242, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3172, d3zosB1, 0.7483, 2.99, 0.224, 301, 254, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3173, d3zepC_, 0.7483, 2.88, 0.250, 276, 252, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3174, d5mqvD_, 0.7482, 2.93, 0.195, 287, 257, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3175, d5j79B_, 0.7482, 2.67, 0.224, 277, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
3176, d5cf8B1, 0.7482, 2.92, 0.260, 287, 254, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3177, d4xg3A_, 0.7482, 2.48, 0.202, 262, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3178, d4lg4B_, 0.7482, 2.63, 0.280, 284, 246, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3179, d5c8mA_, 0.7481, 2.76, 0.201, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
3180, d4qt1A_, 0.7481, 2.75, 0.254, 277, 252, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
3181, d2pvyC_, 0.7481, 2.68, 0.234, 285, 248, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3182, d4u5jB_, 0.7480, 2.57, 0.248, 267, 246, C-SRC IN COMPLEX WITH RUXOLITINIB
3183, d4ftoA_, 0.7480, 2.45, 0.279, 252, 244, CRYSTAL STRUCTURE OF THE CHK1
3184, d3l9pA_, 0.7480, 2.92, 0.201, 303, 254, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3185, d2c47C_, 0.7480, 2.61, 0.200, 282, 250, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3186, d5ih9A_, 0.7479, 2.32, 0.335, 308, 242, MELK IN COMPLEX WITH NVS-MELK8A
3187, d4bieA_, 0.7479, 2.56, 0.291, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3188, d3h10A_, 0.7479, 2.66, 0.316, 268, 247, AURORA A INHIBITOR COMPLEX
3189, d2w1fA1, 0.7479, 2.33, 0.311, 253, 244, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3190, d1o6yA_, 0.7479, 2.55, 0.259, 260, 247, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
3191, d5nkbA_, 0.7478, 2.62, 0.214, 285, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
3192, d3eknA_, 0.7478, 3.00, 0.205, 297, 254, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3193, d5nk2A_, 0.7477, 2.62, 0.214, 290, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
3194, d5ia0B_, 0.7477, 2.49, 0.219, 266, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3195, d5di1A_, 0.7477, 2.87, 0.254, 285, 252, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3196, d4yjqA_, 0.7477, 2.82, 0.194, 264, 252, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
3197, d4hvdA_, 0.7477, 2.77, 0.254, 276, 252, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
3198, d4at3A1, 0.7477, 2.68, 0.228, 286, 250, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
3199, d3zepA_, 0.7477, 2.87, 0.259, 274, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3200, d2x4fB_, 0.7477, 2.75, 0.270, 288, 252, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3201, d2eb3A_, 0.7477, 2.72, 0.209, 294, 249, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
3202, d5cf8A1, 0.7476, 2.93, 0.260, 284, 254, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3203, d4kbaD_, 0.7476, 2.62, 0.189, 274, 249, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3204, d4hvhA_, 0.7476, 2.76, 0.254, 278, 252, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
3205, d4fz7A1, 0.7476, 2.52, 0.202, 261, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
3206, d3lxkA_, 0.7476, 2.89, 0.252, 279, 254, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3207, d2b7aA_, 0.7476, 2.98, 0.259, 284, 255, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3208, d4j95D_, 0.7475, 2.69, 0.251, 271, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3209, d2zmcA_, 0.7475, 2.36, 0.303, 260, 244, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
3210, d5nttA1, 0.7474, 2.52, 0.302, 268, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
3211, d5khwA_, 0.7474, 2.63, 0.257, 276, 249, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
3212, d3uysB_, 0.7474, 2.54, 0.181, 279, 248, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3213, d3r21A_, 0.7474, 2.63, 0.308, 254, 247, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3214, d3fe3A_, 0.7474, 2.57, 0.320, 317, 247, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3215, d2ym8A_, 0.7474, 2.23, 0.270, 246, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3216, d5w86C_, 0.7473, 2.67, 0.262, 273, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3217, d3tjcB_, 0.7473, 2.90, 0.260, 287, 254, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3218, d5oneA_, 0.7472, 2.62, 0.314, 257, 245, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
3219, d5nk1A_, 0.7472, 2.65, 0.218, 284, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
3220, d3bizA_, 0.7472, 2.42, 0.222, 250, 243, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
3221, d2xngA_, 0.7472, 2.37, 0.303, 253, 244, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
3222, d2wtvD_, 0.7472, 2.53, 0.318, 262, 245, AURORA-A INHIBITOR STRUCTURE
3223, d1b6cD_, 0.7472, 3.18, 0.220, 326, 255, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3224, d4zegA_, 0.7471, 2.38, 0.305, 260, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3225, d4ji9A_, 0.7471, 2.99, 0.263, 284, 255, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3226, d4equB_, 0.7471, 2.33, 0.324, 282, 241, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
3227, d3zhpC1, 0.7471, 2.63, 0.264, 267, 250, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3228, d5nk9A_, 0.7470, 2.63, 0.214, 285, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
3229, d5n87A1, 0.7470, 2.39, 0.300, 252, 243, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
3230, d5i9xA_, 0.7470, 2.63, 0.218, 284, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
3231, d4o0wA_, 0.7470, 2.46, 0.305, 259, 246, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3232, d5obrA_, 0.7469, 2.57, 0.313, 255, 246, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
3233, d2wtvA_, 0.7469, 2.54, 0.318, 262, 245, AURORA-A INHIBITOR STRUCTURE
3234, d5canA_, 0.7468, 2.77, 0.201, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
3235, d4p7eB_, 0.7468, 3.00, 0.259, 285, 255, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3236, d4e26A_, 0.7468, 2.72, 0.204, 270, 250, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3237, d3zfxA_, 0.7468, 2.56, 0.227, 267, 247, CRYSTAL STRUCTURE OF EPHB1
3238, d3tt0A_, 0.7468, 3.17, 0.243, 305, 255, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
3239, d2qobA_, 0.7468, 2.55, 0.210, 279, 248, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
3240, d2wmqA_, 0.7467, 2.32, 0.285, 246, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3241, d6bu6D_, 0.7466, 3.12, 0.153, 318, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3242, d5cf4A_, 0.7466, 2.92, 0.264, 283, 254, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3243, d5casA_, 0.7466, 2.72, 0.202, 299, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
3244, d5nkcA_, 0.7465, 2.66, 0.214, 286, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
3245, d5ew8A_, 0.7465, 3.05, 0.244, 291, 254, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3246, d5ttsA_, 0.7464, 2.69, 0.256, 274, 250, JAK3 WITH COVALENT INHIBITOR 4
3247, d4bc6A_, 0.7464, 2.74, 0.324, 285, 247, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
3248, d3dk3A_, 0.7464, 2.92, 0.214, 266, 252, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3249, d3zfxD_, 0.7463, 2.58, 0.227, 265, 247, CRYSTAL STRUCTURE OF EPHB1
3250, d5nk7A_, 0.7462, 2.66, 0.218, 284, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
3251, d4i6qA_, 0.7462, 2.81, 0.254, 277, 252, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
3252, d4g5jA_, 0.7462, 2.43, 0.208, 307, 245, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
3253, d3gfwA1, 0.7462, 2.30, 0.298, 249, 242, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
3254, d3dk6A_, 0.7462, 2.83, 0.220, 262, 250, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3255, d5c8nA_, 0.7461, 2.71, 0.202, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
3256, d4z55A_, 0.7461, 2.93, 0.202, 294, 252, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
3257, d3r22A_, 0.7461, 2.62, 0.296, 255, 247, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3258, d5uvfB_, 0.7460, 3.01, 0.147, 316, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3259, d5mqvE_, 0.7460, 2.95, 0.195, 287, 257, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3260, d5ap6A1, 0.7460, 2.27, 0.306, 259, 242, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3261, d3zfxH_, 0.7460, 2.58, 0.227, 266, 247, CRYSTAL STRUCTURE OF EPHB1
3262, d3lpbB1, 0.7460, 2.94, 0.257, 283, 253, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3263, d4v0gB_, 0.7459, 2.77, 0.261, 272, 249, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3264, d4asxB1, 0.7459, 2.94, 0.226, 296, 252, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3265, d3fqhA_, 0.7459, 2.53, 0.198, 262, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
3266, d5nk3A_, 0.7458, 2.65, 0.218, 281, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
3267, d4twoA_, 0.7458, 2.45, 0.220, 278, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
3268, d3hmpA_, 0.7458, 2.39, 0.309, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
3269, d3dk7A_, 0.7458, 2.93, 0.226, 265, 252, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3270, d5n84A1, 0.7457, 2.50, 0.307, 253, 244, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
3271, d2w1eA1, 0.7457, 2.32, 0.313, 252, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3272, d5em7A_, 0.7456, 2.74, 0.202, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3273, d4xg8A_, 0.7456, 2.59, 0.201, 258, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3274, d4i0rA1, 0.7456, 2.55, 0.202, 260, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
3275, d4hgtA_, 0.7456, 2.81, 0.193, 283, 254, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3276, d2wtkF1, 0.7456, 2.29, 0.286, 250, 241, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3277, d2wmuA_, 0.7456, 2.37, 0.269, 246, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3278, d1wvyA_, 0.7456, 2.93, 0.270, 273, 256, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3279, d6btwA_, 0.7455, 3.03, 0.155, 317, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3280, d3rhxA_, 0.7455, 3.05, 0.244, 289, 254, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
3281, d4uwcB_, 0.7454, 2.95, 0.245, 301, 253, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3282, d4qpsA_, 0.7454, 2.47, 0.265, 270, 245, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3283, d4c02A_, 0.7454, 3.06, 0.237, 313, 253, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
3284, d3nyxA1, 0.7454, 2.95, 0.205, 285, 254, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
3285, d3fqhB_, 0.7454, 2.45, 0.199, 258, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
3286, d2pvyB_, 0.7454, 2.67, 0.235, 286, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3287, d5uvfA_, 0.7453, 3.04, 0.147, 317, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3288, d4xeyB2, 0.7453, 2.54, 0.215, 264, 246, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
3289, d4hgeB_, 0.7453, 3.03, 0.259, 288, 255, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3290, d2b7aB_, 0.7453, 3.02, 0.259, 287, 255, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
3291, d5tiuA1, 0.7452, 2.49, 0.202, 262, 247, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
3292, d4e1zA_, 0.7452, 2.93, 0.225, 288, 253, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
3293, d4aotA1, 0.7452, 2.64, 0.336, 276, 247, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3294, d4p5qA_, 0.7451, 2.41, 0.220, 275, 245, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3295, d4hzrB_, 0.7451, 2.40, 0.258, 258, 244, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
3296, d3wyxA_, 0.7451, 2.53, 0.307, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
3297, d3uytD_, 0.7451, 2.72, 0.194, 268, 252, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3298, d3d15A_, 0.7451, 2.55, 0.287, 256, 247, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
3299, d5w86D_, 0.7450, 2.62, 0.263, 272, 247, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3300, d2fumB_, 0.7450, 2.65, 0.265, 262, 249, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3301, d2fumA_, 0.7450, 2.73, 0.264, 263, 250, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3302, d1jktB_, 0.7450, 3.08, 0.260, 276, 258, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3303, d4rwiA_, 0.7449, 2.98, 0.250, 305, 252, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
3304, d6bu6B_, 0.7448, 3.10, 0.151, 307, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3305, d5xdlA_, 0.7448, 2.66, 0.202, 292, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
3306, d5c8kA_, 0.7448, 2.75, 0.202, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
3307, d4uynA_, 0.7448, 2.35, 0.320, 249, 241, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3308, d4c4jA1, 0.7448, 2.28, 0.302, 258, 242, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3309, d2qokA_, 0.7448, 2.45, 0.224, 281, 246, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
3310, d1zmwA_, 0.7448, 2.54, 0.314, 302, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3311, d1lufA_, 0.7448, 2.49, 0.237, 275, 245, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
3312, d4yjvA_, 0.7447, 2.80, 0.195, 263, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
3313, d2etmB_, 0.7447, 2.47, 0.265, 263, 245, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3314, d1u46B_, 0.7447, 2.28, 0.269, 257, 242, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
3315, d5nkdA_, 0.7446, 2.63, 0.215, 287, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
3316, d5nk4A_, 0.7446, 2.60, 0.219, 290, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
3317, d5n7vA1, 0.7446, 2.44, 0.309, 257, 243, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
3318, d5ehoA1, 0.7446, 2.27, 0.307, 255, 241, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3319, d4rj4A_, 0.7446, 2.74, 0.202, 299, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
3320, d1mruA_, 0.7446, 2.60, 0.267, 269, 247, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3321, d5i9yA_, 0.7445, 2.72, 0.218, 287, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
3322, d5capA_, 0.7445, 2.89, 0.208, 303, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
3323, d4yjrA_, 0.7445, 2.82, 0.191, 263, 251, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
3324, d4uwbB_, 0.7445, 2.82, 0.247, 299, 251, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3325, d4rwkA1, 0.7445, 2.95, 0.247, 307, 251, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
3326, d4f4pA1, 0.7445, 2.55, 0.210, 260, 248, SYK IN COMPLEX WITH LIGAND LASW836
3327, d3js2B_, 0.7445, 2.98, 0.245, 291, 253, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3328, d2vx0A_, 0.7445, 2.76, 0.220, 273, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3329, d2dylA_, 0.7445, 2.39, 0.230, 272, 243, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
3330, d1b6cB_, 0.7445, 3.35, 0.218, 326, 257, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3331, d5ar4B_, 0.7444, 2.72, 0.220, 279, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3332, d5ap0A1, 0.7444, 2.41, 0.302, 250, 242, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3333, d5a46B_, 0.7444, 3.18, 0.243, 297, 255, FGFR1 IN COMPLEX WITH DOVITINIB
3334, d4bi0A1, 0.7444, 2.31, 0.307, 251, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3335, d3h9fA1, 0.7444, 2.39, 0.305, 256, 243, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
3336, d3k5uA_, 0.7443, 2.44, 0.306, 260, 245, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3337, d4wrgA1, 0.7442, 2.52, 0.216, 287, 245, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
3338, d4hviA_, 0.7442, 2.74, 0.256, 274, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
3339, d6bp0A_, 0.7441, 3.06, 0.151, 317, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3340, d5n9sA1, 0.7441, 2.34, 0.306, 256, 242, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
3341, d5ia3A_, 0.7441, 2.56, 0.215, 275, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
3342, d5f1zA1, 0.7441, 2.53, 0.232, 280, 246, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
3343, d5ew8B_, 0.7441, 3.01, 0.245, 290, 253, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3344, d4useA_, 0.7441, 2.88, 0.319, 286, 248, HUMAN STK10 (LOK) WITH SB-633825
3345, d4c4iA1, 0.7440, 2.38, 0.298, 250, 242, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3346, d3h10B_, 0.7440, 2.61, 0.317, 267, 246, AURORA A INHIBITOR COMPLEX
3347, d3f6xD_, 0.7440, 2.55, 0.249, 267, 245, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3348, d3dj7A_, 0.7440, 2.68, 0.297, 257, 249, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
3349, d5feeA_, 0.7439, 2.50, 0.204, 287, 245, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3350, d4cvaA1, 0.7439, 2.37, 0.298, 250, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3351, d3hmoA_, 0.7439, 2.35, 0.310, 257, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
3352, d3fupB_, 0.7439, 3.02, 0.263, 287, 255, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3353, d2vwyA_, 0.7439, 2.76, 0.220, 274, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3354, d5ar2A_, 0.7438, 2.68, 0.229, 277, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3355, d4p7eA_, 0.7438, 2.96, 0.264, 281, 254, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
3356, d4fobA_, 0.7438, 3.07, 0.198, 295, 253, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
3357, d4c4fA1, 0.7438, 2.33, 0.299, 250, 241, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3358, d5i9zA_, 0.7437, 2.64, 0.224, 273, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
3359, d4uwbA_, 0.7437, 3.12, 0.244, 299, 254, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3360, d4rj8A_, 0.7437, 2.72, 0.202, 298, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
3361, d3tjcA_, 0.7437, 3.05, 0.263, 284, 255, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
3362, d3d2iA_, 0.7437, 2.55, 0.296, 255, 247, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
3363, d4hgeA_, 0.7436, 2.97, 0.268, 284, 254, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
3364, d2vx1A_, 0.7436, 2.77, 0.220, 274, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3365, d2ivsB1, 0.7436, 2.84, 0.254, 272, 248, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3366, d5uhnB_, 0.7435, 2.77, 0.251, 269, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
3367, d5hcyA_, 0.7435, 2.88, 0.200, 302, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
3368, d5ehyA1, 0.7435, 2.38, 0.302, 251, 242, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3369, d5cauA_, 0.7435, 2.73, 0.202, 297, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
3370, d1yi6B_, 0.7435, 2.84, 0.243, 274, 251, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
3371, d5ftoA1, 0.7434, 3.03, 0.198, 297, 253, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
3372, d4k8aB_, 0.7434, 2.46, 0.258, 258, 244, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
3373, d4bi2A1, 0.7434, 2.31, 0.307, 250, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3374, d3fupA_, 0.7434, 2.99, 0.268, 284, 254, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3375, d2wzjA_, 0.7434, 2.37, 0.315, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3376, d2vwzA_, 0.7434, 2.75, 0.228, 274, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3377, d2vwxA_, 0.7434, 2.75, 0.228, 274, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3378, d2jfmA_, 0.7434, 2.33, 0.277, 287, 242, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
3379, d1jqhA_, 0.7434, 2.95, 0.202, 291, 253, IGF-1 RECEPTOR KINASE DOMAIN
3380, d5v19A_, 0.7433, 2.28, 0.300, 250, 240, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3381, d3gxlA_, 0.7433, 2.66, 0.211, 285, 247, ALK-5 KINASE COMPLEX WITH GW857175
3382, d4cd0A_, 0.7432, 2.96, 0.203, 295, 251, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
3383, d3lpbA_, 0.7432, 2.92, 0.269, 278, 253, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
3384, d4u5jA_, 0.7431, 2.68, 0.251, 267, 247, C-SRC IN COMPLEX WITH RUXOLITINIB
3385, d4mneB_, 0.7431, 2.74, 0.184, 270, 250, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3386, d1jqhC_, 0.7431, 2.97, 0.202, 291, 253, IGF-1 RECEPTOR KINASE DOMAIN
3387, d1bi7A_, 0.7431, 2.77, 0.457, 269, 247, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
3388, d5njzA_, 0.7430, 2.51, 0.216, 273, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
3389, d4p2kA_, 0.7430, 2.56, 0.215, 259, 247, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3390, d4c7tA_, 0.7430, 2.64, 0.264, 259, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
3391, d3etaB_, 0.7430, 2.88, 0.205, 292, 249, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3392, d2j51A_, 0.7430, 2.34, 0.277, 288, 242, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
3393, d5vndB_, 0.7429, 2.96, 0.245, 295, 253, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3394, d5j7hA_, 0.7429, 2.70, 0.202, 291, 248, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
3395, d3uzpB_, 0.7429, 2.74, 0.183, 284, 252, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3396, d3tjdA_, 0.7429, 3.04, 0.259, 284, 255, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
3397, d3js2A_, 0.7429, 3.19, 0.243, 295, 255, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3398, d5ih8A_, 0.7428, 2.33, 0.329, 306, 240, MELK IN COMPLEX WITH NVS-MELK1
3399, d4zp5A_, 0.7428, 2.94, 0.246, 284, 252, MAP4K4 IN COMPLEX WITH INHIBITOR
3400, d4yc8A_, 0.7428, 2.53, 0.224, 259, 245, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
3401, d4bhnA_, 0.7428, 2.55, 0.296, 256, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3402, d4bf2B_, 0.7428, 2.35, 0.304, 252, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3403, d3zfxI_, 0.7428, 2.52, 0.233, 263, 245, CRYSTAL STRUCTURE OF EPHB1
3404, d5aafA_, 0.7427, 2.47, 0.306, 254, 245, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
3405, d3d14A1, 0.7427, 2.70, 0.297, 257, 249, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
3406, d2xa4A_, 0.7427, 2.82, 0.268, 276, 250, INHIBITORS OF JAK2 KINASE DOMAIN
3407, d1mruB_, 0.7427, 2.69, 0.255, 271, 247, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3408, d5hhwA_, 0.7426, 2.83, 0.200, 306, 250, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
3409, d4u40A_, 0.7426, 3.06, 0.262, 295, 256, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
3410, d4c8bB_, 0.7426, 2.83, 0.216, 281, 250, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3411, d3q4tA1, 0.7426, 2.78, 0.229, 294, 249, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3412, d3dqxA_, 0.7426, 2.69, 0.251, 267, 247, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
3413, d2helA_, 0.7426, 2.40, 0.197, 256, 244, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
3414, d2hakF_, 0.7426, 2.60, 0.325, 318, 246, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3415, d5ttuA_, 0.7425, 2.72, 0.249, 271, 249, JAK3 WITH COVALENT INHIBITOR 7
3416, d4qrcA_, 0.7425, 2.84, 0.256, 297, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
3417, d4e26B_, 0.7425, 2.68, 0.202, 264, 247, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3418, d4b8lA_, 0.7425, 2.36, 0.307, 249, 241, AURORA B KINASE P353G MUTANT
3419, d3socA1, 0.7425, 3.01, 0.230, 296, 252, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3420, d3lauA1, 0.7424, 2.35, 0.317, 250, 240, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
3421, d3hmiA_, 0.7424, 3.01, 0.217, 268, 253, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
3422, d2zmdA_, 0.7424, 2.39, 0.298, 259, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
3423, d6bu6C_, 0.7423, 3.02, 0.148, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3424, d3wf7A_, 0.7423, 2.89, 0.311, 288, 251, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
3425, d3vw6A_, 0.7423, 2.48, 0.293, 255, 242, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3426, d3fzrA_, 0.7423, 2.66, 0.215, 261, 247, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
3427, d1zmwB_, 0.7423, 2.58, 0.314, 302, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
3428, d5uglB_, 0.7422, 2.78, 0.255, 271, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
3429, d5ajqB_, 0.7422, 2.60, 0.335, 267, 245, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3430, d5aagA_, 0.7422, 2.47, 0.306, 253, 245, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
3431, d3vw6B_, 0.7422, 2.40, 0.303, 253, 241, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3432, d2jflA_, 0.7422, 2.35, 0.277, 286, 242, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
3433, d4qpsC_, 0.7421, 2.90, 0.261, 276, 253, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3434, d4gu9B_, 0.7421, 2.59, 0.257, 255, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
3435, d5khwB_, 0.7420, 2.70, 0.257, 276, 249, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
3436, d3wyyA_, 0.7420, 2.59, 0.307, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
3437, d3f69B_, 0.7420, 3.05, 0.234, 282, 256, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3438, d2gsfA_, 0.7420, 2.45, 0.220, 281, 245, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3439, d5calA_, 0.7419, 2.79, 0.202, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
3440, d2jkmA_, 0.7419, 2.49, 0.262, 260, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3441, d4focA_, 0.7418, 3.02, 0.198, 296, 252, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
3442, d3fdnA_, 0.7418, 2.57, 0.297, 261, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3443, d6bruC_, 0.7417, 3.03, 0.148, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3444, d5ap5A1, 0.7417, 2.30, 0.299, 248, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3445, d4fodA_, 0.7417, 2.98, 0.198, 308, 252, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
3446, d3hmnA_, 0.7417, 2.39, 0.306, 255, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
3447, d3dbqA_, 0.7417, 2.54, 0.299, 259, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
3448, d2qluA1, 0.7417, 3.03, 0.224, 295, 250, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
3449, d4e6dA_, 0.7416, 3.02, 0.268, 286, 254, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3450, d4c4eA1, 0.7416, 2.35, 0.311, 253, 241, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3451, d4at4A1, 0.7416, 2.89, 0.234, 289, 252, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
3452, d3zepB_, 0.7416, 2.84, 0.253, 268, 249, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3453, d3g6hA_, 0.7416, 2.58, 0.249, 266, 245, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
3454, d3vquA_, 0.7415, 2.52, 0.309, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
3455, d3et7A_, 0.7415, 2.67, 0.211, 261, 247, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
3456, d1fvrA_, 0.7415, 2.76, 0.242, 299, 248, TIE2 KINASE DOMAIN
3457, d4u43A_, 0.7414, 2.92, 0.272, 287, 254, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3458, d4o6lA_, 0.7413, 2.48, 0.306, 257, 242, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3459, d4c4gA1, 0.7413, 2.26, 0.304, 247, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3460, d4hvsA1, 0.7412, 2.70, 0.227, 323, 247, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
3461, d3tjdB_, 0.7412, 2.99, 0.260, 287, 254, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
3462, d2j0mB_, 0.7412, 2.34, 0.260, 257, 242, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
3463, d5j7bA_, 0.7411, 2.75, 0.224, 277, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3464, d4o6lB_, 0.7411, 2.40, 0.307, 256, 241, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
3465, d3pp0A_, 0.7411, 2.91, 0.205, 286, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
3466, d3h3cA_, 0.7411, 2.46, 0.217, 263, 244, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
3467, d3c4fA_, 0.7411, 3.15, 0.244, 290, 254, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3468, d2x4fA_, 0.7411, 2.80, 0.264, 289, 250, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3469, d2w5bA1, 0.7411, 2.46, 0.285, 263, 242, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
3470, d6bp0C_, 0.7410, 3.04, 0.148, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3471, d5mrbA1, 0.7410, 2.44, 0.314, 259, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
3472, d5aadA_, 0.7410, 2.45, 0.299, 252, 244, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
3473, d5a46A_, 0.7410, 3.05, 0.238, 289, 252, FGFR1 IN COMPLEX WITH DOVITINIB
3474, d4uzhA1, 0.7410, 2.40, 0.317, 250, 240, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3475, d4e6dB_, 0.7410, 3.03, 0.264, 286, 254, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
3476, d4c3rA_, 0.7410, 2.66, 0.297, 252, 246, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3477, d3fzpA_, 0.7410, 2.41, 0.214, 259, 243, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
3478, d2xruA_, 0.7410, 2.49, 0.299, 253, 244, AURORA-A T288E COMPLEXED WITH PHA-828300
3479, d1b6cH_, 0.7410, 3.40, 0.218, 326, 257, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3480, d5em6A_, 0.7409, 2.81, 0.202, 301, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3481, d5ap3A1, 0.7409, 2.28, 0.300, 250, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3482, d5ap1A1, 0.7409, 2.26, 0.290, 264, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3483, d4wa9B1, 0.7409, 2.75, 0.222, 263, 248, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3484, d3lw0A_, 0.7409, 2.81, 0.214, 292, 248, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3485, d2wzjC_, 0.7409, 2.42, 0.315, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3486, d1fvrB_, 0.7409, 2.92, 0.236, 300, 250, TIE2 KINASE DOMAIN
3487, d6btwC_, 0.7408, 3.04, 0.148, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3488, d5edpA_, 0.7408, 2.69, 0.206, 295, 247, EGFR KINASE (T790M/L858R) APO
3489, d5bvnA_, 0.7408, 3.02, 0.229, 278, 253, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3490, d4rj6A_, 0.7408, 2.75, 0.202, 297, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
3491, d4js8A_, 0.7408, 2.42, 0.302, 259, 242, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
3492, d3lw0C_, 0.7408, 2.82, 0.214, 292, 248, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3493, d3ckwA_, 0.7408, 2.08, 0.277, 255, 238, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
3494, d3c4fB_, 0.7408, 3.04, 0.245, 290, 253, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3495, d2zv8A1, 0.7408, 2.62, 0.237, 256, 245, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
3496, d1jqhB_, 0.7408, 2.97, 0.202, 287, 252, IGF-1 RECEPTOR KINASE DOMAIN
3497, d5ljjA1, 0.7407, 2.42, 0.307, 260, 241, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
3498, d4xcuA1, 0.7406, 2.96, 0.244, 287, 250, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
3499, d4lg4E_, 0.7406, 2.48, 0.279, 275, 244, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3500, d4f0iB_, 0.7406, 2.55, 0.224, 294, 245, CRYSTAL STRUCTURE OF APO TRKA
3501, d3m11A_, 0.7406, 2.47, 0.303, 256, 244, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3502, d3lw0D_, 0.7406, 2.82, 0.214, 292, 248, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3503, d2wzjF_, 0.7406, 2.43, 0.315, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3504, d1ol6A_, 0.7406, 2.28, 0.304, 245, 240, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
3505, d6bp0B_, 0.7405, 3.05, 0.148, 304, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3506, d5uorA_, 0.7405, 2.36, 0.300, 249, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3507, d4ztsA_, 0.7405, 2.55, 0.307, 249, 244, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
3508, d4ymjA1, 0.7405, 2.60, 0.241, 267, 245, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3509, d4rvtA_, 0.7405, 2.85, 0.269, 281, 249, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3510, d4rj7A_, 0.7405, 2.74, 0.203, 295, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
3511, d4dfyE_, 0.7405, 2.66, 0.271, 312, 251, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3512, d4cv9A1, 0.7405, 2.42, 0.293, 250, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3513, d4bi1A1, 0.7405, 2.21, 0.301, 249, 239, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3514, d2w5aA1, 0.7405, 2.49, 0.277, 259, 242, HUMAN NEK2 KINASE ADP-BOUND
3515, d2w1dA1, 0.7404, 2.36, 0.314, 251, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3516, d1m7nB_, 0.7404, 2.78, 0.206, 299, 248, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3517, d5j7bB_, 0.7403, 2.81, 0.220, 281, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3518, d5hicA_, 0.7403, 2.79, 0.202, 302, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
3519, d3lw0B_, 0.7403, 2.82, 0.214, 292, 248, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3520, d2i1mA_, 0.7403, 2.82, 0.214, 311, 248, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
3521, d2etmA_, 0.7403, 2.75, 0.267, 262, 247, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3522, d1p4oA_, 0.7403, 2.83, 0.213, 308, 249, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3523, d4mxxA_, 0.7402, 2.53, 0.242, 266, 244, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3524, d4c62A_, 0.7402, 2.80, 0.274, 273, 248, INHIBITORS OF JAK2 KINASE DOMAIN
3525, d1yi6A_, 0.7402, 3.05, 0.241, 274, 253, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
3526, d5oy6D_, 0.7401, 3.17, 0.237, 292, 253, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3527, d5a4cB1, 0.7401, 2.86, 0.240, 284, 250, FGFR1 LIGAND COMPLEX
3528, d3zmmA_, 0.7401, 2.79, 0.274, 273, 248, INHIBITORS OF JAK2 KINASE DOMAIN
3529, d3q4zB_, 0.7401, 2.55, 0.300, 279, 243, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3530, d3f6xB_, 0.7401, 2.51, 0.251, 267, 243, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3531, d5vndA_, 0.7400, 3.04, 0.245, 302, 253, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3532, d5nadA1, 0.7400, 2.60, 0.292, 253, 243, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
3533, d5n93A1, 0.7400, 2.42, 0.289, 256, 242, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
3534, d5ia4A_, 0.7400, 2.80, 0.221, 269, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
3535, d5hcxA_, 0.7400, 2.74, 0.202, 298, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
3536, d5ar7B_, 0.7400, 2.77, 0.224, 278, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3537, d5ap2A1, 0.7400, 2.36, 0.307, 253, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3538, d4kabB_, 0.7400, 2.61, 0.257, 258, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
3539, d4gu6A_, 0.7400, 2.81, 0.263, 271, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
3540, d4cljA_, 0.7400, 2.90, 0.200, 295, 250, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3541, d3w1fA_, 0.7400, 2.52, 0.296, 259, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
3542, d2uv2A1, 0.7400, 2.29, 0.275, 286, 240, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
3543, d2ja0A_, 0.7400, 2.30, 0.275, 285, 240,  
3544, d1fgiA_, 0.7400, 3.00, 0.250, 283, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
3545, d5nkaA_, 0.7399, 2.51, 0.213, 271, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
3546, d2z7rA_, 0.7399, 2.32, 0.315, 265, 241, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
3547, d5e1eA_, 0.7398, 2.82, 0.256, 279, 250, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
3548, d4u0iA_, 0.7398, 2.69, 0.223, 297, 247, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
3549, d2ijmB_, 0.7398, 2.47, 0.266, 261, 244, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
3550, d2bdfB_, 0.7398, 2.73, 0.251, 265, 247, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
3551, d6eimA_, 0.7397, 2.60, 0.313, 286, 243, HUMAN STK10 BOUND TO GW683134A
3552, d5t0pB_, 0.7397, 2.47, 0.252, 263, 242, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3553, d1t45A_, 0.7397, 2.78, 0.230, 331, 248, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
3554, d5vamA_, 0.7396, 2.69, 0.198, 269, 248, BRAF IN COMPLEX WITH RAF709
3555, d5grnA_, 0.7396, 2.91, 0.208, 285, 250, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
3556, d4zsaA_, 0.7396, 3.08, 0.245, 289, 253, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
3557, d4xg8C_, 0.7396, 2.51, 0.200, 254, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3558, d4ckrA1, 0.7396, 3.04, 0.229, 294, 253, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
3559, d4bkiA1, 0.7396, 3.04, 0.229, 294, 253,  
3560, d1m7nA_, 0.7396, 2.80, 0.206, 299, 248, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3561, d2jkqA_, 0.7395, 2.46, 0.263, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3562, d1p4oB_, 0.7395, 2.84, 0.213, 314, 249, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
3563, d5uoxB_, 0.7394, 2.43, 0.296, 252, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3564, d5tq6A_, 0.7394, 3.02, 0.265, 274, 253, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3565, d5na0A1, 0.7394, 2.42, 0.299, 250, 241, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
3566, d4zjiB_, 0.7394, 2.68, 0.294, 276, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3567, d4h58B_, 0.7394, 2.61, 0.204, 262, 245, BRAF IN COMPLEX WITH COMPOUND 3
3568, d3uqgA_, 0.7394, 2.46, 0.252, 263, 242, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
3569, d3dqxB_, 0.7394, 2.81, 0.250, 268, 248, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
3570, d2x9fA_, 0.7394, 2.47, 0.221, 265, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3571, d2j7tA_, 0.7394, 2.67, 0.325, 285, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
3572, d1muoA_, 0.7394, 2.65, 0.316, 251, 244, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
3573, d1k9aE3, 0.7394, 2.63, 0.233, 268, 245, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3574, d5kbqB_, 0.7393, 2.56, 0.293, 273, 242, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3575, d5ia5A_, 0.7393, 2.82, 0.217, 273, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
3576, d5edqA_, 0.7393, 2.76, 0.210, 298, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
3577, d4rwjA1, 0.7393, 3.07, 0.250, 306, 252, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3578, d4mxzB_, 0.7393, 2.51, 0.251, 264, 243, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3579, d4mxyB_, 0.7393, 2.51, 0.251, 264, 243, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3580, d4cv8A1, 0.7393, 2.50, 0.305, 252, 243, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
3581, d2zv9A1, 0.7393, 2.73, 0.236, 255, 246, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
3582, d2bdjA_, 0.7393, 2.66, 0.250, 254, 244, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
3583, d1t46A_, 0.7393, 2.77, 0.234, 297, 248, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
3584, d5vo6A_, 0.7392, 2.82, 0.252, 271, 250, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
3585, d5bvkA_, 0.7392, 3.15, 0.229, 278, 253, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3586, d5ia1A_, 0.7391, 2.37, 0.215, 261, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
3587, d4aojC_, 0.7391, 2.36, 0.230, 261, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3588, d2xvdA_, 0.7391, 2.68, 0.228, 270, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3589, d2qonA_, 0.7391, 2.49, 0.220, 281, 245, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
3590, d5am7A_, 0.7390, 2.89, 0.245, 294, 249, FGFR1 MUTANT WITH AN INHIBITOR
3591, d5tq4A_, 0.7389, 3.03, 0.258, 290, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3592, d5m57A1, 0.7389, 2.24, 0.298, 253, 238, NEK2 BOUND TO ARYLAMINOPURINE 6
3593, d5kmnA1, 0.7389, 2.67, 0.224, 290, 245, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3594, d5kmlA1, 0.7389, 2.67, 0.224, 290, 245, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3595, d5hx8A_, 0.7389, 2.92, 0.254, 291, 252, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3596, d5bvwA_, 0.7389, 3.09, 0.230, 274, 252, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3597, d4uwcA_, 0.7389, 3.20, 0.244, 300, 254, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3598, d4at5A1, 0.7389, 2.90, 0.234, 291, 252, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
3599, d5ia0C_, 0.7388, 2.31, 0.220, 269, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3600, d5caoA_, 0.7388, 2.76, 0.203, 300, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
3601, d5ap7A1, 0.7388, 2.29, 0.304, 253, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3602, d3wf6A_, 0.7388, 2.38, 0.322, 277, 242, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
3603, d2hakD_, 0.7387, 2.52, 0.328, 309, 244, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3604, d5tq7A_, 0.7386, 2.96, 0.262, 275, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3605, d3zfxE_, 0.7386, 2.55, 0.234, 262, 244, CRYSTAL STRUCTURE OF EPHB1
3606, d3wf5A_, 0.7386, 2.38, 0.322, 277, 242, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
3607, d5f20A_, 0.7385, 2.52, 0.230, 274, 244, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
3608, d3ky2A1, 0.7385, 2.98, 0.244, 305, 250, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
3609, d2xneA_, 0.7385, 2.28, 0.303, 246, 241, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
3610, d3gxjA_, 0.7384, 2.75, 0.206, 288, 247,  
3611, d1mqbA_, 0.7384, 2.47, 0.217, 263, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3612, d4zjiA_, 0.7383, 2.89, 0.311, 278, 251, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3613, d4mneG_, 0.7383, 2.65, 0.191, 259, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3614, d4bb4A_, 0.7383, 2.48, 0.221, 265, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3615, d3mdyA_, 0.7383, 2.98, 0.234, 320, 252, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
3616, d3h10D_, 0.7383, 2.45, 0.314, 255, 242, AURORA A INHIBITOR COMPLEX
3617, d3etaA_, 0.7383, 2.93, 0.205, 293, 249, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3618, d3cohB_, 0.7383, 2.46, 0.307, 247, 241, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3619, d5i9wA_, 0.7382, 2.44, 0.215, 267, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
3620, d5cwzC_, 0.7382, 2.36, 0.256, 271, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3621, d5wr7A_, 0.7381, 2.50, 0.230, 301, 244, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
3622, d5edrA_, 0.7381, 2.68, 0.207, 299, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
3623, d5ap4A1, 0.7381, 2.41, 0.307, 253, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
3624, d4mxoA_, 0.7381, 2.56, 0.246, 266, 244, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
3625, d4bf2A_, 0.7381, 2.52, 0.295, 253, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3626, d2jkkA_, 0.7381, 2.57, 0.259, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3627, d2hakE_, 0.7381, 2.55, 0.327, 318, 245, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
3628, d5nk0A_, 0.7380, 2.49, 0.218, 273, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
3629, d5e1sA_, 0.7380, 2.66, 0.192, 284, 245, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
3630, d4zloB_, 0.7380, 2.21, 0.303, 263, 238, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
3631, d4oa2A_, 0.7380, 3.10, 0.221, 280, 253,  
3632, d4kb8A_, 0.7380, 2.75, 0.205, 265, 249, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3633, d4gu6B_, 0.7380, 2.58, 0.257, 258, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
3634, d5m51A1, 0.7379, 2.31, 0.289, 253, 239, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
3635, d4mxoB_, 0.7379, 2.53, 0.247, 264, 243, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
3636, d3q4uB1, 0.7379, 3.09, 0.238, 298, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3637, d3dk6B_, 0.7379, 2.86, 0.220, 259, 246, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3638, d3cohA_, 0.7379, 2.47, 0.307, 247, 241, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3639, d2oiqB_, 0.7379, 2.59, 0.254, 265, 244, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
3640, d4ztrA_, 0.7378, 2.53, 0.300, 249, 243, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
3641, d4rwlB_, 0.7378, 2.84, 0.229, 285, 249, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
3642, d2wzjE_, 0.7378, 2.46, 0.315, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3643, d1zmvB_, 0.7378, 2.36, 0.311, 296, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
3644, d1zmuB_, 0.7378, 2.37, 0.315, 296, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
3645, d5w5oM_, 0.7377, 2.69, 0.226, 276, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3646, d5hczA_, 0.7377, 2.77, 0.202, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
3647, d4c4hA1, 0.7377, 2.17, 0.298, 245, 238, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
3648, d2wzjB_, 0.7377, 2.50, 0.315, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3649, d5xy1A1, 0.7376, 2.63, 0.242, 252, 244, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
3650, d4ymjB1, 0.7376, 2.59, 0.242, 272, 244, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3651, d4aojA_, 0.7376, 2.40, 0.226, 260, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3652, d4c61A_, 0.7375, 2.78, 0.271, 272, 247, INHIBITORS OF JAK2 KINASE DOMAIN
3653, d5ia0A_, 0.7374, 2.40, 0.219, 263, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3654, d4hniA_, 0.7374, 2.87, 0.190, 284, 253, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3655, d4brxA_, 0.7374, 2.75, 0.264, 259, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
3656, d3zz2A_, 0.7374, 2.69, 0.329, 281, 243,  
3657, d3g0fB_, 0.7374, 2.78, 0.231, 293, 247, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3658, d1i44A_, 0.7374, 2.76, 0.206, 282, 247, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3659, d5w86B_, 0.7373, 2.64, 0.258, 267, 244, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3660, d5am6A1, 0.7373, 2.82, 0.250, 294, 248, NATIVE FGFR1 WITH AN INHIBITOR
3661, d4yhtB_, 0.7373, 2.66, 0.207, 258, 246, BRAF COMPLEXED WITH AN INHIBITOR
3662, d4cmoA_, 0.7373, 2.92, 0.201, 295, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
3663, d3g0eA1, 0.7373, 2.74, 0.235, 330, 247, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
3664, d3beaA_, 0.7373, 2.84, 0.214, 310, 248, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
3665, d5w5oE_, 0.7372, 2.75, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3666, d5lpzA_, 0.7372, 3.07, 0.222, 283, 252, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
3667, d4o0uA_, 0.7372, 2.63, 0.305, 259, 246, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3668, d4fk6A_, 0.7372, 3.11, 0.248, 285, 254, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3669, d4c8bA_, 0.7372, 2.80, 0.218, 279, 248, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3670, d4k77A_, 0.7371, 2.97, 0.254, 282, 252, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
3671, d4cnhB_, 0.7371, 2.94, 0.201, 293, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3672, d3uojB_, 0.7371, 2.57, 0.317, 263, 243, AURORA A IN COMPLEX WITH RPM1715
3673, d3uojA_, 0.7371, 2.57, 0.317, 263, 243, AURORA A IN COMPLEX WITH RPM1715
3674, d3g0fA_, 0.7371, 2.77, 0.235, 291, 247, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3675, d5wfjA_, 0.7370, 2.75, 0.254, 265, 248, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
3676, d5aaaA_, 0.7370, 2.91, 0.205, 294, 249, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3677, d3ppkB_, 0.7370, 2.67, 0.203, 264, 246, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3678, d3mygA_, 0.7369, 2.48, 0.300, 252, 243, AURORA A KINASE COMPLEXED WITH SCH 1473759
3679, d3mdyC_, 0.7369, 3.18, 0.232, 320, 254, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
3680, d3gqlB_, 0.7369, 2.86, 0.230, 276, 248, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3681, d1zmuA_, 0.7369, 2.45, 0.315, 293, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
3682, d5xp7A_, 0.7368, 2.55, 0.251, 265, 243, C-SRC IN COMPLEX WITH ATP-CHCL
3683, d4fk6B_, 0.7368, 3.08, 0.248, 284, 254, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3684, d3nw6A_, 0.7368, 2.74, 0.211, 301, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
3685, d6bruD_, 0.7367, 3.12, 0.152, 311, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3686, d5wo4A_, 0.7367, 2.96, 0.246, 292, 252, JAK1 COMPLEXED WITH COMPOUND 28
3687, d4nkaB_, 0.7367, 2.97, 0.233, 287, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
3688, d3ewhA1, 0.7367, 2.93, 0.225, 295, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
3689, d5e1eB_, 0.7366, 2.90, 0.255, 280, 251, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
3690, d4e4nB_, 0.7366, 2.92, 0.255, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3691, d3wzkA_, 0.7366, 2.57, 0.305, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
3692, d5aaeA_, 0.7365, 2.47, 0.300, 252, 243, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
3693, d4mneC_, 0.7365, 2.73, 0.178, 260, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3694, d4aszA1, 0.7365, 2.94, 0.219, 286, 251, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
3695, d2zv7A1, 0.7365, 2.71, 0.237, 256, 245, LYN TYROSINE KINASE DOMAIN APO FORM
3696, d2ijmA_, 0.7365, 2.47, 0.259, 260, 243, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
3697, d5iuiA_, 0.7364, 3.08, 0.194, 303, 252, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
3698, d4nk9B_, 0.7364, 3.12, 0.228, 282, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3699, d4gk2A_, 0.7364, 2.42, 0.219, 265, 242, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
3700, d5tq6B_, 0.7363, 3.02, 0.266, 271, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3701, d4ibmA_, 0.7363, 2.95, 0.200, 301, 250, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3702, d4dfyA_, 0.7363, 2.63, 0.273, 310, 249, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
3703, d3prfA_, 0.7363, 2.58, 0.197, 262, 244, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3704, d5owrA_, 0.7362, 2.59, 0.324, 282, 241, HUMAN STK10 BOUND TO DASATINIB
3705, d5kmjA_, 0.7362, 2.69, 0.225, 300, 244, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
3706, d5bvoA_, 0.7362, 3.04, 0.226, 276, 252, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3707, d4nk9A_, 0.7362, 3.10, 0.228, 281, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3708, d3uo6A_, 0.7362, 2.48, 0.318, 264, 242, AURORA A IN COMPLEX WITH YL5-083
3709, d3d4qA_, 0.7362, 2.75, 0.203, 264, 246, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3710, d2xa4B_, 0.7362, 2.75, 0.271, 275, 247, INHIBITORS OF JAK2 KINASE DOMAIN
3711, d6eixA_, 0.7361, 3.33, 0.239, 312, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
3712, d6b4wA_, 0.7361, 2.40, 0.307, 259, 241, TTK IN COMPLEX WITH INHIBITOR
3713, d5am6B_, 0.7361, 2.89, 0.246, 280, 248, NATIVE FGFR1 WITH AN INHIBITOR
3714, d3uo6B_, 0.7361, 2.49, 0.318, 264, 242, AURORA A IN COMPLEX WITH YL5-083
3715, d5l8jA_, 0.7360, 2.54, 0.306, 253, 242, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
3716, d5kz0A_, 0.7360, 2.94, 0.205, 293, 249, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
3717, d5dg5B_, 0.7360, 2.89, 0.219, 297, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
3718, d5dg5A_, 0.7360, 2.94, 0.218, 297, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
3719, d5j9zA_, 0.7359, 2.75, 0.220, 291, 246, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
3720, d5aa9A_, 0.7359, 3.01, 0.208, 295, 250, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
3721, d4ccbA_, 0.7359, 2.89, 0.198, 287, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
3722, d4bkjB1, 0.7359, 3.11, 0.206, 296, 253, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3723, d3d94A_, 0.7359, 2.78, 0.215, 288, 246, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
3724, d3d7tB_, 0.7359, 2.64, 0.238, 265, 244, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3725, d2hz0A_, 0.7359, 3.11, 0.222, 265, 252, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
3726, d5w5oA_, 0.7358, 2.77, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3727, d4qqjA_, 0.7358, 2.93, 0.245, 282, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
3728, d3txoA_, 0.7358, 2.91, 0.272, 317, 246, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
3729, d1zmvA_, 0.7358, 2.35, 0.312, 293, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
3730, d5ar7A_, 0.7357, 2.87, 0.228, 278, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3731, d4jbpA_, 0.7357, 2.58, 0.303, 255, 244, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3732, d4cmuA_, 0.7357, 3.02, 0.204, 294, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
3733, d4cliA_, 0.7357, 3.03, 0.204, 294, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
3734, d3kfaB1, 0.7357, 2.82, 0.244, 283, 246, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3735, d3kfaA1, 0.7357, 2.82, 0.244, 283, 246, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3736, d2qoqA_, 0.7357, 2.46, 0.214, 284, 243, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
3737, d5oxgD_, 0.7356, 3.17, 0.237, 293, 253, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3738, d5fdxA_, 0.7356, 3.03, 0.229, 280, 253, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3739, d4zjjA_, 0.7356, 2.82, 0.309, 280, 249, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3740, d3o23A_, 0.7356, 2.80, 0.206, 293, 247, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
3741, d2yjrA_, 0.7356, 2.52, 0.198, 278, 242, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
3742, d2wkmA_, 0.7356, 2.90, 0.222, 286, 248, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
3743, d5v24A_, 0.7355, 2.42, 0.301, 249, 239, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3744, d4yjsA_, 0.7355, 2.57, 0.196, 257, 245, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
3745, d3unzB_, 0.7355, 2.50, 0.318, 263, 242, AURORA A IN COMPLEX WITH RPM1679
3746, d3unzA_, 0.7355, 2.50, 0.318, 263, 242, AURORA A IN COMPLEX WITH RPM1679
3747, d2xb7A_, 0.7355, 2.67, 0.200, 286, 245, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
3748, d2wzjD_, 0.7355, 2.45, 0.317, 313, 240, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
3749, d4oa6A_, 0.7354, 3.03, 0.223, 279, 251,  
3750, d3d4qB_, 0.7354, 2.76, 0.203, 264, 246, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3751, d5ftqA1, 0.7353, 3.03, 0.200, 292, 250, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
3752, d4ivdB_, 0.7353, 2.92, 0.255, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
3753, d4aotB1, 0.7353, 2.77, 0.336, 277, 247, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3754, d3uohB_, 0.7353, 2.61, 0.317, 264, 243, AURORA A IN COMPLEX WITH RPM1722
3755, d3uohA_, 0.7353, 2.61, 0.317, 264, 243, AURORA A IN COMPLEX WITH RPM1722
3756, d3oy3A1, 0.7353, 2.96, 0.242, 283, 248, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3757, d3h0zA_, 0.7353, 2.54, 0.310, 248, 242, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3758, d2reiA1, 0.7353, 2.43, 0.223, 274, 242, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
3759, d5kmiA_, 0.7352, 2.63, 0.226, 300, 243, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
3760, d5ajqA_, 0.7352, 2.93, 0.337, 280, 249, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3761, d4tygA1, 0.7352, 3.00, 0.252, 290, 250, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3762, d4k77B_, 0.7352, 2.93, 0.255, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
3763, d4gt5A_, 0.7352, 2.57, 0.225, 290, 244, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
3764, d3zzeA_, 0.7352, 2.97, 0.218, 286, 248, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
3765, d2j50B_, 0.7352, 2.80, 0.303, 249, 244, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3766, d2j50A_, 0.7352, 2.80, 0.303, 249, 244, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3767, d6bp0D_, 0.7351, 3.16, 0.152, 311, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3768, d5w5oO_, 0.7351, 2.83, 0.225, 276, 249, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3769, d4v05B_, 0.7351, 2.90, 0.241, 286, 249, FGFR1 IN COMPLEX WITH AZD4547.
3770, d3u6jA1, 0.7351, 2.82, 0.222, 305, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
3771, d3oy3B1, 0.7351, 3.05, 0.241, 283, 249, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3772, d3bz3A_, 0.7351, 2.62, 0.258, 259, 244, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
3773, d2wmsA_, 0.7351, 2.39, 0.276, 243, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3774, d5vamB_, 0.7350, 2.59, 0.201, 260, 244, BRAF IN COMPLEX WITH RAF709
3775, d5ihaA_, 0.7350, 2.29, 0.333, 303, 237, MELK IN COMPLEX WITH NVS-MELK8F
3776, d5uvfC_, 0.7349, 3.05, 0.153, 301, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3777, d5lpvA_, 0.7349, 3.05, 0.222, 282, 252, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
3778, d4v05A_, 0.7349, 2.97, 0.248, 287, 250, FGFR1 IN COMPLEX WITH AZD4547.
3779, d4rj5A_, 0.7349, 2.75, 0.200, 296, 245, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
3780, d4h58A_, 0.7349, 2.61, 0.204, 263, 245, BRAF IN COMPLEX WITH COMPOUND 3
3781, d4e5wA1, 0.7348, 2.97, 0.247, 291, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3782, d3my0M1, 0.7348, 3.11, 0.235, 297, 251, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3783, d5w5oJ_, 0.7347, 2.78, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3784, d4ag8A_, 0.7347, 2.91, 0.226, 296, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
3785, d3gqlA_, 0.7347, 2.98, 0.245, 287, 249, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3786, d3en4B_, 0.7347, 2.66, 0.254, 266, 244, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
3787, d3d7uC1, 0.7347, 2.62, 0.230, 255, 244, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3788, d3d7uA1, 0.7347, 2.62, 0.230, 255, 244, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3789, d2fb8A_, 0.7347, 2.64, 0.208, 259, 245, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3790, d1k9aA3, 0.7347, 2.62, 0.225, 267, 244, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3791, d5w86A_, 0.7346, 2.68, 0.258, 269, 244, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3792, d5kmoA1, 0.7346, 2.44, 0.228, 290, 241, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
3793, d4usfB1, 0.7346, 3.17, 0.282, 283, 252, HUMAN SLK WITH SB-440719
3794, d4k8aA_, 0.7346, 2.45, 0.257, 251, 241, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
3795, d4i5cA_, 0.7346, 2.89, 0.256, 279, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3796, d2x9eA_, 0.7346, 2.58, 0.302, 253, 242, HUMAN MPS1 IN COMPLEX WITH NMS-P715
3797, d4uxqA_, 0.7345, 3.01, 0.237, 286, 249, FGFR4 IN COMPLEX WITH PONATINIB
3798, d4e4nA1, 0.7345, 2.91, 0.256, 290, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3799, d4bibA_, 0.7345, 2.59, 0.295, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3800, d4bhzA1, 0.7345, 2.31, 0.307, 248, 238, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
3801, d4agcA_, 0.7345, 2.90, 0.226, 304, 248, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
3802, d5am7B_, 0.7344, 3.01, 0.236, 287, 250, FGFR1 MUTANT WITH AN INHIBITOR
3803, d4bkjA1, 0.7344, 3.13, 0.194, 294, 253, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
3804, d3krjA_, 0.7344, 2.74, 0.211, 304, 246, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
3805, d3ik3A1, 0.7344, 3.10, 0.237, 279, 249, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3806, d5jfvA_, 0.7343, 2.64, 0.230, 277, 243, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
3807, d4c61B_, 0.7343, 2.69, 0.269, 274, 245, INHIBITORS OF JAK2 KINASE DOMAIN
3808, d4asdA_, 0.7343, 2.93, 0.226, 305, 248, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
3809, d3zmmB_, 0.7343, 2.69, 0.273, 274, 245, INHIBITORS OF JAK2 KINASE DOMAIN
3810, d3my0N1, 0.7343, 3.05, 0.236, 299, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3811, d3my0L1, 0.7343, 3.08, 0.236, 295, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3812, d2c6eB_, 0.7343, 2.47, 0.308, 246, 240, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3813, d5w5oK_, 0.7342, 2.79, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3814, d5oxgC1, 0.7342, 3.19, 0.237, 299, 253, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3815, d5nkiA_, 0.7342, 2.46, 0.216, 268, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
3816, d4usdA_, 0.7342, 2.69, 0.332, 268, 247, HUMAN STK10 (LOK) WITH SB-633825
3817, d4f64B_, 0.7342, 2.79, 0.248, 272, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
3818, d4b0gA_, 0.7342, 2.27, 0.311, 247, 238, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
3819, d3uokB_, 0.7342, 2.51, 0.318, 265, 242, AURORA A IN COMPLEX WITH YL5-81-1
3820, d3uokA_, 0.7342, 2.51, 0.318, 265, 242, AURORA A IN COMPLEX WITH YL5-81-1
3821, d2c6dA_, 0.7342, 2.60, 0.317, 254, 243, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
3822, d5lpwA_, 0.7341, 2.98, 0.225, 280, 249, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
3823, d5ihcA_, 0.7341, 2.49, 0.326, 305, 239, MELK IN COMPLEX WITH NVS-MELK12B
3824, d3vo3A_, 0.7341, 2.93, 0.226, 303, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
3825, d3ppkA_, 0.7341, 2.62, 0.205, 262, 244, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3826, d5w5oI_, 0.7340, 2.71, 0.227, 275, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3827, d5w5oH_, 0.7340, 2.71, 0.227, 275, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3828, d5w5oD_, 0.7340, 2.79, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3829, d4v04B_, 0.7340, 2.82, 0.227, 287, 247, FGFR1 IN COMPLEX WITH PONATINIB.
3830, d4oa9A_, 0.7340, 3.10, 0.222, 280, 252,  
3831, d5w5oG_, 0.7339, 2.80, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3832, d4oacA_, 0.7339, 3.10, 0.222, 280, 252,  
3833, d4bidA_, 0.7339, 2.61, 0.295, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3834, d3vntA_, 0.7339, 2.93, 0.226, 301, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3835, d5k9iB_, 0.7338, 2.57, 0.252, 262, 242, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
3836, d4kbaA_, 0.7338, 2.74, 0.202, 263, 248, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3837, d3q4uD_, 0.7338, 3.20, 0.237, 299, 253, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3838, d3el8A_, 0.7338, 2.56, 0.252, 263, 242, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
3839, d2wgjA_, 0.7338, 2.84, 0.211, 289, 246, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
3840, d2jkoA_, 0.7338, 2.50, 0.252, 256, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3841, d5jfsA_, 0.7337, 2.66, 0.222, 277, 243, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
3842, d4r7hA_, 0.7337, 2.85, 0.219, 308, 247, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
3843, d4o2pB_, 0.7337, 2.57, 0.256, 265, 242, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
3844, d4kaoB_, 0.7337, 2.47, 0.260, 254, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
3845, d3my0B_, 0.7337, 3.07, 0.228, 295, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3846, d2bdfA_, 0.7337, 2.74, 0.253, 261, 245, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
3847, d1irkA_, 0.7337, 2.93, 0.198, 303, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
3848, d4qqtA_, 0.7336, 2.74, 0.244, 283, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
3849, d4mxzA_, 0.7336, 2.67, 0.254, 266, 244, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3850, d4mxyA_, 0.7336, 2.67, 0.254, 266, 244, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3851, d4aojB_, 0.7336, 2.44, 0.224, 258, 241, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3852, d3ik3B1, 0.7336, 2.86, 0.240, 285, 246, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3853, d6bruB_, 0.7335, 2.99, 0.154, 301, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3854, d5hx8B_, 0.7335, 2.96, 0.247, 279, 251, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3855, d4mxcA_, 0.7335, 2.82, 0.227, 290, 247, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3856, d4ivcB_, 0.7335, 2.95, 0.255, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3857, d3nw5A_, 0.7335, 2.87, 0.210, 302, 248, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
3858, d3cjgA_, 0.7335, 2.65, 0.217, 280, 244, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
3859, d4mcvB_, 0.7334, 2.64, 0.251, 265, 243, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
3860, d4bggB_, 0.7334, 3.15, 0.238, 293, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3861, d3i81A_, 0.7334, 2.86, 0.211, 296, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
3862, d2jitB_, 0.7334, 3.28, 0.169, 312, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3863, d5em5A_, 0.7333, 2.78, 0.204, 298, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3864, d4ehzA_, 0.7333, 3.00, 0.258, 290, 252, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3865, d3tudA1, 0.7333, 2.63, 0.197, 255, 244, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
3866, d1pkgB_, 0.7333, 2.98, 0.235, 277, 247, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3867, d5ar4A_, 0.7332, 2.75, 0.223, 274, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3868, d4bggA_, 0.7332, 3.17, 0.238, 296, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3869, d4aw5A_, 0.7332, 2.46, 0.227, 261, 242, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
3870, d3b2wA_, 0.7332, 2.89, 0.231, 261, 247, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
3871, p5x02A_, 0.7331, 2.73, 0.224, 305, 246, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
3872, d3eqfA_, 0.7331, 3.02, 0.262, 314, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
3873, d5wo4B_, 0.7330, 2.97, 0.247, 280, 251, JAK1 COMPLEXED WITH COMPOUND 28
3874, d4r7iA_, 0.7330, 2.81, 0.220, 290, 246, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
3875, d3zclA_, 0.7330, 2.74, 0.216, 289, 245, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
3876, d2fb8B_, 0.7330, 2.50, 0.210, 259, 243, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
3877, d5oxgB_, 0.7329, 3.15, 0.238, 296, 252, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3878, d3wzeA_, 0.7329, 2.86, 0.223, 298, 247, KDR IN COMPLEX WITH LIGAND SORAFENIB
3879, d1f3mC_, 0.7329, 2.94, 0.312, 287, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
3880, d4ap7A_, 0.7328, 2.85, 0.211, 289, 246, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
3881, d3q4uC_, 0.7328, 3.19, 0.237, 296, 253, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3882, d3a62A_, 0.7328, 2.40, 0.329, 263, 240, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
3883, d2w5hA1, 0.7328, 2.52, 0.296, 257, 240, HUMAN NEK2 KINASE APO
3884, d5t0pA_, 0.7327, 2.60, 0.252, 264, 242, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
3885, d5khxA_, 0.7327, 2.91, 0.253, 276, 249, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
3886, d3uolB_, 0.7327, 2.66, 0.317, 263, 243, AURORA A IN COMPLEX WITH SO2-162
3887, d3uolA_, 0.7327, 2.66, 0.317, 263, 243, AURORA A IN COMPLEX WITH SO2-162
3888, d3qquA_, 0.7327, 2.76, 0.207, 285, 246, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
3889, d1agwB_, 0.7327, 2.80, 0.248, 272, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
3890, d5w5oP_, 0.7326, 2.72, 0.227, 275, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3891, d5w5oL_, 0.7326, 2.83, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3892, d5w5oC_, 0.7326, 2.83, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3893, d4yhtA_, 0.7326, 2.60, 0.209, 256, 244, BRAF COMPLEXED WITH AN INHIBITOR
3894, d4mneF_, 0.7326, 2.57, 0.193, 258, 243, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3895, d5oxgA_, 0.7325, 3.00, 0.229, 293, 249, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3896, d5htiA_, 0.7325, 2.84, 0.223, 290, 247, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
3897, d4zjjB_, 0.7325, 2.66, 0.282, 277, 245, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3898, d4hw7A_, 0.7325, 2.83, 0.220, 289, 246, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
3899, d4h1jA_, 0.7325, 2.75, 0.194, 263, 248, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
3900, d3rhxB_, 0.7325, 2.80, 0.248, 275, 246, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
3901, d2hz4B1, 0.7325, 2.57, 0.226, 248, 243, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3902, d2fgiB_, 0.7325, 2.79, 0.248, 272, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
3903, d5kmmA1, 0.7324, 2.66, 0.226, 300, 243, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
3904, d5jfxA_, 0.7324, 2.42, 0.224, 277, 241, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
3905, d4ivbB_, 0.7324, 2.96, 0.247, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3906, d3prfB_, 0.7324, 2.65, 0.197, 262, 244, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3907, d4mnfA_, 0.7323, 2.62, 0.206, 257, 243, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
3908, d2i0vA_, 0.7323, 2.84, 0.215, 303, 246, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
3909, d1fgkB_, 0.7323, 2.80, 0.248, 272, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
3910, d5jfwA_, 0.7322, 2.67, 0.222, 277, 243, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
3911, d4ivcA1, 0.7322, 2.94, 0.256, 290, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3912, d4ei4B_, 0.7322, 2.98, 0.255, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
3913, d3my0U1, 0.7322, 3.04, 0.237, 284, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3914, d3eqhA_, 0.7322, 3.33, 0.262, 314, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
3915, d4b9dB1, 0.7321, 2.95, 0.252, 291, 250, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3916, d3wzjA_, 0.7321, 2.54, 0.295, 257, 241, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
3917, d1k9aB3, 0.7321, 2.66, 0.234, 267, 244, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3918, d4y95A1, 0.7320, 2.81, 0.188, 265, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3919, d4pmmA1, 0.7320, 2.56, 0.227, 281, 242, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
3920, d3nw7A_, 0.7320, 2.84, 0.211, 297, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
3921, d2ogvA_, 0.7320, 2.96, 0.214, 317, 248, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
3922, d4rfyA_, 0.7319, 2.80, 0.184, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
3923, d4d2rA_, 0.7319, 2.80, 0.211, 300, 247, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
3924, d4apcB1, 0.7319, 2.93, 0.252, 291, 250, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3925, d3my0A1, 0.7319, 3.28, 0.229, 295, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3926, d4pmsA1, 0.7318, 2.45, 0.228, 279, 241, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
3927, d4nksB_, 0.7318, 2.78, 0.245, 271, 245, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
3928, d4agdA_, 0.7318, 2.96, 0.222, 303, 248, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
3929, d4y95D_, 0.7317, 2.81, 0.188, 265, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3930, d4rwiB_, 0.7317, 3.03, 0.238, 280, 248, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
3931, d4rfzA_, 0.7317, 2.80, 0.184, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
3932, d4mwiA_, 0.7317, 2.66, 0.205, 266, 244, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
3933, d4usdB_, 0.7316, 2.69, 0.333, 267, 246, HUMAN STK10 (LOK) WITH SB-633825
3934, d3og7B_, 0.7316, 2.50, 0.219, 254, 242, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3935, d5w5oF_, 0.7315, 2.75, 0.227, 275, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3936, d5lpyA_, 0.7315, 3.07, 0.224, 282, 250, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
3937, d5hezB_, 0.7315, 3.07, 0.272, 289, 250, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
3938, d4y95C1, 0.7315, 2.91, 0.187, 265, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3939, d4f63A_, 0.7315, 2.89, 0.243, 278, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
3940, d4d4sB_, 0.7315, 2.69, 0.266, 260, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3941, d3be2A1, 0.7315, 2.55, 0.226, 285, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
3942, d5kmkA1, 0.7314, 2.68, 0.226, 302, 243, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
3943, d4y95B1, 0.7314, 2.91, 0.187, 265, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3944, d4ansA_, 0.7314, 3.00, 0.202, 293, 248, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3945, d4tt7A_, 0.7313, 2.84, 0.196, 291, 245, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
3946, d4i5cB1, 0.7313, 2.97, 0.256, 290, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3947, d4bggD_, 0.7313, 3.14, 0.240, 286, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3948, d4anqA_, 0.7313, 3.01, 0.206, 293, 248, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3949, d3cc6A_, 0.7313, 2.92, 0.201, 269, 249, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
3950, d3aoxA_, 0.7313, 3.02, 0.198, 298, 248, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
3951, d5oy6B_, 0.7312, 3.22, 0.238, 292, 252, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
3952, d5a4cA_, 0.7312, 3.01, 0.230, 294, 248, FGFR1 LIGAND COMPLEX
3953, d4fnwA_, 0.7312, 3.01, 0.202, 304, 248, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3954, d3zbxA_, 0.7312, 2.76, 0.216, 282, 245, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
3955, d4otqA_, 0.7311, 2.82, 0.184, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
3956, d4f64A_, 0.7311, 2.91, 0.243, 278, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
3957, d4f0iA_, 0.7311, 2.47, 0.228, 284, 241, CRYSTAL STRUCTURE OF APO TRKA
3958, d4ccuA_, 0.7311, 2.98, 0.202, 292, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
3959, d4aoiA_, 0.7311, 2.88, 0.228, 289, 246, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
3960, d5w5oB_, 0.7310, 2.85, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3961, d4oabA_, 0.7310, 3.08, 0.223, 279, 251,  
3962, d4anlA_, 0.7310, 2.92, 0.202, 292, 247, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
3963, d3cthA_, 0.7310, 3.11, 0.216, 295, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
3964, d5l4qB_, 0.7309, 2.37, 0.254, 287, 240, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3965, d4yneA1, 0.7309, 2.67, 0.231, 276, 242, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3966, d4otrA_, 0.7309, 2.82, 0.184, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
3967, d1p14A_, 0.7309, 2.73, 0.205, 287, 244, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3968, d1agwA_, 0.7309, 2.89, 0.243, 278, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
3969, d4mcvA_, 0.7308, 2.77, 0.257, 267, 245, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
3970, d4e4lD_, 0.7308, 3.05, 0.247, 281, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3971, d3my0C1, 0.7308, 3.07, 0.237, 298, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3972, d3h0yA_, 0.7308, 2.48, 0.299, 250, 241, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3973, d6btwB_, 0.7307, 3.02, 0.150, 301, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3974, d5p9gA_, 0.7307, 2.82, 0.189, 265, 244, STRUCTURE OF BTK WITH RN486
3975, d4jt3A_, 0.7307, 2.48, 0.304, 254, 240, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
3976, d4ivbA1, 0.7307, 2.95, 0.256, 290, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3977, d4i4eA_, 0.7307, 2.45, 0.246, 254, 240, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
3978, d4fg7A_, 0.7307, 2.31, 0.283, 250, 237, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
3979, d4aseA_, 0.7307, 2.91, 0.223, 305, 247, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
3980, d3op5D_, 0.7307, 3.02, 0.146, 302, 253, HUMAN VACCINIA-RELATED KINASE 1
3981, d1fgkA_, 0.7307, 2.92, 0.242, 278, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
3982, d5p9fA_, 0.7306, 2.86, 0.188, 266, 245, BTK IN COMPLEX WITH GDC-0834
3983, d4rwkB_, 0.7306, 3.17, 0.240, 282, 250, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
3984, d4rg0A_, 0.7306, 2.83, 0.184, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
3985, d1f3mD_, 0.7306, 2.87, 0.313, 285, 249, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
3986, d5lpbA_, 0.7305, 3.07, 0.224, 280, 250, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
3987, d5l6pA_, 0.7305, 2.64, 0.209, 274, 244, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
3988, d5fxsA1, 0.7305, 2.88, 0.210, 307, 248, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
3989, d5aabA_, 0.7305, 2.98, 0.198, 293, 248, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
3990, d4e5wB_, 0.7305, 3.07, 0.250, 278, 252, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3991, d3w10A_, 0.7305, 2.69, 0.311, 263, 244, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
3992, d4hgtB_, 0.7304, 2.80, 0.169, 280, 249, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
3993, d3zxzA_, 0.7304, 2.99, 0.223, 289, 247, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
3994, d3ekkA_, 0.7304, 2.79, 0.204, 285, 245, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3995, d4ot5A_, 0.7303, 2.82, 0.184, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
3996, d4kabA_, 0.7303, 2.48, 0.254, 255, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
3997, d4f63B_, 0.7303, 2.83, 0.244, 271, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
3998, d4ctbA_, 0.7303, 2.89, 0.199, 292, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
3999, d4gu9A_, 0.7302, 2.43, 0.246, 252, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4000, d3tl8D_, 0.7302, 3.47, 0.202, 306, 257, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4001, d5fdpA_, 0.7301, 3.14, 0.229, 285, 253, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
4002, d4rwlA_, 0.7301, 3.09, 0.236, 282, 250, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
4003, d4pmpA1, 0.7301, 2.53, 0.228, 276, 241, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
4004, d4ivdA1, 0.7301, 2.92, 0.257, 289, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4005, d4hniB_, 0.7301, 2.89, 0.191, 284, 251, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4006, d2xyuA_, 0.7301, 2.48, 0.195, 260, 241, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
4007, d2jiuB_, 0.7301, 3.50, 0.168, 309, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
4008, d2fgiA_, 0.7301, 2.93, 0.239, 274, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
4009, d4prjA_, 0.7300, 2.48, 0.307, 251, 241, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
4010, d3l8vA_, 0.7300, 2.96, 0.219, 293, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
4011, d4ztqA_, 0.7299, 2.56, 0.307, 247, 241, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
4012, d3pixA_, 0.7299, 2.85, 0.200, 268, 245, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
4013, d3op5C_, 0.7299, 3.23, 0.151, 308, 258, HUMAN VACCINIA-RELATED KINASE 1
4014, d3my0G1, 0.7299, 3.04, 0.238, 293, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4015, d3g6gA_, 0.7299, 2.54, 0.249, 264, 241, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4016, d2yfxA_, 0.7299, 3.02, 0.194, 292, 248, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4017, d5tq7B_, 0.7298, 2.93, 0.257, 269, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4018, d5fboA_, 0.7298, 2.69, 0.198, 255, 242, BTK-INHIBITOR CO-STRUCTURE
4019, d4ehzB_, 0.7298, 3.04, 0.247, 280, 251, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4020, d3tt0B_, 0.7298, 2.67, 0.251, 272, 243, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
4021, d3my0R1, 0.7298, 3.03, 0.234, 293, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4022, d4f65B_, 0.7297, 2.87, 0.236, 279, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4023, d3oomA_, 0.7297, 3.28, 0.237, 297, 253, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
4024, d3my0H1, 0.7297, 3.04, 0.238, 293, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4025, d3ii5A_, 0.7297, 2.80, 0.200, 262, 245, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4026, d5xgmA_, 0.7296, 2.69, 0.218, 288, 243, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
4027, d3f6xA_, 0.7296, 2.46, 0.250, 264, 240, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4028, d5u9dA_, 0.7295, 2.89, 0.188, 271, 245, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
4029, d4zsaB_, 0.7295, 2.81, 0.227, 282, 247, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
4030, d4k9yA_, 0.7294, 3.04, 0.244, 271, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
4031, d2qo7A_, 0.7294, 2.47, 0.216, 278, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
4032, d4d58B_, 0.7293, 2.74, 0.266, 261, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4033, d3my0S1, 0.7293, 3.05, 0.238, 293, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4034, d3my0D1, 0.7293, 3.04, 0.238, 297, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4035, d2y6oA_, 0.7293, 2.50, 0.195, 263, 241, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
4036, d5hezD_, 0.7292, 3.09, 0.272, 289, 250, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4037, d4ehzD_, 0.7292, 3.06, 0.247, 280, 251, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4038, d3f6xC_, 0.7292, 2.58, 0.249, 265, 241, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4039, d3geqB1, 0.7291, 2.67, 0.252, 270, 242, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4040, d1fgiB_, 0.7291, 2.98, 0.247, 272, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
4041, d3my0F1, 0.7290, 3.04, 0.234, 293, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4042, d5fdxB_, 0.7289, 3.09, 0.232, 274, 250, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4043, d5p9kA_, 0.7288, 2.86, 0.188, 271, 245, CRYSTAL STRUCTURE OF BTK WITH CNX 774
4044, d4mnfB_, 0.7288, 2.67, 0.210, 257, 243, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4045, d4b9dA1, 0.7288, 2.97, 0.253, 286, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
4046, d3zfxB_, 0.7288, 2.32, 0.231, 254, 238, CRYSTAL STRUCTURE OF EPHB1
4047, d3zewB_, 0.7288, 2.26, 0.228, 252, 237, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
4048, d3wj6B_, 0.7288, 3.00, 0.238, 277, 248,  
4049, d3pxkB_, 0.7288, 2.62, 0.267, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4050, d3dajA_, 0.7288, 2.47, 0.301, 245, 239, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4051, d2xp2A_, 0.7288, 2.84, 0.204, 285, 245, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
4052, d4k6zA_, 0.7287, 3.12, 0.257, 279, 253, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
4053, d4c3pA_, 0.7287, 2.76, 0.289, 264, 242, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4054, d3wj6A_, 0.7287, 2.91, 0.247, 282, 247,  
4055, d3uqfA_, 0.7287, 2.50, 0.251, 260, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
4056, d2hakC_, 0.7287, 2.70, 0.328, 310, 244, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4057, d5oy6C_, 0.7286, 3.11, 0.229, 291, 249, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4058, d5b7vA_, 0.7286, 2.92, 0.247, 282, 247, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
4059, d4tyeA_, 0.7286, 2.95, 0.230, 292, 248, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4060, d4p4cA_, 0.7286, 2.45, 0.204, 266, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4061, d4d5hB_, 0.7286, 2.75, 0.266, 260, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4062, d1jpaA_, 0.7286, 2.44, 0.208, 273, 240, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4063, d4ot6A_, 0.7285, 2.83, 0.184, 265, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
4064, d2i0yA_, 0.7285, 2.81, 0.217, 289, 244, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
4065, d4uwyA_, 0.7284, 3.04, 0.242, 296, 248, FGFR1 APO STRUCTURE
4066, d4rwjB_, 0.7284, 2.99, 0.243, 282, 247, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
4067, d4cmtA_, 0.7284, 2.79, 0.205, 284, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
4068, d3zfxF_, 0.7284, 2.33, 0.231, 254, 238, CRYSTAL STRUCTURE OF EPHB1
4069, d3eqiA_, 0.7284, 3.24, 0.264, 315, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
4070, d5ur1A_, 0.7283, 3.00, 0.236, 278, 246, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4071, d3my0Q1, 0.7283, 3.06, 0.234, 293, 248, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4072, d3my0E1, 0.7283, 3.22, 0.227, 293, 251, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4073, d2nruA_, 0.7283, 3.31, 0.265, 293, 253, CRYSTAL STRUCTURE OF IRAK-4
4074, d5dbxA_, 0.7282, 3.14, 0.260, 284, 246, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4075, d4o2pA_, 0.7282, 2.66, 0.241, 265, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4076, d3c1xA_, 0.7282, 2.86, 0.209, 290, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
4077, d2yhvA_, 0.7282, 2.92, 0.195, 291, 246, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
4078, d4zloA_, 0.7281, 2.71, 0.285, 277, 242, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4079, d4bggC_, 0.7281, 3.26, 0.239, 279, 251, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4080, d3fztA_, 0.7281, 2.68, 0.199, 259, 246, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
4081, d2qo2A_, 0.7281, 2.50, 0.207, 282, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
4082, d3zc5A_, 0.7280, 2.83, 0.212, 289, 245, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
4083, d5xp7B_, 0.7279, 2.75, 0.251, 267, 243, C-SRC IN COMPLEX WITH ATP-CHCL
4084, d5j87A_, 0.7279, 2.85, 0.184, 263, 244, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4085, d4lmnA1, 0.7279, 3.26, 0.268, 291, 254, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
4086, d5b7vB_, 0.7278, 2.93, 0.239, 277, 247, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
4087, d4p5zA_, 0.7278, 2.45, 0.208, 267, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4088, d3qquB_, 0.7278, 2.95, 0.215, 288, 247, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4089, d5w5oN_, 0.7277, 2.67, 0.230, 272, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4090, d4d4yB_, 0.7277, 2.77, 0.266, 260, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4091, d4d4vB_, 0.7277, 2.63, 0.264, 255, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4092, d3tubA_, 0.7277, 2.51, 0.199, 253, 241, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
4093, d3eqdA_, 0.7277, 3.07, 0.266, 315, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
4094, d6btwD_, 0.7276, 3.14, 0.154, 307, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4095, d3zlsA_, 0.7276, 3.33, 0.263, 315, 255, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
4096, d3ky2B_, 0.7276, 3.11, 0.234, 280, 248, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
4097, d3b8qA1, 0.7276, 2.67, 0.218, 285, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4098, d1s9iB_, 0.7276, 3.32, 0.264, 291, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
4099, d3zlxA_, 0.7275, 3.15, 0.261, 312, 253, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
4100, d1k9aF3, 0.7275, 2.66, 0.241, 264, 241, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4101, d5l4qA_, 0.7274, 2.68, 0.248, 293, 242, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4102, d5ew3A_, 0.7274, 2.63, 0.222, 274, 243, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4103, d1k9aD3, 0.7274, 2.66, 0.231, 268, 242, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4104, d5vgoA1, 0.7273, 2.83, 0.180, 264, 244, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
4105, d5p9jA_, 0.7273, 2.93, 0.188, 263, 245, BTK1 COCRYSTALLIZED WITH IBRUTINIB
4106, d5oy6A_, 0.7273, 3.28, 0.238, 291, 252, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4107, d5aa8A_, 0.7273, 2.96, 0.203, 292, 246, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4108, d5a9uA_, 0.7273, 2.96, 0.199, 292, 246, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4109, d4apcA1, 0.7273, 2.98, 0.253, 289, 249, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
4110, d3my0O1, 0.7273, 3.03, 0.243, 296, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4111, d3ggfA_, 0.7273, 3.02, 0.283, 275, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4112, d3cjfA_, 0.7273, 2.73, 0.209, 276, 244, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4113, d2hiwA1, 0.7273, 2.80, 0.235, 270, 243, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
4114, d2cl1A_, 0.7273, 2.56, 0.292, 250, 240,  
4115, d4v01B_, 0.7272, 2.96, 0.220, 275, 246, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4116, d3vvhA1, 0.7272, 3.41, 0.259, 286, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4117, d3qquD_, 0.7272, 2.93, 0.218, 292, 248, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4118, d1iepA1, 0.7272, 2.87, 0.237, 270, 245, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
4119, d4uwyB_, 0.7271, 2.75, 0.246, 273, 244, FGFR1 APO STRUCTURE
4120, d3zlwA_, 0.7271, 3.16, 0.261, 312, 253, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
4121, d3eqgA_, 0.7271, 3.30, 0.263, 314, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
4122, d3e8nA1, 0.7271, 3.30, 0.271, 290, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
4123, d2y6mA_, 0.7271, 2.49, 0.196, 262, 240, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
4124, d2nryB_, 0.7271, 3.20, 0.268, 286, 250, CRYSTAL STRUCTURE OF IRAK-4
4125, d5tehA_, 0.7270, 2.44, 0.239, 261, 238, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4126, d5kupA1, 0.7270, 2.84, 0.180, 264, 244, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
4127, d5ko1A_, 0.7270, 2.65, 0.202, 265, 242, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
4128, d5jkgA_, 0.7270, 2.58, 0.237, 266, 241, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
4129, d4zjiD_, 0.7270, 3.10, 0.309, 280, 249, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4130, d4twnA1, 0.7270, 2.74, 0.208, 275, 245, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
4131, d2z7sA_, 0.7270, 2.15, 0.323, 256, 235, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
4132, d4ibmB_, 0.7269, 2.86, 0.207, 294, 246, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4133, d4arkA1, 0.7269, 3.25, 0.268, 290, 254, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
4134, d2oiqA_, 0.7269, 2.66, 0.248, 265, 242, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4135, d1uwhA_, 0.7269, 2.79, 0.205, 264, 244, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4136, d5p9iA_, 0.7268, 2.92, 0.180, 271, 245, BTK1 SOAKED WITH IBRUTINIB-REV
4137, d4e4lE_, 0.7268, 3.07, 0.248, 280, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4138, d3mtfB_, 0.7268, 3.32, 0.237, 298, 253, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4139, d3h9rA_, 0.7268, 2.92, 0.245, 312, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
4140, d3dbdA_, 0.7268, 2.37, 0.266, 261, 237, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
4141, d3db8A_, 0.7268, 2.38, 0.266, 261, 237, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
4142, d5eobA_, 0.7267, 3.17, 0.229, 288, 249, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4143, d5aacA_, 0.7267, 2.96, 0.199, 292, 246, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4144, d3v5qB1, 0.7267, 2.67, 0.229, 262, 240, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4145, d3q4uA_, 0.7267, 3.30, 0.237, 298, 253, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4146, d5up3B_, 0.7266, 2.23, 0.312, 243, 234, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4147, d5fxqA1, 0.7266, 2.89, 0.206, 301, 247, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4148, d3qriA1, 0.7266, 2.89, 0.242, 270, 244, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4149, d3gqlC_, 0.7266, 2.92, 0.243, 275, 247, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4150, d2oh4A1, 0.7266, 2.83, 0.220, 296, 245, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
4151, d5kbrA_, 0.7265, 2.21, 0.312, 259, 234, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4152, d4equA_, 0.7265, 2.39, 0.321, 274, 234, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4153, d3my0P_, 0.7265, 3.03, 0.231, 290, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4154, d3k5vA1, 0.7265, 2.83, 0.239, 281, 243, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
4155, d3eqcA_, 0.7265, 3.22, 0.264, 312, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
4156, d2nruC_, 0.7265, 3.36, 0.265, 293, 253, CRYSTAL STRUCTURE OF IRAK-4
4157, d3zm4A_, 0.7264, 3.27, 0.261, 309, 253, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
4158, d2qu5A_, 0.7264, 2.83, 0.232, 292, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
4159, d4m67A_, 0.7263, 2.62, 0.203, 264, 241, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
4160, d4eevA_, 0.7263, 2.82, 0.220, 283, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
4161, d2iwiB_, 0.7263, 2.18, 0.264, 249, 235, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4162, d4f65A_, 0.7262, 2.83, 0.239, 279, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4163, d4d5kB_, 0.7262, 2.66, 0.264, 256, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4164, d3my0V1, 0.7262, 3.04, 0.240, 281, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4165, d3fzoA_, 0.7262, 2.94, 0.206, 262, 248, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
4166, d4dceA_, 0.7261, 2.74, 0.189, 288, 243, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4167, d2w96B_, 0.7261, 3.01, 0.482, 267, 247, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4168, d1y8gA_, 0.7261, 2.65, 0.321, 292, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4169, d5p9hA_, 0.7260, 2.87, 0.184, 264, 244, BTK1 COCRYSTALLIZED WITH RN983
4170, d5ar8B_, 0.7260, 2.97, 0.223, 274, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4171, d4rx5A1, 0.7260, 2.84, 0.176, 264, 244, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
4172, d4obqA_, 0.7260, 2.88, 0.275, 275, 244, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4173, d3pxkA_, 0.7260, 2.45, 0.262, 256, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4174, d2nruB_, 0.7260, 3.36, 0.265, 294, 253, CRYSTAL STRUCTURE OF IRAK-4
4175, d1mp8A_, 0.7260, 2.46, 0.243, 252, 239, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
4176, d5uq0A_, 0.7259, 2.78, 0.236, 266, 242, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4177, d3svvA_, 0.7259, 2.54, 0.238, 261, 239, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4178, d3dv3A_, 0.7259, 3.16, 0.270, 288, 252, MEK1 WITH PF-04622664 BOUND
4179, d3a4pA_, 0.7259, 3.28, 0.237, 285, 249, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
4180, d4wunB_, 0.7258, 2.86, 0.245, 268, 245, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4181, d4nkaA_, 0.7258, 2.95, 0.224, 279, 245, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
4182, d4mxxB_, 0.7258, 2.53, 0.238, 260, 239, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4183, d3dkfA1, 0.7258, 3.02, 0.237, 293, 245, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4184, d2hiwB1, 0.7258, 2.72, 0.240, 270, 242, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
4185, d5fxrA1, 0.7257, 2.89, 0.206, 299, 247, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4186, d4pdoA_, 0.7257, 2.43, 0.209, 261, 239, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4187, d4fnzA_, 0.7257, 2.75, 0.189, 287, 243, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
4188, d3zfxG_, 0.7257, 2.33, 0.232, 253, 237, CRYSTAL STRUCTURE OF EPHB1
4189, d3qquC_, 0.7257, 2.95, 0.214, 293, 248, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4190, d4z3vA_, 0.7256, 2.94, 0.188, 271, 245, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
4191, d4pdoB_, 0.7256, 2.44, 0.209, 261, 239, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4192, d4afeA1, 0.7256, 2.39, 0.274, 245, 237, NEK2 BOUND TO HYBRID COMPOUND 21
4193, d3vapA_, 0.7256, 2.59, 0.311, 249, 241, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
4194, d2qoiA_, 0.7256, 2.49, 0.204, 274, 240, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
4195, d2qodA_, 0.7256, 2.49, 0.204, 274, 240, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
4196, d1opjB1, 0.7256, 3.03, 0.232, 284, 246, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4197, d3zlyA_, 0.7255, 3.13, 0.266, 310, 252, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
4198, d4zjiC_, 0.7254, 3.01, 0.308, 281, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4199, d4u43B_, 0.7254, 3.32, 0.259, 302, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
4200, d4fnyA_, 0.7254, 2.73, 0.187, 273, 241, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4201, d4d4vA_, 0.7254, 2.52, 0.261, 256, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4202, d3p86A_, 0.7254, 2.58, 0.233, 250, 240, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4203, d3f69A_, 0.7254, 2.76, 0.248, 270, 246, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
4204, d2yn8B_, 0.7254, 2.45, 0.213, 260, 239, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4205, d1fpuA1, 0.7254, 2.70, 0.236, 271, 242, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4206, d5d12A_, 0.7253, 2.47, 0.252, 260, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4207, d5bx0A_, 0.7253, 3.20, 0.277, 315, 253, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
4208, d4u7zA1, 0.7253, 3.28, 0.272, 290, 254, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
4209, d4tyjA1, 0.7253, 2.70, 0.237, 275, 241, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4210, d3my0I1, 0.7253, 3.25, 0.228, 292, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4211, d3geqA1, 0.7253, 2.68, 0.253, 269, 241, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4212, d2iwiA_, 0.7253, 2.23, 0.264, 244, 235, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4213, d5m53A1, 0.7252, 2.32, 0.298, 248, 235, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4214, d5fbnC_, 0.7252, 2.88, 0.181, 256, 243, BTK KINASE DOMAIN WITH INHIBITOR 1
4215, d3tz8B_, 0.7252, 2.62, 0.246, 263, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4216, d2qofA_, 0.7252, 2.50, 0.204, 280, 240, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
4217, d2henB1, 0.7252, 2.57, 0.207, 258, 241, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4218, d1uwhB_, 0.7252, 2.82, 0.205, 264, 244, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4219, d4gg7A_, 0.7251, 2.87, 0.209, 278, 244, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4220, d2qooA_, 0.7251, 2.48, 0.212, 273, 240, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
4221, d4ehzC_, 0.7250, 3.08, 0.256, 278, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4222, d3ocsA1, 0.7250, 2.87, 0.176, 262, 244, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
4223, d3mtfA_, 0.7250, 3.29, 0.238, 296, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
4224, d3f3vA_, 0.7250, 2.53, 0.251, 261, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4225, d5uvfD_, 0.7249, 3.02, 0.159, 296, 251, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4226, d4wunA_, 0.7249, 3.14, 0.235, 282, 247, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4227, d4c62B_, 0.7249, 2.87, 0.264, 271, 246, INHIBITORS OF JAK2 KINASE DOMAIN
4228, d3l8pA_, 0.7249, 2.59, 0.241, 292, 241, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
4229, d3gvuA1, 0.7249, 2.91, 0.234, 261, 244, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
4230, d3d2kA_, 0.7249, 2.53, 0.305, 245, 239, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
4231, d3g6gB_, 0.7248, 2.60, 0.233, 263, 240, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4232, d1iepB1, 0.7248, 2.85, 0.238, 270, 244, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
4233, d5nk8A_, 0.7247, 2.46, 0.214, 266, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
4234, d3dtwA1, 0.7247, 2.60, 0.212, 281, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4235, d2wd1A_, 0.7247, 3.15, 0.218, 289, 248, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
4236, d4v04A_, 0.7246, 3.08, 0.219, 290, 247, FGFR1 IN COMPLEX WITH PONATINIB.
4237, d4u41A_, 0.7246, 2.97, 0.272, 275, 246, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4238, d4ei4A1, 0.7246, 2.97, 0.258, 288, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
4239, d3ugcA_, 0.7246, 2.77, 0.273, 274, 242, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
4240, d3krlA_, 0.7246, 2.68, 0.216, 281, 241, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
4241, d3f3wB_, 0.7246, 2.53, 0.251, 260, 239, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4242, d3f3uA_, 0.7246, 2.53, 0.247, 261, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4243, d2henD1, 0.7246, 2.57, 0.207, 258, 241, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4244, d3uc3A_, 0.7245, 2.72, 0.299, 272, 241, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.3
4245, d3qlgA_, 0.7245, 2.49, 0.239, 259, 238, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4246, d3f66A_, 0.7245, 3.30, 0.217, 288, 249, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4247, d3f3wA_, 0.7245, 2.53, 0.251, 261, 239, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4248, d4d4sA_, 0.7244, 2.60, 0.257, 255, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4249, d3tucA_, 0.7244, 2.60, 0.199, 257, 241, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4250, d2oibD_, 0.7244, 3.27, 0.267, 288, 251, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4251, d3mblA_, 0.7243, 3.21, 0.265, 290, 253, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
4252, d3dkoA1, 0.7243, 2.51, 0.208, 272, 240, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
4253, d1y8gB_, 0.7243, 2.64, 0.326, 292, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
4254, d5ur1B_, 0.7242, 2.74, 0.235, 265, 243, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4255, d3pp1A1, 0.7242, 3.28, 0.268, 290, 254, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
4256, d2w9fB_, 0.7242, 3.12, 0.470, 261, 247, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4257, d5hezC_, 0.7241, 3.15, 0.272, 289, 250, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4258, d4r1vA_, 0.7241, 3.16, 0.226, 289, 248, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
4259, d4otfA1, 0.7241, 2.88, 0.180, 261, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
4260, d4dymA_, 0.7241, 3.31, 0.239, 293, 251, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
4261, d4ctcA_, 0.7241, 2.86, 0.197, 288, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4262, d3wzdA_, 0.7241, 2.61, 0.224, 278, 241, KDR IN COMPLEX WITH LIGAND LENVATINIB
4263, d3qgyA1, 0.7241, 2.42, 0.215, 244, 237, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4264, d3q6uA1, 0.7241, 2.85, 0.212, 281, 245, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
4265, d1uwjA_, 0.7241, 2.76, 0.193, 264, 243, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4266, d5j87C_, 0.7240, 2.87, 0.184, 261, 244, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4267, d5j87B_, 0.7240, 2.88, 0.184, 274, 244, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4268, d5hezA_, 0.7240, 3.17, 0.268, 287, 250, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4269, d4ypsA1, 0.7240, 2.59, 0.222, 275, 239, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4270, d4d2sA_, 0.7240, 2.34, 0.305, 249, 236, HUMAN TTK IN COMPLEX WITH A DYRK1B INHIBITOR
4271, d4c3pD_, 0.7240, 2.85, 0.298, 260, 242, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4272, d3my0T1, 0.7240, 3.22, 0.229, 291, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4273, d3g6hB_, 0.7240, 2.52, 0.252, 259, 238, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
4274, d2hznA2, 0.7240, 2.62, 0.237, 268, 240, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
4275, d4zlyA_, 0.7239, 2.87, 0.189, 270, 244, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
4276, d4q9sA_, 0.7239, 2.50, 0.247, 252, 239, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
4277, d4cnhA_, 0.7239, 2.77, 0.198, 285, 242, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
4278, d3tz9A_, 0.7239, 2.53, 0.251, 261, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4279, d3f3vB_, 0.7239, 2.56, 0.247, 262, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4280, d3eqbA1, 0.7239, 3.21, 0.269, 288, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4281, d3daeB_, 0.7239, 2.57, 0.304, 246, 240, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4282, d4gg5A_, 0.7238, 2.66, 0.208, 274, 240, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4283, d4f0gA1, 0.7237, 2.76, 0.237, 260, 240, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
4284, d3qlgB_, 0.7237, 2.43, 0.249, 260, 237, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4285, d3g5dB_, 0.7237, 2.41, 0.254, 257, 236, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4286, d3dzqA_, 0.7237, 2.60, 0.203, 268, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
4287, d4kioC1, 0.7236, 2.70, 0.220, 249, 241, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4288, d3qgwA_, 0.7236, 2.49, 0.214, 244, 238, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4289, d2hyyA_, 0.7236, 2.78, 0.235, 263, 243, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4290, d4yhfA_, 0.7235, 2.89, 0.176, 268, 244, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
4291, d4i4fA_, 0.7235, 2.83, 0.267, 255, 243, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4292, d4ebwA_, 0.7235, 2.83, 0.267, 259, 243, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4293, d3mj2A_, 0.7235, 2.89, 0.217, 259, 244, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
4294, d3ce3A_, 0.7235, 2.91, 0.215, 293, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
4295, d2henA1, 0.7235, 2.59, 0.199, 258, 241, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4296, d2a19B1, 0.7235, 2.77, 0.255, 261, 243, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
4297, d1rjbA_, 0.7235, 2.62, 0.229, 298, 240, CRYSTAL STRUCTURE OF FLT3
4298, d1fpuB1, 0.7235, 2.83, 0.226, 266, 243, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4299, d3tz8A_, 0.7234, 2.56, 0.251, 261, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4300, d3oriB_, 0.7234, 2.96, 0.248, 267, 246, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4301, d2vwvA_, 0.7234, 2.40, 0.227, 255, 238, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4302, d2rl5A1, 0.7234, 2.71, 0.219, 290, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
4303, d2p55A2, 0.7234, 3.32, 0.276, 288, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4304, d2fumD_, 0.7234, 2.68, 0.247, 258, 243, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4305, d2nruD_, 0.7233, 3.35, 0.268, 293, 254, CRYSTAL STRUCTURE OF IRAK-4
4306, d3tl8G_, 0.7232, 3.61, 0.206, 301, 257, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4307, d5swhA_, 0.7231, 2.50, 0.241, 258, 237, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4308, d5fbnD_, 0.7230, 2.86, 0.178, 255, 242, BTK KINASE DOMAIN WITH INHIBITOR 1
4309, d4p90B_, 0.7230, 2.40, 0.318, 262, 233, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4310, d4oboA_, 0.7230, 3.15, 0.274, 275, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4311, d3u6iA_, 0.7230, 3.02, 0.211, 281, 246, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
4312, d3qrkA1, 0.7230, 2.81, 0.240, 268, 242, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
4313, d2oj9A_, 0.7230, 3.22, 0.203, 295, 251, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
4314, d2oicD_, 0.7230, 3.02, 0.260, 284, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4315, d2g15A_, 0.7230, 3.38, 0.208, 301, 250, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
4316, d5j87D_, 0.7229, 2.89, 0.184, 263, 244, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4317, d5h3qA_, 0.7229, 2.72, 0.228, 302, 241, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
4318, d5bpyA1, 0.7229, 2.87, 0.189, 262, 244, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4319, d4yo6C_, 0.7229, 3.26, 0.269, 286, 249, IRAK4-INHIBITOR CO-STRUCTURE
4320, d4ebvA1, 0.7229, 2.81, 0.260, 261, 242, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
4321, d4e4lB_, 0.7229, 3.07, 0.249, 279, 249, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4322, d3o50A_, 0.7229, 2.41, 0.308, 246, 237, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4323, d3piyA_, 0.7228, 2.45, 0.203, 262, 236, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
4324, d4ztmA_, 0.7227, 3.24, 0.264, 287, 250, IRAK4-INHIBITOR CO-STRUCTURE
4325, d4zlzA_, 0.7227, 2.83, 0.181, 270, 243, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
4326, d4u81A1, 0.7227, 3.28, 0.277, 288, 253, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
4327, d3daeA_, 0.7227, 2.60, 0.304, 248, 240, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
4328, d5iuhA_, 0.7226, 2.74, 0.191, 285, 241, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
4329, d4g5pB_, 0.7226, 3.29, 0.164, 303, 256, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
4330, d4e4lA_, 0.7226, 3.03, 0.250, 277, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
4331, d3byuA_, 0.7226, 2.65, 0.229, 256, 240, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
4332, d2henC1, 0.7226, 2.70, 0.198, 258, 242, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4333, d3oriA_, 0.7225, 2.97, 0.248, 267, 246, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4334, d3of0A_, 0.7225, 2.53, 0.239, 260, 238, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
4335, d3ctjA_, 0.7225, 2.93, 0.209, 289, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4336, d3bqrA1, 0.7225, 2.99, 0.252, 273, 246, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
4337, d4h1mA_, 0.7224, 2.65, 0.202, 256, 243, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
4338, d3p9jA_, 0.7224, 2.53, 0.308, 249, 240, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
4339, d3f3tA_, 0.7224, 2.59, 0.251, 261, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4340, d2oibB_, 0.7224, 3.02, 0.269, 278, 245, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4341, d4qq5A1, 0.7223, 2.89, 0.229, 272, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4342, d3v04A1, 0.7223, 3.28, 0.277, 288, 253, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4343, d3oezA_, 0.7223, 2.57, 0.247, 261, 239, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4344, d5ew9A_, 0.7222, 2.79, 0.296, 257, 243, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
4345, d4qqcA1, 0.7222, 2.87, 0.230, 271, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4346, d2xnpA1, 0.7222, 2.36, 0.275, 245, 236, STRUCTURE OF NEK2 BOUND TO CCT244858
4347, d2p2iA2, 0.7222, 2.67, 0.236, 283, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4348, d1opjA1, 0.7222, 3.00, 0.237, 282, 245, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4349, d4dceB_, 0.7220, 2.73, 0.187, 284, 241, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4350, d4dbnA_, 0.7220, 2.64, 0.203, 257, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4351, d4d5hA_, 0.7220, 2.64, 0.257, 255, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4352, d3h0zC_, 0.7220, 2.51, 0.307, 246, 238, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4353, d5l6oA_, 0.7219, 2.68, 0.216, 267, 241, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
4354, d4dggA_, 0.7219, 2.55, 0.239, 261, 238, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4355, d4a4xA1, 0.7219, 2.46, 0.278, 245, 237, NEK2-EDE BOUND TO CCT248662
4356, d3w16A_, 0.7219, 2.54, 0.308, 249, 240, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
4357, d3qlfB_, 0.7219, 2.45, 0.245, 258, 237, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
4358, d3ii5B_, 0.7219, 2.75, 0.207, 257, 242, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4359, d3u6hA_, 0.7218, 2.99, 0.212, 280, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
4360, d2e2bA1, 0.7218, 2.77, 0.237, 266, 241, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4361, d1uwjB_, 0.7218, 2.86, 0.205, 263, 244, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4362, d1snuA_, 0.7218, 2.56, 0.218, 245, 238, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4363, d4nwmB_, 0.7217, 2.86, 0.189, 261, 243, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
4364, d2vwwA_, 0.7217, 2.39, 0.219, 253, 237, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4365, d5t1sC_, 0.7215, 3.16, 0.271, 284, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4366, d3fmeA1, 0.7215, 2.95, 0.260, 267, 242, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
4367, d1s9jA1, 0.7215, 3.20, 0.274, 288, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4368, d5iugA_, 0.7214, 2.77, 0.195, 285, 241, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
4369, d4nksA_, 0.7214, 2.76, 0.231, 265, 242, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
4370, d2yn8A_, 0.7214, 2.42, 0.215, 253, 237, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4371, d2xnmA1, 0.7214, 2.47, 0.300, 250, 237, STRUCTURE OF NEK2 BOUND TO CCT
4372, d4u80A_, 0.7213, 3.31, 0.277, 286, 253, MEK 1 KINASE BOUND TO G799
4373, d3en4A_, 0.7213, 2.44, 0.242, 257, 236, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4374, d1vr2A_, 0.7213, 2.80, 0.214, 275, 243, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
4375, d1sm2A_, 0.7213, 2.56, 0.218, 245, 238, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4376, d5p9mA_, 0.7212, 3.01, 0.189, 271, 244, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
4377, d3b8rA1, 0.7212, 2.65, 0.216, 282, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4378, d5t1tC_, 0.7211, 3.18, 0.270, 286, 248, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4379, d4x7qB_, 0.7211, 2.15, 0.261, 243, 234, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
4380, d4fnxA_, 0.7211, 3.07, 0.191, 292, 246, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4381, d3el8B_, 0.7211, 2.41, 0.258, 259, 236, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4382, d3c4cB1, 0.7211, 2.58, 0.200, 256, 240, B-RAF KINASE IN COMPLEX WITH PLX4720
4383, d2yjsA_, 0.7211, 2.94, 0.201, 286, 244, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
4384, d3mpmA_, 0.7210, 2.91, 0.214, 257, 243, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
4385, d1r0pA_, 0.7210, 3.05, 0.234, 301, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
4386, d3v01A1, 0.7209, 3.31, 0.277, 288, 253, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4387, d4ztnC_, 0.7208, 3.12, 0.272, 284, 246, IRAK4-INHIBITOR CO-STRUCTURE
4388, d4d5kA_, 0.7208, 2.65, 0.257, 255, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4389, d3my0W1, 0.7208, 3.12, 0.236, 280, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4390, d3d5vA_, 0.7208, 2.41, 0.267, 260, 236, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
4391, d3b8qB_, 0.7208, 2.72, 0.211, 271, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4392, d1jpaB_, 0.7208, 2.40, 0.203, 269, 237, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4393, d5xgnB_, 0.7207, 3.45, 0.163, 308, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
4394, d5csxA_, 0.7207, 2.86, 0.209, 261, 244, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
4395, d4fc0A_, 0.7207, 2.60, 0.204, 254, 240, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4396, d4d4yA_, 0.7207, 2.66, 0.257, 255, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4397, d3tl8H_, 0.7207, 3.37, 0.206, 303, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4398, d4kspA_, 0.7206, 2.70, 0.199, 257, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4399, d4gfoA1, 0.7206, 2.65, 0.237, 270, 240, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
4400, d3genA_, 0.7206, 2.79, 0.187, 264, 241, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
4401, d3c4dB1, 0.7206, 2.60, 0.200, 256, 240,  
4402, d4usfA1, 0.7205, 3.23, 0.285, 275, 249, HUMAN SLK WITH SB-440719
4403, d5imxA_, 0.7204, 2.65, 0.201, 266, 239, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
4404, d4nwmA_, 0.7204, 2.97, 0.189, 261, 244, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
4405, d4d4rA_, 0.7204, 2.68, 0.249, 251, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4406, d3v5qA1, 0.7204, 2.56, 0.228, 260, 237, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4407, d2xkfA1, 0.7204, 2.32, 0.283, 242, 233, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2
4408, d3zfxC_, 0.7203, 2.31, 0.234, 248, 235, CRYSTAL STRUCTURE OF EPHB1
4409, d1k9aC3, 0.7203, 2.71, 0.233, 266, 240, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4410, d5ct7A_, 0.7202, 2.71, 0.203, 257, 241, BRAF IN COMPLEX WITH RAF265
4411, d4v01A_, 0.7202, 3.03, 0.216, 273, 245, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4412, d3d7tA_, 0.7202, 2.42, 0.237, 249, 236, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4413, d4d4rB_, 0.7201, 3.06, 0.245, 270, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4414, d3o50B_, 0.7200, 2.66, 0.312, 249, 240, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4415, p2y4iC_, 0.7200, 3.32, 0.254, 313, 252, KSR2-MEK1 HETERODIMER
4416, d2vwuA_, 0.7200, 2.41, 0.219, 253, 237, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4417, d5to8A_, 0.7199, 2.36, 0.216, 250, 236, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4418, d4d58A_, 0.7198, 2.62, 0.258, 255, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4419, d3rhkA_, 0.7198, 3.09, 0.199, 298, 246, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
4420, d3ms9B1, 0.7198, 2.79, 0.228, 267, 241, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4421, d3f66B_, 0.7198, 2.89, 0.231, 269, 242, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4422, d2xnnA1, 0.7198, 2.32, 0.286, 243, 234, STRUCTURE OF NEK2 BOUND TO CCT242430
4423, d4c3fA_, 0.7197, 2.92, 0.214, 257, 243, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
4424, d2xkdA1, 0.7197, 2.43, 0.282, 243, 234, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
4425, d3ma6B_, 0.7196, 3.08, 0.302, 266, 245, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4426, d3b8rB_, 0.7196, 2.52, 0.223, 267, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4427, d2wqbA_, 0.7196, 2.70, 0.232, 289, 241, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
4428, d1snxA_, 0.7196, 2.54, 0.215, 245, 237, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4429, d4yhfB_, 0.7195, 2.91, 0.184, 269, 244, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
4430, d3ormA_, 0.7195, 3.05, 0.236, 266, 246, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
4431, d4useB_, 0.7194, 2.84, 0.322, 278, 239, HUMAN STK10 (LOK) WITH SB-633825
4432, d2p2hA1, 0.7194, 2.91, 0.209, 289, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
4433, d5t1sA_, 0.7193, 3.25, 0.265, 280, 249, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4434, d3tl8A_, 0.7193, 3.46, 0.209, 300, 254, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
4435, d4xyfA_, 0.7192, 3.28, 0.235, 290, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
4436, d3ggfB_, 0.7192, 3.09, 0.283, 270, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4437, d3t9tA_, 0.7191, 2.91, 0.205, 263, 244, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
4438, d3pj2A_, 0.7190, 2.50, 0.191, 248, 235, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
4439, d2z7qA_, 0.7190, 2.16, 0.330, 255, 233, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
4440, d2xk4A1, 0.7190, 2.37, 0.268, 244, 235, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 17
4441, d3dpkA_, 0.7189, 2.68, 0.222, 279, 239, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
4442, d1yomA_, 0.7189, 2.52, 0.237, 260, 236, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4443, d4l7sB1, 0.7188, 2.71, 0.222, 248, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4444, d4kaoA_, 0.7188, 2.72, 0.244, 252, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4445, d3tz9B_, 0.7188, 2.50, 0.236, 259, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4446, d4xi2A2, 0.7187, 2.97, 0.184, 274, 244, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
4447, d3rhkB_, 0.7187, 3.07, 0.207, 299, 246, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
4448, d3octA_, 0.7187, 2.45, 0.191, 244, 236, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
4449, d3an0A_, 0.7187, 3.52, 0.242, 291, 256,  
4450, d5ew3B_, 0.7186, 2.62, 0.212, 266, 240, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4451, d4l7sA1, 0.7186, 2.77, 0.221, 248, 240, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4452, d3k5vB1, 0.7186, 2.91, 0.236, 279, 242, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
4453, d5eydA_, 0.7185, 3.31, 0.235, 289, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
4454, d4u44B_, 0.7185, 3.35, 0.251, 296, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
4455, d2qolA_, 0.7185, 2.59, 0.197, 271, 239, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
4456, d2javA1, 0.7185, 2.43, 0.305, 245, 236, HUMAN KINASE WITH PYRROLE-INDOLINONE LIGAND
4457, p5yj9D_, 0.7184, 2.99, 0.292, 333, 243, CRYSTAL STRUCTURE OF TRIBOLIUM CASTANEUM PINK1 KINASE DOMAIN IN COMPLEX WITH AMP-PNP 
4458, d4deiA_, 0.7184, 3.12, 0.233, 287, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
4459, p4cfxA2, 0.7184, 0.46, 1.000, 215, 213, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4460, d3vn9A_, 0.7184, 3.52, 0.242, 291, 256, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
4461, d3oezB_, 0.7184, 2.58, 0.239, 261, 238, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4462, d5kx8C_, 0.7183, 3.27, 0.269, 287, 249, IRAK4-INHIBITOR CO-STRUCTURE
4463, d4y73C_, 0.7183, 3.30, 0.272, 290, 250, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4464, d3f3tB_, 0.7183, 2.46, 0.250, 259, 236, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4465, d4yo6A_, 0.7181, 3.30, 0.264, 286, 250, IRAK4-INHIBITOR CO-STRUCTURE
4466, d4xs2A_, 0.7181, 3.26, 0.249, 283, 249, IRAK4-INHIBITOR CO-STRUCTURE
4467, d3famB_, 0.7181, 2.46, 0.311, 239, 235,  
4468, d2eueB_, 0.7181, 2.46, 0.306, 239, 235,  
4469, d3g5dA_, 0.7180, 2.36, 0.248, 256, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4470, d3fzsA_, 0.7180, 2.62, 0.195, 254, 241, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
4471, d3efkA_, 0.7180, 2.96, 0.217, 276, 244, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4472, d3cs9A_, 0.7180, 2.68, 0.247, 264, 239, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4473, d1snxB_, 0.7180, 2.62, 0.218, 245, 238, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4474, d4yp8C_, 0.7179, 3.22, 0.270, 287, 248, IRAK4-INHIBITOR CO-STRUCTURE
4475, d3vw8A_, 0.7179, 3.03, 0.217, 303, 244, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
4476, d3vvhC1, 0.7179, 3.40, 0.263, 282, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4477, d4pp9B1, 0.7178, 2.75, 0.222, 246, 239, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4478, d3qtiA_, 0.7178, 3.22, 0.234, 292, 244, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4479, d5sysB_, 0.7177, 2.56, 0.241, 258, 237, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4480, d3oxzA1, 0.7177, 2.75, 0.238, 267, 239, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
4481, d3cp9B_, 0.7177, 2.74, 0.199, 269, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4482, d5swhB_, 0.7176, 2.63, 0.241, 261, 237, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4483, d5j95B_, 0.7176, 3.40, 0.255, 300, 255, MAP4K4 IN COMPLEX WITH INHIBITOR
4484, d4u40B_, 0.7176, 3.42, 0.261, 299, 257, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4485, d4r6vA1, 0.7176, 2.96, 0.233, 271, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4486, d3eflA1, 0.7176, 2.64, 0.217, 279, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4487, p5lqeC2, 0.7175, 0.54, 1.000, 213, 213, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
4488, d5c9cA_, 0.7174, 2.75, 0.209, 254, 239, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4489, d4hcuA_, 0.7174, 3.10, 0.215, 263, 247, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
4490, d5eycA_, 0.7171, 3.26, 0.236, 288, 246, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
4491, d4mf1B1, 0.7171, 2.57, 0.224, 244, 237, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4492, d3idpA_, 0.7170, 2.92, 0.206, 255, 243, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4493, d3eflB_, 0.7170, 2.66, 0.196, 263, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4494, d2xbaA_, 0.7170, 2.92, 0.194, 283, 242, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
4495, d4ztlD_, 0.7169, 3.21, 0.262, 285, 248, IRAK4-INHIBITOR CO-STRUCTURE
4496, d4hctA_, 0.7169, 3.12, 0.215, 265, 247, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
4497, d3qgyB1, 0.7169, 2.58, 0.218, 244, 238, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
4498, d3f3uB_, 0.7169, 2.55, 0.245, 259, 237, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
4499, d3bysA_, 0.7169, 2.65, 0.231, 255, 238, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
4500, d5k76B_, 0.7168, 3.23, 0.272, 281, 246, IRAK4 IN COMPLEX WITH COMPOUND 28
4501, d5di1B_, 0.7167, 3.48, 0.254, 300, 256, MAP4K4 IN COMPLEX WITH AN INHIBITOR
4502, d4zp5B_, 0.7167, 3.48, 0.254, 300, 256, MAP4K4 IN COMPLEX WITH INHIBITOR
4503, d4ztmC_, 0.7166, 3.11, 0.275, 282, 244, IRAK4-INHIBITOR CO-STRUCTURE
4504, p4cfxC2, 0.7166, 0.55, 1.000, 215, 213, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4505, d3hyhA_, 0.7165, 2.42, 0.316, 238, 234, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
4506, d3q96A_, 0.7164, 2.74, 0.208, 253, 240, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4507, d3q96B_, 0.7163, 2.77, 0.203, 262, 241, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4508, d2og8B2, 0.7163, 2.69, 0.231, 247, 238, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4509, d5ng3A_, 0.7162, 3.24, 0.227, 283, 251, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4510, d4byjA_, 0.7162, 2.48, 0.300, 246, 237, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4511, d2wqnA_, 0.7162, 2.69, 0.324, 259, 241, STRUCTURE OF ADP-BOUND HUMAN NEK7
4512, d5a6nA1, 0.7161, 2.89, 0.251, 270, 243, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4513, d4dbnB_, 0.7161, 2.77, 0.203, 263, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4514, d3w2rA_, 0.7161, 2.97, 0.191, 297, 246, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
4515, d3vvhB1, 0.7161, 3.42, 0.267, 289, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4516, d3cs9B_, 0.7161, 2.59, 0.233, 247, 236, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4517, d2fumC_, 0.7161, 2.72, 0.241, 254, 241, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4518, d5j5sA_, 0.7160, 2.60, 0.241, 258, 237, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4519, d4ztnA_, 0.7160, 3.24, 0.266, 286, 248, IRAK4-INHIBITOR CO-STRUCTURE
4520, d4rvtB_, 0.7160, 3.50, 0.261, 297, 257, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4521, d3lq8A_, 0.7160, 2.83, 0.221, 278, 240, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
4522, p5lqeA2, 0.7159, 0.39, 0.995, 212, 212, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
4523, d4zk5B_, 0.7158, 3.26, 0.250, 294, 252, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
4524, d2xnoA1, 0.7158, 2.37, 0.278, 243, 234, STRUCTURE OF NEK2 BOUND TO CCT243779
4525, d5uitB_, 0.7157, 3.26, 0.270, 283, 248, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4526, d5lohB_, 0.7157, 2.63, 0.321, 250, 237, KINASE DOMAIN OF HUMAN GREATWALL
4527, d3dtwB_, 0.7157, 2.74, 0.212, 269, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4528, d5w84A_, 0.7156, 3.10, 0.261, 279, 245, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
4529, d3is5F1, 0.7156, 3.24, 0.298, 259, 248, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4530, d3zfyA_, 0.7155, 2.75, 0.200, 260, 240, CRYSTAL STRUCTURE OF EPHB3
4531, d5hzeA_, 0.7153, 3.24, 0.248, 305, 250, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
4532, d4pp9A1, 0.7153, 2.74, 0.223, 245, 238, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
4533, d4hcvA_, 0.7153, 3.10, 0.215, 263, 246, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
4534, d3idpB_, 0.7153, 2.94, 0.206, 256, 243, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4535, d5dbxB_, 0.7152, 3.17, 0.269, 282, 242, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4536, d4fc0B_, 0.7152, 2.77, 0.203, 263, 241, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4537, d5t3qA1, 0.7151, 2.99, 0.206, 277, 243, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
4538, d5uiqC_, 0.7150, 3.23, 0.271, 280, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4539, d4ztnD_, 0.7150, 3.41, 0.268, 285, 250, IRAK4-INHIBITOR CO-STRUCTURE
4540, d3mssA1, 0.7150, 2.64, 0.236, 260, 237, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4541, d1ywnA_, 0.7150, 2.62, 0.214, 279, 238, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
4542, d5jrsA1, 0.7149, 2.82, 0.192, 257, 240, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
4543, d4xmoA_, 0.7149, 3.23, 0.237, 289, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
4544, d3oriD_, 0.7149, 3.09, 0.248, 267, 246, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4545, d5k75C_, 0.7148, 3.22, 0.272, 282, 246, IRAK4 IN COMPLEX WITH COMPOUND 1
4546, d5fd2A_, 0.7148, 3.09, 0.208, 264, 245, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
4547, d3c4cA1, 0.7148, 2.68, 0.201, 257, 239, B-RAF KINASE IN COMPLEX WITH PLX4720
4548, d4kspB_, 0.7147, 2.69, 0.204, 256, 240, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4549, d2hakA_, 0.7147, 2.97, 0.325, 309, 246, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4550, d3uqgB_, 0.7146, 2.42, 0.248, 257, 234, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4551, d2x7fE_, 0.7146, 2.08, 0.266, 251, 229, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4552, d1yomB_, 0.7146, 2.63, 0.236, 261, 237, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
4553, d3mssC1, 0.7145, 2.67, 0.236, 260, 237, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4554, d1s9iA_, 0.7145, 3.52, 0.278, 303, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
4555, d4rmzA_, 0.7144, 3.29, 0.274, 284, 248, CRYSTAL STRUCTURE OF IRAK-4
4556, d4knbA_, 0.7144, 2.99, 0.227, 273, 242, C-MET IN COMPLEX WITH OSI LIGAND
4557, d3slsA1, 0.7144, 3.52, 0.271, 289, 255, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4558, d5uq0B_, 0.7143, 2.76, 0.231, 256, 238, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4559, d4dehA_, 0.7143, 3.26, 0.237, 286, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
4560, d3qriB_, 0.7142, 2.87, 0.238, 262, 239, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4561, d3is5A1, 0.7142, 3.00, 0.307, 254, 244, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4562, d5c9cB_, 0.7141, 2.82, 0.208, 251, 240, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4563, d3oriC_, 0.7141, 3.10, 0.248, 267, 246, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4564, d3ikaB_, 0.7141, 3.63, 0.158, 310, 259, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
4565, d3c4dA1, 0.7141, 2.81, 0.204, 257, 240,  
4566, d2e2bB1, 0.7141, 2.65, 0.236, 258, 237, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4567, d2x81A_, 0.7140, 2.62, 0.304, 242, 237, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4568, d5hu9A1, 0.7139, 3.09, 0.221, 262, 244, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
4569, d3ms9A1, 0.7139, 2.69, 0.236, 261, 237, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
4570, d5t18A1, 0.7138, 2.86, 0.192, 259, 240, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
4571, d3mssB1, 0.7138, 2.76, 0.235, 260, 238, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4572, d5kx7B_, 0.7137, 3.36, 0.269, 286, 249, IRAK4-INHIBITOR CO-STRUCTURE
4573, d4h58C_, 0.7137, 2.98, 0.201, 272, 244, BRAF IN COMPLEX WITH COMPOUND 3
4574, d3cs9D_, 0.7137, 2.91, 0.237, 263, 241, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4575, d5w85B_, 0.7135, 3.09, 0.262, 279, 244, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4576, d5t1tA_, 0.7135, 3.26, 0.271, 283, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4577, d3mssD1, 0.7135, 2.77, 0.235, 260, 238, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
4578, d5hlwA_, 0.7134, 3.05, 0.219, 284, 242, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
4579, d4agwB_, 0.7134, 2.58, 0.242, 257, 236, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4580, d5kx8A_, 0.7133, 3.34, 0.265, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
4581, d3f82A_, 0.7133, 2.86, 0.222, 278, 239, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4582, d5d11B_, 0.7132, 2.39, 0.262, 255, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4583, d5k75D_, 0.7131, 3.19, 0.269, 280, 245, IRAK4 IN COMPLEX WITH COMPOUND 1
4584, d4m13A_, 0.7131, 3.20, 0.219, 264, 247, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4585, d2nryC_, 0.7131, 3.12, 0.261, 280, 245, CRYSTAL STRUCTURE OF IRAK-4
4586, p5w5qB_, 0.7130, 3.41, 0.247, 297, 255, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
4587, d3zutA_, 0.7130, 2.95, 0.270, 281, 244, THE STRUCTURE OF OST1 (D160A) KINASE
4588, d5p9lA_, 0.7129, 2.88, 0.184, 252, 239, BTK1 IN COMPLEX WITH CC 292
4589, d2rioA_, 0.7129, 2.51, 0.306, 396, 235, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4590, d4m0zA_, 0.7128, 3.11, 0.215, 264, 246, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
4591, d3v5lC1, 0.7128, 2.69, 0.219, 242, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4592, d5t1tD_, 0.7127, 3.32, 0.270, 283, 248, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4593, d5i8aA1, 0.7127, 2.39, 0.232, 265, 233, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
4594, d4m12A_, 0.7127, 3.12, 0.215, 264, 246, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4595, d3zuuA_, 0.7127, 2.96, 0.270, 281, 244, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4596, d3cpbA1, 0.7127, 2.66, 0.210, 278, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4597, d4pqnA_, 0.7126, 2.47, 0.219, 240, 233, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
4598, d3pizA_, 0.7126, 2.40, 0.198, 245, 232, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
4599, d2bmcC_, 0.7126, 2.79, 0.300, 257, 237, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4600, d5w85A_, 0.7125, 3.08, 0.272, 278, 243, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4601, d5tobA_, 0.7125, 2.35, 0.215, 245, 233, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
4602, d5d11A_, 0.7125, 2.43, 0.249, 254, 233, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
4603, d2nryD_, 0.7125, 3.12, 0.249, 282, 245, CRYSTAL STRUCTURE OF IRAK-4
4604, d2bmcF_, 0.7125, 2.82, 0.300, 257, 237, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4605, d5sysA_, 0.7124, 2.67, 0.241, 258, 237, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
4606, d4degA_, 0.7124, 3.26, 0.234, 286, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
4607, d4ztlC_, 0.7122, 3.29, 0.279, 282, 247, IRAK4-INHIBITOR CO-STRUCTURE
4608, d3efwB_, 0.7122, 2.40, 0.318, 242, 233, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4609, d3cp9A1, 0.7122, 2.72, 0.218, 281, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4610, d5k75B_, 0.7121, 3.16, 0.275, 274, 244, IRAK4 IN COMPLEX WITH COMPOUND 1
4611, d3is5B1, 0.7121, 3.04, 0.305, 255, 243, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4612, d2qu6B_, 0.7121, 2.70, 0.205, 260, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4613, d5knjB_, 0.7120, 2.57, 0.198, 259, 237, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4614, d3c7qA_, 0.7120, 2.87, 0.212, 286, 241, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
4615, d5valA_, 0.7119, 2.64, 0.206, 254, 238, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4616, d5a6nB1, 0.7119, 2.88, 0.257, 265, 241, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4617, d4zjjD_, 0.7119, 3.03, 0.307, 274, 244, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4618, d4u3yB_, 0.7119, 3.51, 0.257, 300, 257, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4619, d4agwA_, 0.7119, 2.61, 0.237, 258, 236, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
4620, d3w2sA_, 0.7119, 3.41, 0.203, 307, 251, EGFR KINASE DOMAIN WITH COMPOUND4
4621, d5tehB_, 0.7117, 2.72, 0.243, 262, 239, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4622, d5mo4A3, 0.7117, 2.78, 0.224, 271, 237, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
4623, d4ybjA_, 0.7117, 2.59, 0.243, 255, 235, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4624, d4m15A_, 0.7117, 3.12, 0.215, 263, 246, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
4625, d2pl0A_, 0.7117, 2.94, 0.231, 268, 242, LCK BOUND TO IMATINIB
4626, d4eqmB_, 0.7116, 2.93, 0.249, 269, 245, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4627, d2bmcD_, 0.7116, 2.97, 0.297, 256, 239, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4628, d5t1sD_, 0.7115, 3.22, 0.268, 281, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4629, d4pmtA1, 0.7115, 2.54, 0.225, 269, 236, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
4630, d5k72A_, 0.7114, 3.03, 0.269, 277, 242, IRAK4 IN COMPLEX WITH COMPOUND 21
4631, d1r1wA_, 0.7114, 2.99, 0.237, 287, 240, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
4632, d5a6oB1, 0.7113, 2.96, 0.252, 264, 242, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4633, d5ct7B_, 0.7112, 2.67, 0.197, 254, 238, BRAF IN COMPLEX WITH RAF265
4634, d4m0yA_, 0.7112, 3.14, 0.215, 263, 246, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
4635, d2og8A_, 0.7112, 2.78, 0.235, 246, 238, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
4636, d4m14A_, 0.7111, 3.14, 0.215, 263, 246, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
4637, d3vs1A3, 0.7110, 3.03, 0.244, 268, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
4638, d4mneD_, 0.7108, 3.52, 0.273, 285, 253, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4639, d4eqmA_, 0.7108, 3.03, 0.248, 269, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4640, d3vs7A3, 0.7108, 2.96, 0.249, 267, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4641, d1vzoA_, 0.7108, 3.12, 0.276, 319, 243, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
4642, d4rmzB_, 0.7107, 3.25, 0.272, 282, 246, CRYSTAL STRUCTURE OF IRAK-4
4643, d4othA_, 0.7107, 2.44, 0.286, 305, 234, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
4644, p3c4wB3, 0.7107, 2.45, 0.251, 287, 231, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
4645, d5kx8D_, 0.7106, 3.32, 0.266, 283, 248, IRAK4-INHIBITOR CO-STRUCTURE
4646, d5kbrB_, 0.7106, 2.36, 0.297, 260, 229, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4647, d2hw7A1, 0.7105, 2.62, 0.250, 269, 232, CRYSTAL STRUCTURE OF MNK2-D228G IN COMPLEX WITH STAUROSPORINE
4648, d1yolB_, 0.7105, 2.50, 0.236, 253, 233, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4649, d5valB_, 0.7104, 2.72, 0.205, 254, 239, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4650, d4mneH_, 0.7104, 3.53, 0.273, 275, 253, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4651, d2bmcA_, 0.7104, 3.04, 0.296, 256, 240, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4652, d4lg4D_, 0.7103, 2.13, 0.289, 250, 228, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4653, d4eqmC_, 0.7103, 3.04, 0.248, 269, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4654, d3slsB1, 0.7102, 3.57, 0.259, 291, 255, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4655, d3k54A_, 0.7102, 2.31, 0.203, 243, 231, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
4656, d3u51A_, 0.7101, 2.76, 0.244, 256, 238, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4657, d6b8uA_, 0.7100, 2.70, 0.210, 253, 238, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4658, d4ztmD_, 0.7100, 3.31, 0.250, 282, 248, IRAK4-INHIBITOR CO-STRUCTURE
4659, d4yp8A_, 0.7100, 3.41, 0.269, 284, 249, IRAK4-INHIBITOR CO-STRUCTURE
4660, d3efkB_, 0.7100, 2.89, 0.212, 272, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4661, d2oibC_, 0.7100, 3.13, 0.241, 278, 245, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4662, d2bmcB_, 0.7100, 2.90, 0.286, 258, 238, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4663, d5j5sB_, 0.7099, 2.61, 0.243, 258, 235, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
4664, p4e3cF1, 0.7099, 3.60, 0.259, 290, 255, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4665, d3cpcA1, 0.7099, 2.71, 0.210, 277, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4666, d2rioB_, 0.7099, 2.52, 0.303, 395, 234, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4667, d4mneA_, 0.7098, 3.58, 0.272, 286, 254, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4668, d2xk3A1, 0.7098, 2.27, 0.270, 239, 230, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 35
4669, d4u45B_, 0.7097, 3.49, 0.245, 295, 253, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
4670, d3qtiB_, 0.7097, 2.98, 0.244, 280, 238, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4671, d2p2iB_, 0.7097, 2.58, 0.195, 263, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4672, d1snuB_, 0.7097, 2.72, 0.216, 241, 236, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4673, d4y73A_, 0.7096, 3.37, 0.270, 289, 248, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4674, d3dkgA_, 0.7096, 3.01, 0.229, 281, 240, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4675, d2bmcE_, 0.7096, 2.91, 0.294, 256, 238, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4676, d5ng3D_, 0.7095, 3.28, 0.224, 278, 250, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4677, d5k9iA_, 0.7095, 2.75, 0.248, 258, 238, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4678, d4eqmF_, 0.7095, 2.95, 0.258, 268, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4679, d3efwA_, 0.7095, 2.40, 0.310, 240, 232, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4680, d4ztlA_, 0.7094, 3.26, 0.264, 280, 246, IRAK4-INHIBITOR CO-STRUCTURE
4681, d4eqmD_, 0.7094, 2.95, 0.258, 268, 244, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4682, d5t1sB_, 0.7093, 3.15, 0.262, 282, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4683, d5a6oA_, 0.7093, 2.96, 0.245, 265, 241, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4684, d4ybjB_, 0.7093, 2.50, 0.249, 253, 233, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
4685, d4obqB_, 0.7093, 3.31, 0.251, 293, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4686, d1sm2B_, 0.7093, 2.69, 0.216, 241, 236, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
4687, d5uitA_, 0.7090, 3.30, 0.267, 284, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4688, d4yo6D_, 0.7090, 3.33, 0.270, 285, 248, IRAK4-INHIBITOR CO-STRUCTURE
4689, d4eqmE_, 0.7089, 3.01, 0.253, 268, 245, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4690, d5ng3B_, 0.7088, 3.28, 0.229, 275, 249, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4691, d5lohA_, 0.7088, 2.68, 0.319, 248, 235, KINASE DOMAIN OF HUMAN GREATWALL
4692, d3cpbB_, 0.7088, 2.61, 0.208, 263, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4693, d2qi8A_, 0.7088, 2.46, 0.262, 255, 233, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4694, d4x7hA_, 0.7086, 2.98, 0.275, 256, 240, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
4695, d4mneE_, 0.7086, 3.50, 0.265, 286, 253, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4696, d2xm9A_, 0.7086, 3.00, 0.288, 287, 236, STRUCTURE OF A SMALL MOLECULE INHIBITOR WITH THE KINASE DOMAIN OF CHK2
4697, p4e3cC1, 0.7084, 3.58, 0.268, 290, 254, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4698, d3wzuA_, 0.7084, 2.78, 0.251, 270, 239, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
4699, d3vs7B3, 0.7084, 2.94, 0.250, 266, 240, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
4700, d3vs1B3, 0.7084, 3.08, 0.256, 268, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
4701, d3u51B_, 0.7084, 2.74, 0.245, 255, 237, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
4702, p3eocA2, 0.7084, 0.82, 0.976, 216, 212, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
4703, d2xkcA1, 0.7084, 2.21, 0.276, 236, 228, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 14
4704, d4nifD_, 0.7083, 3.01, 0.287, 313, 240, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4705, d3oroA_, 0.7083, 3.09, 0.241, 272, 245, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
4706, d3mn3A_, 0.7082, 2.59, 0.326, 252, 236, AN INHIBITED CONFORMATION FOR THE PROTEIN KINASE DOMAIN OF THE SACCHAROMYCES CEREVISIAE AMPK HOMOLOG SNF1
4707, d2yzaA_, 0.7082, 2.86, 0.283, 258, 240, CRYSTAL STRUCTURE OF KINASE DOMAIN OF HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE ALPHA-2 SUBUNIT MUTANT (T172D)
4708, d4ztnB_, 0.7081, 3.20, 0.266, 282, 244, IRAK4-INHIBITOR CO-STRUCTURE
4709, d4rfmA1, 0.7081, 2.99, 0.224, 248, 241, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
4710, d2cn5A1, 0.7081, 3.14, 0.290, 281, 238, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP
4711, d2c0tB3, 0.7081, 3.00, 0.228, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
4712, d2xk8A1, 0.7079, 2.31, 0.275, 238, 229, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 15
4713, d3vrzB3, 0.7078, 3.05, 0.231, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
4714, d3efjA_, 0.7078, 3.24, 0.220, 276, 245, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
4715, d3cpcB_, 0.7078, 2.69, 0.198, 262, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4716, d2hyyC1, 0.7078, 2.66, 0.238, 249, 235, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4717, d4xs2C_, 0.7077, 3.29, 0.275, 281, 244, IRAK4-INHIBITOR CO-STRUCTURE
4718, d4uy9A_, 0.7077, 3.12, 0.275, 313, 244, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
4719, d4oboB_, 0.7077, 3.50, 0.248, 297, 254, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4720, d4gt4B_, 0.7077, 2.96, 0.198, 273, 242, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4721, d2xkeA1, 0.7077, 2.10, 0.286, 235, 227, STRUCTURE OF NEK2 BOUND TO AMINIPYRAZINE COMPOUND 5
4722, d5hx6A_, 0.7076, 3.10, 0.219, 259, 242, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4723, d3w18B_, 0.7076, 2.45, 0.307, 236, 231, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4724, p5uq1A2, 0.7075, 1.05, 1.000, 214, 213, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
4725, d4yfiB_, 0.7075, 2.56, 0.215, 262, 233, TNNI3K COMPLEXED WITH INHIBITOR 1
4726, d2exeA_, 0.7075, 2.45, 0.285, 262, 228, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED CLK3
4727, d5k7gC_, 0.7074, 3.28, 0.279, 283, 247, IRAK4 IN COMPLEX WITH AZ3862
4728, d4u42B_, 0.7074, 2.76, 0.244, 265, 238, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
4729, d4mf1A1, 0.7074, 2.57, 0.218, 241, 234, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
4730, d3en5B_, 0.7074, 2.77, 0.256, 261, 238, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4731, p3ej1A2, 0.7074, 0.88, 0.976, 216, 212, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
4732, d4xs2D_, 0.7073, 3.28, 0.252, 277, 246, IRAK4-INHIBITOR CO-STRUCTURE
4733, p3eocC2, 0.7073, 0.87, 0.976, 214, 212, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
4734, d2c0tA3, 0.7073, 3.01, 0.228, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
4735, d2wqmA_, 0.7072, 2.76, 0.322, 258, 239, STRUCTURE OF APO HUMAN NEK7
4736, d2hyyB1, 0.7072, 2.82, 0.241, 252, 237, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4737, d4otiA_, 0.7071, 2.40, 0.293, 303, 232, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH TOFACITINIB
4738, d3zuuB_, 0.7071, 3.04, 0.270, 282, 244, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
4739, d3vrzA3, 0.7071, 3.09, 0.248, 268, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
4740, d3v5lD1, 0.7071, 2.68, 0.229, 244, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4741, d2qu6A1, 0.7071, 2.62, 0.220, 276, 236, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4742, d4uy9B_, 0.7070, 3.13, 0.275, 315, 244, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
4743, d4x7jA_, 0.7069, 2.98, 0.272, 257, 239, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
4744, d3miyB1, 0.7069, 2.37, 0.221, 238, 231, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4745, d2oidB_, 0.7069, 3.03, 0.253, 272, 241, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4746, d2c0iA3, 0.7069, 3.00, 0.232, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
4747, d5we8A_, 0.7068, 3.33, 0.257, 270, 245, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4748, d4kioD1, 0.7068, 2.51, 0.226, 240, 234, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4749, d3efjB_, 0.7068, 3.22, 0.213, 275, 244, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
4750, d5u6bA_, 0.7067, 3.15, 0.220, 270, 246, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4751, d3vs0B3, 0.7067, 3.02, 0.232, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
4752, d3qgwB_, 0.7067, 2.61, 0.217, 240, 235, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
4753, d5y8uA_, 0.7066, 2.89, 0.252, 267, 238, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
4754, d5itaA_, 0.7066, 2.68, 0.219, 250, 237, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4755, d5itaB_, 0.7065, 2.68, 0.208, 252, 236, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4756, d3zutB_, 0.7065, 3.06, 0.270, 282, 244, THE STRUCTURE OF OST1 (D160A) KINASE
4757, d3vs2A3, 0.7065, 3.01, 0.228, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
4758, d4u41B_, 0.7064, 3.50, 0.248, 297, 254, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4759, d5cenA_, 0.7063, 2.97, 0.276, 281, 239, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
4760, d4x7lA_, 0.7062, 3.03, 0.275, 260, 240, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4761, d3zzwA_, 0.7062, 3.06, 0.202, 269, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
4762, d3v8tB1, 0.7062, 2.65, 0.217, 242, 235, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
4763, d3pj1A_, 0.7062, 2.25, 0.202, 241, 228, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
4764, d5b2kA_, 0.7061, 2.71, 0.241, 264, 237, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4765, d4x7kA_, 0.7061, 3.03, 0.275, 260, 240, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4766, d2c0oB3, 0.7061, 3.00, 0.232, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
4767, p3ej1C2, 0.7060, 0.94, 0.976, 215, 212, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
4768, d3vs3B3, 0.7059, 3.15, 0.239, 271, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
4769, d2xbjA_, 0.7059, 3.05, 0.292, 286, 236, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4770, d2wqeA_, 0.7059, 2.52, 0.309, 241, 233, STRUCTURE OF S155R AURORA-A SOMATIC MUTANT
4771, d3zxtA_, 0.7058, 2.48, 0.272, 249, 232, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4772, d3zfyB_, 0.7056, 2.55, 0.205, 255, 234, CRYSTAL STRUCTURE OF EPHB3
4773, d3zfmA_, 0.7056, 2.42, 0.198, 248, 232, CRYSTAL STRUCTURE OF EPHB2
4774, d2c0oA3, 0.7056, 3.03, 0.232, 268, 241, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
4775, d3vs0A3, 0.7055, 3.11, 0.244, 268, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
4776, d5bpyB1, 0.7054, 2.86, 0.190, 246, 237, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4777, d4a9tA1, 0.7054, 3.17, 0.287, 288, 237, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4778, d2oibA_, 0.7054, 3.13, 0.239, 280, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4779, d3i5nA_, 0.7053, 3.15, 0.233, 280, 240, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
4780, d2ac3A1, 0.7053, 2.92, 0.256, 275, 234, STRUCTURE OF HUMAN MNK2 KINASE DOMAIN
4781, d5ng3C_, 0.7052, 3.05, 0.234, 272, 244, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4782, d5d12B_, 0.7052, 2.51, 0.259, 253, 232, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4783, d4bdiA1, 0.7052, 3.07, 0.285, 289, 235, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4784, d5k7gD_, 0.7051, 3.40, 0.278, 283, 248, IRAK4 IN COMPLEX WITH AZ3862
4785, d4dggB_, 0.7051, 2.74, 0.254, 259, 236, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
4786, d2c0iB3, 0.7051, 3.11, 0.248, 268, 242, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
4787, d2xk7A1, 0.7048, 2.32, 0.279, 238, 229, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 23
4788, p4d28C_, 0.7046, 3.07, 0.291, 279, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4789, d2rfnB_, 0.7046, 2.99, 0.208, 269, 240, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4790, d4x7nA_, 0.7045, 2.96, 0.276, 259, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4791, d4gt4A_, 0.7045, 2.98, 0.212, 274, 241, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4792, d2j90A1, 0.7044, 2.84, 0.252, 259, 238, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4793, d5flfE_, 0.7042, 2.66, 0.226, 258, 235, DISEASE LINKED MUTATION IN FGFR
4794, d4u3zB_, 0.7042, 3.33, 0.231, 294, 251, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4795, d4itjB_, 0.7042, 3.32, 0.208, 276, 245, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4796, d3vs2B3, 0.7042, 3.01, 0.228, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
4797, d3vs3A3, 0.7040, 3.12, 0.231, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
4798, d3uc4A_, 0.7040, 3.22, 0.264, 295, 246, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
4799, d3dy7A_, 0.7040, 3.29, 0.280, 260, 246, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4800, d3famA_, 0.7039, 2.56, 0.303, 235, 231,  
4801, d2eueA_, 0.7039, 2.56, 0.303, 235, 231,  
4802, d3vs4A3, 0.7038, 3.20, 0.230, 270, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4803, d5k7gA_, 0.7037, 3.15, 0.269, 277, 242, IRAK4 IN COMPLEX WITH AZ3862
4804, d2rfnA_, 0.7037, 3.00, 0.208, 268, 240, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4805, d2r4bA_, 0.7037, 3.18, 0.192, 292, 245, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
4806, d4zjjC_, 0.7036, 2.99, 0.308, 276, 240, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4807, d4obpB_, 0.7036, 3.29, 0.249, 290, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
4808, d2rfsA_, 0.7036, 3.06, 0.230, 264, 239, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
4809, d2h6dA_, 0.7036, 2.85, 0.286, 256, 238, PROTEIN KINASE DOMAIN OF THE HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (AMPK ALPHA-2 CHAIN)
4810, d4yfiD_, 0.7035, 2.57, 0.211, 261, 232, TNNI3K COMPLEXED WITH INHIBITOR 1
4811, d4fg8B_, 0.7035, 3.04, 0.280, 268, 239, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4812, d3ulzA_, 0.7035, 3.32, 0.195, 291, 246, CRYSTAL STRUCTURE OF APO BAK1
4813, d3svvB_, 0.7034, 2.68, 0.244, 257, 234, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4814, d1yolA_, 0.7034, 2.67, 0.236, 256, 233, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
4815, d5hnvA1, 0.7033, 2.72, 0.212, 278, 236, CRYSTAL STRUCTURE OF PPKA
4816, d3plsA_, 0.7033, 3.40, 0.210, 298, 248, RON IN COMPLEX WITH LIGAND AMP-PNP
4817, d5jsmB1, 0.7032, 3.24, 0.217, 259, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4818, d5cswA_, 0.7032, 2.87, 0.206, 254, 238, B-RAF IN COMPLEX WITH DABRAFENIB
4819, d3is5C1, 0.7032, 3.10, 0.311, 254, 241, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4820, d5u6bC_, 0.7031, 3.20, 0.220, 270, 246, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4821, d3aqvA_, 0.7031, 3.14, 0.275, 267, 244, HUMAN AMP-ACTIVATED PROTEIN KINASE ALPHA 2 SUBUNIT KINASE DOMAIN (T172D) COMPLEXED WITH COMPOUND C
4822, d3cd8A_, 0.7030, 3.14, 0.234, 278, 239, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4823, d4cqeA_, 0.7029, 2.90, 0.206, 250, 238, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4824, d2yitA_, 0.7029, 3.10, 0.287, 286, 237, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH PV1162 A NOVEL INHIBITOR
4825, d2xk6A1, 0.7029, 2.35, 0.276, 235, 228, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 36
4826, d5uiuA_, 0.7028, 3.45, 0.275, 286, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4827, d4ludB3, 0.7028, 2.92, 0.234, 264, 239, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4828, d3pj3A_, 0.7028, 2.31, 0.194, 240, 227, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
4829, d2hyyD1, 0.7028, 2.85, 0.237, 251, 236, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
4830, d4y73D_, 0.7027, 3.42, 0.271, 288, 247, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4831, d3vs6A3, 0.7026, 3.11, 0.236, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
4832, d3p08A_, 0.7026, 2.99, 0.197, 252, 238, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4833, d3cs9C_, 0.7026, 2.80, 0.248, 243, 234, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4834, d5uisB_, 0.7025, 3.14, 0.273, 274, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4835, d3a60A_, 0.7025, 2.51, 0.315, 263, 232, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM I)
4836, d3v8wA1, 0.7024, 2.72, 0.209, 241, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4837, d3v5lA1, 0.7024, 2.54, 0.219, 238, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4838, d4y73B_, 0.7023, 3.40, 0.268, 289, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4839, d2r4bB_, 0.7023, 3.15, 0.193, 291, 244, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
4840, d5uiuB_, 0.7022, 3.42, 0.267, 287, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4841, d4yp8D_, 0.7022, 3.55, 0.277, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
4842, d4u97A_, 0.7022, 2.99, 0.256, 272, 238, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4843, d3vryA3, 0.7022, 3.14, 0.231, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
4844, d2wqoA1, 0.7022, 2.22, 0.279, 234, 226, STRUCTURE OF NEK2 BOUND TO THE AMINOPYRIDINE CCT241950
4845, d5k72D_, 0.7021, 3.15, 0.275, 276, 240, IRAK4 IN COMPLEX WITH COMPOUND 21
4846, d2qq7A_, 0.7021, 2.38, 0.266, 251, 229, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
4847, d3v8wB1, 0.7020, 2.60, 0.223, 240, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
4848, d5tx5A_, 0.7019, 3.18, 0.224, 259, 241, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4849, d2y4pC_, 0.7019, 2.69, 0.268, 264, 235, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4850, d5k72C_, 0.7018, 3.20, 0.278, 277, 241, IRAK4 IN COMPLEX WITH COMPOUND 21
4851, d3miyA1, 0.7017, 2.41, 0.217, 237, 230, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4852, d2wtiA_, 0.7017, 3.00, 0.282, 286, 234, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4853, d5jrqA1, 0.7016, 3.22, 0.217, 257, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4854, d4cqeB_, 0.7016, 2.76, 0.208, 248, 236, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4855, d5knjA_, 0.7015, 2.50, 0.210, 252, 233, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4856, d4u9aA_, 0.7015, 3.00, 0.256, 272, 238, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4857, d3vs4B3, 0.7015, 3.14, 0.231, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4858, d5h0gA3, 0.7013, 3.18, 0.230, 281, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
4859, d4d9tA_, 0.7013, 3.07, 0.292, 299, 240, RSK2 C-TERMINAL KINASE DOMAIN WITH INHIBITOR (E)-METHYL 3-(4-AMINO-7- (3-HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4860, d3hyhB_, 0.7013, 2.39, 0.306, 233, 229, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
4861, d3w18A_, 0.7012, 2.34, 0.300, 234, 227, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4862, d2a1aB1, 0.7012, 2.91, 0.253, 266, 241, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
4863, d4ztmB_, 0.7011, 3.18, 0.260, 280, 242, IRAK4-INHIBITOR CO-STRUCTURE
4864, d3dxnA_, 0.7011, 3.34, 0.305, 258, 243, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
4865, d2wtdA_, 0.7010, 3.05, 0.282, 285, 234, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4866, d2oidD_, 0.7010, 3.05, 0.264, 274, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4867, d2jboA_, 0.7010, 2.81, 0.250, 295, 236, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
4868, d4kioA1, 0.7009, 2.50, 0.221, 238, 231, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4869, p4d28B_, 0.7008, 3.12, 0.307, 277, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4870, d3vs6B3, 0.7008, 3.10, 0.231, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
4871, d3uimA_, 0.7008, 3.35, 0.199, 291, 246, STRUCTURAL BASIS FOR THE IMPACT OF PHOSPHORYLATION ON PLANT RECEPTOR- LIKE KINASE BAK1 ACTIVATION
4872, d5t1tB_, 0.7007, 3.21, 0.269, 280, 242, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4873, d5cswB_, 0.7007, 2.79, 0.212, 252, 236, B-RAF IN COMPLEX WITH DABRAFENIB
4874, d2wtcA_, 0.7007, 3.04, 0.286, 284, 234, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4875, d3v5lB1, 0.7006, 2.54, 0.220, 239, 232, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
4876, d3el7A_, 0.7006, 2.53, 0.251, 254, 231, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
4877, d2yirA_, 0.7006, 3.14, 0.287, 286, 237, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1352
4878, d3ccnA_, 0.7005, 3.07, 0.236, 275, 237, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
4879, d1bygA_, 0.7005, 2.77, 0.243, 246, 235, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
4880, d3vs5A3, 0.7004, 3.11, 0.232, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4881, d5uafA_, 0.7003, 2.98, 0.233, 291, 236, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4882, d5uadA_, 0.7003, 2.98, 0.233, 291, 236, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4883, d4zseC_, 0.7003, 3.36, 0.202, 301, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4884, d4knbC_, 0.7003, 3.12, 0.227, 271, 238, C-MET IN COMPLEX WITH OSI LIGAND
4885, d5owqB_, 0.7002, 2.67, 0.329, 254, 231, HUMAN STK10 BOUND TO DOVITINIB
4886, d3h0zB_, 0.7002, 2.48, 0.304, 240, 230, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4887, d5o21B_, 0.7001, 3.51, 0.239, 273, 247, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4888, d5k76A_, 0.7001, 3.07, 0.269, 270, 238, IRAK4 IN COMPLEX WITH COMPOUND 28
4889, d4d9uA_, 0.7001, 3.15, 0.295, 307, 241, RSK2 C-TERMINAL KINASE DOMAIN (E)-TERT-BUTYL 3-(4-AMINO-7-(3- HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4890, d3qrjB1, 0.7001, 2.93, 0.242, 252, 236, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4891, d2rfeD_, 0.7001, 3.22, 0.198, 278, 243, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4892, d5owqA_, 0.7000, 2.68, 0.333, 255, 231, HUMAN STK10 BOUND TO DOVITINIB
4893, d4r1yA_, 0.7000, 2.74, 0.215, 265, 233, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
4894, d4nifA_, 0.7000, 3.03, 0.276, 313, 239, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4895, d3p86B_, 0.7000, 2.23, 0.257, 239, 226, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4896, d5hieB_, 0.6999, 2.97, 0.203, 259, 237, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4897, d5h0eA3, 0.6998, 3.20, 0.230, 281, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
4898, d4jg8A_, 0.6998, 3.11, 0.292, 300, 240, STRUCTURE OF RSK2 T493M CTD MUTANT BOUND TO 2-CYANO-N-(1-HYDROXY-2- METHYLPROPAN-2-YL)-3-(3-(345-TRIMETHOXYPHENYL)-1H-INDAZOL-5-YL) ACRYLAMIDE
4899, d4a9uA1, 0.6998, 3.11, 0.285, 286, 235, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4900, d3pyyA1, 0.6998, 2.79, 0.235, 251, 234, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
4901, d4zseA_, 0.6997, 3.49, 0.196, 297, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4902, d3v5jA1, 0.6997, 2.67, 0.223, 239, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4903, d5uiqA_, 0.6996, 3.10, 0.264, 268, 239, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4904, d5k75A_, 0.6995, 2.95, 0.267, 271, 236, IRAK4 IN COMPLEX WITH COMPOUND 1
4905, p3hdmA_, 0.6995, 3.08, 0.273, 285, 242, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
4906, d4xs2B_, 0.6994, 3.21, 0.260, 278, 242, IRAK4-INHIBITOR CO-STRUCTURE
4907, d4kioB1, 0.6994, 2.46, 0.222, 237, 230, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4908, d2jc6A_, 0.6994, 2.83, 0.289, 278, 235, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4909, d5jsmA1, 0.6992, 3.32, 0.213, 262, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4910, d5h09A3, 0.6992, 3.20, 0.230, 281, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
4911, d4u3zA_, 0.6992, 3.47, 0.214, 282, 248, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4912, d4lghB_, 0.6992, 2.32, 0.251, 247, 227, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4913, d2ycqA_, 0.6992, 3.12, 0.288, 285, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1115
4914, d3p08B_, 0.6991, 2.92, 0.195, 258, 236, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4915, d5uiqB_, 0.6990, 3.21, 0.273, 272, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4916, d4yfiC_, 0.6989, 2.69, 0.227, 269, 233, TNNI3K COMPLEXED WITH INHIBITOR 1
4917, d4m69B_, 0.6989, 3.20, 0.204, 264, 245, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
4918, d5h0bA3, 0.6988, 3.21, 0.230, 281, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
4919, d4zseB_, 0.6988, 3.54, 0.193, 313, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4920, d3udbB_, 0.6988, 3.17, 0.266, 278, 244, CRYSTAL STRUCTURE OF SNRK2.6
4921, d5we8B_, 0.6986, 3.27, 0.256, 272, 242, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
4922, d3udbA_, 0.6986, 3.12, 0.267, 275, 243, CRYSTAL STRUCTURE OF SNRK2.6
4923, d3g51A_, 0.6985, 2.91, 0.318, 280, 239, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
4924, d5h0hA3, 0.6984, 3.21, 0.230, 281, 243, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
4925, d2wtjA1, 0.6984, 3.06, 0.282, 286, 234, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4926, d1xkkA_, 0.6984, 3.43, 0.210, 289, 248, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
4927, d2jc6C_, 0.6983, 2.81, 0.291, 277, 234, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4928, d4yffA_, 0.6981, 2.70, 0.227, 264, 233, TNNI3K COMPLEXED WITH INHIBITOR 2
4929, d4bdgA1, 0.6981, 3.13, 0.291, 285, 234, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4930, d3vs5B3, 0.6981, 3.10, 0.228, 268, 241, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
4931, d2x7fD_, 0.6981, 2.33, 0.258, 236, 225, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4932, d4yfiA_, 0.6980, 2.66, 0.233, 268, 232, TNNI3K COMPLEXED WITH INHIBITOR 1
4933, d4yffB_, 0.6980, 2.70, 0.232, 264, 233, TNNI3K COMPLEXED WITH INHIBITOR 2
4934, d5tf9A_, 0.6978, 3.37, 0.261, 262, 241, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4935, d5o21A_, 0.6978, 3.45, 0.240, 272, 246, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4936, d3vryB3, 0.6976, 3.15, 0.227, 269, 242, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
4937, d3dj6A_, 0.6976, 2.97, 0.288, 252, 236, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 823.
4938, d5hieA_, 0.6975, 2.96, 0.210, 258, 238, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4939, d3pozA_, 0.6975, 3.33, 0.187, 293, 246, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
4940, d2ycfA_, 0.6975, 3.15, 0.292, 286, 236, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1531
4941, d1gzoA_, 0.6975, 2.73, 0.300, 271, 237, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
4942, d4ludA3, 0.6974, 2.79, 0.244, 261, 234, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4943, d3uc4B_, 0.6974, 3.15, 0.270, 277, 244, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
4944, d2qi8B_, 0.6973, 2.43, 0.259, 249, 228, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
4945, d5jsmD1, 0.6972, 3.31, 0.222, 255, 243, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4946, d5jrsB1, 0.6972, 2.75, 0.194, 239, 232, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
4947, d3qlfA_, 0.6972, 2.40, 0.241, 249, 228, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
4948, d2qr8A_, 0.6972, 3.14, 0.292, 298, 240, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2 (RSK2)
4949, d5hieC_, 0.6971, 2.81, 0.203, 253, 236, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4950, d5gtyH_, 0.6971, 3.46, 0.215, 300, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4951, d4bdfA1, 0.6971, 3.11, 0.292, 284, 233, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4952, d2qlqB_, 0.6970, 2.31, 0.265, 248, 226, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
4953, d2o8yB_, 0.6969, 3.10, 0.259, 266, 239, APO IRAK4 KINASE DOMAIN
4954, d1gzkA_, 0.6969, 2.74, 0.295, 271, 237, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
4955, d4ynzB1, 0.6967, 3.21, 0.272, 316, 246, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
4956, d3kc3E_, 0.6967, 2.93, 0.250, 287, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4957, d5eymB_, 0.6966, 3.06, 0.262, 292, 240, MEK1 IN COMPLEX WITH BI 847325
4958, d4a9rA_, 0.6966, 3.09, 0.283, 285, 233, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4959, d3dj5A_, 0.6966, 2.91, 0.277, 252, 235, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 290.
4960, d1ad5A3, 0.6966, 3.41, 0.246, 271, 244, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
4961, d3my0X_, 0.6965, 2.85, 0.249, 257, 233, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4962, d2xk9A_, 0.6965, 3.11, 0.294, 284, 235, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 (CHK2) IN COMPLEX WITH INHIBITOR PV1533
4963, d5eymA_, 0.6964, 3.06, 0.258, 292, 240, MEK1 IN COMPLEX WITH BI 847325
4964, d2w7xA_, 0.6964, 3.12, 0.294, 285, 235, CELLULAR INHIBITION OF CHECKPOINT KINASE 2 AND POTENTIATION OF CYTOTOXIC DRUGS BY NOVEL CHK2 INHIBITOR PV1019
4965, d3v5jB1, 0.6963, 2.62, 0.221, 239, 231, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
4966, d3udbD_, 0.6963, 3.14, 0.263, 279, 243, CRYSTAL STRUCTURE OF SNRK2.6
4967, d3w33A_, 0.6962, 3.36, 0.203, 297, 246, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
4968, d3my0K_, 0.6962, 2.70, 0.251, 261, 231, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4969, d1gznA_, 0.6962, 2.75, 0.304, 271, 237, STRUCTURE OF PKB KINASE DOMAIN
4970, d3u4wA_, 0.6961, 3.32, 0.246, 275, 244, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
4971, d3og7A_, 0.6961, 2.64, 0.211, 247, 232, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4972, d4yffC_, 0.6959, 2.65, 0.212, 258, 231, TNNI3K COMPLEXED WITH INHIBITOR 2
4973, d4af3A_, 0.6959, 2.92, 0.283, 253, 233, HUMAN AURORA B KINASE IN COMPLEX WITH INCENP AND VX-680
4974, d5k7iA_, 0.6958, 3.05, 0.274, 272, 237, IRAK4 IN COMPLEX WITH AZ3864
4975, d5d7vB1, 0.6958, 3.32, 0.241, 262, 245, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
4976, d4yffD_, 0.6958, 2.64, 0.212, 257, 231, TNNI3K COMPLEXED WITH INHIBITOR 2
4977, d2hckA3, 0.6958, 3.30, 0.251, 271, 243, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
4978, d6b8uB_, 0.6956, 2.66, 0.210, 248, 233, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4979, d5uiqD_, 0.6956, 3.10, 0.259, 271, 239, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4980, d5jsmC1, 0.6956, 3.22, 0.219, 259, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4981, d2rgpA_, 0.6955, 3.44, 0.211, 284, 247, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
4982, d5gtyD_, 0.6954, 3.37, 0.204, 297, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4983, d2ycrA_, 0.6954, 3.17, 0.291, 282, 234, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV976
4984, d4itjA_, 0.6953, 3.14, 0.209, 261, 239, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
4985, d3kc3L_, 0.6953, 2.93, 0.250, 291, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4986, d3kc3H_, 0.6953, 3.06, 0.245, 290, 237, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4987, d1qcfA3, 0.6953, 3.33, 0.229, 281, 245, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
4988, d3my0J_, 0.6952, 2.67, 0.229, 252, 231, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4989, d3dkcA1, 0.6952, 3.46, 0.194, 310, 247, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
4990, d5h2uB1, 0.6951, 3.30, 0.242, 261, 244, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
4991, d3kmwA_, 0.6951, 3.26, 0.164, 268, 244, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
4992, d4i24B_, 0.6950, 3.54, 0.198, 304, 248, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
4993, d3repA_, 0.6950, 3.26, 0.164, 268, 244, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
4994, d3belA_, 0.6950, 3.27, 0.201, 280, 244, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
4995, d5uabA_, 0.6949, 2.92, 0.232, 288, 233, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
4996, d2oicC_, 0.6948, 3.16, 0.255, 277, 239, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4997, d5gtyE_, 0.6947, 3.39, 0.200, 297, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4998, d3ujgA_, 0.6947, 3.39, 0.279, 290, 244, CRYSTAL STRUCTURE OF SNRK2.6 IN COMPLEX WITH HAB1
4999, d5d10A_, 0.6945, 2.42, 0.242, 248, 227, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
5000, d4itiB_, 0.6945, 3.28, 0.199, 270, 241, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
